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Abstract 
 
The contractility of human heart samples from patients diagnosed with hypertrophic 
cardiomyopathy were studied using a quantitative in vitro motility assay. The aim of 
this work was to investigate the molecular phenotype of thin filament proteins in the 
HCM heart. Three biopsy samples with thin filament mutations were studied 
alongside samples acquired from a subset of HCM patients classified with 
hypertrophic obstructive cardiomyopathy. 
 
The primary effect of thin filament mutations was investigated by reconstituting F-
actin with ACTC E99K into thin filament with donor troponin. The E99K actin 
filaments had a higher Ca2+-sensitivity then filaments composed of donor F-actin 
(with no mutation) (EC50 E99K/donor 0.78±0.14, p=0.02). A similar higher Ca2+-
sensitivity was found when recombinant TnT K273N was incorporated into donor 
troponin and compared to native donor troponin (EC50 K273N/donor 0.54±0.17, 
p=0.006).  
 
Troponin was also purified from HOCM heart samples. This troponin did not contain 
a causative mutation but behaved abnormally in the response of thin filament Ca2+-
sensitivity to changes in TnI phosphorylation (EC50 PKA-HOCM/HOCM 1.08±0.25, 
p=0.3) as mean TnI phosphorylation of PKA-HOCM was 1.56 molsPi/molsTnI and 
HOCM was 0.29 molsPi/molsTnI. Thus, thin filament Ca2+-sensitivity was uncoupled 
from TnI phosphorylation in thin filaments with HOCM troponin. When the native 
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TnT subunits were replaced with recombinant TnT this coupling was restored (EC50 
HOCM rTnT/HOCM 0.63±0.26, p=0.03). 
 
It would appear that the result of HCM-causing mutations are two-fold. The primary 
effect of the HCM-causing mutations is to increase thin filament Ca2+-sensitivity. 
However, the contraction machinery appears to be the target of secondary 
modifications, that occur due to the pathology of the disease. Resulting in further 
changes, such as changes in protein composition and post-translational modification. 
One major consequence of these modifications may be to uncouple the relatively 
labile regulation of thin filament Ca2+-sensitivity by TnI phosphorylation. 
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1 Introduction 
1.1 The cardiovascular system 
The cardiovascular system is a vital transport system for the delivery of oxygen and 
nutrients, hormones and heat to different parts of the body as well as the removal of 
carbon dioxide and excretory products. This system consists of a series of distribution 
and collecting tubes and the pump, the heart. The heart consists of two muscular 
pumps, the right and left ventricles, which are filled from respective atria present on 
the same side of the heart. The right side of the heart pumps deoxygenated blood to the 
lungs for reoxygenation after which is it returned to the heart (left atrium), this is 
described as the pulmonary circulation system. Simultaneously oxygenated blood is 
pumped from the left ventricle to the rest of the body and returned to the right atrium, 
this is the systemic circulation system. 
34 
 
1.1.1 The heart 
Figure 1.1: Diagram of the heart 
 
Taken from http://heartfacts.co.uk/  
 
The heart is made up of a number of different types of specialised cells. The 
cardiomyocytes are the workhorse cells of the heart as they contain the contractile 
apparatus required for the pumping action of the heart. Although cardiomyocytes 
account for the majority of the mass of the heart, by number only approximately 30% 
of the heart cells are cardiomyocytes with the remainder consisting of fibroblasts, 
smooth muscle cells, epithelial and endothelial cells (Katz, 2006). The heart is 
contained within the pericardial sac which consists of an outer fibrous layer and the 
serous pericardium, which in turn consists of two parts the parietal (closely associated 
with the fibrous outer layer) and visceral layer. The parietal and visceral layers are 
separated by the pericardial cavity which contains a small amount of lubricating fluid. 
The inner visceral layer forms part of the epicardium, a mixture of epithelial cells and 
connective tissue. An inner layer of endocardium lines the ventricles and atria. 
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Inbetween the epicardium and endocardium is the myocardium. It is within the 
myocardium where the majority of cardiomyocytes are located.  
Figure 1.2: Diagram of the heart wall 
 
A) Diagram of layers of heart wall, illustrating the endocardium, myocardium and epicardium, taken 
from (Ashley and Niebauer, 2004)  B) Position of heart within the chest, taken from 
http://www.fightmesotheliomacancer.com/  
 
The arrangement of the myocardium that comprises the ventricle was unravelled by Dr. 
Francisco Torrent-Guasp (Torrent-Guasp et al., 2001). The model (helical ventricular 
myocardial band - HVMB) presented by Torrent-Guasp et al suggests the ventricular 
myocardium is formed from a continuous band of muscle arranged into two simple 
loops, beginning at the pulmonary artery and ended at the aorta. A heart beat occurs, 
similar to a peristaltic like wave, with each consecutive region contracting thus forcing 
the uni-directional flow of blood through the heart. Also within the myocardium, 
cardiomyocytes are arranged into distinct myocardial laminars or fibres composed of 
four to six myocytes that are separated from adjacent fibres by extracellular matrix 
(mainly collagen) (LeGrice et al., 1995).  
  
1.1.2 The cardiac cycle 
Blood is pumped from the atria to the ventricles and through uni-directional values. 
The valve between the right atrium and ventricle is known as the tricuspid value and 
A B 
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the valve between the left atrium and ventricle is known as the mitral valve. The 
semilunar values are present in the aorta and pulmonary artery to prevent blood 
flowing back into the left and right ventricles respectively.  
 
The heart and circulatory vasculature is a closed system and therefore the blood 
remains at a (relatively) constant volume. Blood is moved from one part to another by 
the development and deterioration of a pressure gradient between different sections. 
The heart creates a pressure gradient by contracting specific chambers at certain times. 
When the heart contracts this is described as systole and relaxation is diastole. How 
this leads to the movement of blood is described below and illustrated by the diagram 
(Figure 1.3) of the cardiac cycle of the left ventricle. By convention the cardiac cycle 
begins at the start of systole and can be divided into four main stages; isovolumetric 
contraction, ejection, isovolumic relaxation and ventricular filling.  
Figure 1.3: Diagram of changes in pressure and volume of the left ventricle during the cardiac 
cycle 
 
Diagram of cardiac cycle is split into two main parts, the top part is concerned with pressure changes 
and the lower part the changes in volume. The stages of the cardiac cycle are marked at the top. Taken 
from http://en.wikipedia.org/wiki/File:Cardiac_Cycle_Left_Ventricle.PNG 
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1.1.3 The heart beat  
The initial stimulus for the heart to contract arises at the cardiac pacemaker, the 
sinoatrial node (SAN). The SAN myocytes are electrically unstable and spontaneously 
depolarise initiating a wave of depolarisation which will spread across the heart. As the 
atria and ventricles are electrically isolated from one another by the annulus fibrosus, 
the depolarising wave can only move across both atria. The atrioventricular node 
(AVN) is a small area of cells in the posterior region of the atrial septum. The AVN is 
the beginning of the only route through which the depolarising wave can pass from the 
atria to the ventricles (Levick, 2009). The AVN is responsible for a delay in the 
propagation of the depolarising wave. This is so the blood present in the atria has 
enough time to move into their respective ventricles. Linked to the AVN is the bundle 
of His, this is a group of fast conducting fibres which pass through the annulus 
fibrosus. These fibres then pass down the intraventricular septum and pass out over the 
ventricles. Purkinje fibres are located at the termini of the bundle of His fibres. 
Purkinje fibres distribute the wave of depolarision over the ventricles stimulating 
contraction of the ventricular myocytes.  
Figure 1.4: Diagram showing direction of depolarisation in the heart 
 
Diagram illustrates the path of depolarising wave across the heart (Cunningham, 2002). 
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1.1.4 Excitation contraction coupling - Ca2+ is key 
An array of t-tubules carries the wave of depolarisation from the surface into the centre 
of the cardiomyocytes, where it causes L-type Ca2+ channels to open. The opening of 
these channels allows a small influx of extracellular Ca2+ into the cell, which in turn 
triggers a larger release of Ca2+ from the intra-cellular Ca2+ store, the sarcoplasmic 
reticulum (SR), via the ryanodine receptor, this is known as Ca2+-induced Ca2+ release 
(CICR). This larger release of Ca2+ is the trigger for contraction of the cardiomyocytes. 
The transduction of the electrical signal to mechanical work is described as excitation-
contraction coupling (Bers, 2001). Central to this process is the movement of Ca2+ 
ions. The influx and efflux of Ca2+ ions into the sarcomeric cytosol control the duration 
and force of contraction of the myocyte. The acute effects of raising the cytosolic 
[Ca2+] are mediated by troponin, the Ca2+-binding element of the thin filament that 
switches on the contractile apparatus. Thus any changes or modifications to the ability 
of troponin to sense changes in the level of cytosol [Ca2+] are important and may be 
involved in the development of contractile dysfunction.  
Figure 1.5: Diagram of downstream effects of β-adrenergic regulation 
 
The β-adrengeric receptor (βAR) is present in the top left, the downstream G-protein coupled receptor 
signalling through adenyl cyclase (AC) and protein kinase A (PKA) is illustrated. The targets of PKA, 
namely the ryanodine receptor (RYR) and phospholamban (PLAB) are also shown. As is the influx of 
Ca2+ into the cell via L-type Ca2+ channels and the RYR, and the efflux by SERCA and the Na+/Ca2+ 
exchanger (NCX). The activation effect of Ca2+ on myofilaments is also shown. (Brum et al., 2006) 
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1.1.5 β-adrenergic regulation of cardiac output 
Cardiac output is defined as the amount of blood pumped out of the (left) ventricle in a 
given time. From rest, when the demand for nutrients and oxygen is increased in an 
adult human, e.g. when they undergo exertion, the heart must increase the cardiac 
output to meet these demands. The heart can increase the rate at which it beats 
(chronotropy), the strength with which the heart pumps (inotropy) and the rate at which 
the heart relaxes (lusitropy).  
 
The inotropic pathway is stimulated by the hormone, adrenaline, which is released into 
the blood stream from the adrenal glands, and the neurotransmitter noradrenaline 
which is released from the post ganglionic synapses of the sympathetic nervous 
system, both of these bind to β-adrenergic receptors (G-protein coupled receptors) 
present in the plasma membrane of cardiomyocytes. This stimulates the Gsα subunit of 
the G-protein to associate and activate the membrane associated enzyme adenyl 
cyclase. Activated adenyl cyclase catalyses the conversion of ATP into cyclic-AMP 
(cAMP). cAMP can bind and activate a number of targets including protein kinase A 
(PKA). PKA can phosphorylate a number of targets, including the TnI subunit of 
troponin, phospholamban, myosin binding protein-C (MyBP-C), L-type Ca2+-channel 
and possibly the ryanodine receptor. Phospholamban is associated with and regulates 
the Sarcoplamsic/Endoplasmic reticulum Ca2+-ATPase (SERCA 2b) which is 
responsible for pumping Ca2+ back (re-uptake) into the sarcoplasmic reticulum (S.R.) 
during diastole. When phospholamban is unphosphorylated it has an inhibitory action 
on the SERCA, upon phosphorylation this inhibition is removed and the SERCA; can 
pump Ca2+ out of the cytosol faster. The effect of changes in phosphorylation of TnI 
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and MyBP-C is discussed later. The effect of phosphorylation of the ryanodine 
receptor is as yet unresolved. Another mechanism that modulates myofilaments Ca2+-
sensitivity is described as length-dependent activation (LDA). LDA modifies 
myofilaments Ca2+-sensitivity on a beat-to-beat basis as a consequence of changes to 
sarcomeric length, although the molecular mechanism for this is yet to be determined 
(de Tombe et al., 2010).  
1.2 Contractility in the human heart 
1.2.1 Techniques used for measuring contractility and Ca2+-regulation 
Several techniques are generally used to study the contractility and Ca2+-regulation of 
muscle. The first type of techniques use chemically skinned strips of muscle from 
papillary muscle or trabeculae (Kerrick et al., 2009) or myocytes to measure relative 
force and velocity over a range of [Ca2+] (Brenner, 1988, Palmer and Kentish, 1997, 
Hofmann and Moss, 1992, van der Velden et al., 2002). Chemically skinned cells have 
been demembraned usually by treatment with a detergent. Thus, skinned muscle cells 
can be driven to contract or relax by changing the [Ca2+] of the solution within which 
they are held. There is also a relatively new technique that uses isolated myofibrils in a 
similar manner (Stehle et al., 2002, Belus et al., 2008, Poggesi et al., 2005). The 
second type of techniques can only measure velocity of muscle contraction. The in 
vitro motility assay (IVMA), was first devised by Kron and Spudich (Kron and 
Spudich, 1986), to measure the movement of fluorescently labelled F-actin over an 
immobilised layer of heavy meromyosin (HMM). This was further developed for 
quantitative analysis, so the speed and fraction of filaments moving could be 
determined over a range of [Ca2+](Fraser and Marston, 1995). This is the main 
experimental technique utilised for this thesis. The final technique measures changes in 
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ATPase activity of actomyosin (Marston et al., 1980, Elliott et al., 2000). The IVMA 
measures individual filaments whereas the ATPase assay measures changes in the bulk 
solution. 
 
1.2.2 The structure of the cardiomyocyte 
The cardiomyocytes are the workhorses of the heart, they contain the myofilament 
contractile apparatus that allows the heart to function as a pump. Cardiomyocytes have 
a similar striated pattern to skeletal muscle cells but are smaller, branched and roughly 
cylindrical measuring 10-20µm wide by 50-150µm long (Kocica et al., 2006). 
Cardiomyocytes are mechanically and electrically associated with their neighbouring 
cells by intercalated discs. Like all cells, there is a potential difference across the 
plasma membrane of a cardiomyocyte, described as its membrane potential. The 
resting membrane potential is around -80mV to -90mV. The triggered opening of 
specific membrane ion channels cause this membrane potential to change or 
depolarise. The intercalated disc is an area of association of the plasma membranes 
from two adjacent cardiomyocytes, these contains two forms of cell junctions. Gap 
junctions allow the passing of an electrical or chemical signal between adjoining cells 
and thus facilitate the synchronous spread of depolarisation through the heart. 
Desmosomes link the intermediate filaments of bordering cells bolting them together. 
Typically myofibrils comprise 47% and mitochondria 36% of the total cell volume of a 
cardiomyocyte, the remainder consists of cytosol 11.5%, sarcoplasmic reticulum 3.5% 
and nucleus 2% (Page, 1978). Myofibrils are the contractile units and the mitochondria 
supply the energy for contraction and maintenance of ion gradients.  
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Figure 1.6: Picture of cardiomyocyte 
 
A) Cardiac myocytes cut into longitudinal sections, the intercalated disc can also marked. B) Individual 
myocyte visualisd by immunostaining of α-actinin and viewed by confocal microscopy Taken from 
(Severs, 2000).  
 
1.2.3 The cardiac sarcomere 
1.2.3.1 Structure of the cardiac sarcomere 
The sarcomere is the basic contractile unit of a striated muscle cell. A sarcomere is 
composed of interdigitating arrays of thick and thin filaments bordered by a Z-disk at 
either end and a central M-line. The thick filament is mainly composed of the motor 
protein, myosin and its associated protein, myosin binding protein-C (MyBP-C). The 
thin filament is primarily composed of actin filaments with associated regulation 
proteins tropomyosin and troponin. Also present in the sarcomere is the giant protein 
titin, which is responsible for generation of passive tension. There are also the 
component proteins of the Z-disk and M-band. Different regions of the sarcomere were 
named due to their appearance under a polarising microscope. The A-band 
(anisotropic) is the region of the sarcomere which contains the thick filament, this can 
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be sub-divided into regions where MyBP-C is present (C-band) and where there is no 
thin filament present (H-band). The I-band (isotropic) region contains only the thin 
filament.  
Figure 1.7: Diagram of the sarcomere 
 
The thin filaments composed of actin (white spheres), tropomyosin (orange strands) and troponin (red 
ovals) are shown interdigitating with the thick thick composed of myosin (mauve rectangles) and 
MyBP-C (red stripes). Titin is also shown in lime green. (Morimoto, 2008) 
  
1.2.4 Non-contractile proteins and structures of the sarcomere 
1.2.4.1 Titin 
Titin has been described as the third filament of striated muscle as it reaches from N-
terminal insertions to the Z-disk to C-terminal associations with the myosin rod and the 
M-band (LeWinter et al., 2007). In both the M-band and the Z-disk titin filaments from 
opposite sides overlap and interconnect to form a contiguous filament throughout the 
myofibril (LeWinter and Granzier, 2010). The main mechanical role of titin is to 
contribute to passive tension of the cardiomyocyte, along with collagen (LeWinter et 
al., 2007). Titin also has a role in the alignment of sarcomeric structural, regulatory and 
contractile elements (Linke, 2008). There are two mammalian isoforms of titin; N2B 
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and N2BA. The stiffer N2B isoform is the dominant in the adult left ventricle, but this 
dominance is changed in patients with systolic heart failure (Kruger and Linke, 2009). 
The stiffness of both isoforms is reduced when specific serine and threonine residues 
are phosphorylated by PKA (Linke, 2008). Titin also has numerous interactions with 
other elements of the sarcomere including the Z-disk, I band and M-band regions 
(Linke, 2008, Kruger and Linke, 2009), thus titin has an important structural role and it 
is a vital integrator of intracellular signalling in the cardiomyocyte in healthy and 
diseased states. 
Figure 1.8: Schematic diagram of titin structure 
 
The composition of the two halves of titin structure is shown. The I-band half or elastic half which 
contains the N2B domains and the A-band half which binds to the thick filament (Linke, 2008) 
1.2.4.2 The M-band 
The M-band is the transverse structure at the centre of the sarcomere that connects the 
parallel thick filaments. The M-band is required for regular packing of the thick 
filament and may help titin counteract force imbalances between adjacent thick 
filaments (Agarkova and Perriard, 2005). The majority of the M-band consists of two 
evolutionarily related proteins: myomesin and M-protein (Agarkova and Perriard, 
2005). Both of these proteins interact with myosin and creatine kinase, but only 
myomesin interacts with titin (Agarkova and Perriard, 2005). The region of titin within 
the M-band can interact with a number of proteins implicated in cell signalling and 
may be involved in shear force sensing and signal transduction (Agarkova and 
Perriard, 2005). 
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Figure 1.9: Model of M-band 
 
A) Model of myomesin arrangement in the M-band. B) Model of the M-band. Myosin is shown in blue 
and M-band structural elements in red (Agarkova and Perriard, 2005). 
1.2.4.3 The Z-disk 
The Z-disk marks the border of the sarcomere where actin filaments are anchored and, 
as with the M-band, was originally thought to be only have a structural role. The most 
prominent constituent proteins of the Z-disk are α-actinin, telethonin, capZ and MLP 
(muscle LIM protein). The outermost Z-disks of a cardiomyocyte are also linked to a 
structure described as a costamere, reviewed by (Cox et al., 2008). The structural role 
of costameres is to transmit force from the sarcomere to the extracellular matrix (ECM) 
and to neighbouring cardiomyocytes (Hoshijima, 2006). Costameres also form part of a 
signalling pathway between the inside and outside of the myocyte.  
A B 
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Figure 1.10: Schematic diagram of the Z-disk 
 
The diagram illustrates the Z-disk not only contains structural proteins but also interacts with a number 
of signalling molecules including muscle LIM protein (MLP), muscle ankyrin repeat proteins (MARP) 
and muscle-specific ring finger proteins (MURF) and costameres (Hoshijima, 2006) 
 
1.2.5 The sliding filament theory 
 
In the sarcomere the thick and thin filaments are arranged in parallel and are 
interdigitated. When muscle shortens the length of the thick and thin filaments does not 
change, but they slide past each other as the total length of the sarcomere shortens. It 
has been demonstrated that the production of force is proportional to the amount of 
filament overlap. This is because the number of myosin heads that can form generating 
cross bridges depends upon the degree of filament overlap. 
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Figure 1.11: Structure of the sarcomere 
 
A) Thin section electron micrograph showing the structure of two myofibrils separated by a row of 
mitochondria. B) Diagrammatic representation of thick (shown in red) and thin filaments (shown in 
green). Figure kindly provided by Prof. Nick Severs (Imperial College London) 
1.2.6 The cross-bridge cycle 
Myosin is a motor protein that uses energy liberated by ATP hydrolysis to drive 
muscle contraction. The myosin ATPase activity is activated in the presence of actin 
and inhibited by ADP and Pi. The theory of the cross bridge cycle, published by A.F. 
Huxley (Huxley, 1957), stated that muscle kinetics can be explained by the sum of 
individual force generators. Subsequently H.E. Huxley (Huxley, 1969) was able to 
obtain electron microscopy (E.M.) images of cross-bridges. Work completed by Lymn 
and Taylor elucidated how myosin, as an enzyme, uses ATP hydrolysis to power the 
cross bridge cycle, summarised as the Lymn-Taylor cycle (Lymn and Taylor, 1971). 
Throughout the cycle the myosin head can only exist in two conformations described 
as the 90° (up) and 45° (down) corresponding to the two positions of the lever arm. By 
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convention, the cycle begins with the cross-bridge in rigor, the head is in the down 
position bound to the actin molecule and in the absence of a bound nucleotide. During 
the next step a nucleotide binds and this induces a fast dissociation of actin. The third 
step occurs as the bound nucleotide is hydrolysed, this process results in the myosin 
head moving from the down to the up conformation. After which the myosin.ADP.Pi 
will rebind to actin. The binding of actin allows the release of the products of 
hydrolysis (Pi and ADP). As Pi is released the power stroke occurs where the myosin 
head (bound to the actin) returns to its original down conformation, thus moving 
(pulling) the actin along by ~10nm in this process (Spudich, 2001, Holmes, 1997). 
  
Figure 1.12: The cross-bridge cycle 
 
 
Mechanochemical scheme for the acto-myosin crossbridge cycle. The diagram illustrates the different 
states of myosin and actin interactions (unbound, weak and strong), the different nucleotide species 
(ATP, ADP, Pi) and the conformation of the lever arm during the different stages of the cross bridge 
cycle (Geeves and Holmes, 2005, Geeves et al., 2005). 
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1.2.7 Length-tension relationship in the heart 
 
Work completed by Otto Frank and Ernest Starling is summarised as Frank-Starling’s 
law of the heart which states: the stroke volume of the heart increases in response to an 
increase in the volume of blood filling the heart. The mechanism responsible for this is 
the length-tension relationship of cardiac muscle. The length-tension relationship for a 
cardiomyocyte is illustrated in Figure 1.13. This is described in three phases, the 
ascending limb (between 1.2-2.0µm), the plateau phase (2.0-2.2µm), and the 
descending limb (2.2µm-3.5µm). This relationship is explained by the relation of the 
thin and thick filaments to one another.  
 
Figure 1.13: Length-tension relationship 
 
A) Diagram of relationship between sarcomere length and tension (steady-state) redrawn by Prof. 
Marston from (Gordon et al., 1966) B) Diagrammatic representation of overlap of thick and 
thin filaments at different sarcomere lengths compiled by Prof. Marston.  
Sarcomere length 
1 2      3      
4 
A 
B 
4 
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At very short sarcomere lengths (<1.6µm) the thick filament and the Z-disk contact and 
interfere with each other. As the sarcomere length increases (1.6 – 2.0 µm) this contact 
is lost, however the thin filament still cross over (as shown illustrated at line B1) 
impeding maximal tension generation. When the sarcomere length is between 2.0-
2.2µm there is no over lap of thin filaments and maximum tension can be generated 
(illustrated in B2 & B3). If the sarcomere length is >2.2µm the central region of the 
thick filament no longer overlaps with a thin filament and thus cannot bind, as the 
proportion of overlap decreases so does the tension. (illustrated in B4). The range of 
physiological sarcomere length of cardiomyocytes is shown in blue, over the ascending 
limb. Therefore if more blood is returned to the heart, this will stretch the sarcomere, 
increasing sarcomere length, which will inturn cause a greater increase in tension, and 
thus a stronger heart beat.  
1.3 The thick filament 
1.3.1 Myosin 
1.3.1.1 The structure of myosin 
The major constituent of the thick filament is the molecular motor protein, myosin. The 
class of myosin found in muscle is myosin II. Myosin II consists of two heavy chains 
(~200 kDa) and four light chains (~20 kDa) (Gordon et al., 2000) There are two forms 
of cardiac myosin heavy chain (α and β) encoded by two genes (MHY6 and MHY7) on 
chromosome 14 (Jaenicke et al., 1990), β-MHC is the predominant form found in 
human adult ventricles. There are two forms of myosin light chains, regulatory (RLC) 
and essential (ELC), each heavy chain is associated with one of each of these light 
chains.  
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A myosin molecule can be divided into two distinct structural regions, a globular head 
located at the N-terminus and a C-terminal α-helical rod. Each globular head is formed 
from one MHC and associated regulatory and essential light chain subunits. Two 
MHCs intertwine to form a double-headed structure with a single α-helical tail that 
forms a coiled-coil rod region. The α-helical tails pack together to form the basis of 
thick filament from which the myosin heads protrude axially outwards.  
 
Figure 1.14: Diagram of myosin structure  
 
Myosin II is composed of two myosin heavy chains each associated with two light chains. Myosin can 
be cleaved into heavy meromyosin (HMM) and light meromyosin (LMM). (Voet and Voet, 1995) 
1.3.1.2 Myosin - The ATP fuelled motor that drives muscle contraction 
 
Myosin is the molecular motor that drives muscle contraction. Myosin transduces the 
energy released from the hydrolysis of ATP into kinetic energy via the cross-bridge 
cycle, resulting in a small movement of the myosin head. The myosin head also binds 
to F-actin. Movement of the myosin head while F-actin is attached results in the 
translocation of the F-actin. Due to the arrangement of the sarcomere, the movement of 
F-actin results in the Z-disks being pulled towards each other or shortening of the 
HOOC 
HOOC 
20 Å 
Regulatory Light Chain 
Essential Light Chain 
Heavy Chain 
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sarcomere. Both these functions are performed within the globular head or S-1 region 
of the molecule. The first X-ray crystal structure of myosin was obtained by Rayment 
et al (Rayment et al., 1993) of S-1 fragment of chicken skeletal muscle myosin (Figure 
1.15). This showed the structural basis of the S-1 domain is a 7-stranded anti-parallel 
β-sheet, this was further divided into three regions which were named after their 
respective masses after tryptic digestion, the N-terminal 25K(Da) domain (green), the 
middle 50K domain (red and grey) and the C-terminal 20K domain (blue) (Balint et al., 
1975, Geeves and Holmes, 1999). The two light chains are also shown with the 
essential light chain (yellow) and the regulatory light chain (magenta). The ATP 
binding site consists of a P-loop motif flanked by two switch motifs (named switch 
(SW) 1 & 2) similar to those found in G-proteins (Smith and Rayment, 1996, Sprang, 
1997, Squire and Parry, 2005). Other important structural features are the relay helix, 
the SH helix, the converter domain and the lever arm. The converter domain forms a 
socket for the lever arm. The lever arm is an extended α-helical structure which binds 
two light chains and forms the link to the highly ordered C-terminal tail (Geeves and 
Holmes, 2005). Briefly, energy from the hydrolysis of ATP drives conformational 
changes in the β-sheet structure that are transduced to the converter domain which then 
rotates ~70°, causing a displacement of ~10nm of the lever arm (Geeves and Holmes, 
2005). Thus the majority of the cross bridge does not move and the part that does move 
is ~3nm from the actin surface (Geeves and Holmes, 2005).  
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Figure 1.15: Ribbon structure of myosin 
 
 Ribbon structure of Myosin S1, the different regions are labelled and colour coded, the 25K N-terminal 
domain (green), the 50K domain (red), lower 50K domain or actin-binding domain (grey), 20K domain 
(blue). The two light chains associated with the neck are also shown, the essential light chain (yellow) 
and regulatory light chain (magenta) (Geeves and Holmes, 1999)  
 
1.3.2 Myosin light chains 
Two light chains bind to the neck region of myosin II; the essential light chain (ELC) 
(also known as light chain-1 and alkali light chain) and the regulatory light chain 
(RLC) (also known as light chain-2 or phosphorylated (P) light chain). The molecular 
mass for the ELC and the RLC is ~22 and ~19kDa respectively (Schaub et al., 1998). 
Both these light chains belong to the same superfamily as TnC: the EF-hand proteins. 
Each light chain is formed of a pair of helix-loop-helix structures that resemble a 
dumbbell-like shape (Xie et al., 1994). The ELC binds to the N-terminal portion of the 
neck and the RLC binds around the C-terminal part with minimal contact between the 
light chains (Xie et al., 1994). A common feature of all myosins are regions to which 
EF-hand proteins can bind, these are described as IQ-motifs. Both the light chains bind 
to their respective IQ motifs via C-terminal domain interactions (Xie et al., 1994).  
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1.3.3 Myosin binding protein-C 
Cardiac myosin binding protein-C (MyBP-C) is a 137kDa protein that represents ~2% 
of the total protein mass of a myofibril (Oakley et al., 2007). It is only found in a 
subsection of the A band described as the C zone, and is present in a regular pattern of 
seven to nine transverse strips, 43nm apart (Luther and Vydyanath, 2011). The cardiac 
isoform is encoded by a separate gene (MYBPC3) to the fast and slow skeletal forms 
(Flashman et al., 2004). The structure of MyBP-C is mainly composed of 8 IgI-like and 
3 fibronectin domains (see Figure 1.16) (Flashman et al., 2004). Cardiac MyBP-C has 
at least three potential phosphorylation sites in total (Copeland et al., 2010b) which are 
located in the region between the C1 and C2 domains (the MyBP-C motif or M-
domain) (Barefield and Sadayappan, 2010) 
Figure 1.16: Schematic diagram of MyBP-C sequence
 
Domain structure of MyBP-C. Note the cardiac specific C0 domain, LAGGGRRIS insertion (between 
C1 & C2) and the 28 amino acid loop in C5. (Flashman et al., 2004) 
 
Two structural models currently exist for MyBP-C, these are described as the axial 
model (Squire et al., 2003) and the other is the trimeric collar (Moolman-Smook et al., 
2002). Both these models suggest that the C7-10 domains are involved in interactions 
with the thick filament (and possibly titin) and that the MyBP-C motif interact with S2. 
The complete physiological role of MyBP-C is yet to be completely resolved 
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(Pohlmann et al., 2007). MyBP-C does not appear to be essential for life, as MyBP-C 
knock out mice were viable, however these mice did develop a large degree of 
hypertrophy and impaired systolic and diastolic function (Harris et al., 2002). However 
MyBP-C does have a role in modulating contractility (Stelzer et al., 2007).  
1.4 The thin filament 
The thin filament is composed of F-actin, tropomyosin and troponin. Troponin and 
tropomyosin both can bind to actin in the absence of the other, but when complexed 
together as in the cardiac thin filament troponin-tropomyosin binds F-actin 100-1000 
times more strongly than just tropomyosin alone (Tobacman, 1996). Troponin may 
promote association of tropomyosin with actin either by binding simultaneously to 
both of these proteins or by promoting polymerisation of the tropomyosin filament 
(Tobacman, 1996). The position of troponin and tropomyosin complex on the actin 
filament is precisely controlled so that one is present every seven actin monomers. The 
complex is positioned so that the N-terminus of the TnT subunit lays over the head-to-
tail connection between adjacent tropomyosin dimers (Palm et al., 2001). 
Figure 1.17: Diagram of the thin filament 
 
Atomic model of the thin filament. Actin monomers are shown in grey, tropomyosin is red, TnC is 
magneta, TnI is pink and TnT is yellow. Plotted with PyMol using pdb files of (Pirani et al., 2006) 
1.4.1 Actin 
Actin is a highly conserved protein that is ubiquitous within eukaryotes. Actin exists in 
two forms, globular and filamentous. A single monomer of actin is formed of a single 
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polypeptide chain of 375 residues and is bound to a nucleotide (ATP or ADP) and a 
divalent cation (dos Remedios and Moens, 1995). An actin monomer consists of two 
domains designated large (inner) and small (outer) separated by a cleft which contains 
both the nucleotide and divalent ion binding site (Hodgkinson, 2000). Monomeric or 
globular actin (G-actin) polymerises to form filamentous actin (F-actin). The structure 
of F-actin has been shown by electron microscopy studies to be helical with 13 actin 
molecules over each of 6 (left handed) turns (Holmes et al., 1990). More recent work 
by Oda et al (Oda et al., 2009) more clearly identified the conformation of actin within 
the filament. 
Figure 1.18: Structure of actin 
                              
 
I) Structure of G-actin monomer, showing the outer (1 & 2) domains and the inner (3 & 4) domains. II) 
Atomic modelof F-actin. III) Structure of actin filament, A) monomers represented as spheres to show 
the 2-strand right handed helix. B) E.M. reconstruction shows actual shape of an F-actin filament 
(Hodgkinson, 2000)  
I II
 
III 
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1.4.2 Tropomyosin 
Tropomyosin is a key component for the cooperative regulation of the thin filament. 
Four genes encode α, β, γ and δ tropomyosin, all of which are alternatively spliced 
(Gunning et al., 2005). In the heart the predominant form of tropomyosin is α-Tm, 
encoded for by the TPM1 gene (Perry, 2001). Tropomyosin forms both homodimer and 
heterodimers in vivo. Tropomyosin dimers form a left handed coiled coil structure, as 
summarised by Mason & Arndt (Mason and Arndt, 2004). The structure of a coiled-
coil tropomyosin dimer contains seven pseudo repeats, which correspond to seven 
actin binding sites, one for each actin monomer in a regulatory unit (Hitchcock-
DeGregori and Singh, 2010). Each tropomyosin dimer forms head-to-tail interaction 
with adjacent dimers forming a contiguous structure along the F-actin filament 
(Greenfield et al., 2006). The coiled-coil structure of tropomyosin is not a completely 
pure coil-coiled, irregular interruptions of hydrophobic interactions allow the 
tropomyosin to bend and thus wrap around the actin filament (Hitchcock-DeGregori 
and Singh, 2010). Individual interaction between tropomyosin and actin monomers are 
relatively weak (Kd 0.1-1mM) as the majority of interactions are electrostatic (Lehman 
and Craig, 2008). Nevertheless, the summation of many weak interactions between 
filamentous tropomyosin and actin results in an overall strong affinity. However as the 
local interaction are weak, the tropomyosin filament is able to move between different 
positions on the actin filament, this is vital for regulation of muscle contraction (Li et 
al., 2011). The mechanism by which the concave surface of tropomyosin moves over 
the convex surface of the actin filament has not yet been elucidated but a rolling model 
and a sliding model have been proposed (Lehman and Craig, 2008). A tropomyosin 
filament is relatively rigid, this property is required to transduce the cooperative 
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regulation of the thin filament as the Ca2+-sensing complex of the thin filament, 
troponin, is only in contact with half of the regulatory unit.   
 
Figure 1.19: Structure of tropomyosin 
 
Ribbon diagram showing coiled-coil structure of striated muscle α-tropomyosin. The numbers 
correspond to the 7 actin-binding repeats. Proposed actin binding sites are shown in cyan. (Hitchcock-
DeGregori and Singh, 2010) 
 
1.4.3 Troponin  
Troponin is the Ca2+-sensitive switch which regulates interaction between actin and 
myosin, and thus muscle contraction. Troponin is composed of three subunits, troponin 
C (TnC), troponin I (TnI) and troponin T (TnT). Each of these subunits have cardiac 
specific isoforms encoded by the genes TNNC1 (also found in slow skeletal muscle), 
TNNI3 and TNNT2 (respectively) (Barton et al., 1997). The troponin C subunit is so-
called because it is the subunit to which Ca2+ binds. Purified troponin I was initially 
found to inhibit the interaction between actin and myosin. Finally, troponin T is the 
backbone of the troponin complex which also interacts with tropomyosin. 
 
1.4.3.1 Troponin C 
Troponin C (TnC) is composed of two globular regions at the N and C termini 
separated by a linker helix. Both of these globular regions contain two E-F hand motifs 
which act as binding sites for a divalent ion (either Ca2+ or Mg2+). Each of these sites 
are numbered from I-IV starting from the N-terminus. In skeletal muscle sites I & II 
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are described as the physiological binding sites, as these selectively bind Ca2+ (Kd ~ 
105 M-1). Sites III & IV are described as structural sites as binding of a divalent ion 
strengthens the interaction between TnC and TnI, these sites bind Mg2+ ions under 
physiological conditions (Kd ~107 M-1) (Gordon et al., 2000). Site I of cardiac TnC 
cannot bind a divalent ion as a critical region of the sequence is not present (van Eerd 
and Takahashi, 1975). Therefore site II is the only site where Ca2+ can bind and 
dissociate under physiological conditions and thus this site is the primary site of 
regulation of cardiac contraction (Tobacman, 1996). 
Figure 1.20: Structure of TnC 
 
Stereo view of structure of skeletal TnI is shown with the two physiological Ca2+ binding sites (I & II) at 
the N-terminus, these are separated from the C-terminal binding sites (III & IV) by the D/E linker helix 
(Houdusse et al., 1997) 
1.4.3.2 Troponin I 
Troponin I (TnI) is described as the inhibitory subunit of troponin as purified TnI was 
shown to inhibit acto-myosin ATPase activity in early experiments. The TnI subunit is 
responsible for the majority of actin binding. The structure of cardiac TnI can be 
divided into 6 regions. 1) is the N-terminal extension, this is unique to cardiac TnI, 2) 
is a region that binds to the C-lobe of TnC, 3) is a region that binds to a C-terminal 
section of TnT forming half a coiled-coil, 4) the first actin-binding region (containing 
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the inhibitory peptide), 5) is a regulatory region and 6) is the second actin-binding 
region (Kobayashi and Solaro, 2005). The first actin-binding region contains a 
sequence described as the inhibitory peptide, comprising residues 96-116 in rabbit fast 
skeletal muscle, this region was the only fragment from a cyanogen bromide digest that 
inhibited myosin ATPase activity (Perry, 1999). Thus initially this region was thought 
to be primary in the regulation of muscle contraction. Subsequent studies suggest that 
the C-terminus of TnI, which contains the second actin-binding, is the more important 
facilitator of Ca2+-sensitive regulation of the thin filament (Takeda et al., 2003).  
 
The N-terminal extension of cardiac TnI is composed of 31 amino acids (Sadayappan 
et al., 2008). The N-terminal comprises three regions; an acidic N-terminal region, an 
extended rigid polyproline helix and a C-terminal helix containing the 
bisphosphorylation site (Solaro et al., 2008). The bisphosphorylation site consists of 
two serine residues (numbered 22 & 23), these are the only residues phosphorylated by 
PKA under physiological conditions (Ayaz-Guner et al., 2009, Messer et al., 2007). 
Phosphorylation of TnI by PKA leads to a decrease in sensitivity to Ca2+ (lower Ca2+-
sensitivity) of muscle contraction (Solaro et al., 2008). A study by Roberston et al 
suggested that phosphorylation of TnI directly affects the affinity of the TnC subunit 
for Ca2+ by decreasing the rate of Ca2+ dissociation 2-3 fold (Robertson et al., 1982). 
Kentish et al suggested that decreased Ca2+-sensitivity of the thin filament had direct 
effects on the kinetics of cross-bridge detachment (Palmer and Kentish, 1998, Kentish 
et al., 2001). Other putative TnI phosphorylation sites have been suggested, these 
included serine 31, 43/45 & 77, threonine 145 and serine 149 (Layland et al., 2005b, 
Solaro and van der Velden, 2010), but these are not a physiological target of PKA 
(Ayaz-Guner et al., 2009, Marston and Walker, 2009). 
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A study by Howarth et al proposes a mechanism for how the phosphorylation of the N-
terminal extension of cardiac TnI can affect the affinity of TnC for Ca2+ and thus thin 
filament Ca2+-sensitivity (Howarth et al., 2007). This study suggests that the N-
terminal extension exists in two different conformations depending upon the 
phosphorylation status of serine residues 22 & 23. When these residues are 
unphosphorylated the N-terminal extension conforms to a rod like structure which is in 
close proximity to the (Ca2+-binding) N-lobe of the TnC subunit. In this position the N-
terminal extension interacts with the TnC subunit, increasing the affinity for Ca2+. 
However, when these residues are phosphorylated the N-terminal extension develops a 
bend, moving the extreme N-terminus to a position lateral to the TnC subunit. In this 
position it can no longer influence the binding of Ca2+ to the TnC subunit and thus 
Ca2+-sensitivity is reduced. 
Figure 1.21:Different conformation of cardiac specific N-terminal extension 
 
TnI is blue and TnC/cTnT is shown in red. A) Serines 23/23 are not phosphorylated and the N-terminus 
of TnI covers the bottom of the N-terminal lobe of TnC. B) Serines 22/23 are bis-phosphorylated 
(magenta) and the N-terminus moves distal to the bottom of the molecule, as it develops a bend TnC N-
terminus is uncovered. (Howarth et al., 2007) 
A B 
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1.4.3.3 Troponin T 
Troponin T (TnT) is vital for regulation of muscle contraction, it has been described as 
the glue that holds the regulatory system together (Tobacman, 1996). Cardiac TnT is a 
rod shaped ~35kDa protein and is responsible for holding the troponin complex on the 
thin filament through interactions with tropomyosin. The structure of TnT is normally 
denoted (due to enzymatic cleavage) as two parts: the N-terminal TnT1 and C-terminal 
TnT2. Within the TnT1 region is an N-terminal acidic sequence of ~15 residues and a 
Tm binding domain located towards the C-terminus (Perry, 1998). The TnT1 region is 
described as the tail of TnT because the structure is generally α-helical. TnT1 is 
associated with the overlap region between adjacent tropomyosin dimers and this 
association is not sensitive to [Ca2+]. The TnT2 section contributes partly to the 
structure of the globular head of the troponin complex and interacts with the two other 
troponin subunits (TnC and TnI) and tropomyosin (Perry, 1998). The interaction 
between the TnT2 region and tropomyosin is sensitive to [Ca2+] (Takeda et al., 2003). 
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1.4.4 The thin filament switch  
Figure 1.22: Malnic model of the thin filament switch 
 
Schematic representation of the structure of the thin filament in the A) absence and B) presence of Ca2+ 
(Malnic et al., 1998) 
 
Troponin is the Ca2+-sensing component of the thin filament. In the presence of Ca2+ 
troponin facilitates muscle contraction and in the absence of Ca2+ troponin inhibits this. 
The exact mechanism of how troponin completes this role is not yet fully elucidated, 
however a number of theories have been published on this topic. For example, Malnic 
et al produced the model (shown in Figure 1.22) (Malnic et al., 1998). The model takes 
into account the two different interactions between troponin and actin-tropomyosin. 
The interaction between C-terminal of TnT, N-terminal of TnI & the C-terminal of 
TnC and actin-tropomyosin is independent of [Ca2+], whereas the interaction between a 
C-terminal portion of TnT, C-terminal of TnI & N-terminal of TnC and actin-
tropomyosin is dependent upon [Ca2+]. The model proposes that in the absence of Ca2+ 
(A) the C-terminal of TnI interacts strongly with actin, thus inhibiting contraction, and 
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weakly with the N-terminal of TnC. In the presence of Ca2+ (B) this situation is 
reversed with the N-terminal of TnC and C-terminal of TnI interacting strongly and 
only weakly with the thin filament, thus reducing inhibition.  
 
Figure 1.23: Structure of core domain of troponin 
 
Ribbon representation of the structure of the core domain of troponin, comprising TnC (blue), TnI red 
and TnT (green). Ca2+ ions are shown in black. Molecular graph image was drawn from atomic 
coordinates published by (Takeda et al., 2003). 
 
The Malnic model is supported by structural evidence. The structure of the troponin 
subunit has been classified as two parts, there is the filamentous region where the 
elongated N-terminus of TnT associates with tropomyosin which anchors troponin to 
the thin filament and the core globular region which is composed of TnC, TnI and the 
C-terminus of TnT (this is well illustrated in the Malnic model). The core domain 
cTnC N lobe 
cTnC C 
lobe 
cTnT  
N terminal 
cTnT C terminal 
cTnI N terminal 
cTnI C 
terminal 
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consists of the dumbbell shaped TnC subunit associated with a W-shape composed of 
multiple α-helices from TnI & TnT (Pirani et al., 2006). The structure of the core 
domain can be subdivided into regions described as the regulatory head domain, the IT 
arm. Also within the core domain is a region defined by Takeda et al as the TnI 
regulatory domain (TnIreg), this is comprised of the C-terminus of the TnI subunit 
(residues 137 to 210) (Takeda et al., 2003). Takeda et al suggest that in the absence of 
Ca2+ the TnIreg domain anchors the actin-tropomyosin in a specific position inhibiting 
contraction and that this tether is removed in the presence of Ca2+ (Takeda et al., 2003) 
(see Figure 1.24). A model for the conformation changes that occur in the troponin 
complex in the presence and absence of Ca2+ was suggested by Vinogradova et al. This 
suggested that when Ca2+ is bound to TnC, a hydrophobic patch within the N-terminus 
of the TnC subunit is opened, to which a region of TnI (the switch segment which 
corresponds to the inhibitory peptide sequence) can associate with. The result of this 
association is that the TnIreg domain is pulled away from the actin-tropomyosin and 
thus inhibition is released. Once Ca2+is removed, the TnC expels the switch segment 
and the core domain will reorder so that the TnIreg domain can bind to actin and inhibit 
the thin filament (Vinogradova et al., 2005). Pirani et al have produced evidence for 
the location of a segment of troponin on the actin filament in the absence of Ca2+. 
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Figure 1.24: Possible troponin conformational changes in muscle regulation 
 
Diagram illustrates how the C-terminus of TnI may move from a position proximal to actin and 
tropomyosin in the absence of Ca2+ and to distal position when Ca2+ is present. Actin is shown in green, 
tropomyosin in brown, the Ca2+-insensitive section is in yellow, the inhibitor region and TnIreg domain 
are blue (Takeda et al., 2003).  
 
1.4.5 Regulation of muscle contraction is both cooperative and allosteric 
 
Current analysis of the mechanism of Ca2+-regulation of the thin filament indicates that 
the filament can exist in several states defined by their activity, protein interactions and 
structure. Results from solution studies suggest that thin filament regulation is a 
cooperative system. The main evidence for this is that Ca2+ is neither sufficient nor 
necessary to activate the ATPase activity of myosin in solution but that the presence of 
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myosin heads (more specifically S1) is (Lehrer and Geeves, 1998). This led to the 
proposal of the two-state model. 
 
1.4.5.1 The Two-State model of regulation 
 
The two state model is summarised by Lehrer & Geeves (Geeves and Lehrer, 1994), 
assumptions made for this model are: 
1) The cooperative unit (of the thin filament) comprises seven actin monomers 
bridged by a single tropomyosin 
2) The cooperative unit exists as a dynamic equilibrium between an open and 
closed state. 
3) The affinity of actin for S1 is independent of the presence of S1 bound to an 
adjacent actin monomer. 
4) S1 binds to actin in two steps. 
I. Weakly bound – equilibrium constant K1 
II. Strongly bound – equilibrium constant K2 
5) Only those actin monomers in the open state allow S1 to proceed from weak to 
strong binding states. 
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Figure 1.25: Two-state model of regulation 
 
The actin.tropomyosin unit is represented by 7 spheres and the back line. The different states are marked 
by changes in the position of the tropomyosin. The myosin (S1) heads are represented by the black filled 
triangles. These move orientation depending upon strength of actin bindin, as actin binds in two stages, 
first weakly (A-state) and then strongly (R-state) (Maytum et al., 1999) 
 
In the model myosin (more specially S1) binds to the thin filament cooperative unit (1 
Tm/7 actins) in two steps. The first step involves the relatively weak binding of S1 to 
the thin filament, this is described as the A-state (attached). S1 bound to the thin 
filament in the A-state can isomerise to form a strongly bound R-state (rigor). This can 
only occur if the thin filament is in the open conformation. Actin alone would exist 
only in the open state, thus it is the presence of tropomyosin that produces the 
equilibrium between two states (open & closed) (Geeves and Lehrer, 1994). In the 
absence of S1 heads, the predominant state, of the cooperative units in equilibrium, is 
the closed state. The addition of S1 heads changes the equilibrium (KT) to favour the 
open state. Myosin has to be in the R-state to generate force. Thus S1 heads are 
required for activation of myosin ATPase, and modulation of the equilibrium between 
the open and closed states is a point of control for the regulation of muscle. Thus, KT is 
Ca2+-dependent and so Ca2+ controls switching between the closed and open states. 
 
The two-state model was modified to add a third state, the three-state model, due to 
discord between the equilibrium and kinetic experiments (binding of S1 to regulated 
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actin) which distinguished two substrates of the closed state (McKillop and Geeves, 
1993). Thus a third state, described as the blocked state, was added. In this system the 
blocked-closed equilibrium is Ca2+-regulated. Therefore, the blocked state only occurs 
in the absence of Ca2+.  
 
In summary: 
1) Blocked state: does not bind S1  
2) Closed state: can only bind S1 weakly, to form the A state (as 2-state) 
3) Open state: can bind S1 in the A state and isomerise to the strongly bound R 
state (as 2-state) 
Only when myosin is bound to the thin filament in the open state is the ATPase 
uninhibited. 
 
Figure 1.26: Three-state model of regulation 
 
Shows the additional third state, the blocked state and thus additional position of the actin.tropomyosin 
structural unit. (Maytum et al., 1999) 
 
In a review Lehrer & Geeves describe the thin filament as a classical 
cooperative/allosteric regulatory system (Lehrer and Geeves, 1998). In this review they 
suggest that regulation of myosin ATPase activity is regulated in a manner similar to 
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oxygen binding to haemoglobin, otherwise described as a MWC (Monod, Wyman, 
Changeux) cooperative/allosteric system. Within this model there are two points at 
which regulation occurs. The first point controls the binding of S1-ADP-Pi to actin, 
this is a non cooperative effect whereby in the absence of Ca2+ S1 heads are unable to 
bind to the thin filament because the majority are in the blocked state (3-state model). 
The second point regulates the isomerisation of S1-ADP-Pi (from A to R states). 
Troponin in the presence of Ca2+ is described as an allosteric effector, as it cannot 
switch the thin filament on in the absence of S1, but it does modify the equilibrium 
between the closed and open states in favour of the open state (2-state model). Thus in 
muscle, where the concentration of S1 is fixed (at a high level), the presence of Ca2+ 
modifies the equilibrium to favour the open state, allowing contraction to be activated. 
Therefore the activity of native muscle is regulated by the [Ca2+].  
 
1.4.5.2 The structural three-state steric blocking model 
Structural studies have identified three structural states in the thin filament and 
proposed a similarly named three-state steric blocking model. The steric blocking 
model was proposed following electron micrograph and X-ray diffraction experiments 
(Lehman et al., 1995, Xu et al., 1999, Squire and Morris, 1998). This model suggests 
that the tropomyosin physically blocks myosin binding to actin and that the position of 
the tropomyosin is controlled by the associated troponin complex. Thus the binding of 
Ca2+ to the TnC subunit provokes the movement of tropomyosin, which allows cross-
bridge cycling. There is, in fact, no evidence that tropomyosin does block, rather the 
position of tropomyosin is dynamic between structural states that correspond to the, 
‘blocked’, ‘closed’ and ‘open’ states.  
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Figure 1.27: Electron micrograph of the position of tropomyosin on actin in the a) open state b) 
closed state c) both  
 
Reconstructions of thin filaments showing the position of tropomyosin on the surface of actin (gold) in 
the a) absence of Ca2+ (red) b) presence of Ca2+ (green) and c) direct comparison demonstrating the 
movement of the tropomyosin filament across the surface of the actin filament (Xu et al., 1999) 
 
1.4.6 Implications for the in vitro motility assay 
The majority of experimental work completed for this thesis utilised the in vitro 
motility assay (IVMA). This technique tracks the movement of fluorescently labelled 
individual thin filaments over an immobilised bed of heavy meromyosin (HMM). 
Movement is analysed in terms of the density of attached filaments, the speed of 
filaments moving and the fraction of filaments moving. It has been established that 
Ca2+ primarily regulates the fraction of filaments moving, that corresponds to the 
fraction of filaments in the open vs closed states (K1). Ca2+ also controls sliding speed, 
but the range is small and variable depending on the proteins involved, ranging from 
no change to 50% change in sliding speed (Fraser and Marston, 1995, Marston, 2003). 
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1.5 Hypertrophic cardiomyopathy: a genetic disease of the 
sarcomere 
 
1.5.1.1 Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) was first described by Sir Russell Brock and Dr. 
Donald Teare in the 1950’s (Brock, 1957, Teare, 1958) since then it has been a subject 
of intense investigation. The prevalence of HCM is thought to be 1 in 500 adults 
(Maron et al., 1995). Therefore HCM is a highly prevalent disease that will affect a 
large number of the world’s population, and is thus a burden to the different health 
services around the world that warrants the investigative efforts made to-date and in 
the future. HCM is clinically characterised by the presence of asymmetric hypertrophy 
of the left (or right) ventricle and most commonly of the interventricular septum in the 
absence of another disease capable of producing such a degree of hypertrophy 
(Richardson et al., 1996, Maron et al., 2003a). The area affected and amount of 
hypertrophy is highly variable throughout the population of HCM patients (Wigle et 
al., 1985). Myocyte disarray has also been shown to occur in myocardium from HCM 
hearts. 
Figure 1.28: Myocyte disarray in HCM 
 
Disarray of cardiomyoctyes from a sample of hypertrophied interventricular septum, these cells are not 
arranged in regular pattern as normally found. (Maron, 2002) 
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Figure 1.29: Heart from a HCM patient 
 
 Heart sectioned in a cross-sectional plane demonstrating asymmetrical left ventricular wall thickening 
Labelled region are: left atrium (LA), aorta (Ao), right ventricle (RV), left ventricular free wall (FW) 
and ventricular septum (VS) (Maron, 1997) 
 
1.5.1.2 Diagnosis and prognosis of HCM patients 
The diagnosis of HCM is most commonly confirmed with two-dimensional 
echocardiography used to measure the size of left ventricular wall thickness. Sudden 
cardiac death may occur in HCM patients as the first sign of the disease without any 
previous symptoms. Sudden cardiac death is defined by Maron et al as ‘unexpected 
sudden collapse occurring <1 hour from the onset of symptoms in patients who had 
previously experienced a relatively stable and uneventful clinical course’(Maron et al., 
2000). However the majority of HCM patients will be non-symptomatic for the 
majority of their lives and 25% will achieve a normal longevity with an overall 
mortality rate of ~1% (Maron et al., 2003a). 
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Figure 1.30: Prognosis of HCM patients 
 
Flow chart illustrating prognosis and treatment strategy for HCM patients. Note the width of the arrow is 
representative of the proportion of patients affected (Maron, 2002) 
 
1.5.1.3 Symptoms of HCM 
Symptoms for HCM include exertional dyspnoea (laboured breathing), fatigue, 
orthopnoea (breathlessness that prevents the patient from lying prone), chest pain and 
palpitations (awareness of heartbeat) (Maron, 1997). HCM does not generally begin to 
affect patients until adolescence, when remodelling and hypertrophy commence 
(Maron and Spirito, 1998). These symptoms shown by HCM patients are due to 
dysfunction of the heart.  
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1.5.1.4 HCM is caused by mutations of sarcomeric proteins 
HCM is the result of either an inherited autosomal dominant trait or of a sporadic 
mutation (Haber, 1995). The first gene identified with a HCM causing mutation was 
the β-cardiac myosin heavy chain gene (MHY7) (Geisterfer-Lowrance et al., 1990). 
This was followed by identification of HCM causing mutations in the genes for myosin 
regulatory (MYL2) and essential light chains (MYL3), myosin binding protein-C 
(MYBPC3), cardiac troponin T (TNNT2) and cardiac troponin I (TNNI3) (Redwood et 
al., 1999). As the majority of affected genes encoded sarcomeric proteins HCM 
became know as a ‘disease of the sarcomere’.  
 
Figure 1.31: HCM: a disease of the sarcomere 
 
Diagram of the components of sarcomere, each element labelled with a proportion of HCM-causing 
mutations identified for that component (Spirito et al., 1997)  
 
Richard et al demonstrated that the MYBPC3 (42%) and MHY7 (40%) genes were the 
by far most commonly affected in a study of 124 patients (Richard et al., 2003). As 
further work is completed, more mutations in different genes are being identified that 
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cause HCM. In fact, recently rare mutations in genes that encode non-sarcomeric 
proteins are being linked to HCM, such as the Z-disk protein α-actinin (ACTN2) (Chiu 
et al., 2010). Thus, it would seem mutations in different genes lead to a common 
disease phenotype. Even an early report by Solomon et al recognised that HCM was a 
heterogeneous disease, e.g. a disease where different mutations caused the same 
phenotype (Solomon et al., 1990). 
Figure 1.32: Pie chart of distribution of HCM causing mutation in sarcomeric genes 
 
Pie chart of the frequency of HCM-causing mutations identified in sarcomeric genes. (Marston, 2011) 
 
1.5.1.5 Molecular phenotype of mutant proteins encoded by genes identified with 
HCM-causing mutations 
 
Once HCM-causing mutations had been identified, the quest began to understand how 
such mutations could cause the disease phenotype. A number of different mutations in 
different sarcomeric proteins have been investigated using a range of techniques. A 
complete list of mutations that have been studied functionally are summarised in Table 
1.1 & Table 1.2. The sources of proteins included recombinant expression systems, 
those purified from transgenic mouse models and human tissue samples. The different 
techniques utilised were the IVMA (motility), measurements on skinned myocytes (in 
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some cases the mutant recombinant protein was exchanged into the system) and Acto-
myosin Mg2+ ATPase assay. A unifying result from all of these studies is that HCM-
causing mutations cause a higher Ca2+-sensitivity of the contractile apparatus. This 
higher Ca2+-sensitivity was documented in systems that investigated mutations in eight 
contractile protein genes. Two other common patterns also observed are a faster 
crossbridge turnover rate and incomplete relaxation in low [Ca2+] (10-9M), but these 
findings were not universal. Thus, HCM-causing mutations seem to result in a gain-of 
–function. How an increase in thin filament Ca2+-sensitivity causes the onset of HCM 
is still unclear and is the topic of a large amount of on-going work. 
Table 1.1: Summary of published functional studies investigating HCM-causing mutations 
GENE MUTATION System Ca2+-sensitivity, 
∆pCa50 
relaxation Max turnover 
rate 
ACTC E99K TG mouse tissue, motility +0.39 normal normal 
  Human tissue, motility +0.12 normal normal 
  TG mouse tissue, force +0.11 normal  
  Baculovirus, motility +0.05 normal  
MYBPC3 IVS17+4A>T 
Truncated at 868 
Human tissue, skinned 
cels 
+0.1   
 c.2864_2865delCT 
Truncated at 860 
Human tissue, skinned 
cels 
+0.06   
MYL2 R58Q Recombinant 
Exchange, force 
+0.11   
 D166V TG mouse tissue, force +0.25 normal reduced 
MYH7 R403Q Human tissue, motility   increased 
  Recombinant, motility   increased 
*  TG mouse tissue, force  +0.15 normal  
* R453C TG mouse tissue, force  +0.30 normal  
 R719Q Recombinant, motility   normal 
 R719W Recombinant, motility   normal 
 D778G Recombinant, motility   increased 
 L908V Human tissue, motility   increased 
*mutation was expressed in MYH6 gene  
Relaxation is defined as ‘normal’ when similar to the non-mutant control at low [Ca2+]. It is defined as ‘incomplete’ when the 
reduction in the measured parameter was less than that measured in control at low [Ca2+]. ‘None’ refers to where no reduction in 
measured parameter was found at low [Ca2+]. 
 
Adaption of table compiled by Prof. Steven Marston. (Marston, 2011) 
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Table 1.2: Summary of published functional studies investigating HCM-causing mutations 
GENE MUTATION System Ca2+-sensitivity, 
∆pCa50 
relaxation Max turnover 
rate 
TNNI3 R145G Recombinant, ATPase +0.56 NONE  
  Recombinant, ATPase +0.32 incomplete increased 
  Recombinant 
Exchange, force 
+0.16   
 R145Q Recombinant, ATPase +0.23 incomplete increased 
  Recombinant 
Exchange, force 
+0.10   
 R162W Recombinant, ATPase +0.11 incomplete normal 
  Recombinant 
Exchange, force 
+0.06   
  Recombinant, ATPase +0.13 incomplete  
 ∆K182 Recombinant, ATPase +0.18 normal normal 
  Recombinant 
Exchange, force 
+0.1   
 K206Q Recombinant, ATPase +0.18 normal  
  Recombinant 
Exchange, force 
+0.04   
 G203S Recombinant, ATPase +0.10 normal  
  Recombinant 
Exchange, force 
+0.02   
TNNT2 Exon 16/17del (truncated at 
267) 
Recombinant, ATPase +0.43 NONE normal 
 I79N Recombinant 
Exchange, force 
+0.15 incomplete  
 R92Q Recombinant, ATPase +0.24 incomplete  
  Recombinant 
Exchange, force 
+0.18   
 R94L Recombinant 
Exchange, force 
+0.11   
 F110I Recombinant 
Exchange, force 
+0.37 incomplete decreased 
 ∆E160 Recombinant 
Exchange, force 
+0.15   
 E163K Recombinant 
Exchange, force 
+0.07 incomplete increased 
 R278C Recombinant 
Exchange, force 
+0.34 incomplete increased 
TPM1 A63V Recombinant, ATPase, 
motility 
+0.30   
 K70T Recombinant, ATPase, 
motility 
+0.33   
 D175N Recombinant, motility +0.082 normal normal 
  Human tissue, Force +0.09 normal normal 
  TG mouse tissue, force +0.10   
 E180G Recombinant, motility +0.115 normal normal 
 
Relaxation is defined as ‘normal’ when similar to the non-mutant control at low [Ca2+]. It is defined as ‘incomplete’ when the 
reduction in the measured parameter was less than that measured in control at low [Ca2+]. ‘None’ refers to where no reduction in 
measured parameter was found at low [Ca2+]. 
 
Adaption of table compiled by Prof. Steven Marston. (Marston, 2011) 
 
Two preceding studies that investigated the molecular phenotype of HCM mutations 
within the Marston laboratory were completed by Dr. Andrew Messer, Dr. Adam 
Jacques and Dr. Emma Dyer. Dr Messer & Dr Jacques investigated samples from 
patients with hypertrophic obstructive cardiomyopathy (HOCM) (see 1.5.2) as tissue 
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was available to study (see 1.5.2.3) (Jacques et al., 2006, Jacques et al., 2007, Jacques 
et al., 2008a). The findings of the study were two-fold, firstly that the level of 
phosphorylation of sarcomeric phosphoproteins was reduced similar to level of that 
measured in failing heart. Secondly, when troponin was purified from these samples 
and reconstituted into thin filaments and examined by IVMA, despite a difference in 
TnI phosphorylation there was no difference in thin filament Ca2+-sensitivity. This 
suggested that troponin in HOCM heart was abnormal and that this warranted further 
investigation. A number of HOCM tissue samples were available to study which made 
this possible. Dr Dyer investigated F-actin with an HCM-causing mutation from a 
transgenic mouse model (Song et al., 2011, Dyer et al., 2008). Thin filaments that 
contained this actin were more Ca2+-sensitive. Also, the Ca2+-sensitivity of thin 
filaments that contained this mutant actin seemed to be unresponsive to changes in TnI 
phosphorylation. This was another phenomena which merited further investigation. 
This was made possible by the acquisition of two biopsy samples with the same 
mutation and the mouse model.  
 
1.5.2 Hypertrophic obstructive cardiomyopathy 
1.5.2.1 Diagnosis of hypertrophic obstructive cardiomyopathy 
A proportion of HCM patients develop an obstruction to the ejection of blood from the 
left ventricle during systole, these are sub classified as hypertrophic obstructive 
cardiomyopathy (HOCM). These patients present with exertional dyspnea (laboured or 
difficult breathing) and associated chest pain, dizziness, presyncope (feeling faint) and 
syncope (fainting) (Maron et al., 2003a). The obstruction is clinically described as a 
left ventricular outflow tract obstruction (LVOTO). Two methods used to determine 
the presence of the LVOTO are cardiac catheterisation and Echocardiography. A 
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cardiac catheter is used to measure the peak systolic outflow gradient (under resting 
conditions) between the left ventricle. If the pressure gradient is >30mm Hg then a 
LVOTO is deemed present (Maron et al., 1981, Maron, 2002, Elliott et al., 2006). The 
proportion of HCM patients that develop LVOTO is considered to be around 25-35% 
(Maron et al., 2003b, Elliott et al., 2006, Maron et al., 2006). However this incidence is 
measured at specialist referral centres, therefore incidence of LVOTO occurring in the 
wider HCM population is probably lower. 
 
1.5.2.2 Cause and remedy of outflow obstruction  
Systolic anterior motion (SAM) of the mitral value is the most common cause of 
subaortic obstruction in HCM patients with asymmetric septal hypertrophy (Maron et 
al., 2003a). SAM is the mechanism where the anterior mitral valve leaflet contacts the 
interventricular septum during systole, thus obstructing the outflow. 
 
Figure 1.33: Diagram illustrating how SAM can lead to LVOTO 
 
The left ventricle (LV) and mitral value (MV) are shown. A) The ventricular septum is not enlarged and 
thus there is no obstruction to blood leaving the ventricle. B) The ventricular septum has enlarged to a 
point where the mitral value is in contact with it, this presents a hindrance to blood leaving the ventricle 
(Wigle et al., 1985) 
 
The obstruction may not persist permanently and in many cases is only apparent when 
the patient undergoes exertion. The overall mortality rate of HCM patients is generally 
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very low (~1%), however the presence of a permanent LVOTO increases the 
probability of progression to heart failure and death and also the chance of sudden 
cardiac death (Maron et al., 2003b). The symptoms of HOCM patients are managed 
medically using the same remedies used for the general HCM population, nevertheless, 
a proportion of HCM patients will reach a drug-refractory point where the only further 
medical option is a heart transplant (Spirito et al., 1997). A small (5%) sub-population 
of HCM patients that possess an outflow gradient >50 mm Hg (at rest or with 
provocation) and are in the later stages of heart failure (NYHA III or IV) qualify for 
surgical intervention (Maron et al., 2003a).  
 
1.5.2.3 Septal myotomy-myectomy operation – a good opportunity for study 
There are very few opportunities to obtain human myocardium from patients who are 
alive. In the instances where HOCM patients qualify for surgical intervention, the point 
of the surgery is to remove tissue, which can be considered unwanted (by the patient). 
Thus, tissue removed from a HOCM patient presents a unique opportunity to study 
diseased human myocardium. There are currently two techniques used to reduce 
LVOTO in HOCM patients; the septal myotomy-myectomy and alcohol septal 
ablation. The septal myotomy-myectomy, also known as the Morrow procedure, was 
first used in 1960 (Morrow et al., 1975). The operation procedure for a septal 
myectomy involves stopping and draining the heart of blood. Access to the left 
ventricle is obtained through the aortic valve through which a retractor and knife are 
passed (Morrow et al., 1975). These are used to remove a section of the hypertrophied 
septum leaving a 1.4 x 1 x 4 cm channel between the septum and apex (Morrow et al., 
1975). The amount of tissue removed is usually 2 to 5g (Maron, 2007).  
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Figure 1.34: Diagram for procedure of septal myotomy-myectomy 
 
After access has been gained to the heart and the heart has been arrested the hypertrophied septum can 
be reduced (Morrow et al., 1975) 
 
Septal mytomy-myectomy operations are routinely completed at the Heart Hospital, 
London, and thanks to a collaboration with Prof. W. McKenna a portion of the tissue 
removed was made available to the Marston laboratory to study. This tissue presents a 
rare opportunity to investigate human myocardial tissue from a number of patients with 
HOCM. 
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1.6 Aims of the thesis 
The purpose of this thesis is to investigate contractile proteins purified from 
myocardium samples from HCM patients (biopsies) and HOCM patients (tissue from 
myectomy operations). A set of over 20 myectomy samples removed from HOCM 
patients was available to study alongside a couple of biopsy sample from HCM 
patients. The HOCM samples were screened and a HCM-causing mutation was 
identified in several samples, affecting the MYH7 and MYBPC3 genes. However, no 
mutation was identified for the majority of samples, this is in line with studies by other 
investigators. Both the biopsy samples were genotyped and a mutation was identified 
in the TNNT2 and ACTC genes respectively. Previous studies have addressed 
sarcomeric protein phosphorylation, MyBP-C haploinsufficiency, contractility in 
skinned myocytes and, in preliminary work, myosin and troponin function by IVMA in 
these samples (Jacques et al., 2008a, Messer et al., 2009, Copeland et al., 2010b, 
Hoskins et al., 2010, Jacques et al., 2006). These have raised a number of questions 
that this thesis is aimed at addressing: 
 
1) What is the basic molecular phenotype of HCM mutations? 
2) What are the modifications that occur in non-mutated proteins from a HCM 
heart? 
3) What is the molecular phenotype of thin filaments that contain these modified 
proteins? 
 
The main technique used to answer these questions was the IVMA. This was used to 
investigate the relationship between TnI phosphorylation and thin filament Ca2+-
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sensitivity in HOCM troponin. The level of TnI phosphorylation was increased using 
PKA-treatment. An exchange protocol was also used to replace native subunits with 
recombinant equivalents. This was used to screen for post-translational modifications 
that may affect the molecular phenotype of the constituent thin filament. The exchange 
protocol was also used to determine the primary effect of a TnT mutation, which was 
masked in troponin purified from the native diseased tissue. The primary effects of an 
actin mutation was also investigated. Finally, the effect of isoform changes in different 
thin filament proteins were also investigated.  
 
 
85 
 
2 Materials and Methods 
2.1 Heart Samples 
2.1.1 Donor human hearts 
All donor heart samples used in this study originated from St. Vincent’s hospital, Sydney and 
kindly made available for study by Prof. C. dos Remedios. Adult myocardium was obtained 
from surplus donor hearts where no suitable recipient was found or the heart was deemed 
unusable for other reasons. The donors had no history of cardiac disease, a normal cardiac 
examination, a normal admission ECG and normal ventricular function on transthoracic 
echocardiography performed within 24 hours before heart explantation. These criteria were 
set to exclude any potential donor hearts with myocardial dysfunction or damage. 
Immediately following explantation, the ventricular wall was cut up into 1g segments and 
frozen in liquid nitrogen.  
2.1.2 Failing human hearts 
The failing heart samples used in this study also originated from St. Vincents’s hospital, 
Sydney and were collected and stored as described for donor heart. The source of failing 
heart tissue were patients classed as NYHA class III or IV with an ejection fraction of <20%.  
2.1.3 Hypertrophic Cardiomyopathy human hearts 
Three heart samples were obtained from patients diagnosed with hypertrophic 
cardiomyopathy. The causative mutation was identified for all samples. Two were from 
patients with the cardiac actin mutation (ACTC) glutamate to lysine at residue 99(E99K). 
This sample was supplied by Professor Lorenzo Monserrat, CHU Juan Canalejo, A Coruña. 
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The second sample was from a patient with a mutation in the gene encoding troponin 
(TNNT2) and coded for a lysine to asparagine change at residue 273 (K273N). This sample 
was provided by Professor Cris Dos Remedios, St. Vincents’s hospital, Sydney. 
 
Ethical approval was obtained from: Brompton, Harefield and NHLI Research Ethics 
Committee, London, St. Vincent’s’ Hospital Human Research Ethics Committee, Sydney 
and the Comite´ E´tico de Investigatio´n Clínica de Galicia. Upon reception all samples were 
designated a unique identity and stored in liquid nitrogen. The investigation conformed with 
the principles outlined in the Declaration of Helsinki. 
 
2.1.4 Hypertrophic Obstructive Cardiomyopathy human hearts 
Samples of interventricular septum tissue were obtained from myectomy operations to 
relieve the left ventricular outflow tract obstruction (LVOTO) of patients diagnosed with 
hypertrophic obstructive cardiomyopathy. Samples were collected by Dr. Adam Jacques and 
Dr. Clare Gallon from Professor William McKenna and Mr. Victor Tsang at the Heart 
hospital, UCL, London. Samples were frozen in liquid nitrogen upon excision. Ethical 
approval had been obtained for all samples used. These samples were screened by 
Healthcode, La Corunña for the 630 known HCM and DCM causing mutations found in the 
9 major sarcomeric protein encoding genes (see Table 7.1). 
87 
 
2.1.5 Table of clinical details  
Below is a table of all samples used in this study. 
Table 2.1:Clinical details of all the heart samples studied in this thesis 
Sample Diagnosi
s 
Operation Gender Age NYHA 
Class 
LVEF on 
ECHO 
N9  Donor   - - 
NC SAH Donor male 27 - - 
ND SAH Donor female 49 - - 
NE HBI Donor male 29 - - 
NH SAH Donor female 48 - - 
NI SAH Donor female 42 - - 
Donor 
NL Aneurism Donor female  42 - - 
        
FC IDCM OCT male 30 III 10-15% Failing  
 FH DCM OCT female 34 - 30% 
        
ACTC 
E99K 1 
HCM OCT female 55 IV - 
ACTC 
E99K 2 
HCM ASD repair male 32 I - 
TNNT3 
K280N 
HCM OCT male 26 - - 
HCM 
       
MM HOCM Myectomy male 58 - 68% 
MR HOCM Myectomy male 33 - - 
MT HOCM Myectomy female 46 III 44% 
MU HOCM Myectomy male 63 - - 
HOCM 
 
MV HOCM Myectomy male 53 - - 
 
Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Idiopathic dilated cardiomyopathy 
(IDCM), Orthotopic cardiac transplant (OCT), Atrial-Septal defect repair (ASD), Subarachnoid haemorrhage 
(SAH), Hypoxic brain injury (HBI). No details of drug treatments were available.   
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2.2 Protein preparation from tissue 
2.2.1 Preparation of motor protein 
2.2.1.1 Fast Skeletal Myosin Preparation 
The in vitro motility assay (IVMA) is a functional assay that over the period of this study 
required a relatively large amount of myosin or its derivative heavy meromyosin (HMM). To 
purify this from a human source was completely unfeasible, therefore rabbit back muscle 
was used. Skeletal muscle myosin was prepared by the method of Margossian and Lowey 
(Margossian and Lowey, 1982). The protocol ran over three days and all steps were carried 
out at 4°C. 
 
Day 1: A rabbit was sacrificed and the back muscle was removed. The excised back muscle 
was then cooled on ice for 1 hour. It was then skinned and diced before being thoroughly 
minced in a pre-cooled meat grinder. The minced muscle was then weighed, on average 
around 300g of minced muscle was obtained from one rabbit. Myosin was extracted from the 
minced muscle in three volumes of myosin extraction buffer (300mM KCl (Fisher 
Scientific), 150mM Potassium phosphate ((48mM K2HPO4 / 102mM KH2PO4)) (BDH), 
20mM EDTA (BDH), 5mM MgCl2 (Fisher Scientific), 1mM ATP and 5mM DTT (both 
Sigma) pH 6.5 and protease inhibitors: E-64, chymostatin, leupeptin & pepstatin A (all 
Scientific Marketing Association) for exactly 10 minutes with continual stirring. The extract 
was centrifuged at 25,000xg (13,000rpm, Sorvall Evolution RC, SLA-1500 rotor) for 5 
minutes. The pellet was saved for F-actin preparation (see section 2.2.2). The supernatant 
was filtered through glass wool and diluted gradually with 12 volumes of cold distilled H2O. 
Myosin was allowed to precipitate overnight with no agitation.  
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Day 2: The myosin was then pelleted by centrifugation at 25,000xg (13,000rpm, Sorvall 
Evolution RC, SLA-3000 rotor) for 6 minutes. The resulting pellet was resuspended with 3M 
KCl at the ratio of 220ml per kg of starting muscle. Once dissolved, the myosin solution was 
dialysed overnight against (600mM KCl, 25mM potassium phosphate ((8mM K2HPO4 / 
17mM KH2PO4)), 10mM EDTA and 2mM DTT, pH 6.5 and protease inhibitors: E-64, 
chymostatin, leupeptin & pepstatin A). 
 
Day 3: The dialysate was gradually diluted two-fold with cold distilled H2O and stirred for 
30 minutes, it was then centrifuged at 50,000xg (20,000rpm Sorvall Evolution RC SS-34 
rotor) for 1 hour. This step was designed to remove any actomyosin still present.  The 
resulting supernatant was diluted eight-fold with cold distilled H2O and left for 1 hour to 
allow the myosin to precipitate. The myosin was then pelleted by centrifugation at 25,000xg 
(13,000rpm, Sorvall Evolution RC, SLA-1500 rotor) for 10 minutes. This pellet was 
resuspended in 1/4 volume of 4M KCl. Finally the dissolved myosin was centrifuged at 
146,000xg (45,000rpm, Sorvall Discovery 90SE, T-865 rotor) for 1 hour. After which the 
final product (present in the supernatant) was preserved by dropping 100µl aliquots directly 
into liquid nitrogen to form myosin pellets, which were then stored in liquid nitrogen for 
future use. The concentration of the myosin was determined by Lowry assay (see 2.3.1.2) 
this was usually in the range of 30-60mg/ml. 
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Figure 2.1: Flow diagram of rabbit skeletal myosin preparation 
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2.2.1.2 Preparation of Heavy Meromyosin 
Heavy Meromyosin (HMM) is an enzymatically cleaved version of myosin consisting of 
sub-fragment 1 and the two light chains (Weeds and Taylor, 1975). This form of myosin, 
without the majority of the long hydrophobic C-terminal rod, is required as the immobilized 
motor protein in the IVMA. The protocol is based on the method of Okamoto (Okamoto and 
Sekine, 1985). A myosin pellet (see 2.2.1.1) was removed from the liquid nitrogen and 
allowed to thaw. ‘HMM preparation buffer A’ (HA) (0.1mM NaHCO3 (BDH), 0.1mM 
EGTA (Sigma), 2mM DTT, pH 7.4) was prepared. The thawed myosin was diluted to 
1.9mg/ml in 1.5ml of buffer HA, mixed thoroughly and left to precipitate at 4°C for 20 
minutes. The myosin was pelleted by centrifugation at 21,100xg (14,800rpm,Thermo 
Scientific Heraecus Fresco 21) for 10 minutes at 4°C. The supernatant was discarded and the 
pellet dissolved gently in 100µl of ‘HMM preparation buffer B’ (HB) (1M KCl, 20mM 
imidazole (BDH), 4mM MgCl2 (Fisher Scientific) 2mM DTT, pH 7) and incubated at 4°C 
for ten minutes. The total volume was then made up to 200µl with the addition of buffer HA 
and incubated at 25°C for ten minutes. The myosin was then cleaved by incubation with 
7.5µl of 0.4mg/ml N-α-Tosyl-L-lysyl-chloromethyl-ketone (TLCK) treated α-chymotrypsin 
(Sigma type VII, C-3142) for 7-9 minutes (depending on batch) at 25°C. The digestion was 
halted by the addition of 2.7ml of chilled buffer HA containing additional 3mM MgCl2 and 
0.1mM phenylmethyisulfonyl fluoride (PMSF) (Sigma). The mixture was incubated at 4°C 
for 1 hour and then centrifuged at 337,000xg (100,000 rpm. Sorvall MC-120SE, S100-AT6 
rotor) for 20 minutes at 4°C. The supernatant contained pure HMM which was stored at 4°C 
for use with the IVMA. HMM prepared by this method could be used for up to five days. 
The concentration was determined by Bradford assay (see 2.3.1.1). The range of 
concentrations usually obtained was 0.3-0.7mg/ml. If the concentration measured was lower 
than 0.3mg/ml then the preparation was discarded. 
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Figure 2.2: Flow diagram of HMM preparation 
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2.2.1.3 Preparation of human cardiac myosin 
The method used to purify human cardiac myosin was developed from the protocol designed 
by Palmiter (Palmiter et al., 2000) and adapted by Jacques (Jacques et al., 2008b). The 
reason for further development was to improve the yield and functional half-live of the 
product from a smaller amount of starting material. To start, 60-100mg of cardiac tissue was 
pulverized with a percussion mortar under liquid nitrogen. This was washed and manually 
homogenized with a micropestle in a 1.5ml eppendorf tube with 1.5ml of myofibril wash 
buffer (5mM NaH2PO4, 5mM Na2HPO4, 0.1M NaCl (VWR), 5mM MgCl2, 0.5mM EGTA, 
0.1% Triton X-100 (Sigma), 5mM DTT, pH 7, and 2µg/ml of the protease inhibitors E-64, 
chymostatin, leupeptin and pepstatin A) and centrifuged at 14,000xg (13,300 rpm, Sorvall 
Microspin 24S, 24x3g rotor) for 3 minutes at 4°C. The supernatant was discarded and the 
pellet washed and centrifuged a further two times. The resulting pellet was then dissolved in 
250µl of ‘cardiac myosin extraction buffer’ (0.3M KCl, 2mM ATP, 50µM blebbistatin 
(Sigma), 75mM K2HPO4, 75mM KH2PO4, 1mM DTT pH 6.5 and protease inhibitors: E-64, 
chymostatin, leupeptin & pepstatin A). This mixture was homogenized both with the 
micropestle and then on the sample mixer (Dynal) for 15 minutes at 4°C and then 
centrifuged at 337,000xg (100,000 rpm. Sorvall MC-120SE, S100-AT6 rotor) for 30 minutes 
at 4°C. The supernatant was removed and used immediately for IVMA experimentation. The 
protein concentration was determined by Bradford assay, and the myosin was diluted to 
0.1mg/ml in a final volume of 1ml with cardiac myosin extraction buffer.  
 
An additional purification step was used for preliminary experimentation. The final product 
of the cardiac myosin was diluted 20-fold in cold distilled H2O and mixed on the rotating 
wheel for 15 minutes at 4°C. This mixture was then centrifuged at 15,000xg (18,000 rpm, 
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Sorvall Evolution, SS-34 rotor) for 20 minutes at 4°C. The resulting pellet was then 
dissolved in 100µl of 2x sample buffer.  
2.2.2 Preparation of F-actin 
2.2.2.1 Preparation of F-actin acetone powder from rabbit skeletal muscle 
The F-actin preparation was run in parallel to the fast skeletal myosin preparation (2.2.1.1) 
and used the same starting material. The pellet formed from the first centrifugation, which 
otherwise would have been discarded, was treated to a series of wash steps before being 
dried to form the acetone powder. For each step the muscle residue was homogenized by 
manual stirring and then filtered through nylon mesh and squeezed to drain liquid. The 
following steps were then completed: 
1) 10 volumes of distilled H2O for 5 minutes at 4°C, repeated twice. 
2) 4 volumes of 0.4% NaHCO3 (VWR) for 45 minutes at room temperature with stirring 
3) 2 volumes of 1mM Tris-HCl (Sigma) pH 8.5 for 5 minutes at 4°C, repeated twice 
4) 4 volumes of acetone (Fisher Scientific), for 10 minutes at 4°C, repeated four times. 
Following the final acetone wash the residual matter was dried to a powder in a fume hood 
overnight at room temperature and then stored at -20°C ready for further use. This protocol 
is based on the methods of Straub (Straub, 1942). 
2.2.2.2 Preparation of rabbit skeletal F-actin from acetone powder 
The method for preparation of F-actin from acetone powder is based on the Spudich method 
(Spudich and Watt, 1971) with an additional step of a S300 gel filtration column. 2.5g of 
acetone powder (2.2.2.1) was removed from the -20°C storage and allowed to warm to 4°C. 
The acetone powder was then dissolved in 50ml of G-actin buffer (2mM Tris-HCl, 0.2mM 
ATP, 0.1mM CaCl2 (BDH), 1mM NaN3 (VWR), 500nM DTT, pH 8.0) and stirred for 30 
minutes at 4°C. The solution was centrifuged at 15,000xg (18,000rpm, Sorvall Evolution 
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RC. SS-34) for 20 minutes at 4°C. The pellet was re-extracted in an additional 15ml of G-
actin buffer and centrifuged as before. The supernatants were combined and filtered through 
glass wool into a measuring cylinder. G-actin polymerization was initiated by the addition of 
0.1 volume of 10xKME buffer, (0.5M KCl, 100mM Tris-HCl, 25mM MgCl2, 10mM EGTA, 
10 mM NaN3, pH 8.0). Upon addition of 10xKME buffer the solution was gently mixed by 
sealing the measuring cylinder with parafilm™ and inverted slowly several times. It was 
then incubated in a water bath at 30°C for 45 minutes. The KCl concentration was then 
adjusted to 0.8M by the addition of 0.34 volumes of 3M KCl. This solution was mixed at 
room temperature for 20 minutes by intermittent inversion of the resealed measuring 
cylinder. The F-actin was pelleted by centrifugation at 146,000xg (45,000rpm Sorvall 
Discovery 90SE, T-865 rotor) for 1.5 hours at 4°C. The supernatant was discarded, the 
pellets rinsed in distilled H2O and then dissolved in 12-13ml of G-actin buffer. The dissolved 
actin was then homogenized using a Dounce homogeniser before being dialysed against G-
actin buffer for 48 hours, the reduction in the concentration of KCl caused the actin to 
depolymerise. The dialysate was centrifuged at 146,000xg (45,000rpm, Sorvall Discovery 
90SE, T-865 rotor) for 1.5 hours at 4°C. 
 
The G-actin supernatant was filtered through glass wool and loaded onto a 2.5 x 90cm 
Sephacryl S300 gel filtration column, which had previously been equilibriated with 1.5L of 
G-actin buffer, and run overnight at a flow rate of 50ml/hour, fractions were collected every 
6 minutes. A single peak was recorded on Pharmacia U.V. monitor II system. Fractions 
producing the peak were checked by measuring their optical density (absorbance) at 290nm 
in a quartz cuvette. Any fractions that gave reading of higher than 0.35 were pooled together.  
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The G-actin was polymerized for the final time by the addition of 0.1 volumes of 10xKME 
buffer at 30°C for 45 minutes and centrifuged at 146,000xg (45,000rpm, Sorvall Discovery 
90SE, T-865 rotor) for 1.5hours at 4°C as before. The supernatant was discarded and the F-
actin pellets were dissolved in ATPase buffer (100mM KCl, 5mM PIPES-K2, 2.5mM MgCl2, 
1mM DTT, 10mM NaN3, pH 7.3) at around 10mg/ml. This was stored for up to a month at 
4°C for experimental use. 
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Figure 2.3: Flow diagram of rabbit skeletal F-actin preparation  
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2.2.2.3 Preparation of human cardiac F-actin  
 
F-actin was prepared from smaller tissue samples by a direct method which did not involve 
depolymerisation and polymerisation (Song et al., 2010). 50-100mg of human cardiac tissue 
was pulverised with the percussion mortar under liquid nitrogen. The tissue was washed and 
manually homogenized with 10X tissue volume of ‘actin wash buffer’ (0.1M NaCl, 5mM 
NaH2PO4.H2O, 5mM Na2HPO4.12H2O, 5mM MgCl2, 0.5mM EGTA, 0.1%Triton-X 100, 
5mM DTT, pH 7 and (as previously stated) protease inhibitors). The homogenate was 
centrifuged at 17,000xg (13,300 rpm, Thermo Scientific Heraeus Fresco 21) at 4°C for 3 
minutes and the pellet retained and washed again in the same manner. After the second 
centrifugation step the pellet was washed in the same volume of ‘actin wash buffer II’ 0.1M 
NaCl, 5mM NaH2PO4.H2O, 5mM Na2HPO4.12H2O, 5mM MgCl2, 0.5mM EGTA, 5mM 
DTT, pH 7 and inhibitors and centrifuged in the same manner. In total four wash steps were 
completed, two with buffer I (with detergent) and two with buffer II (without detergent). 
Thin filaments were then extracted by manually homogenization in 1.5 volumes of ‘thin 
filament extraction buffer’ (0.1M NaCl, 5mM NaH2PO4.H2O, 5mM Na2HPO4.12H2O, 5mM 
MgCl2, 0.5mM EGTA, 5mM Mg2+-ATP 5mM, 50µM Blebistatin, 5mM DTT, pH 7). The 
homogenate was centrifuged at 21,100xg (14,800 rpm, Thermo Scientific Heraeus Fresco 
21) at 4°C for 3 minutes and supernatant retained. The thin filament extract step was 
completed twice in total, and the supernatants pooled. The pooled supernatants were 
centrifuged at 111,700xg (50,000 rpm, Sorvall RCM120SE, S100-AT6) for 5 minutes at 
4°C. Again the supernatant was retained and subjected to a further centrifugation of 
446,800xg (100,000 rpm, Sorvall RCM120SE, RCM-120 rotor) for 25 minutes at 4°C. The 
resultant pellets were resuspended in 150µl of ‘actin resuspension buffer’ (0.1M NaCl, 
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10mM NaH2PO4.H2O, 10mM Na2HPO4.12H2O, 5mM MgCl2, 1mM Mg2+-ATP, 50µM 
blebbistatin, 5mM DTT pH 6). To dissociate actin from the other thin filament proteins 0.5 
volumes of 3M KCl was added to the supernatant to raise the salt concentration to 0.8M. 
150nM TRITC-phalloidin was also added. The actin solution was centrifuged at 446,800xg 
(100,000 rpm, Sorvall RCM120SE, S100-AT6 rotor) for 25 minutes at 4°C. Finally the pellet 
containing the F-actin was resuspended in 50µl of ‘ACEX buffer’ (2mM Tris-HCl, 0.2mM 
CaCl2, 0.2mM ATP, 1mM DTT, pH8.0) overnight at 4°C. The F-actin was then labelled with 
TRITC-phalloidin for IVMA investigation. 
100 
Figure 2.4: Flow diagram of human F-actin preparation 
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2.2.3 Preparation of tropomyosin 
2.2.3.1 Preparation of human cardiac tropomyosin (large scale) 
Human cardiac tropomyosin was prepared by O’Neal Copeland by a method based on that of 
Eisenberg and Kielley (Eisenberg and Kielley, 1974). An ethanol-ether powder was prepared 
from 300g of human cardiac muscle from which the tropomyosin was purified.  
2.2.3.2 Preparation of human cardiac tropomyosin (small scale) 
The initial buffers for this preparation were the same as those used for preparation of human 
cardiac troponin (see 2.2.4.1). These will just be referred to as ‘wash’ and ‘extraction’ buffer. 
60-100mg of human cardiac tissue was pulverised under liquid nitrogen in the percussion 
motor. The tissue was homogenized in 1.5ml of wash buffer with the electric homogeniser 
(Heidolph, DIAX 900) for 10 seconds. The homogenate was centrifuged at 17,000xg (13,300 
rpm, Thermo Scientific Heraeus Fresco 21) at 4°C for 3 minutes. The supernatant was 
removed and the pellet was washed a further two times by the same procedure. The 
myofilament proteins were then homogenized with 2x tissue volume of extraction buffer 
with the Heidolph homogeniser for 10 seconds. After which the myofilament proteins were 
extracted for 5 minutes on the rotating wheel at 4°C. The homogenate was centrifuged at 
21,100xg (14,800rpm, Thermo Scientific Heraeus Fresco 21) for 10 minutes at 4°C. The 
supernatant was removed and heated at 100°C for 10 minutes to precipitate the majority of 
other proteins present in the myofilament fraction. The precipitate was pelleted by 
centrifugation at 21,100xg (14,800rpm, Thermo Scientific Heraeus Fresco 21) for 10 minutes 
at 4°C. To the resultant supernatant 42.5% ammonium sulphate (250mg/ml) (MP 
Biomedicals) was added gradually and mixed on the sample mixer (Dynal) for 10 minutes at 
4°C to precipitate any troponin and actin that remained. The precipitate was pelleted by 
centrifuagtion at 21,100xg (14,800rpm, Thermo Scientific Heraeus Fresco 21) for 15 minutes 
at 4°C. To remove the ammonium sulphate, the supernatant was dialysed against 
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‘tropomyosin dialysis buffer’ 1M NaCl, 5mM PIPES (Sigma), 5mM DTT, pH 7.1 for 4 
hours at 4°C. After which the solution was centrifuged at 21,100xg (14,800rpm, Thermo 
Scientific Heraeus Fresco 21) for 10 minutes at 4°C. The supernatant was removed and 
dialysed again ‘tropomyosin precipitation buffer I’ (1M NaCl, 50mM NaH2PO4, 5mM DTT, 
pH 4.5) overnight at 4°C. The solution was centrifuged 21,100xg (14,800rpm, Thermo 
Scientific Heraeus Fresco 21) for 10 minutes at 4°C to pellet the precipitated tropomyosin. 
The tropomyosin pellet was resuspended in 100µl of ‘tropomyosin dialysis buffer II’ (1M 
NaCl, 5mM PIPES, 3mM DTT, pH 7.1). The resuspended pellet was then dialysed against 
tropomyosin dialysis buffer II for 2.5 hours at 4°C. A final centrifugation at 337,000xg 
(100,000rpm, Sorvall MC-120SE, S100-AT6 rotor) for 20 minutes at 4°C was designed to 
remove any remaining impurities. Samples were taken at the different stages of the protocol 
for SDS-PAGE to determine the effectiveness of each step. The concentration of the final 
product ranged from 0.2-0.3mg/ml and was determined by Lowry assay. 
2.2.4 Preparation of troponin 
2.2.4.1 Preparation of human cardiac troponin 
Troponin was purified by human cardiac tissue by the method of Messer (Messer et al., 
2007) (see Figure 2.8 green section). The desired tissue sample was removed from storage in 
liquid nitrogen. 100-150mg was detached and immediately pulverized in a percussion 
mortar, which was cooled with liquid nitrogen. After pulverisation the tissue sample was 
washed and manually homogenized with a micropestle in 1.5ml of ‘myofibril wash buffer’ 
(5mM NaH2PO4, 5mM Na2HPO4, 0.1M NaCl, 5mM MgCl2, 0.5mM EGTA, 0.1% Triton X-
100, 5mM DTT, pH 7, and 2µg/ml of the protease inhibitors E-64, chymostatin, leupeptin 
and pepstatin A) (Figure 2.8 – washed myofibril pellet). The homogenate was then 
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centrifuged at 14,000xg (13,400rpm, Sorvall Microspin 24S, 24x3g rotor) for 3 minutes at 
4°C. The pellet was kept and washed in the same fashion a further three times. 
 
The myofilament proteins present in the pellet were dissolved in 5 volumes of ‘troponin 
extraction buffer’ (0.7M LiCl, 25mM Tris, 5mM EGTA , 0.1mM CaCl2, 5mM DTT, pH 7.5 
and protease inhibitors) (Figure 2.8 – extracted myofibrils). The mixture was homogenized 
with a micropestle and then mixed on a rotating wheel for 25 minutes at 4°C. After which 
the homogenate was centrifuged at 14,000xg (13,400rpm,Sorvall Microspin 24S, 24x3g 
rotor) for 3 minutes at 4°C. The supernatant was retained and kept at 4°C, while the pellet 
underwent three subsequent extractions stages spending 20, 15 and 10 minutes on the sample 
mixer respectively. The supernatant was added to the pool of supernatant at the end of each 
stage. After the final extraction the pooled supernatant was centrifuged at 337,000xg 
(100,000rpm, Sorvall MC-120SE, S100-AT6 rotor) for 20 minutes at 4°C. This was referred 
to as the ‘spun extract’ (Figure 2.8 – spun extract).  
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Figure 2.5: The affinity separation process using an anti-TnI antibody 
 
 
The troponin was purified from the spun extract by affinity column chromatography (Figure 
2.8 – affinity chromatography). The affinity column consisted of 0.6ml of Sepharose column 
matrix coated with a monoclonal anti-troponin I antibody (14G5) (see Figure 2.5). The 
matrix was equilibrated in 4.5mls of troponin extraction buffer prior to the addition of spun 
extract. The column was then mixed for 15 minutes on the rotating wheel at 4°C. 
Concurrently eight 2ml tubes were setup and labelled: flow through (FT), wash 1 & 2 
(W1&2), elution fraction 1-5 (E1-5) (see Figure 2.6) In each of the elution fractions tubes 
50µl of 1M MOPS (Sigma) pH 8 was aliquoted, this was to neutralize the low pH of the 
elution buffer. 
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Figure 2.6: Elution stages of affinity chromatography 
 
 
Flow through (FT), Wash (W) and Elution (E) fractions are labelled. 
 
After 15 minutes on the rotating wheel the liquid phase of the column was completely eluted 
into the FT 2ml tube. The column matrix was then washed twice with 0.8ml of troponin 
extraction buffer. Finally the troponin was eluted by the five elution stages where 0.4ml of 
elution buffer, 0.1M glycine, 5mM DTT pH 2 and protease inhibitors, was added 
sequentially. The elution fraction in which the troponin was present was determined by SDS-
PAGE. Samples were taken from each stage of the column elution process, 20µl of each 
stage was mixed with 20µl of 2x Sample buffer (see 2.3.2.1). The troponin usually eluted in 
fraction E2, and sporadically in E1. Therefore, immediately after elution these samples were 
put into dialysis against ‘troponin dialysis buffer’ 1M KCl, 10mM MES (Sigma), 0.1mM 
CaCl2, 5mM DTT, pH 6 with protease inhibitors (Figure 2.8 – dialysis). These samples were 
dialysed overnight at 4°C. The following day the elution fraction which contained the 
troponin was kept and the other discarded. The troponin was then centrifuged at 14,000xg 
(13,400 rpm, Sorvall Microspin 24S, 24x3g rotor) for 3 minutes at 4°C. The supernatant was 
kept and stored at 4°C for use with the IVMA. The final concentration was determined by 
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Lowry assay, this was normally in the range of 5-10µM and around 400µl was normally 
obtained. 
Figure 2.7: Example of SDS-PAGE gel loaded with samples from the different stages of the troponin 
purification protocol 
 
An Excelgel loaded with 20µl of a sample from each stage of the troponin purification protocol mixed 1:1 with 
sample buffer and stained with Coomassie blue. M represents a molecular weight markers. The other stages 
loaded are spun extract (SE), flow through (FT), wash 1 (W1), wash 2 (W2), elution fractions 1 – 5 (E1-5). The 
three subunits of troponin are marked on the right. The majority of troponin has eluted in the E2 fraction in this 
gel. 
 
2.2.4.2 Preparation of rabbit skeletal troponin 
Rabbit skeletal troponin was purified from an ethanol-ether powder by the method of Potter 
(Potter, 1982) (see 2.2.3.1). The starting material was 300g of rabbit skeletal back muscle. 
This was prepared by O’Neal Copeland. 
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2.2.5 Further manipulation of purified troponin 
2.2.5.1 Protein kinase A treatment of human cardiac troponin 
To investigate the relationship between thin filament Ca2+-sensitivity and constituent TnI 
phosphorylation it was desirable to be able to manipulate the level of TnI phosphorylation. 
As the level of TnI phosphorylation is low in HOCM troponin a protocol was developed to 
increase this level with a protein kinase A (PKA treatment). PKA from bovine pancreas 
(Sigma, P2645-400) was dissolved in 200µl of ‘phosphorylation buffer A’ (50mM MOPS, 
20mM NaF (BDH), 10mM MgCl2, 1mM DTT, pH 7) and aliquoted into 20µl aliquots with 
an activity of 2,000units/ml and stored at -80°C.  
 
HOCM troponin was purified as described in section 2.2.4.1 with some modifications (see 
Figure 2.8 – green & purple sections). Firstly, double the amount of tissue was used to start 
with. This was to allow double the amount of troponin to be produced, thus enough for a 
PKA-treated sample and an untreated control sample. The spun extract was split into two 
equal volumes and sequentially loaded and eluted from the troponin affinity column. 
Secondly, the final dialysis buffer was changed to ‘phosphorylation buffer B’ 0.5M KCl, 
50mM MOPS, 20mM NaF, 10mM MgCl2, 0.1M CaCl2, 5mM DTT, pH 7. The two troponin 
samples were dialysed in this for at least 4 hours. After this the two samples were eluted. The 
PKA treatment reaction mixture consisted of 400µl of purified troponin, 32µl of PKA (2,000 
units/ml), 9µl of Mg2+-ATP (100mM) and 9µl of phosphorylation buffer B. The control 
reaction mixture consisted of 400µl of purified troponin and 50µl of phosphorylation buffer 
B. These mixtures were added to a 1.5ml eppendorf and incubated overnight at 4°C on a gel 
agitator. Finally, they were centrifuged at 17,000xg (13,300 rpm, Thermo Scientific Heraeus 
Fresco 21) for 3 minutes at 4°C, the supernatant collected and stored at 4°C. 
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2.2.5.2 Exchange of native troponin subunits with recombinant TnI or TnT 
The final method used to manipulate human cardiac troponin was to exchange native 
subunits with recombinant proteins (see Figure 2.8 – green & blue sections). All recombinant 
proteins used in this study were kindly provided by Charles Redwood, University of Oxford. 
In this study either the native troponin I (TnI) subunits were replaced by a recombinant TnI 
subunits or the native troponin T (TnT) subunits were replaced by a recombinant TnT 
subunits. The exchange protocol was based on troponin purification (see section 2.2.4.1) 
with an addition section. This addition section came after the centrifugation step to obtain the 
spun extract (see Figure 2.8). Instead of being loaded onto the affinity column, the pair of 
spun extract samples were both dialysed in ‘denaturing buffer’ (3M Urea (United States 
Biochemicals), 1M KCl, 10mM MES, 0.1mM CaCl2, 5mM DTT, pH 6 with protease 
inhibitors) for six hours (Figure 2.8 – dialysis in 3M urea). This step was designed to 
denature the troponin complexes. After dialysis in denaturing buffer, a 10-fold excess of 
recombinant protein was added to one sample (exchange mixture) (Figure 2.8 – addition of 
recombinant subunit), no addition was made to the other (control) sample. The two samples 
were then dialysed in troponin dialysis buffer overnight, to remove the urea and allow the 
troponin complexes to renature (Figure 2.8 – dialysis (renature)). The final volume of the 
exchange mixture was fixed at 2ml and consisted of either the spun extract (with a troponin 
concentration of >5µM) and the recombinant subunit (50µM) or only the spun extract. The 
two samples were then centrifuged at 21,000xg (14,800, Thermo Scientific Heraeus Fresco 
21) for 20 minutes at 4°C. The samples were then sequentially loaded and eluted from the 
antibody affinity column (Figure 2.8 – affinity chromatography) and troponin containing 
fractions were dialysed for a minimum of 4 hours in troponin dialysis buffer (Figure 2.8 – 
dialysis). Different antibody affinity columns were used depending on the subunit being 
exchanged, e.g. if TnT was being exchanged an anti-troponin I column (14G5) was used and 
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if TnI was being exchanged an anti-troponin T column (7F4) was used. Finally the renatured 
troponin samples were centrifuged at 17,000xg (13,300 rpm, Thermo Scientific Heraeus 
Fresco 21) for 3 minutes at 4°C, the supernatant was collected and used immediately in the 
IVMA. These exchanged troponin samples had a relatively short functional half-life and 
therefore it was vital to perform all desired IVMA experiments within 12 hours of 
preparation.  
 
Figure 2.8: Flow diagram of troponin purification protocols 
 
The basic troponin purification protocol is shown in green. The addition steps for the exchange protocol are 
shown in blue and the PKA-treatment is shown in purple. 
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2.3 Analysis of proteins 
2.3.1 Determination of protein concentration 
2.3.1.1 The Bradford assay 
The Bradford assay was used to determine the concentration of the HMM preparation 
(Bradford, 1976). 100µl of HMM was mixed thoroughly and incubated with 1ml of Bradford 
reagent (Sigma, B6916) for 5 minutes at room temperature. A blank was also incubated for 
the same time which consisted of 1ml of Bradford reagent. The absorbance of the solution 
was measured at 595nm on (Ultrospec III, Pharmacia LKB) after zeroing the 
spectrophotometer using the blank. The concentration was determined using the previously 
established calibration curve (see Figure 2.9).  
 
Figure 2.9: Calibration curve for the Bradford assay 
 
Bradford assay was calibrated using rabbit skeletal HMM. 
2.3.1.2 The Lowry assay 
The Bradford assay was a useful tool to determine protein concentration in solutions where 
the protein content was relatively high. The Lowry assay was used for solutions where the 
protein concentration was relatively low (Lowry et al., 1951), for example to determine the 
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concentration of human cardiac troponin. To start, Lowry solution A was prepared which 
consisted of 48ml of 2% Na2CO3 (BDH), 1ml of 0.5% CuSO4 (BDH) and 1 ml of 1% NaK 
tartrate (BDH). Aliquots of 5µl, 10µl and 15µl of the protein solution were taken and made 
up to 500µl with NaOH, to which 5ml of Lowry solution A was added. This mixture was 
vortexed and incubated at room temperature for 10 minutes. Following this 500µl of Lowry 
solution B (1 part Folin and Ciocalteu’s reagant (VWR) to 1 part distilled H2O) was added 
and the mixture vortexed and incubated at room temperature for 30 minutes. Finally the 
absorbance of each aliquot was measured at 700nm and the protein concentration determined 
from a previously established calibration curve. This calibration was completed with rabbit 
skeletal myosin and actin. 
2.3.2 Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
2.3.2.1 Sample preparation 
Protein solutions were diluted 1:1 (v/v) with ‘2x SDS sample buffer’ (125mM Tris-HCl, 
10% Sodium dodecylsulphate (SDS) (Fisher Scientific), 130mM DTT, 0.05% bromophenol 
blue (BDH), pH 6.8). The samples were then boiled at 100°C for 3 minutes. Some myofibril 
solutions were prepared with ‘Chad’s sample buffer’ (8M Urea, 2M Thiourea (Sigma), 
0.05M Tris-HCl, 3% SDS, 0.05% bromophenol blue pH 6.8) as this gave a higher band 
resolution when whole myofibril preparations were separated by SDS-PAGE (Layland et al., 
2005a).  
2.3.2.2 The Pharmacia system 
Two forms of discontinuous SDS PAGE were used during this study. The Pharmacia system 
and the mini PROTEAN system. The Pharmacia system was used preferentially, as the set-
up time was shorter, and thus could be used after lengthy purification protocols, e.g. troponin 
purification. However, the Excel gels used in the Pharmacia system were affixed to a 
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backing, which had to be removed if the gel was to be stained with a fluorescent stain. Once 
the backing was removed, the difficulty in handling and visualising these gels was greatly 
increased and thus mini PROTEAN gels, which were more robust were used instead.  
 
For the Pharmacia system, precast gels on plastic backings (Excelgel-SDS 8-18% gradient, 
Pharmacia LKB) were orientated on the pre-cooled horizontal plate of a Multiphor II 
(Pharmacia LKB) electrophoresis system. Polyacrylamide anodic and cathodic buffer strips 
were placed horizontal and parallel at the top and bottom edges of the gel. Loading strips, 
consisting of precut pieces of filter paper 5mm x 10mm, were placed approximately 5mm 
apart adjacent to the cathodic buffer strip. Up to 20µl of prepared samples were pipetted into 
the loading strips in a predetermined order. Electrophoresis of a full gel was completed at 
50mA/600V/30W (a half gel was run at 25mA/600V/15W) for 80 minutes at 10°C.  
2.3.2.3 The mini PROTEAN system  
Two types of gel were used with the mini PROTEAN tetra system (BioRad laboratories). 
The most commonly used was a 12% resolving/4% stacker polyacrylamide gel (37.5:1 
acrylamide:bisacrylamide ratio (Biorad)). For resolution of whole myofibril preparation a 
different composition of gel was used. This consisted of 15% resolving gel (199:1 
acrylamide (Sigma):bisacrylamide (Biorad)) / stacker polyacrylamide gel (5.667:1 
acrylamide:DATD) (N,N’-diallytartardiamide (Biorad) (Layland et al., 2005a). 
Electrophoreis was completed at 25mA/200V for 90minutes in standard ‘Laemmli running 
buffer’ (25mM Tris-Base (Sigma), 192mM glycine (Fisher Scientific), 0.1% SDS) 
(Laemmli, 1970).  
2.3.2.4 Phosphate affinity SDS-PAGE and Western blotting 
Phosphate affinity SDS-PAGE is a relatively novel technique which resolves the phospho-
species of the same protein by retarding them relative to phosphate content. This technique 
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has been used to investigate the phosphorylation site distribution of cardiac troponin I in 
human heart muscle (Messer et al., 2009).The advantage of phosphate affinity SDS-PAGE is 
that you can determine the amount of phosphate per amount of protein without the need for 
an internal (radioactive) standard. In this study phosphate affinity SDS-PAGE was used to 
determine the level of TnI phosphorylation. For this technique phos-tag pendent moieties 
(NARD Institute, Hyogo Japan) are included in the ingredients of the polyacrylamide gel 
(Kinoshita et al., 2006) (Kinoshita-Kikuta et al., 2007). The gel was composed of 10% 
resolving (+50µM Mn-Phos-tag acrylamide)/4% stacker polyacrylamide gel (29:1 
acrylamide:bisacrylamide ratio). The phos-tag gels were electrophoresed (25mA/200V for 90 
minutes) and Western blotted (see 2.3.4.). 
 
Figure 2.10: Example of Phosphate-affinity SDS-PAGE gel that has been Western blotted completed by 
Dr. Messer 
 
This example is from the study by Messer et al who treated recombinant TnI was with PKA at 30°C for 120 
minutes. Samples were taken at time points 0 minutes, 10 minutes, 40 minutes and 120 minutes and mixed 1:1 
with sample buffer and 5µl was loaded onto a phosphate-affinity mini gel and electrophoresed and then 
Western blotted. The blot was then probed with the anti-TnI antibody (14G5). The different phosphospecies of 
TnI that were present through the course of the experiment are labelled on the left, unphosphorylated (0-P), 
mono-phosphorylated (1-P), bis-phosphorylated (2-P), tris-phosphorylated (3-P), tetra kis-phosphorylated (4-P) 
and penta kis-phosphorylated (5-P). This image was taken from the study by Messer et al (Messer et al., 2009). 
This demonstrates the ability of phosphate-affinity SDS PAGE to resolve the different phospho-species of TnI. 
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2.3.3 Protein staining 
2.3.3.1 Coomassie blue 
Coomassie blue staining solution (800mls) was made up from 2 PhastGel™Blue R tablets 
(GE Healthcare, 17-0518-01) dissolved in 60% methanol (Fisher Scientific) for 30 minutes 
and then diluted 1:1 with 20% acetic acid (Fisher Scientific). Upon completion of 
electrophoresis the gel was immersed in fixing solution (50% methanol, 10% acetic acid) for 
20 minutes with agitation at room temperature. The gel was then immersed in ~100mls 
Coomassie Blue staining solution for 20 minutes with agitation at room temperature. The gel 
was then destained by immersion in ‘destain solution’ (25% methanol, 8% acetic acid) with 
agitation for 1 hour or until satisfactorily destained at room temperature. Coomassie blue 
staining solution was also used after Pro-Q Diamond stain (2.3.3.2) for which the same 
staining protocol was used but without the initial fix steps. 
2.3.3.2 Pro-Q Diamond phosphoprotein stain 
Pro-Q Diamond phosphoprotein gel stain (Invitrogen - Molecular Probes, P333000) is a 
fluorescent stain that is specific for proteins with phosphate moieties bound to threonine, 
serine and tyrosine residues (Steinberg et al., 2003, Schulenberg et al., 2003). It was a useful 
tool for analysing the phosphorylation profile of different myofilament proteins together or 
individually in pure solutions. Pro-Q Diamond phosphoprotein gel stain (Pro-Q Diamond) 
has also been shown to bind in a linear fashion for the amount of phosphate moieties present, 
therefore facilitating the measurement of changes in the level of phosphorylation of a 
particular protein.  
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Figure 2.11: Example of mini gel stained with Pro-Q Diamond 
 
A mini gel loaded over the range 5µl - 40µl (loading stated under lanes) with a pure HOCM troponin (MU) 
sample mixed 1:1 with sample and stained with Pro-Q Diamond. As the TnT and TnI subunits have a degree of 
phosphorylation these are stained, TnC is not phosphorylated and thus does not appear. Two different 
molecular weight markers were also loaded (M). 
 
 
After completion of electrophoresis the gel was immersed in 100ml of freshly made Pro-Q 
Diamond fixing solution (50% methanol, 10% acetic acid) with agitation for 30 minutes at 
room temperature. The Pro-Q Diamond fixing solution was then replaced with a fresh 100ml 
in which the gel was immersed overnight with agitation. The following day the gel was 
washed three times in 100ml of distilled H2O for 10 minutes. The gel was immersed in 60ml 
of Pro-Q Diamond stain for 90 minutes in complete darkness. The gel was then destained by 
three 30 minute washes with 90ml of Pro-Q Diamond phosphoprotein gel destaining solution 
(Invitrogen, P-33311) and washed twice for 5 minutes in distilled H2O. All immersion steps 
were completed with gentle agitation. If the gel was an Excelgel the backing was removed 
and the gel was not agitated. A digital image of the gel was then visualised, using the U.V. 
transiluminator settings, by a cooled CCD camera based gel imager (G:Box Chemi XT16, 
Syngene) (G:BOX). After an image had been obtained the gel was then stained with a total 
protein stain, this was either Coomassie blue or a fluorescent total protein stain. 
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2.3.3.3 Fluorescent total protein stains 
Two fluorescent total protein stains were used during this study: SYPRO Ruby protein gel 
stain (SYPRO) (Invitrogen - Molecular Probes, S12000) and Flamingo fluorescent gel stain 
(Flamingo) (Bio-Rad, 161-0491). Both stains were used as primary stains and secondary to 
Pro-Q Diamond staining. SYPRO was the fluorescent total protein stain used primarily 
within the Marston laboratory, however it stains tropomyosin very weakly and therefore an 
alternative (Flamingo) was found that stained tropomyosin more strongly,  
 
The Staining protocol for SYPRO was started by fixing the electrophoresed gel with two 30 
minute immersions in 100ml of SYPRO-fixing solution (50% methanol, 7% acetic acid). The 
gel was then immersed in 60ml of the SYPRO Ruby protein gel stain in complete darkness 
overnight. Following this the gel was washed once with 100ml of Sypro-washing solution 
(10%methanol, 7% acetic acid) and subsequently twice with distilled H2O for 5 minutes 
each. It was then visualised, using the U.V. transiluminator setting, on the G:BOX. If the gel 
had already been through the Pro-Q Diamond staining protocol then the fix steps were not 
required.  
 
The first step for staining protocol for Flamingo was immersion in 100ml of ‘Flamingo 
fixing solution’ (40% ethanol (Fisher Scientific), 10% acetic acid) for 3 hours at room 
temperature with agitation. The Flamingo gel stain solution was diluted 10x in distilled water 
to a final volume of 100ml. The gel was immersed in this overnight in the dark at room 
temperature with agitation. After which the gel was visualised using the transiluminator 
settings on the G:BOX.  
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2.3.4 Western blot analysis 
Protein samples were separated by discontinuous SDS-PAGE (see 2.3.2.3), the gel was then 
immersed in pre-chilled ‘transfer buffer’ 25mM Tris-Base, 192mM glycine, 20% methanol 
for 10 minutes. Polyvinylidene fluoride (PVDF) Transfer membrane (Hybond-P, GE 
Healthcare) was soaked in methanol for 10 seconds, washed in distilled water for 5 minutes 
and equilibriated with transfer buffer for 10 minutes. The proteins were then transferred from 
the gel to the PVDF membrane for 1 hour at 100V, 350mA in the presence of transfer buffer 
using the Mini Trans-Blot cell (BioRad). After transfer, the PVDF membrane was immersed 
in PBS-Tween (PBS, 0.1% TWEEN-20) for 10 minutes. The PVDF membrane was then 
blocked in 50ml of PBS-Tween-Milk (PBS, 0.1% TWEEN-20, 1% skinned dried milk 
powder) to prevent non-specific binding of the antibody to the PVDF membrane. The protein 
of interest was probed using a specific primary antibody. Two antibodies were used in this 
study: anti-TnI (14G5) (1/2,000) (abcam  ab10234) and anti-TnI with phosphoserine 22/23 
(1/1,000) (abcam ab58545). The antibody was diluted in an appropriate manner (shown 
previously in brackets) in 10ml of PBS-Tween-Milk and the PVDF membrane was immersed 
in this overnight at 4°c with agitation.  
 
The following day the PVDF membrane was rinsed briefly three times in PBS-Tween, and 
then washed for 5 minutes, 3 times, in PBS-Tween. The secondary antibody was then added. 
This study either used anti-mouse IgG, horseradish peroxidase linked whole antibody (from 
sheep) (GE Healthcare, NXA931) or anti-rabbit IgG, horseradish peroxidase linked whole 
antibody (from donkey) (GE Healthcare, NA934V), which were diluted 1/10,000 in 10ml of 
PBS-Tween-Milk. The PVDF membrane was immersed in this for 1 hour. The PVDF 
membrane was then rinsed briefly three times in PBS-Tween, and then washed for 5 minutes, 
three times, in PBS-Tween. The proteins were then visualised using the ECL Plus Western 
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Blotting Detection system (GE Healthcare, RPN2132) and the chemiluminscence was 
detected by the a cooled CCD camera based gel imager (G:BOX Chemi XT16, Syngene). All 
immersion steps were completed at room temperature with agitation unless otherwise stated. 
 
If the blot was required to be probed with two different primary antibodies, then the initial 
primary antibody was removed by the following stripping protocol. The PVDF membrane 
was immersed in 100ml of ‘stripping buffer’ 62.5mM Tris-HCl, 2% SDS, 100mM β-
mercaptoethanol, pH 6.7 at 60°C for 30 minutes. The PVDF membrane was washed twice in 
PBS-Tween for 10 minutes. The PVDF membrane was then treated as before starting with a 
1 hour immersion in PBS-Tween-Milk.  
2.3.5 Densitometric analysis  
Digital images of gels and Western blots were visualised with a cooled CCD camera based 
gel imager (G:BOX Chemi XT16, Syngene) and GeneSnap (version 7.05, Synoptics Ltd) 
software. Protein bands were analysed by scanning densitometry using GeneTools (version 
4.00, Synoptics Ltd) software (Messer et al., 2009, Copeland et al., 2010b). Background 
fluorescence was subtracted using the ‘rolling disc’ function of the GeneTools software 
package. 
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2.4 The in vitro motility assay 
2.4.1 Affinity precipitation of HMM 
The product of the HMM preparation (see 2.2.1.2) was pure HMM, but not necessarily fully 
functional HMM. If more than 1% of the HMM heads were locked in rigor this would 
severely restricted movement (Marston et al., 1996). Therefore an addition step, the affinity 
precipitation, was used to remove these rigor or dead heads (Kron and Spudich, 1986). The 
stock HMM was diluted to 0.2mg/ml in a final volume of 1.5mls of ‘motility buffer A’ 
(50mM KCl, 25mM imidazole, 4mM MgCl2, 1mM EDTA. 5mM DTT. pH 7.4) with 0.15 
mg/ml F-actin in the presence of 1mM Mg2+-ATP. The mixture was incubated at 4°C for 10 
minutes and then centrifuged at 337,000xg (100,000 rpm, Sorvall MC-120SE, S100-AT6 
rotor), for 15 minutes at 4°C. The ultra centrifugation caused the F-actin to pellet out, thus 
removing any HMM heads bound to F-actin leaving only functioning HMM in the 
supernatant. For effective affinity precipitation F-actin stock should be not more than four 
weeks old. The functionality of the affinity precipitated HMM was assessed during the initial 
stages of an IVMA experiment. HMM remained functional after affinity precipitation for 3-4 
hours. 
2.4.2 Buffers for IVMA 
Alongside motility buffer A, motility buffers B, C & D are required for the IVMA. Buffer B 
consists of 4ml of buffer A and 12µl of 22.5% BSA. Buffer C consisted of 425µl of cold 
distilled H2O, 26µl of catalase (Sigma, C3515) stock (26mg/ml), 26µl of glucose oxidase 
(Sigma, G6641) stock (19mg/ml), 20µl of glucose stock (100mg/ml), 3µl of 22% BSA and 
500µl of methylcellulose 1% dissolved in ‘motility buffer 2A’ (100mM KCl, 50mM 
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Imidazole, 8mM MgCl2, 2mM EDTA, pH 7.4). Buffer D was almost identical but contained 
415µl of distilled H2O and an addition of 10µl of 100mM Mg2+-ATP.  
2.4.3 Fluorescent labelling of F-actin 
F-actin was labelled with tetramethyl rhodamine B isothiocyanate (TRITC)-phalloidin (φ) 
(Sigma, P1951). The TRITC-phalloidin was dissolved in 2.32ml of methanol and vortexed 
for 30 seconds. This stock solution (33µM) was kept in the dark and stored at -20°C. To 
label F-actin, 36µl of the 33µM TRITC-phalloidin was added to 438µl of motility buffer A 
and mixed with the vortex. Stock F-actin was diluted to 1mg/ml in a final volume of 20µl of 
motility buffer A and added to the aforementioned solution very gently. The tube was then 
wrapped in aluminium foil and incubated for 16-18 hours at 4°C before use. Labelled actin 
was useable for 4 weeks after which another batch was prepared. 
2.4.4 Preparation of the IVMA flow cell 
Flow cells were constructed for the IVMA. All flow cells and solutions had to be kept dry by 
storage in a dessicator cabinet (Nalgene, 5317-0120). These consisted of a microscope slide 
(Sigma, S8400) and a coverslip (VWR, 631-0125) which were adhered by silicon grease 
(BDH, 63608 2B). The coverslips were given a siliconised coating by immersing and 
drawing backwards and forward in a solution of 40ml of chloroform (Sigma, 496189) with 
0.2% dichloromethylsilane (Fluka, 39909) for 1 minute, before slowly being withdraw. This 
was performed in a fume hood where the coverslips were left to dry for 30 minutes. The 
result of this process was to produce clean coverslips with a hydrophobic surface to which 
the motor protein (HMM normally) would adhere. Subsequent to the cell coating the 
microscope slides were lined with three parallel longitudinal rows of silicon grease at the 
top, middle and bottom of the slide. These lines of grease were applied through a polyvinyl 
template which was lined up with the borders of the microscope slide. Half way along the 
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top and bottom rows of grease a 2-3cm piece of lacquered copper wire (100µm diameter) 
was placed. To complete construction a siliconised coverslip was placed across all three rows 
of silicon grease (see Figure 2.12). The internal volume of each channel of the flow cell is 
approximately 50µl. Flow cells were prepared at least one day before they were used in the 
IVMA experiments. 
Figure 2.12: Construction of flow cell 
 
 
2.4.5 Reconstitution of thin filaments 
Stock solutions of 2µM tropomyosin and troponin were made up with motility buffer A and 
kept on ice with the TRITC-phalloidin labelled actin (φ -actin). Thin filament solutions were 
prepared with the appropriate components added at ten-fold the required concentration for 
IVMA analysis. The motility buffer A was added first, followed by tropomyosin and 
troponin. This was thoroughly mixed before the φ- actin was added and mixed gently. These 
were incubated at 4°C for 15 minutes before ten-fold dilution in motility buffer A 
immediately before being loaded into the flow cells. Actin (plain actin) and actin and 
tropomyosin (A-Tm) were also analysed by this method.  
 
 
2 Flow Chambers 
coverslip 
grease 
wire 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2.4.6 Loading protocol for flow cells  
 
The flow cell was set at an angle of 30° with the opaque end of the microscope slide at the 
zenith. The protocol for loading the flow cell is illustrated in Figure 2.14. Each step is 
separated by a 30s gap. First 100µl of affinity precipitated HMM was loaded to each side of 
the flow cell followed by 100µl of Buffer B. 100µl of reconstituted thin filament were then 
loaded. Lastly 50µl of motility buffers C & D were loaded sequentially. 
 
If full thin filaments were being examined then buffers C & D were modified to contain a 
Ca2+-EGTA buffer and troponin. The troponin was diluted in motility buffer A to the same 
concentration as in the 10-fold thin filament incubation. It was then diluted 10-fold by 
addition of 5µl to 40µl of buffers C & D. 5µl of a Ca2+-EGTA buffer were also added. The 
stock solutions and final Ca2+ concentrations in buffers C & D are shown in (Table 2.2). The 
troponin was added in motility buffers C & D to prevent partial dissociation of troponin from 
the reconstituted thin filaments which may have occurred due to the low protein 
concentration of the final solutions. 
 
2.4.7 Composition of IVMA buffers 
All of the IVMA buffers (A, B, C, D) have the same foundation (50mM KCl, 25mM 
Imidazole, 4mM MgCl2 and 1mM EDTA, pH 7.4). This composition was based on the initial 
‘standard buffer’ used by Kron and Spudich (25mM, 4mM MgCl2, 0.2mM CaCl2, 1mM 
ATP, pH 7.4) (Kron and Spudich, 1986) which is where the pH value originates. Buffers for 
Ca2+-regulation in the IVMA were further developed by Dr Ian Fraser in the Marston 
laboratory (Fraser and Marston, 1995). Thus, IVMA buffers A, B, C & D were devised. The 
overall salt concentration of buffer A had to be increased (from 25mM KCl) to reduce 
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dissociation of tropomyosin from actin, which was known to occur at low salt 
concentrations. The salt concentration was not set any higher as higher salt concentrations 
reduced the affinity of HMM for thin filaments at low [Ca2+]. 
 
Buffer B also originates from the original Kron & Spudich method. This buffer is the same 
composition as buffer A with the addition of 0.5mg/ml BSA. The purpose of this buffer is to 
coat any areas of the coverslip that are not covered by HMM. (e.g. to prevent adhesion of 
fluorescently labelled filaments directly to the coverslip).  
 
The final development made by Dr. Fraser was to hold the addition of ATP until the final 
step.  To recap first the coverslip is coated with HMM. Non-specific binding is prevented by 
wash with buffer B. The thin filaments are then infused and bind (in rigor) to the HMM due 
to the absence of ATP. This step is designed so the maximum number of filaments bind to 
HMM in rigor as this is the strongest interaction between actin and myosin. Buffer C is then 
used to wash out any filaments that have not bound to the HMM surface. The presence of the 
methyl cellulose in buffers C & D is designed to prevent filaments dissociating away from 
the HMM surface. Finally, buffer D which contains ATP is added. As mentioned in 2.4.6 
buffers C & D also contain EGTA/Ca2+ which adjusts the [Ca2+] of the overall buffer to a 
predefined concentration (see 2.4.8). Buffers C&D also contained the free radical scavenging 
system, composed of catalase, glucose oxidase and glucose to inhibit photobleaching. 
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Figure 2.13: Composition of buffers used in IVMA 
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Figure 2.14: Flow  cell loading protocol 
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2.4.8 Preparation of Ca2+ -EGTA buffers  
Ca2+-concentrations were varied by the incorporation of Ca2+-EGTA buffers into IVMA 
buffers C & D. Ca2+-EGTA buffers were prepared by methods of (Knott, 2002) adapted from 
the method of (McGuigan et al., 1991). Buffers of different [Ca2+] by mixing an EGTA 
buffer (50mM KCl, 25mM Imidazole pH 7.4, 50mM EGTA, 1mM EDTA, 4mM MgCl2, 
95mM KOH, 1.43mM HCl, 8mM NaCl [pH adjusted using concentrated HCl ) and a Ca2+-
EGTA buffer (50mM KCl, 25mM Imidazole pH 7.4, 50mM EGTA, 50mM CaCl2, 1mM 
EDTA, 4mM MgCl2, 8mM NaCl [pH adjusted using 1M KOH]) at appropriate ratios to 
obtain Ca2+-EGTA buffers ranging from pCa9 to pCa5 (see Table 2.2). pCa values were 
calculated by Dr. Knott with Maxchelator software from total anion and cation 
concentrations in the solution. An example of a data sheet for one such pCa solution is 
shown below (Figure 2.15). 
 
Figure 2.15: Example of output data sheet as calculated by Dr. Fraser 
pH  7.40   Temp.  26.0 C    (Ionic) 0.150 N   [CM] 0.107 N   (CM) 0.100 N     
------------------------------------------------------------------------------ 
 Chelator   ATP            Imidazo          EDTA       EGTA                              
 Total      8.00E-04M  2.50E-02M  1.00E-03M  5.00E-03M                         
 Free       2.86E-05M  2.35E-02M  3.67E-07M  3.91E-03M                         
------------------------------------------------------------------------------ 
 Metal      Ca2                   Mg2             Na1            K 1                               
 Total      5.00E-06M  5.00E-03M  6.00E-03M  6.00E-02M                         
 Free       7.89E-11M  2.11E-03M  5.89E-03M  5.87E-02M                         
 
An example of the output data sheet from the Maxchelator programme under the conditions of the IVMA. This 
is the calculation when zero CaCl2 is added. The result is a free [Ca2+] of 7.89 x10-11 M or a pCa of 10.1. Taken 
from (Knott, 2002) 
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Table 2.2: Preparation of the Ca2+ -EGTA buffers 
 
 
Taken from (Knott, 2002) 
 
2.4.9 Experimental strategy IVMA experiments  
The first stage of any IVMA experiment was to confirm that the basic assay was functioning 
adequately. A flow cell was set up loaded (as previously stated) with plain actin (10nM). The 
experiments were automatically tracked (see 2.4.11.3) and motile parameters analysed. To 
continue both the mean sliding speed had to be above 2µm/s and the fraction motile had to 
be above 80%. If one or both did not meet these criteria there was a problem with either the 
surface of the flow cell, the quality of affinity precipitated HMM or one of the buffers. On 
the occasions when this occurred the only option was to start afresh and replace all of the 
elements mentioned. The initial experiment could either involve both sides of the cell 
containing plain actin, or with one side with plain actin and the other with actin-tropomyosin 
(A-Tm). If an A-Tm mixture was used then the concentration of tropomyosin generally used 
was 60nM. Previously the presence of tropomyosin in the absence of troponin was shown to 
Solution 
Name 
Volume of 
50mM 
EGTA 
buffer 
added (ml) 
Volume of 
50mM 
Ca/EGTA 
buffer added 
(ml) 
Ratio pCa Free [Ca2+] 
A 47 0.5 94/1 9.00 1.00 x 10-9 
C 40 4 10/1 8.14 7.24 x 10-9 
D 40 10 4/1 7.74 1.82 x 10-8 
E 30 15 2/1 7.43 3.72 x 10-8 
F 25 17.5 1/0.7 7.24 5.75 x 10-8 
G 25 25 1/1 7.13 7.41 x 10-8 
H 20 30 1/1.5 6.95 1.12 x 10-7 
I 15 30 1/2 6.84 1.45 x 10-7 
J 10 30 1/3 6.64 2.29 x 10-7 
K 10 40 1/4 6.52 3.02 x 10-7 
L 8 40 1/5 6.42 3.80 x 10-7 
M 7 42 1/6 6.34 4.57 x 10-7 
N 6 42 1/7 6.28 5.25 x 10-7 
P 5 40 1/8 6.23 5.89 x 10-7 
Q 5 45 1/9 6.18 6.61 x 10-7 
R 2 40 1/20 5.88 1.32 x 10-6 
S 1.5 45 1/30 5.75 1.79 x 10-6 
T 0 50 -/1 5.43 3.72 x 10-6 
128 
have a positive effect on motile parameters, however during the majority of experiments 
completed in this study this effect was not detected. Experiments comparing different 
tropomyosins included a titration over a range of tropomyosin concentrations between 10 
and 100nM. Each cell was loaded with the two A-Tm mixtures with the same concentration 
of tropomyosin and the effect on function measured.  
 
The majority of experiments completed for this study analysed fully reconstituted thin 
filaments, with actin-tropomyosin-troponin mixtures. The main method was to compare two 
sets of thin filaments over a range of Ca2+ concentrations (6-10 points between 1nM and 
3.7µM). The output from these results was a Ca2+ concentration titration, which could be 
plotted and fitted with the Hill equation (see 2.4.11.4). By fitting the data with the Hill 
equation two parameters could be determined, the EC50 value, this is the value at which 50% 
of the thin filaments were activated. The second parameter is the Hill Coefficient, this is 
related to the steepness of the fitted curve, and is an indication of system cooperativitity.  
 
Before the Ca2+ concentration titration curve could be undertaken a troponin titration for 
both sets of thin filaments was completed at high (3.7µM) and low (1nM) Ca2+ 
concentrations. Generally troponin was titrated at 2-4 points between 10 and 100nM 
depending upon functionality of the protein. The tropomyosin concentration was generally 
60nM. These data were automatically tracked and analysed. A troponin concentration that 
gave similarly good activation at high [Ca2+] (fraction motile >80%, sliding speed >2.0 
µm/s) and good inhibition at low [Ca2+] (fraction motile <15%, sliding speed <1.5µm/s) was 
selected for each set of thin filaments. Once this had been completed a Ca2+ concentration 
titration could be performed.  
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2.4.10 Recording apparatus 
The movement of thin filament over the immobilised bed of HMM was visualised by the 
fluorescently labelled actin. The microscope and recording apparatus was setup as illustrated 
in Figure 2.16. 
 
Figure 2.16: Schematic diagram of the visualisation and recording apparatus 
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The flow cell was placed in the metal temperature control chamber on the stage of the Zeiss 
Axiolab micoscope, with a Zeiss 63x/1.40 NA PlanApochromat objective lens (44 07 60-03) 
fitted with an epifluorescence illuminator (Zeiss, 39 26 42-9901) containing a 50W mercury 
high pressure arc lamp (Osram, HBO 50W/3), and a rhodamine compatible filter set 
(Chrome technology, emission: HQ 595-50, excitation: D539-25, dichroic: 565-DRLP 
special). The microscope was connected through a C-mount (45 61 05), to a highly sensitive 
video camera (DAGE MTI VE1000SIT), which in turn was linked to both a television 
monitor and a Macintosh G4. A drop of immersion oil, type A (Cargille laboratories, 16482) 
was placed on the coverslip of the flow cell and the image of the fluorescently labelled actin 
filaments were brought into focus on the television screen. 
2.4.10.1 Temperature control of the IVMA 
The temperature at which IVMA experiments were performed was controlled using a 
Bionomic Controller BC-100 (20/20 Technology Inc.) This controller sets and maintains the 
temperature of a metal heating platform onto which a flow cell is placed. The majority of 
IVMA experiments were completed at 28°C. 
2.4.10.2 Analysis of filament movement 
To complete quantitative analysis of filament movement, bespoke computer software had 
been designed and provided by ME Electronics (Reading, UK) for use on a Macintosh 
computer with Operating System 9.(Marston et al., 1996). This name of the software 
package was ‘Filament Tracker 2.0.3’, this was run using LabVIEW-3.1.1 Run-Time image 
analysis application (National Instruments Corp.). The software completes two tasks: the 
first was to digitise a series of filament images; the second was the image analysis function. 
This determines the movement of each filament by comparing sequential images. 
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2.4.10.3 Acquisition of a sequence of images 
To record images using the Filament Tracker 2.0.3 the following command sequence was 
followed (see Figure 2.17). The first step was to select the ‘Acquire Sequence’ in the 
tracking panel (Figure 2.17 A). Next the ‘Capture Set-up’ was selected (Figure 2.17 B). This 
would open the ‘Capture Setup’ screen where the live image from the microscope could be 
viewed in the image window. Also displayed were four parameters that could be adjusted for 
optimal image acquisition. Two of these parameters were the ‘contrast’ and ‘brightness’, 
which along with setting on the microscope could be adjusted to improve the quality of the 
image. The number of images acquired and the time interval between image acquisition 
could also be adjusted. The setting for the number of images acquired depended on the 
density of the filaments in the microscope field. The aim was to record 250-500 filament 
vectors which usually meant 10-16 images were acquired (Marston et al., 1996).  
Figure 2.17: Sequential flow diagram of the process of image acquisition 
 
The time interval was dependant on filament sliding speed, and was set to allow filaments to 
move 1.6-1.8µm between image acquisitions The distance had previously been determined to 
facilitate the most accurate results from the tracker software (Marston et al., 1996). A 
calibration curve for filament velocity and frame interval is shown below (Figure 2.18). 
Once set, time intervals was kept constant during a set of measurements. 
 
A B C 
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Figure 2.18: Graph showing optimal time interval against filament velocity 
 
 
Once all parameters were maximally optimised a sequence of images could be obtained. To 
do this the ‘Ready to Capture’ option was selected, followed by ‘Start Capture’. For any 
given experiment once the optimum parameters had been selected they were kept constant. 
For each side of each cell, 4 sequences were recorded from randomly selected areas of the 
flow cell. Image files were saved into a predetermined data file. Each cell side was 
designated a letter. A record was kept linking the image files to the experiment completed on 
each specific cell side. 
2.4.11 Analysis of filament movement. 
2.4.11.1 Computer hardware 
Image digitization and filament movement was performed on a single hardware unit 
containing integrated software. Computing hardware was a Macintosh G4 computer with a 
PCI Neotech frame grabber. 
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2.4.11.2 Software calibration 
A 100µm microscope graticule was visualized using the transmission lamp filter system on 
the microscope setup. In ‘tracker’ the options ‘acquire image’ and ‘calibrate’ were selected 
from the main on screen options. Using the mouse-controlled cursor, a line was drawn across 
the graticule image (shown in Figure 2.19) and the appropriate length entered to calibrate the 
software for subsequent IVMA experiments. 
Figure 2.19: Calibration of the IVMA image analysis software 
 
A 100 micron graticule as it appears under a transmission microscope. 
 
2.4.11.3 Automatic filament tracking  
Image files of filament movement were analysed using the automatic-tracking segment of the 
tracker programme. Auto tracking was selected from the main ‘Filament tracker’ panel, from 
there the desired set of images were loaded. In the ‘Pre-process’ panel filaments that fulfilled 
the set criteria were displayed and highlighted as green objects on the original black and 
white image. Selection of the ‘Change Settings’ command allowed the adjustment of the 
movement analysis parameters. The maximum velocity cut-off was set at 8µm/s, this is 2.5x 
mean velocity, (as vectors designated with larger velocities were probably due errors in the 
vector tracking). Finally, the selection sensitivity was set to discriminate objects from noise. 
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When these setting had been optimised the ‘Extract Velocities’ command was selected 
(Figure 2.17. A) 
 
Usually settings only needed to be changed at the beginning of a days experimentation. As 
the tracking progresses two images are superimposed over each other on a screen similar to 
the live image screen. In the first image the filaments are coloured green and in the second 
the filaments are coloured red (Figure 2.20 B). Therefore any filaments present in the same 
position in both images will appear yellow. Blue lines connecting two filaments represent the 
vectors of filament movement.  
 
After sequential tracking of all of the images is complete a histogram will appear. On the left 
hand side three parameters to further optimise tracking can be set: the number of bins (e.g. 
size of velocity channels); maximum velocity, and the velocity which defines the threshold 
between non-motile and motile filaments. This velocity is an arbitrarily selected value 
deemed to separate motile and non-motile fractions. Even at low Ca2+ or ATP concentrations 
not all the filaments will be remain static. One weakness of the tracker program is that it 
cannot distinguish between linear movement and oscillatory movement around a fixed point. 
Some filaments may move with a Brownian motion and other filaments may ‘wobble’ if only 
in the ‘weak’ binding state with myosin. By reviewing the results from a set of thin filaments 
in a high Ca2+ concentration in the presence of ATP a value for this threshold is selected. For 
consistency this value must remain constant for the entire data set. This was normally set at 1 
(µm/s). 
 
The calculated parameters: filament density, motile fraction, motile velocity, standard 
deviation of velocities and velocities measures are displayed on the right hand side. These 
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values are manually recorded and linked to the experiment they represent. It was assumed 
the sliding speeds were distributed as a single Gaussian distribution, based on the initial 
setup of this system (Marston et al., 1996), Thus mean values and standard deviation were 
calculated by the software. If the standard deviation was >0.5X mean sliding speed this data 
was discarded. 
Figure 2.20: Sequential flow diagram of automatic filament tracking  
 
 
In the foreground of panel A) Filaments are coloured green, B) two sets are overlayed showing filaments from 
the first (sequential) acquisition (green), filaments from the second acquisition (red), those that havn’t moved 
are therefore coloured yellow. Panel C shows an example of the final histogram. 
A
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2.4.11.4 Production and statistical analysis of a Ca2+-concentation titration 
Figure 2.21: Multiple histograms are used to build a Ca2+-concentration titration curve 
 
1nM 
74.1nM 
229nM 
525nM 
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145nM 
380nM 
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To produce a Ca2+-concentration titration, measurements were completed on the same 
incubation of thin filaments (actin-Tm-Tn) over a range of Ca2+-concentrations from 1nM to 
3.7µM. Figure 2.21 is composed of histograms from measurements at eight different [Ca2+]. 
This demonstrates how the fraction of filaments moving and the sliding speed increases with 
the increase in [Ca2+] and how this is measured by the tracker software. It should be noted 
that for the experiments in this thesis four measurements were completed at each [Ca2+] 
point, therefore there is four histograms per [Ca2+] point from areas of the flow cell chosen at 
random. Data from obviously defective areas (low or zero motility) were discarded. The 
mean fraction motile values from these measurements were then plotted and fitted with the 
Hill equation. The fraction motile was fitted to a 4-parameter Hill Equation using 
KaleidaGraph (Synergy Software). In some cases a and/or b were fixed at reasonable values 
to obtain a 3 or 2-parameter fit. 
 
Hill Equation: 
€ 
X = a + bn[Ca
2+]η
(k + [Ca2+]η)              
 
Two parameters were obtained by fitting this equation to the data, the EC50 which was used 
as a measure of thin filament Ca2+-sensitivity and the Hill co-efficient (η), which is an 
indicator of cooperatively. EC50 was used as the measure of Ca2+-sensitivity as the graphs 
were plotted with the x-axis as Molar [Ca2+] instead of pCa50, this was only because of 
laboratory convention, but analysis of curve fits to [Ca2+] and pCa show little difference so 
both of these would have been acceptable (Walker et al., 2010). Mean data values are shown 
alongside standard deviation of the mean unless otherwise stated. Data was compared for 
statistical significance using the Student t-test where p<0.05 was classed as significant. The 
Student t-test is the best method for significance tests on small populations, such as in this 
a = min value 
b = max-min value 
k = EC50 
η = hill co-efficient  
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thesis provided the distribution of the measured parameter is normal. EC50 donor/failing ratio 
measurements competed by Dr. Messer compared 39 pairs of thin filaments containing donor 
or failing heart troponin and established these data were normally distributed within the same 
IVMA system as used in this thesis (see Figure 2.22). Data obtained for this thesis will also 
be represented in a histogram where relevant.  
Figure 2.22: Normal distribution of EC50 values from work by Dr. Messer 
 
Histogram of experimental data from (Messer et al., 2007) which demonstrates the normal distribution of 39 
donor EC50/failing heart EC50 values measured with the IVMA.  
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3 Chapter 3 – Investigation of the regulation of thin filament 
Ca2+-sensitivity by troponin I phosphorylation in HOCM 
troponin.  
3.1 Introduction 
Troponin I (TnI) is phosphorylated as a downstream effect of β-adrenergic signalling as part 
of the lusitropic response (Bers, 2001). The level of TnI phosphorylation has been shown to 
modify the Ca2+ sensitivity of the constituent thin filament. This has been thoroughly 
investigated using a number of techniques (Kentish et al., 2001, van der Velden et al., 2003, 
Layland et al., 2005b, Hamdani et al., 2008). Such studies include that by Messer et al who 
compared troponin isolated from tissue samples from donor and failing hearts (Messer et al., 
2007). This study measured the mean level of TnI phosphorylation of donor hearts as 
1.62±0.06 molsPi/molsTnI and in failing hearts as 0.26±0.02 molsPi/molsTnI (Messer et al., 
2009, Messer et al., 2007). Isolated troponin samples were reconstituted into thin filaments 
and compared by IVMA. The results of these experiments showed thin filaments 
reconstituted with failing heart troponin had a 2.5 fold higher Ca2+ sensitivity compared to 
thin filaments that contained donor heart troponin (Messer et al., 2007). Thus directly 
demonstrating that a higher level of TnI phosphorylation caused a decrease in thin filament 
Ca2+-sensitivity. 
3.1.1 Existing work comparing troponin from donor and HOCM tissue 
Dr. Andrew Messer and Dr. Adam Jacques completed a preliminary study using donor heart 
tissue and tissue from HOCM patients removed during a septal myectomy operation (Jacques 
et al., 2006). Troponin was extracted from donor and HOCM heart tissue, reconstituted into 
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thin filaments and compared with the IVMA. There was no difference in the Ca2+-sensitivity 
between the two sets of thin filaments (donor EC50 0.069 ±0.018 and HOCM EC50 0.067 
±0.009 µM) (see Figure 3.1). However there was a clear difference in the level of TnI 
phosphorylation of the respective troponins. The level of TnI phosphorylation in donor heart 
troponin was determined as 2.4 ±0.04 molsPi/molsTnI and the HOCM troponin was 0.2 ±0.3 
molsPi/molsTnI. These phosphorylation measurements were calibrated using a set of TnI 
standards which had been phosphorylated with P32 ATP. Further work using phosphate 
affinity PAGE has shown that the values determined for the donor TnI phosphorylation by 
this method were higher than the true values of 1.62±0.06 molsPi/molsTnI (donor) and 
0.29±0.04 molsPi/molsTnI (HOCM) (Messer et al., 2009). These results suggested that the 
relationship between Ca2+-sensitivity and TnI phosphorylation was different from that 
measured in donor and failing heart. To investigate this further, donor and HOCM troponin 
were extracted as before and dephosphorylated by phosphatase treatment (alkaline 
phosphatase, Sigma P-5521 & acid phosphatase, Sigma P-0157). This reduced the TnI 
phosphorylation to a very low level in both the donor and the HOCM troponin. When the 
phosphatase treated troponins were compared using IVMA the thin filaments containing 
dephosphorylated donor troponin were two-fold more Ca2+-sensitive than thin filaments with 
the dephosphorylated HOCM troponin. These experiments suggested that the relationship 
between TnI phosphorylation and thin filament Ca2+-sensitivity is disrupted in thin filaments 
reconstituted with troponin purified from HOCM heart muscle. This chapter further 
investigates this disruption of the relationship between TnI phosphorylation and Ca2+ -
sensitivity in HOCM tissue.  
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Figure 3.1: IVMA experiments completed Dr. Andrew Messer and Dr. Adam Jacques with donor and 
HOCM troponin. 
  
IVMA Ca2+-sensitivity experiments comparing fraction motile of thin filaments reconstituted with A) donor 
(blue) and HOCM (red) troponin and B) dephosphorylated donor (dotted blue) and dephosphorylated HOCM 
(dotted red) troponin (unpublished data by Dr. A. Messer and Dr. A. Jacques). 
 
3.1.2 Sample selection 
A number of tissue biopsy samples had been previously collected from patients diagnosed 
with HOCM who had undergone a septal myectomy operation. A set of tissue samples from 
explanted donor hearts had also been sent from the laboratory of Prof. C. dos Remidos. 
These samples were available for immediate study as they were stored in the on-site tissue 
bank. The comparison completed by Dr. Messer & Dr. Jacques comparing donor and HOCM 
troponin used a HOCM sample that was identified to contain a MyBP-C mutation. Therefore 
the disruption to the relationship between thin filament Ca2+-sensitivity and TnI 
phosphorylation could not be a direct effect of a troponin mutation. Thus to prevent the 
further complication (of using a HOCM sample with a troponin mutation) a sample with a 
MYBP-C mutation (IVS17+4A>T) was selected for the first set of experiments. The tissue 
0
0.2
0.4
0.6
0.8
1
0.001 0.01 0.1 1 10
Donor
HOCM
Fr
ac
tio
n 
m
ot
ile
[Ca2+]  µM
ErrorValue
0.33291.5149Hill Coefficient
0.013550.09452EC50
ErrorValue
0.349361.4997Hill Coefficient
0.0150960.097901EC50
0
0.2
0.4
0.6
0.8
1
0.001 0.01 0.1 1 10
dp Donor
dp HOCM
Fr
ac
tio
n 
m
ot
ile
[Ca2+]  µM
ErrorValue
0.40492.3671Hill Coefficient
0.00365540.04259EC50
ErrorValue
0.258472.1955Hill Coefficient
0.00542630.10012EC50
A B 
142 
bank code for this sample was MT. This sample was from a female aged 46. A donor sample 
NI, from a 42 year old female, was selected as the donor tissue for this study (see Table 2.1). 
Previously laboratory nomenclature referred to the donor samples as ‘non-failing samples’ 
hence the N notation in the sample code and the HOCM samples were referred to as 
‘myectomy samples’ hence the M. However in this chapter these will be described as donor 
(D) and HOCM (HA) samples. For the following experiments two paired troponin 
preparations were completed. Each pair consisted of a troponin purified from the donor heart 
sample NI and the HOCM sample MT. The first pair will be referred to as D1 and HA1 and 
the second pair will be referred to as D2 and HA2. 
3.1.3 TnI phosphorylation was ~5 times higher in donor heart troponin compared to 
HOCM troponin 
The phosphate affinity SDS-PAGE method optimised by Dr Andrew Messer and Dr Clare 
Gallon was used to measure TnI phosphorylation (Messer et al., 2009). As stated in the 
methods (2.3.2.4) phosphate affinity SDS-PAGE can resolve the different phospho-species 
of TnI. A Western blot of this is shown in Figure 3.2, the TnI bands are labelled P-0 
(unphosphorylated), P-1 (mono-phosphorylated), P-2 (bis-phosphorylated). This was used to 
measure the TnI phosphorylation of the troponin samples purified from D1-2 and HA1-2 that 
were investigated with the IVMA. The results for the donor sample were, D1 1.61 & 1.53 
molsPi/molsTnI (n=2) and D2 1.58, 1.5, 1.79 molsPi/molsTnI (n=3), with the P-2 as the 
majority species (~70%). For the HOCM samples, HA1 0.36 & 0.48 molsPi/molsTnI (n=2) 
and HA2 0.12, 0.19, 0.26 molsPi/molsTnI (n=3), with the P-0 as the most abundant band 
(~60 & 80%). These were in line with measurements made on myofibril preparation of these 
samples, by Dr. Andrew Messer, where the donor sample was measured at 1.81±0.06 
molsPi/molsTnI (n=5) and the HOCM 0.32±0.15 molsPi/molsTnI (n=9) (unpublished). 
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These results confirm that the troponin from HOCM heart septal tissue has a relatively low 
level of TnI phosphorylation compared to donor heart troponin. 
 
Figure 3.2: Phosphorylation measurements of TnI from donor and HOCM heart troponin samples 
 
   
 
 D1 HA1 D2 HA2 
2-P 69.04 5.12 71.22 0.97 
1-P 18.93 31.82 19.80 16.87 
0-P 12.04 63.06 8.98 82.15 
 
 
A) Western blot of phosphate affinity (phos-tag) SDS PAGE loaded with 20µl of sample (mixed 1:1 with 
samples buffer of recombinant TnI (TnI), D1, HA1, D2 and HA2. The Western blot was probed with 14G5 
used at 1:2,000 dilution. B) Bar graph summarising TnI phosphorylation measurements. C) Summary table of 
mean occupancy of the different phospho-species of TnI (%). 
 
3.1.4 Donor and HOCM troponin regulate thin filaments in a Ca2+-sensitive manner 
The first stage of an IVMA experiment is to determine the concentration of troponin which 
gives both maximal switch off at low [Ca2+] (1nM) and activation at high [Ca2+] (3.7µM). 
The graphs in Figure 3.3 show the sliding speed and fraction motile of a three point troponin 
paired titration of D1 and HA1, at high and low [Ca2+], with troponin concentrations of 0, 30 
and 60nM. These graphs are representative of troponin titrations completed at the beginning 
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of all the IVMA experiments completed using these samples. Each point is plotted as the 
mean ± standard deviation.  
 
In some previous IVMA studies troponin had been shown to slightly increase the fraction 
motile and sliding speed at high [Ca2+] (3.7µΜ) compared to plain actin. However no such 
activation was measured in these experiments, this was a consistent finding throughout the 
work completed for this thesis. At low [Ca2+] (1nM) there was a small decrease in sliding 
speed and a large decrease in fraction motile to <0.3. The fraction motile graphs better 
illustrate the switch off at low [Ca2+] and the retained activation at high [Ca2+]. From the 
graphs (Figure 3.3) it is clear that 30nM of both donor (D1) and HOCM (HA1) troponin 
gave an adequate switch off (<0.2) at low [Ca2+] without adversely affecting the motility 
parameters at high [Ca2+] (>0.7). The graph of fraction motile at high [Ca2+] (Figure 3.3) 
demonstrates that an excess of troponin has an inhibitory effect on motility, the thin filament 
mixtures with 60nM show a reduction of ~0.1 in the fraction motile.  
145 
 
Figure 3.3: IVMA troponin titration comparing thin filaments composed of human donor and HOCM 
troponin 
 
 
 
IVMA experiments titrating human cardiac donor troponin (D1) (blue) and HOCM (HA1) (red) over the range 
0-60nM. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and 
troponin. The sliding speed of reconstituted thin filaments were measured at A) high [Ca2+] (3.7µM) and B) low 
[Ca2+] (1nM) and the fraction motile were measured at C) high [Ca2+] (3.7µM) and D) low [Ca2+] (1nM). Each 
point is plotted as the mean ± standard deviation. 
 
 
The graph in Figure 3.4 shows that the troponin titrations were consistent across all the donor 
HOCM comparison IVMA experiments. It also shows there was no difference between the 
donor and HOCM troponins in terms of their ability to inhibit filament movement at low 
[Ca2+] and retain it at high [Ca2+]. It is important to prove that the thin filaments are saturated 
with functional troponin by determining an equal amount of inhibition and activation at high 
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and low [Ca2+] during the troponin titration experiment. Thus any differences measured 
between the two sets of filaments during the Ca2+-sensitivity curve experiments will be due 
to the properties of the troponin.  
Figure 3.4: Summary bar graph of fraction motile measurement of the three troponin titrations  
   
Fraction motile data was plotted from all of the troponin titration IVMA experiments completed with thin 
filaments reconstituted with donor (blue) and HOCM (red) troponin at high [Ca2+] (3.7µM) (solid) and low 
[Ca2+] (1nM) (striped). The concentration of troponin used was 30nM for both D1 & HA1, 10nM for D1* & 
HA1, and 60nM for D2 & HA2. 
 
3.1.5 No difference in Ca2+-sensitivity was measured between thin filaments with 
donor and HOCM troponin 
 
After a troponin titration was completed Ca2+-concentration titrations could be performed. 
As described in the methods (2.4), the motility of two sets of thin filaments were measured 
over a range of Ca2+ concentrations and then movement was analysed and parameters plotted 
and fitted with the Hill equation. Eight Ca2+-concentration titrations were completed 
comparing two preparations of donor and HOCM troponin. 
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3.1.5.1 Sliding speed was not used to compare thin filament Ca2+-sensitivity 
 
As there was only a change of ~1µm/s in thin filament speed between low and high [Ca2+] 
and because of the degree of variability in this data only one example of a Ca2+-
concentration titration is shown in this results section (Figure 3.5). The Hill equation was 
fitted to sliding speed data to determine EC50 as for the fraction motile in this figure. 
However the quality of the fit for the majority of these curves was not sufficient. Therefore 
no conclusions could be drawn from these curves, but the unfitted data is plotted in the 
appendix. 
 
Figure 3.5: Example of a Ca2+-concentration titration comparing sliding speed of thin filaments 
containing donor and HOCM troponin 
 
IVMA Ca2+-concentration titrations comparing the sliding speed of troponin purified from donor (D2) (blue) 
and HOCM (HA2) (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human 
cardiac tropomyosin and 60nM troponin. 
0
0.5
1
1.5
2
2.5
3
3.5
0.001 0.01 0.1 1 10
Donor troponin
HOCM troponin
Sl
idi
ng
 s
pe
ed
 (µ
m
/s
)
[Ca2+] µM
ErrorValue
0.876941.988Hill Coefficient
0.0800560.40745EC50
ErrorValue
0.37772.0849Hill Coefficient
0.0282590.29388EC50
148 
 
However the sliding speed at maximal [Ca2+] (3.7µM) could be compared and this is 
summarised in Table 3.1. This demonstrates that there is no difference in the maximal sliding 
speed of the donor troponin and HOCM troponin containing thin filaments (unpaired student 
t-test =0.06, paired student t-test = 0.09).  
 
Table 3.1: Summary of the sliding speed for thin filaments that contained either donor or HOCM 
troponin at high [Ca2+] (3.7µM) 
No. Donor max 
sliding 
speed 
(µm/s) 
SD HOCM max 
sliding 
speed 
(µm/s)
 
SD HOCM/Donor 
I     D1 HA1 2.25 ± 0.12 2.26 ± 0.12 1.00 
II 2.77 ± 0.09 2.73 ± 0.04 0.99 
III 2.28 ± 0.08 2.25 ± 0.08 0.99 
IV 2.68 ± 0.06 2.69 ± 0.09 1.00 
V 2.24 ± 0.22 2.16 ± 0.07 0.96 
VI   D2 HA2 3.30 ± 0.06 3.31 ± 0.08 1.00 
VII 3.06 ± 0.06 2.86 ± 0.26 0.93 
VIII 3.30 ± 0.11 3.04 ± 0.16 0.92 
      
mean 2.74 ± 0.45 2.66 ± 0.41 0.97 
     ± 0.03 
      
Student t test                  (paired):p= 0.09                            (unpaired): p= 0.06 
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3.1.5.2 There was no difference between the fraction motile Ca2+-sensitivity of thin 
filaments reconstituted with donor and HOCM troponin 
 
The eight Ca2+-concentration curves are shown in Figure 3.6 and Figure 3.7. The EC50 values 
determined from these curves are summarised in Table 3.2.  Overall there is no significant 
difference in Ca2+-sensitivity (EC50) between thin filaments containing donor or HOCM 
troponin (paired Student t-test = 0.15). The EC50 ratio of HOCM troponin thin filaments to 
donor troponin thin filaments is 0.88 ±0.22. This ratio was compared to the value one, which 
would signify no difference (unpaired Student t-test 0.15). This ratio does suggest that the 
thin filaments containing HOCM troponin were 12% more Ca2+-sensitive than the donor 
troponin thin filaments. However, when thin filaments with donor or failing heart troponin 
were compared there was a clear 2.5 fold difference in Ca2+-sensitivity (Messer et al., 2007), 
which was not found in this comparison.  
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Figure 3.6: Ca2+-concentration titrations comparing fraction motile of thin filament reconstituted with 
donor and HOCM troponin. 
 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of troponin purified from donor (blue) and 
HOCM (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentration of troponin used was I) 30nM, II) 30nM, III) 20nM, IV) 20nM.  
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Figure 3.7: Ca2+-concentration titrations comparing fraction motile of thin filament reconstituted with 
donor and HOCM troponin. 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of troponin purified from donor (blue) and 
HOCM (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentration of troponin used was V) 10nM, VI) 60nM, VII) 60nM, VII) 
60nM.  
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Table 3.2:  Summary of the fraction motile EC50 for thin filaments that contained either donor or HOCM 
troponin. 
No. Donor EC
50 
(µM) 
SD HOCM 
EC
50
(µM)
 
SD HOCM/Donor 
I   D1HA1 0.10 ± 0.02 0.10 ± 5.26 0.92 
II 0.19 ± 0.04 0.13 ± 0.11 0.66 
III 0.18 ± 0.09 0.14 ± 0.01 0.74 
IV 0.21 ± 0.04 0.16 ± 0.02 0.73 
V   0.10 ± 0.00 0.11 ± 0.00 1.09 
VI  D2HA2 0.36 ± 0.16 0.23 ± 0.05 0.63 
VII 0.18 ± 0.04 0.21 ± 0.05 1.15 
VIII 0.21 ± 0.01 0.23 ± 166.53 1.11 
        
mean 0.19 ± 0.08 0.16 ± 0.05 0.88 
     ± 0.22 
      
Student t 
test 
 (paired): p= 0.15                          (unpaired):p= 0.15 
 
3.1.5.3 Conclusions from the comparison of thin filaments containing donor and HOCM 
troponin. 
HOCM troponin had a reduced level of TnI phosphorylation compared to donor troponin. 
However, when donor and HOCM troponin were reconstituted into thin filaments and 
compared no difference in Ca2+-sensitivity was detected. Together these results suggest that 
the TnI phosphorylation related modification of thin filament Ca2+-sensitivity is abnormal or 
disrupted in HOCM troponin. Two possible explanations for this are 1) that the HOCM 
troponin has lost the ability to regulate thin filament Ca2+-sensitivity thus the relationship 
between thin filament Ca2+-sensitivity and TnI phosphorylation has become uncoupled or 2) 
that this regulation is modified so that the Ca2+-sensitivity of thin filaments with HOCM 
troponin is shifted to a lower range. These ideas are demonstrated in Figure 3.8. 
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Figure 3.8: Hypotheses for disruption of relationship between Ca2+-sensitivity and TnI phosphorylation 
 
   
Representative graphs for the two hypotheses (1, A) uncoupling hypothesis: the Ca2+-sensitivity of thin 
filaments containing HOCM will not change despite a change in TnI phosphorylation compared to thin 
filaments with donor troponin where this relationship is still inplace (2, B) modifying hypothesis: the Ca2+-
sensitivity of thin filaments containing HOCM is still regulated by changes in TnI phosphorylation, but the 
[Ca2+] range at which this modification takes place is higher than the donor containing filaments. Donor 
troponin (blue), HOCM troponin (red), untreated (solid lines), phosphatase treated (dotted lines) 
 
3.2 Comparison of HOCM troponin with native and modified levels of 
TnI phosphorylation 
To investigate the disruption to the relationship between thin filament Ca2+-sensitivity and 
TnI phosphorylation of HOCM troponin further, the level of TnI phosphorylation in HOCM 
troponin was increased with a PKA-treatment. Thin filaments containing PKA-treated 
HOCM troponin were compared to thin filaments with untreated HOCM troponin using the 
IVMA. The sample used for these experiments was MM (see Table 2.1). As sample was 
screened by Healthcode™ and no causative mutation was identified it is unlikely that the 
mutation is present in the any of the troponin subunit genes. Three pairs of troponin 
preparations were produced. Each pair consisted of an untreated HOCM troponin sample and 
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a PKA-treated HOCM troponin sample. The untreated HOCM samples were labelled HB1-3 
and PKA-treated HOCM were labelled PH1-3. 
3.2.1 The level of TnI phosphorylation of HOCM troponin was increased with a PKA 
treatment 
3.2.1.1 Development of PKA-treatment protocol 
Purified troponin had not been previously treated with PKA in the Marston laboratory, 
therefore a protocol was developed. The affinity column chromatography is the stage where 
the majority of unwanted proteins and molecules are removed during the troponin 
preparation protocol (see 2.2.4.1). For the preliminary protocol it was reasoned that if PKA 
was to be added to the sample, it was required to be removed as well, and that the column 
chromatography stage was a good point to do this. Therefore initially the ‘spun extract’ was 
dialysed in troponin phosphorylation buffer (50mM MOPS, 20mM sodium fluoride, 10mM 
magnesium chloride, 1mM DTT, pH 7) for 1 hour, before 2µl of 20,000 units/ml catalytic 
subunit of PKA (Sigma P-2645) and 2µM Mg2+-ATP were added and mixed for 80 minutes 
at 35°C at 300 r.p.m. on a Thermomixter comfort (Eppendorf). After this treatment the 
sample was dialysed in ‘troponin extraction buffer’ for 1 hour before it was loaded into the 
affinity column and eluted as stated in methods. Troponin phosphorylated by this method did 
not form Ca2+-sensitive thin filament (fraction motile >85% at low [Ca2+] (1nM)). The 
protocol was changed so the PKA treatment occurred after the pure troponin had been eluted 
from the column (so there were no other proteins for the PKA to target). Preliminary 
experiments suggested that this treatment was not effective enough, as the level of TnI 
phosphorylation was increased only 2.5-fold. A small set of different conditions were 
analysed and it was found that an overnight incubation at 4°C successfully increased the TnI 
phosphorylation. 
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Troponin treated in this manner was also found to regulate thin filaments in a Ca2+-sensitive 
manner. A Western blot was completed to confirm that PKA treatment increased the 
phosphorylation of the serine 22 and 23 residues (see Figure 3.9). Visualisation of a 
monoclonal antibody specific for TnI phosphorylated at serine 22/23 showed a clear 
difference between PKA-treated HOCM troponin (PH) and untreated (H). The anti-TnI 
antibody 14G5 was used as a loading control. 
Figure 3.9: Western blot of PKA-treated and untreated HOCM troponin 
 
A)Western blot of SDS PAGE gel loaded with 10µl of sample (mixed 1:1 with sample buffer). The three pairs 
of samples were from preliminary experiments, and were either PKA-treated HOCM troponin (PH) or untreated 
HOCM troponin (H). The Western blot was probed first probed with A) a monoclonal anti-phosphoserine 22/23 
Ab used at a dilution of 1:1000 and then striped and B) re-probed with 14G5 used at 1:2,000 dilution. 
 
Small amendments to this protocol were made so for the final protocol the troponin was 
eluted from the column and dialysed in ‘troponin phosphorylation buffer’ for 4 hours. The 
troponin was then removed from dialysis and incubated with 16µl of 2,000 units/ml PKA 
and 2mM Mg2+-ATP in a 1.5ml eppendorf tube at 4°C overnight with agitation as described 
in the final method (see 2.2.5.1). Initial experiments with troponin treated in this manner 
suggested there was no need to remove the PKA as it had no negative effects on motile 
parameters. 
 
A B 
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3.2.1.2 PKA-treatment of HOCM troponin increased the level of TnI phosphorylation ~15-
fold 
Phosphate affinity SDS PAGE was used to determine the level of TnI phosphorylation as 
before. The final protocol for PKA-treatment gave a level of TnI phosphorylation similar to 
that found in donor heart troponin. The level of TnI phosphorylation of the three PKA-
treated troponin were PH1 1.67 ±0.11 molsPi/molsTnI, PH2 1.86 ±0.14 molsPi/molsTnI, 
PH3 1.21 ±0.18 molsPi/molsTnI (n=4). Whereas the TnI phosphorylation level was low in 
the untreated HOCM troponin HB1 0.14 ±0.12 molsPi/molsTnI, HB2 0.06 ±0.04 
molsPi/molsTnI, HB3 0.07 ±0.05 molsPi/molsTnI (n=4). This is illustrated in the (Figure 
3.10). The level of TnI phosphorylation was not increased as much in the third PKA-treated 
troponin sample PH3 and the other two. Although only ~40% of the sample was bis-
phosphorylated this is still a large increase compared to the untreated sample (HB3) ~2%. 
Thus when this pair of troponin samples were reconstituted into thin filaments and 
investigated by IVMA a difference in Ca2+-sensitivity would still expected to be measured in 
non-diseased troponin.  
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Figure 3.10: Measurement of TnI phosphorylation in untreated and PKA-treated HOCM troponin 
  
 
  
 
 HB1 PH1 HB2 PH2 HB3 PH3 
2-P 4.30 68.71 1.65 86.81 1.90 39.38 
1-P 6.05 29.83 2.88 12.61 3.18 43.18 
0-P 89.65 1.46 95.46 0.58 94.93 17.45 
 
A)Western blot of phosphate affinity (phos-tag) SDS PAGE loaded with 20µl of sample (mixed 1:1 with 
sample buffer) a donor troponin sample (DC), HB1, PH1, HB2, PH2, HB3 and PH3. The Western blot was 
probed with 14G5 used at 1:2,000 dilution. B) Bar graph summarising TnI phosphorylation measurements. C) 
Summary table of mean occupancy of the different phospho-species of TnI (%). 
 
3.2.2 PKA-treated HOCM troponin regulated thin filaments in a Ca2+-sensitive 
manner 
The troponin titrations show that the PKA-treatment had no deleterious effects on the ability 
of the troponin to regulate the HOCM troponin. The troponin titration for PH2 and HB2 
(Figure 3.11) show that there was no increase in sliding speed at high [Ca2+] (3.7µM) and a 
small decrease in sliding speed at low [Ca2+] (1nM) over the range of 0 to 30nM of troponin. 
Over this range there was a slight increase in fraction motile. Maximal switch off (<10%) 
was achieved with 10nM of troponin for both the PKA-treated and untreated HOCM 
troponin containing thin filaments. The range of troponin concentrations used over the set of 
experiments was 0-60nM.  
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Figure 3.11: IVMA troponin titration for thin filaments containing H2 (red) and PH2 (green) troponin 
 
 
 
IVMA experiments titrating human cardiac HOCM (HB2) (red) and PKA-treated HOCM (PH2) (green) 
troponin over a range of 0-30nM. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human 
cardiac tropomyosin and troponin. The sliding speed of reconstituted thin filaments were measured at A) high 
[Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile were measured at C) high [Ca2+] (3.7µM) and 
D) low [Ca2+] (1nM).  
 
The bar graph (Figure 3.12) shows that for each troponin titration both the PKA-treated and 
untreated HOCM troponin samples consistently regulated their respective sets of thin 
filaments. 
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Figure 3.12: Summary bar graph of fraction motile measurement of the five troponin titrations  
 
    
Fraction motile data was plotted from all of the troponin titration IVMA experiments completed with thin 
filaments reconstituted with HOCM (red) and PKA-treated HOCM (green) troponin at high [Ca2+] (3.7µM) 
(solid) and low [Ca2+] (1nM) (striped). The concentration of troponin used was 20nM for HB1 & PH1, 10nM 
for HB2, PH2, HB2*, PH2*, HB3, PH3 and 30nM for HB3* & PH3*. 
 
 
3.2.3 No difference in Ca2+-sensitivity was measured between thin filaments with 
HOCM and PKA-treated HOCM troponin 
 
Eight Ca2+-concentration titrations were completed comparing thin filaments reconstituted 
with either PKA-treated HOCM troponin (PH1-3) or untreated HOCM (HB1-3) troponin. 
As found with the previous experiments, the range of sliding speed between high and low 
[Ca2+] was over 1µm/s. Therefore no conclusions about the difference in thin filament Ca2+-
sensitivities could be made. The unfitted data is shown in the appendix. In Ca2+-
concentration titration shown in Figure 3.13 the thin filaments reconstituted with PKA-
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treated HOCM troponin are more Ca2+-sensitive than the thin filaments with untreated 
HOCM troponin, however this pattern was not consistent. 
 
Figure 3.13:  Ca2+-concentration titrations comparing sliding speed of thin filaments containing 
untreated and PKA-treated HOCM troponin 
 
IVMA Ca2+-concentration titrations comparing the sliding speed of untreated HOCM (red) and PKA-treated 
HOCM (green) troponin. The thin filaments were composed of 10nM rabbit skeletal actin, 60nM human 
cardiac tropomyosin and 20nM troponin.  
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A summary of the maximum sliding speed is shown below (Table 3.3). This table shows that 
there is no difference in maximum sliding speed between thin filaments reconstituted with 
PKA-treated HOCM troponin or untreated HOCM troponin. (Student t-test, unpaired = 0.96, 
paired = 0.97) . 
 
Table 3.3: Summary of the sliding speed for thin filaments that contained either HOCM or PKA-treated 
HOCM troponin at high [Ca2+] (3.7µM) 
No. HOCM max. 
sliding speed 
(µm/s) 
SD PKA-HOCM max. 
sliding speed 
(µm/s)
 
SD HOCM/PKA-
HOCM 
I      HB1PH1 2.16 ± 0.05 2.40 ± 0.21 0.90 
II 2.91 ± 0.06 2.60 ± 0.13 1.12 
III    HB2PH2 2.50 ± 0.04 2.41 ± 0.11 1.04 
IV 2.25 ± 0.05 2.33 ± 0.06 0.97 
V 2.40 ± 0.04 2.49 ± 0.13 0.96 
VI    HB3PH3 2.25 ± 0.15 2.35 ± 0.09 0.96 
VII 2.90 ± 0.06 3.01 ± 0.12 0.96 
VIII 2.75 ± 0.20 2.51 ± 0.15 1.10 
      
mean 2.52 ± 0.3 2.51 ± 0.22 1.00 
     ± 0.08 
      
Student t-test:                              (paired):p= 0.97                            (unpaired):p= 0.96 
 
3.2.3.1 No difference was measured in the Ca2+-sensitive of fraction motile of thin 
filaments reconstituted with PKA-treated HOCM and untreated HOCM troponin 
 
The eight Ca2+-concentration titrations are shown in Figure 3.14 and Figure 3.15. The EC50 
values determined from these curves are summarised in Table 3.4. In summary, there was no 
significant difference between the fraction motile EC50 of thin filaments containing either 
PKA-treated HOCM troponin or untreated HOCM troponin. The mean EC50 ratio of HOCM 
to PKA-treated HOCM was 1.08 ±0.25 (Student t-test values unpaired =0.037, paired = 0.3).  
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Figure 3.14: Ca2+-concentration titrations comparing thin filament reconstituted with HOCM and PKA-
treated HOCM troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of untreated HOCM (red) and PKA-treated 
(green) HOCM troponin. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentration of troponin used was I) 20nM, II) 20nM, III) 20nM, IV)10nM 
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Figure 3.15: Ca2+-concentration titrations comparing thin filament reconstituted with HOCM and PKA-
treated HOCM troponin 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of untreated HOCM (red) and PKA-treated 
(green) HOCM troponin. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentration of troponin used was V) 60nM, VI) 10nM, VII) 30nM, VIII) 
30nM 
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Table 3.4: Summary of the fraction motile EC50 for thin filaments that contained either HOCM or PKA-
treated HOCM troponin. 
No. HOCM  
EC
50 
(µM) 
SD PKA-HOCM 
EC
50
(µM)
 
SD HOCM/PKA-
HOCM 
I      HB1 PH1 0.23 ± 0.06 0.17 ± 0.11 1.37 
II 0.09 ± 0.02 0.12 ± 0.05 0.77 
III    HB2 PH2 0.14 ± 0.08 0.16 ± 0.14 0.91 
IV 0.13 ± 0.01 0.15 ± 0.02 0.90 
V 0.14 ± 0.29 0.12 ± 0.02 1.18 
VI    HB3 PH3 0.27 ± 0.06 0.24 ± 0.06 1.13 
VII 0.08 ± 0.02 0.09 ± 0.01 0.95 
VIII 0.17 ± 0.02 0.11 ± 0.02 1.47 
        
mean 0.16 ± 0.07 0.14 ± 0.05 1.08 
     ±  0.25 
      
Student t-test:         (paired): p= 0.30                                  (unpaired):p= 0.37 
 
3.2.3.2 Conclusions from the comparison of thin filaments containing PKA-treated and 
untreated HOCM troponin. 
The aim of comparing PKA-treated and untreated HOCM troponin was to determine if TnI 
phosphorylation of HOCM troponin retained the ability to regulate thin filament Ca2+-
sensitivity. The aim was to select and prove which hypothesis about the relationship between 
TnI phosphorylation and thin filament Ca2+-sensitivity in HOCM troponin was correct. If a 
difference in Ca2+-sensitivitivity between the two sets of filaments had been detected it 
would suggest that TnI phosphorylation could still affect thin filament Ca2+-sensitivity but 
that this relationship was modified. However as no difference was detected, this suggests that 
the thin filament Ca2+-sensitivity and constituent TnI phosphorylation relationship is 
disrupted or uncoupled. It is unlikely that this uncoupling is due to a primary effect of the 
causative mutation as no mutation was identified in any of the troponin subunit genes. 
Therefore this must be due to a secondary consequence of the disease. One possible 
explanation for this is that the troponin complex is post-translational modified. Whatever the 
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cause HOCM troponin is modified functionally in some way. The next stage of this study 
was to attempt to determine which subunit of troponin is affected by exchanging or replacing 
the native subunits with recombinant subunits. 
3.3 The native TnI subunit of HOCM troponin was replaced with 
recombinant cardiac TnI 
To investigate if a disease related modification of the TnI subunit is responsible for the 
disruption of the relationship between thin filament Ca2+-sensitivity and TnI 
phosphorylation, the native TnI was exchanged with recombinant cardiac TnI. The samples 
used for this experiment were MR (unknown mutation) and MV (MyBP-C mutation 
IVS17±5G>T). Three preparations of exchanged TnI HOCM troponin were prepared 
(designated) XI1-3 alongside three control HOCM troponin samples HC1-3. The protocol is 
described in full (see 2.2.5.2), in summary myofilaments were washed and extracted, 
denatured with urea, renatured, and then the troponin purified using an affinity 
chromatography column with an anti-TnT antibody. The control troponin samples were 
treated in exactly the same manner as the exchanged troponin samples except no 
recombinant proteins were added after the denaturing step in 3M urea. The TnI 
phosphorylation of the starting material was measured by Dr. Andrew Messer from myofibril 
preparations. He determined the TnI phosphorylation of MR was 0.5±0.16 molsPi/molsTnI  
(n=4) and MV was 0.12±0.13 molsPi/molsTnI (n=8).  
3.3.1 85% of native TnI subunits were replaced by a recombinant TnI subunit 
The degree of exchange of native subunits with recombinant subunits was determined using 
phosphate affinity SDS PAGE. The recombinant TnI was expressed in an E.Coli system and 
therefore was not phosphorylated. Therefore recombinant TnI had zero TnI phosphorylation. 
It was possible to measure the decrease in TnI phosphorylation between the exchanged and 
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control HOCM troponin samples to calculate the degree of exchange. This would not have 
been possible using Pro-Q Diamond phospho-protein stain, as the level of TnI 
phosphorylation is relatively low in HOCM troponin to begin with. However phosphate 
affinity SDS-PAGE could distinguish between the two. An example of a Western blot of a 
phosphate affinity SDS PAGE is shown in Figure 3.16 and the summary bar graph is shown 
in Figure 3.17. The fourth preparation shown as HC4 and XI4 (prep X) were prepared but 
were not used in IVMA experiments.  
Figure 3.16: Quantification of exchanged TnI subunits 
  
 
 X13 HC3 XI2 HC2 XI1 HC1 XI4 HC4 DC 
2-P 0.24 0.22 0.37 0.28 0.31 0.31 0.16 0.27 15.56 
1-P 1.43 12.22 1.27 16.58 1.05 9.08 1.03 15.02 64.30 
0-P 98.33 87.57 98.36 83.13 98.65 90.60 98.80 84.70 20.14 
 
A)Western blot of phosphate affinity (phos-tag) SDS PAGE loaded with 15µl of sample (mixed 1:1 with 
samples buffer) a donor troponin sample (DC), HC1, XI1, HC2, XI2, HC3, XI3, HC4 and XI4. The Western 
blot was probed with 14G5 used at 1:2,000 dilution. B) Table summarising occupancy of phospho-TnI species 
(%). 
A 
B 
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The bar graph (Figure 3.17) illustrates that the exchange protocol was successful. The 
exchanged samples XI1 and XI3 were 85% exchanged and the XI2 troponin was 90% 
exchanged.  
 
Figure 3.17: Bar graph summarising the TnI phosphorylation measurement in TnI exchanged and non-
exchanged HOCM troponin  
 
  
The measurement of TnI phosphorylation is plotted above, from the respective HOCM (red) and HOCM 
exchanged with recombinant TnI (purple) samples. The graph effectively demonstrates the amount of 
exchange, as the reduction in TnI phosphorylation is due to the replacement of native TnI subunits for 
recombinant ones. 
 
3.3.2  HOCM troponin exchanged with recombinant TnI regulated thin filaments in a 
Ca2+-sensitive manner 
 
Before any Ca2+-sensitivity data could be obtained it was first important to determine if 
exchanged troponin would regulate thin filaments. This was again confirmed by the troponin 
titration experiments. The troponin was not quantified by Lowry assay, as before, due to the 
short lifetime of the protein and the limited amount of functional protein in the sample. 
Concentration was estimated from SDS-PAGE of the elution fractions in comparison with 
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previous non-exchanged troponin preparations. Regulation of thin filaments was obtained in 
preliminary experiments when stock solution of purified troponin was estimated as ~2µM. 
The reason more troponin was required is probably due degradation of troponin. This could 
be due to degradation caused by the denaturing step (in 6M urea) or because of the extra time 
taken (~24 hours) to complete the protocol. Nevertheless the exchanged troponin samples 
only seemed to maintain the ability to regulate thin filaments for ~24 hours and thus had a 
reduced functional lifetime. This meant the troponin titration was vital to show that the thin 
filaments were saturated with functional troponin. The troponin samples were titrated over 
an approximate range of 0-100nM. At high [Ca2+] (3.7µM) there was only a slight increase 
in sliding speed and at low [Ca2+] (1nM) there was a slight decrease as seen before. The 
number of motile filaments were constant over the troponin titration at high [Ca2+], and good 
inhibition of movement was detected at low [Ca2+]. Therefore the exchanged troponin 
samples were functional and regulated thin filaments motility. 
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Figure 3.18: IVMA troponin titration for thin filaments containing unexchanged and TnI exchanged 
HOCM troponin  
 
     
 
   
IVMA experiments titrating unexchanged HOCM troponin (HC2) (red) and HOCM troponin exchanged with 
recombinant TnI (XI2) (purple). Thin filaments were composed of 10nM rabbit skeletal actin, 60nM 
tropomyosin and troponin. The sliding speed was measured at A) high [Ca2+] (3.7µM) and B) low [Ca2+] (1nM) 
and the fraction motile at C) high [Ca2+] (3.7µM) and D) low [Ca2+] (1nM) over a troponin concentration range 
0-60nM. 
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The bar graph (Figure 3.19) demonstrates that all three exchanged troponin samples were 
functional although with slightly more variability than an unexchanged troponin sample. 
This is unsurprising as the exchange protocol does involve exposing troponin to denaturing 
and renaturing conditions, whilst also keeping the troponin in solutions with a low total 
protein concentration at various stages, which has also been shown to reduce troponin 
function.  
 
Figure 3.19: Summary bar graph of fraction motile measurement of the three troponin titrations 
completed before Ca2+-sensitivity data was acquired 
  
Fraction motile data was plotted from all of the troponin titration IVMA experiments completed with thin 
filaments reconstituted with unexchanged HOCM (red) and HOCM troponin exchanged with recombinant TnI 
(purple) troponin at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The concentration of troponin 
used was 20nM for HC1 & XI1, 60nM for HC2 & XI2 and 100nM for HC3 & 80nM for XI3. 
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3.3.3 No difference in Ca2+-sensitivity was measured between thin filaments with 
either HOCM troponin exchanged with recombinant TnI or unexchanged 
HOCM troponin  
 
Four Ca2+-concentration titrations were completed using the samples XI1-3 and their 
respective controls HC1-3. One sliding speed Ca2+-concentration titration is shown in Figure 
3.20. As before all unfitted data is shown in the appendix. Over the four Ca2+-concentration 
titrations there is no trend with the maximum sliding speed. The summary of the data (Table 
3.5) confirms there is no difference in the maximum sliding speed. Taken together with the 
other unfitted sliding speed Ca2+-sensitivity curves the conclusion is that no difference in 
Ca2+-sensitivity was detected between thin filaments with TnI exchanged HOCM troponin 
and those with unexchanged HOCM troponin. 
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Figure 3.20: An example of a Ca2+-concentration titration comparing sliding speed of thin filaments 
containing HOCM and TnI exchanged HOCM troponin.  
 
IVMA Ca2+-concentration titrations comparing the sliding speed of untreated HOCM (red) (HC3) and HOCM 
troponin exchanged with recombinant TnI troponin (purple) (XI3). The thin filaments were composed of 10nM 
rabbit skeletal actin, 60nM human cardiac tropomyosin and HC3 100nM and XI 80nM troponin.  
 
Table 3.5: Summary of the sliding speed for thin filaments that contained either HOCM or TnI 
exchanged HOCM troponin at high [Ca2+] (3.7µM) 
No. 
HOCM XI max. 
sliding speed 
(mm/s)   
SD 
 
 
  
HOCM max.  
sliding speed 
(mm/s) 
SD 
 
 
  
HOCM XI/ 
HOCM 
 
 
I     H1XI1 3.02 ± 0.03 3.16 ± 0.10 0.96 
II    H2XI2 2.68 ± 0.05 2.73 ± 0.06 0.98 
III   H3XI3 3.31 ± 0.10 2.96 ± 0.07 1.12 
IV 3.27 ± 0.12 2.72 ± 0.10 1.20 
      
mean 3.07 ± 0.29 2.89 ± 0.21 1.06 
      ±0.11 
      
Student t-
test 
 (paired):p= 0.36                            (unpaired):p= 0.34 
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3.3.3.1 No difference was measured in the Ca2+-sensitive of fraction motile of thin 
filaments reconstituted with HOCM troponin exchanged with recombinant TnI and 
unexchanged HOCM troponin  
 
As only four Ca2+-sensitivity curves were obtained from these samples only preliminary 
conclusions could be drawn. However there is no significant difference between thin 
filament of fraction motile Ca2+-sensitivity between filaments that contained either 
unexchanged HOCM troponin or HOCM troponin exchanged with recombinant TnI. The 
ratio of fraction motile EC50 of thin filaments with exchanged troponin to unexchanged 
troponin 1.01 ±0.1 and the statistical tests (unpaired student t-test = 0.77, paired student t-test 
= 0.8 n=4). The consistency of the curves adds further weight to this finding. 
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Figure 3.21: Ca2+-concentration titrations comparing thin filament reconstituted with HOCM or HOCM 
troponin exchanged with recombinant TnI  
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of untreated HOCM (red) and HOCM 
troponin exchanged with recombinant TnI troponin (purple). The thin filaments were composed of 10nM rabbit 
skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentration of troponin used was I) 
20nM, II) 60nM, III&IV) XI 80nM, HC 100nM 
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Table 3.6: Summary of the fraction motile EC50 for thin filaments that contained either HOCM or TnI 
exchanged HOCM troponin 
No. 
HOCM  
EC50 (mM)  
SD 
 
 
HOCM XI 
EC50 (mM) 
SD 
 
 
HOCM XI 
/HOCM 
I     HC1XI1 0.13 ± 0.02 0.12 ± 0.04 0.94 
II    HC2XI2 0.20 ± 0.01 0.23 ± 0.03 1.15 
III   HC3XI3 0.15 ± 0.02 0.14 ± 0.01 0.96 
IV 0.31 ± 0.04 0.31 ± 0.01 1.01 
        
mean 0.20 ± 0.08 0.20 ± 0.09 1.01 
          ±0.1 
      
Student t-
test: 
               (paired):p= 0.80                             (unpaired):p= 0.77 
 
3.3.3.2 Conclusions from the comparison of thin filaments containing HOCM troponin 
exchanged with recombinant TnI and unexchanged HOCM troponin 
 
The first conclusion is that the native HOCM TnI subunits were almost fully replaced 
(≥85%) by recombinant subunits in the exchanged samples. By replacing the native TnI 
subunit it was possible to investigate if this subunit was modified in HOCM troponin. If the 
TnI subunit was modified as a consequence of the disease then replacement with a 
recombinant (unmodified) subunit would restore the relationship between Ca2+-sensitivity 
and TnI phosphorylation. Therefore thin filaments reconstituted with exchanged HOCM 
troponin would be more Ca2+-sensitive than thin filaments with unexchanged HOCM 
troponin due to the low level of recombinant TnI phosphorylation. However as the trend 
shown was no difference in Ca2+-sensitivity between the two sets of filaments these results 
suggest that the HOCM TnI subunit is not modified and that the modification lies elsewhere. 
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3.4 The native TnT subunit of HOCM troponin was replaced with 
recombinant TnT3 
To investigate if the native HOCM TnT subunit is modified in the HOCM heart native TnT 
subunit was exchanged with a recombinant TnT3 subunit. The sample used for these 
experiments was MU. Dr. Messer determined that TnI phosphorylation of MU was 0.4 ±0.2 
molsPi/molsTnI using myofibril gel samples and phosphate affinity SDS-PAGE (n=8). Three 
pairs of samples were prepared, the HOCM troponin exchanged with recombinant TnT 
(XT1-3) and the unexchanged HOCM troponin (HD1-3). 
3.4.1 85% of native TnT subunits were replaced by a recombinant TnT subunit 
Phosphate affinity SDS PAGE has not been developed to measure the phosphorylation level 
of TnT yet. Therefore SDS PAGE followed by Pro-Q Diamond and SYPRO staining was 
used. The methodology for measuring the amount of exchange is similar to that used to 
measure TnI exchange. The recombinant TnT subunit had zero phosphorylation. Therefore 
by determining the reduction in the amount of phosphorylated TnT present in the exchanged 
troponin, the exchange was quantified. An example of a gel stained with Pro-Q Diamond and 
SYPRO is shown (Figure 3.22) 
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Figure 3.22: Quantification of exchanged TnT subunits 
 
A) SDS PAGE loaded with 20µl of sample (mixed 1:1 with samples buffer) a donor troponin sample (DC), 
HD1, XT1, HD2, XT2, HD3 and XT3. The gel was fixed and then stained with Pro-Q Diamond 
phosphoproteins stain and post-stained with the total protein stain SYPRO. 
 
The ratio of signal from the Pro-Q Diamond stain to that from the SYPRO stain was 
calculated for each TnT band, these data are illustrated in the bar graph below (Figure 3.23). 
The protocol led to an ≥85% replacement of native TnT subunit with recombinant TnT 
subunits.  
Figure 3.23: Bar graph summarising the TnT phosphorylation measurement in TnT exchanged and non-
exchanged HOCM troponin 
  
The measurement of TnI phosphorylation is plotted above, from the respective HOCM (red) and HOCM 
exchanged with recombinant TnT (black) samples. The graph effectively demonstrates the amount of exchange, 
as the reduction in TnT phosphorylation is due to the replacement of native TnT subunits for recombinant ones. 
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3.4.2 HOCM troponin exchanged with recombinant TnT regulated thin filaments in a 
Ca2+-sensitive manner  
 
A troponin titration was completed to confirm that the exchanged troponin was functional. 
The concentration of functional troponin in the stock solution was estimated as 2µM. The 
two troponin samples were titrated over a range of 0-100nM. The titration shown (Figure 
3.24) shows a slightly higher sliding speed of the unexchanged troponin at high [Ca2+] 
(3.7µM) but this result was not consistent across the three troponin titrations completed and 
there was no other clear patterns. At low [Ca2+] the sliding speed there was also no consistent 
pattern. Both the exchanged and unexchanged troponin samples did inhibit movement of thin 
filaments at low [Ca2+] as shown by the reduction in fraction motile (<0.1). This inhibition 
was not present at high [Ca2+] as there was no reduction of the fraction motile (>0.7). 
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Figure 3.24: A troponin titration for thin filaments containing unexchanged and TnT exchanged HOCM 
troponin 
 
 
 
IVMA titrating unexchanged HOCM troponin (red) and HOCM troponin exchanged with recombinant TnT 
(XT2) (black) Thin filaments were composed of 10nM rabbit skeletal actin, 60nM tropomyosin and troponin. 
The sliding speed was measured at A) high [Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile at 
C) high [Ca2+] (3.7µM) and D) low [Ca2+] (1nM) over a troponin concentration range 0-60nM. 
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The bar graph (Figure 3.25) shows the three sets of troponin samples. It demonstrates that 
when reconstituted into thin filaments both the TnT exchanged and unexchanged HOCM 
troponin regulated thin filament motility. As seen in the TnI exchange experiments there was 
some degree of variability, but again this is probably due to exposure to the exchange 
protocol. 
 
Figure 3.25: Summary bar graph of fraction motile measurement of the three troponin titrations 
completed before Ca2+-sensitivity data was acquired 
  
Fraction motile data was plotted from all of the troponin titration IVMA experiments completed with thin 
filaments reconstituted with unexchanged HOCM (red) and HOCM troponin exchanged with recombinant TnT 
(black) troponin at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The concentration of troponin 
used was 20nM for HD1 & XT1, 30nM for HD2 & XT2 and 100nM for HD3 & XT3.  
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3.4.3 No difference in Ca2+-sensitivity was measured between thin filaments with 
either HOCM troponin exchanged with recombinant TnI or unexchanged 
HOCM troponin  
Four Ca2+-concentration titrations were completed using the samples XT1-3 and their 
respective controls HD1-3. An example of a sliding speed graph is shown in Figure 3.26, the 
unfitted curves are present in the appendix. There is no difference in maximum sliding speed 
between the two sets of filaments (Student t-test unpaired =0.97, paired =0.91). 
 
Figure 3.26: Example of Ca2+-concentration titrations comparing sliding speed of thin filaments 
containing HOCM and TnT exchanged HOCM troponin. 
 
 
IVMA Ca2+-concentration titrations comparing the sliding speed of untreated HOCM (red) (HD2) and HOCM 
troponin exchanged with recombinant TnT troponin (purple) (XT3). The thin filaments were composed of 
10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and 30nM troponin.  
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Table 3.7: Summary of the sliding speed for thin filaments that contained either HOCM or TnT 
exchanged HOCM troponin at high [Ca2+] (3.7µM) 
No. 
 
 
 
HOCM XT 
max. sliding 
speed (µm/s)   
SD 
 
 
 
HOCM max. 
sliding speed 
(µm/s) 
 
SD 
 
 
 
HOCM XT 
/HOCM 
 
 
I    HD1XT1 3.05 ± 0.06 2.57 ± 0.20 1.19 
II   HD2XT2 2.54 ± 0.02 2.91 ± 0.09 0.87 
III 2.69 ± 0.09 2.88 ± 0.38 0.93 
IV  HD3XT3 2.51 ± 0.10 2.52 ± 0.09 1.00 
        
mean 2.70 ± 0.25 2.72 ± 0.20 1.00 
        ±0.14 
        
Student t-
test 
                   (paired):p= 0.91                             (unpaired):p= 0.97 
 
 
3.4.3.1 A two-fold difference was measured in the Ca2+-sensitive of fraction motile of thin 
filaments reconstituted with HOCM troponin exchanged with recombinant TnT and 
unexchanged HOCM troponin 
 
There does seem to be a pattern that HOCM troponin exchanged with recombinant TnT were 
more Ca2+-sensitive than the unexchanged troponin in three out of the four curves. This is 
highlighted by the mean ratio of the EC50 for exchanged HOCM troponin to the EC50 for 
unexchanged HOCM troponin of 0.61 ±0.31. This suggests that the replacement of the native 
TnT subunit with a recombinant subunit leads to an ~2-fold increase in Ca2+-sensitivity 
(student t-test unpaired 0.09, paired 0.13). The other curve showed no difference in Ca2+-
sensitivity between the two sets of thin filaments.  
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Figure 3.27: Ca2+-concentration titrations comparing thin filament reconstituted with HOCM or TnT 
exchanged HOCM troponin 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of untreated HOCM (red) and HOCM 
troponin exchanged with recombinant TnT troponin (black). The thin filaments were composed of 10nM rabbit 
skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentration of troponin used was I) 
20nM, II) 30nM, III) XT 60nM H 50nM, IV) 100nM 
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Table 3.8: Summary of the fraction motile EC50 for thin filaments that contained either HOCM or TnI 
exchanged HOCM troponin. 
No. 
HOCM XT 
EC50 (mM)   
SD 
 
 
HOCM 
EC50 (mM) 
SD 
 
HOCM XT 
/HOCM 
I    HD1XT1 0.05 ± 0.01 0.14 ± 0.19 0.36 
II   HD2XT2 0.05 ± 0.01 0.09 ± 0.01 0.58 
III 0.09 ± 0.05 0.21 ± 0.02 0.43 
IV  HD3XT3 0.14 ± 0.03 0.13 ± 0.02 1.06 
        
mean 0.08 ± 0.04 0.15 ± 0.05 0.61 
        0.31 
        
Student t-
test 
                      (paired):p= 0.13                           (unpaired):p= 0.09 
 
3.4.3.2 Conclusions from the comparison of thin filaments containing HOCM troponin 
exchanged with recombinant TnT and unexchanged HOCM troponin 
 
The pattern shown in ¾ of the Ca2+-concentration titrations comparing TnT exchanged and 
unexchanged troponin samples suggest that by replacing the native TnT subunit with a 
recombinant subunit the relationship between Ca2+-sensitivity and TnI phosphorylation can 
be (at least partially) restored. Therefore the TnT may be modified as a result of HOCM 
remodelling and when this modified subunit is replaced the relationship is restored. Further 
experimentation would be required to confirm this finding. There are other explanations as to 
why this effect was observed. One is that the recombinant TnT is not phosphorylated at 
serine 3 like the native subunit is and this difference in TnT phosphosphorylation may be 
responsible for the difference in Ca2+-sensitivity. Lastly TnC has not been investigated. In 
some respects this is the most likely subunit to affect Ca2+-sensitivity as this is the subunit 
which directly binds Ca2+. Therefore TnC may also be modified as part of the HOCM 
disease process and in combination with the modification of TnT result in the full uncoupling 
of the thin filament Ca2+-sensitivity regulation by constituent TnI phosphorylation.  
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3.5 Discussion 
 
3.5.1 Sources of donor and HOCM tissue 
This study in this chapter follows on from previous work completed investigating HOCM 
troponin. Biopsy tissue was obtained from HOCM patients diagnosed with a severe LVOTO 
that warranted surgical intervention and was stored in an onsite tissue bank along with 
explanted donor heart samples (where no recipient was found) that had been sent from the 
University of Sydney, Australia by Prof. C dos Remedios. The donor heart samples that were 
used in this study are from a group of samples that have been studied previously by the 
Marston laboratory and by other laboratories (Hamdani et al., 2008, Jacques et al., 2008a, 
Messer et al., 2007). Thus they are accepted as a good source of healthy human heart tissue. 
Tissue removed from HOCM patients via a septal myectomy operation has been used as a 
source of tissue in other studies of HOCM (Hoskins et al., 2010, van Dijk et al., 2009, Belus 
et al., 2008). Tissue collected and stored in the onsite tissue bank has also been sent to other 
laboratories for investigation (Hoskins et al., 2010, Vikhorev, 2011)  
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3.5.2 Purification of troponin 
The troponin purification protocol used in this chapter was developed by Dr. Andrew Messer 
(Messer et al., 2007). The main feature of this protocol is the use of a column with an anti-
TnI monoclonal antibody matrix (Katrukha et al., 1995). The troponin purification protocol 
used in this thesis was unchanged from that developed by Messer. The majority of troponin 
preparations were of a good quality, such that they satisfied the following criteria:  
1) High purity, just T, I and C subunits were present in the elution fraction 
2) The concentration, as determined by Lowry assay, was >5µM 
3) TnI phosphorylation level was same as tissue from which it was purified 
4) Capable of regulating thin filament in a Ca2+-sensitivity manner in IVMA 
The troponin was usually functional for up-to two days after purification which is also 
comparable to the preparations by Dr. Messer. 
3.5.3 In vitro motility assay experiments 
The IVMA has been used extensively within the Marston laboratory for the last 10 years. 
Within this time a number of researchers have used the technique to investigate a variety of 
thin filament proteins (Messer et al., 2007, Song et al., 2011, Dyer et al., 2009, Mirza et al., 
2005, Marston, 2003). Most commonly troponin was purified from two sets of tissue (usually 
control and test) and then reconstituted into thin filaments for paired investigation by IVMA. 
Initial experiments were then completed to ensure each respective set of filaments matched 
established criteria for the assay, e.g. a sliding speed of ≥ 2µm/s and a fraction motile of 
>80%. The addition of tropomyosin only resulted in a very small increase in the motile 
parameters, which mirrors results found previously, though not in all studies. The variability 
of the activation effect of tropomyosin seems to depend on the tropomyosin preparation. 
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Lastly fully reconstituted thin filaments were examined at low and high [Ca2+] over a range 
of troponin concentrations to determine the optimum troponin concentration to use for Ca2+-
concentration titrations. In the most recent of these studies, at high [Ca2+] there was no 
consistent increase in sliding speed and fraction motile which remained at ~2µm/s and >80% 
in a fashion very similar to the results shown in this chapter. At low [Ca2+] there was a vast 
decrease in fraction motile to <10% and a small reduction in sliding speed of ~30%. This 
was found in all sets of thin filaments, including those where the level of TnI 
phosphorylation had been increased and those where a native subunit was exchanged with a 
recombinant one. Therefore, the Ca2+-regulated movement of reconstituted filaments as 
measured by the IVMA worked in a manner very similar to that of previous investigators, 
thus validating the experimental technique used to acquire the results for this chapter. 
 
3.5.4 Normal distribution of EC50 values 
Due to the relatively small amount of data individual experiments could not be tested for 
normality. Therefore all of the EC50 values for experiments completed with thin filaments 
containing (untreated/control) HOCM troponin were compiled into the histogram below (see 
Figure 3.28). This histogram shows an approximately normal distribution supported by 
previous work completed by Dr. Messer (see 2.4.11.4). Thus it is appropriate to utilise the 
Student t-test to test for statistical significance.  
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Figure 3.28: Histogram of EC50 values for thin filament with HOCM troponin 
 
The histogram is composed of the EC50 values (µM) of all the experiments completed with HOCM troponin in 
this chapter (MT(8), MM(8), MR(3), MV(1), MU (4) – 24 in total).  
 
3.5.5 Measurements of TnI phosphorylation 
In this chapter the main technique used to measure TnI phosphorylation was phosphate-
affinity SDS PAGE since it is the most accurate and quantitative assay available. Although 
Pro-Q Diamond staining was also used to evaluate some of the work completed in 
developing the PKA-treatment protocol and also to determine the exchange of native TnT for 
recombinant TnT. The majority of phosphate-affinity SDS PAGE measurements of TnI 
phosphorylation recorded in the Marston laboratory used myofibril gel sample preparation. 
However measurements completed for this chapter used purified troponin. These results are 
summarised in the table below (Table 3.9). 
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Table 3.9: Summary of TnI phosphorylation measurements 
Sample 
Measurement of 
pure Tn prep. 
(molsPi/molsTnI) 
Ratio of species 
(2P-1P-0P) 
Measurement of 
myofibrils prep. 
(molsPi/molsTnI) 
Ratio of species 
(2P-1P-OP) 
 
MT 0.28±0.14 3-24-73 0.32±0.15 6-20-74 
MM 0.09±0.08 3-4-93 0.17±0.25 2-16-82 
NI 1.60±0.11 70-19-10 1.81±0.06 82-16-2 
 
All these measurements are similar enough to be considered consistent. Therefore no 
difference occurred as the result of the difference in sample preparation and the results 
obtained from the purified troponin samples are accurate. Thus troponin purified for this 
study retained the relative level of TnI phosphorylation as measured in the tissue from which 
it was extracted. The level of TnI phosphorylation in troponin purified from donor heart was 
~5-fold higher than that measured in troponin purified from HOCM heart. Measurements on 
PKA-treated HOCM troponin and on HOCM troponin exchanged with recombinant TnI can 
also be considered accurate as these were also determined using phosphate-affinity SDS-
PAGE.  
 
3.5.6 IVMA results for donor and HOCM troponin 
The starting point for this chapter is the observation by Dr Jacques and Dr. Messer that the 
Ca2+-sensitivity of thin filaments that contained HOCM troponin was the same as those with 
donor troponin despite a large difference in the level of TnI phosphorylation. Previous 
IVMA comparisons of donor and failing heart troponin showed a difference in TnI 
phosphorylation resulted in a difference in a 2.5-fold difference in thin filament Ca2+-
sensitivity (Messer et al., 2007). However when donor and HOCM troponin were compared 
no difference in thin filament Ca2+-sensitivity was detected. Results of the Messer & Jacques 
study are shown below (Figure 3.29). This shows that failing heart troponin had a low level 
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of TnI phosphorylation and when this was reconstituted into thin filaments, those filaments 
had a higher Ca2+-sensitivity. Also shown are result from donor troponin that have a 
relatively high level of TnI phosphorylation. When donor troponin was reconstituted into 
thin filaments, those filaments had a lower Ca2+-sensitivity. The odd group out is located at 
in the bottom right corner. These are samples of HOCM troponin that despite their low level 
of TnI phosphorylation when reconstituted into thin filaments maintained a relatively low 
Ca2+-sensitivity. 
 
Figure 3.29: Summary of results of Messer study of TnI phosphorylation and effect on thin filament 
Ca2+-sensitivity 
 
This final group compare well to the results in this chapter (see Figure 3.30). The actual EC50 
values are slightly different between all three studies but these differences are not significant. 
The empirical values determined for EC50 are not constant but lay within a range. This 
variation is because this in vitro system is composed of a number of different elements that 
are prepared de novo for each set of experiments due to the short functional half-lives of 
some elements. This is the main reason why paired flow cells are used, so that direct 
comparisons can be made. Thus the results in this chapter reflect those found in a previous 
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study: that despite a difference in TnI phosphorylation when donor and HOCM troponin are 
reconstituted into thin filaments and compared no difference in thin filament Ca2+-sensitivity 
is apparent. In the study by Dr. Messer and Dr Jacques the Hill coefficient of the Ca2+-
sensitivity curves were usually between 1-3 and this was also seen in this chapter. They also 
found no difference in the maximal sliding speed between the two sets of filaments which 
was also found in this work. The result from the work by Dr. Jacques and Dr. Messer was 
confirmed by results in this chapter, thus it was necessary to attempt to explain the reasons 
for this result. 
Figure 3.30: Summary of results from this study comparing thin filaments containing either donor or 
HOCM troponin 
 
 
The implications from the combination of these experiments is that the relationship between 
TnI phosphorylation and thin filament Ca2+-sensitivity appeared to be disrupted in troponin 
from HOCM heart. To determine if this was true further experimentation with HOCM 
troponin was required. Three possible techniques could have been employed. The first of 
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these would have been to purify a pair of troponin samples, one from a donor heart and the 
other from a HOCM heart and treat them both with phosphatase to reduce the level of TnI 
phosphorylation. This would have reduced the level of TnI phosphorylation in both troponin 
samples to ~zero. These dephosphorylated troponin samples would then be investigated by 
IVMA. Phosphatase treatments of troponin have been previously used in the Marston 
laboratory, and in fact Dr. Messer and Dr. Jacques completed this exact experiment, although 
only once (Jacques et al., 2008a). The dephosphorylated donor troponin containing filaments 
were ~2-fold more Ca2+-sensitive than the filaments with dephosphorylated HOCM troponin. 
Again demonstrating the fixed Ca2+-sensitivity of thin filaments reconstituted with HOCM 
troponin in contrast to donor heart. Preliminary work was completed to optimise phosphatase 
treatment to complete further sets of these experiments. However this was not successful and 
a significant reduction in donor troponin phosphorylation could not be obtained using the 
previously successful technique that utilised potato acid phosphatase. A subsequent study 
completed by Dr. Messer concluded that the batches of potato acid phosphatase currently 
available do not work as well as previous batches. Thus this thread of investigation was not 
followed any further.  
 
The second option was to compare by IVMA thin filaments containing either native HOCM 
troponin or HOCM troponin with a higher level of TnI phosphorylation. If the relationship 
between thin filament Ca2+-sensitivity and TnI phosphorylation is not disrupted then a 
difference in thin filament Ca2+-sensitivity would be measured due to the difference in TnI 
phosphorylation. However if this relationship was disrupted no difference would be 
measured. The final option would be replace or exchange the TnI subunit of HOCM troponin 
with either an untreated or PKA-treated recombinant TnI subunit. This again would allow for 
the comparison of two HOCM troponin samples with differing level of TnI phosphorylation. 
193 
The exchange protocol was not used for this purpose as the PKA-treatment of HOCM 
troponin gave a clear result, but it was used to determine which subunit of HOCM troponin 
was modified. 
 
3.5.7 PKA-treatment of HOCM troponin 
PKA had been used previously in the Marston laboratory to phosphorylate recombinant TnI, 
but not to phosphorylate TnI while still in the native troponin complex. Messer et al built on 
previous work to develop a method to phosphorylate recombinant TnI (Messer et al., 2007, 
Messer et al., 2009). The protocol developed by Dr Messer was the starting point for the 
development of the PKA-treatment protocol used in this chapter. It provided useful 
information for the amount of enzyme and the composition of buffer that should be used. 
However the work by Messer involved the phosphorylation of a recombinant protein and 
thus did not have to take into account preservation of the functionality of the troponin 
complex. This is the main reason why further development work was required and why the 
eventual protocol took place at 4°C (overnight) instead of 35°C (for 80 minutes). The final 
protocol increased the level of TnI phosphorylation of HOCM troponin ~15-fold as 
measured by phosphate-affinity SDS-PAGE. This troponin regulated thin filaments in a 
similar manner to untreated HOCM and donor troponin samples used in the previous section 
of work. PKA-treatments have also been successfully used to increase the level of TnI 
phosphorylation in skinned myocytes (van der Velden et al., 2003, Hamdani et al., 2008, 
Hoskins et al., 2010).  
 
In this chapter the phosphorylation of HOCM TnI was increased to a level similar to that 
found in donor heart TnI with PKA-treatment and compared to untreated HOCM troponin by 
IVMA. The overall result from these experiments was that there was no difference in thin 
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filament Ca2+-sensitivity between thin filaments containing either untreated HOCM troponin 
or PKA-treated HOCM troponin (see Figure 3.31). The mean fraction motile EC50 value 
(µM) for HOCM troponin was 0.16±0.065 and 0.14±0.047 for PKA-treated HOCM 
troponin. These values are very close to those measured in the first section comparing donor 
and HOCM troponin which adds further creditability to these results. This result confirmed 
the hypothesis that the relationship between thin filament Ca2+-sensitivity and TnI 
phosphorylation is disrupted in HOCM troponin.  
 
Figure 3.31: Summary of results from this study comparing thin filaments containing either untreated 
HOCM or PKA-treated HOCM troponin 
 
The comparison of donor & HOCM troponin and HOCM & PKA-treated HOCM troponin 
clearly show that the relationship between thin filament Ca2+-sensitivity and TnI 
phosphorylation is disrupted or uncoupled in HOCM troponin. The cause for this uncoupling 
is unlikely to be due to a mutation in the troponin (as none was identified), therefore it was 
hypothesised that this was due to a modification of the troponin complex that occurs as a 
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result of the disease process. The identity of such a modification could not be determined 
during the course of this investigation. However, it was possible to investigate which subunit 
is affected by the putative modification. This was investigated by replacing native TnT or 
TnI subunits with recombinant subunits in HOCM troponin. The replacement of a modified 
subunit with a recombinant subunit would remove such a modification and thus restore the 
coupling of thin filament Ca2+-sensitivity to TnI phosphorylation. As HOCM troponin has a 
low level of TnI phosphorylation, exchange of a modified subunit should result in a higher 
thin filament Ca2+-sensitivity when measured by IVMA. Thus, if a difference in thin filament 
Ca2+-sensitivity is apparent between the two sets of filaments this suggests that the replaced 
subunit was disrupting the coupling of thin filament Ca2+-sensitivity and TnI 
phosphorylation. 
 
3.5.8 The troponin subunit exchange protocol 
The replacement or exchange of native troponin subunits by recombinant proteins was used 
in the study by Messer (Messer et al., 2007). This method was the basis of the protocol used 
in this thesis, although a slight amendment was made to remove a redundant step involving 
dialysis into a low salt buffer. In this chapter both the native TnI and TnT subunits were 
replaced by recombinant versions of the same subunit. The method used for quantifying the 
proportion of exchanged subunits was different for the two different subunits. Native HOCM 
TnI has a low level of phosphorylation, but the difference between a low level and zero (as 
found in recombinant TnI) was still well defined by phosphate affinity SDS PAGE. Thus the 
amount of native HOCM TnI replaced by recombinant TnI was calculated to be >85%. The 
constant level of TnT phosphorylation was the property used to distinguish between native 
HOCM TnT subunits and unphosphorylated recombinant TnT subunits. The method used to 
determine proportion of subunit exchange was SDS PAGE with phospho-protein stain Pro-Q 
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Diamond and SYPRO staining. The proportion of native TnT subunits exchanged with 
recombinant TnT subunits was calculated to be >85%. Thus for both these exchange 
experiments the vast majority of the native subunit was replaced by a recombinant subunit. 
 
3.5.9 IVMA results for HOCM troponin exchanged with recombinant subunits 
When native HOCM troponin and HOCM troponin exchanged with recombinant TnI were 
reconstituted into thin filaments and measured by IVMA, no difference in thin filament Ca2+-
sensitivity was measured between them. The fraction motile EC50 (µM) was 0.2±0.08 for 
HOCM troponin and 0.2±0.09 for HOCM troponin exchanged with recombinant TnI. There 
was a difference in TnI phosphorylation but this was only minimal and although this could 
be used to determine proportion of subunit exchange it would be unlikely to result in a 
resolvable difference in thin filament Ca2+-sensitivity as measured by IVMA. This result was 
confirmed by subsequent experimentation by Dr. Andrew Messer who completed a further 
two Ca2+-sensitivity curves using the same exchange protocol but with sample MS (unknown 
mutation). The ratio of fraction motile EC50 for HOCM XI/HOCM for the two experiments 
were 0.95 and 1.09. Table 3.10 below shows the complete data set. Therefore it would seem 
no modification had been made to the native TnI subunit in HOCM troponin. If such a 
modification had been present, the removal of the native TnI subunit with such a 
modification and exchange with an unmodified recombinant subunit should have resulted in 
an increase in a higher Ca2+-sensitivity when measured by IVMA. To completely prove this 
point, future experiments could take an untreated recombinant TnI and a PKA-treated TnI 
and exchange these into two samples of the same HOCM troponin and be compared using 
the IVMA. This experiment would absolutely determine that the TnI subunit is not modified 
in the HOCM heart. 
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Table 3.10: Summary of the fraction motile EC50 for thin filaments that contained either HOCM or TnI 
exchanged HOCM troponin with addition data from Dr. Messer 
No. 
HOCM  
EC50 (mM)  
SD 
 
 
HOCM XI 
EC50 (mM) 
SD 
 
 
HOCM XI 
/HOCM 
I     HC1XI1 0.13 ± 0.023 0.12 ± 0.037 0.94 
II    HC2XI2 0.20 ± 0.009 0.23 ± 0.031 1.15 
III   HC3XI3 0.15 ± 0.019 0.14 ± 0.008 0.96 
IV 0.31 ± 0.043 0.31 ± 0.014 1.01 
V       Messer 0.12 ± 0.026 0.11 ± 0.015 0.95 
VI 0.08 ± 0.005 0.09 ± 0.012 1.09 
        
mean 0.16 ± 0.080 0.17 ± 0.084 1.01 
          ± 0.09 
      
Student t-
test 
                   ( paired): p = 0.81                (unpaired): p = 0.65 
 
 
When native TnT was exchanged with recombinant TnT3 in HOCM troponin and compared 
by IVMA a difference in thin filament Ca2+-sensitivity was detected in three out for four 
experiments. The mean fraction motile EC50 (µM) for were 0.08±0.04 for HOCM troponin 
exchanged with recombinant TnT and 0.15±0.05 for (non-exchanged) HOCM troponin, 
which are again in the acceptable range. Due to the small number of experiments this 
difference was not statistically significant and no further experiments could be completed 
due to time constraints. The results obtained do suggest that a 2-fold increase in thin filament 
Ca2+-sensitivity may occur due to the replacement of the native TnT subunit with a 
recombinant TnT3 subunit. Which seems to at least partially reinstated the relationship 
between TnI phosphorylation and thin filament Ca2+-sensitivity. The results suggest that the 
TnT subunit is modified in some way due to the disease and that this modification may be 
involved in the disruption of the relationship between TnI phosphorylation and thin filament 
Ca2+-sensitivity. Two subsequent experiments were completed by Dr. Andrew Messer using 
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the same exchange protocol and HOCM sample MR (unknown mutation). The ratio of 
fraction motile EC50 for HOCM XT/HOCM for the two experiments were 0.81 and 0.51. 
Table 3.11 below shows the combined data 
 
Table 3.11: Summary of the fraction motile EC50 for thin filaments that contained either HOCM or TnT 
exchanged HOCM troponin with addition data from Dr. Messer 
No. 
HOCM XT 
EC50 (mM)   
SD 
 
 
HOCM 
EC50 (mM) 
SD 
 
HOCM XT 
/HOCM 
I    HD1XT1 0.05 ± 0.01 0.14 ± 0.19 0.36 
II   HD2XT2 0.05 ± 0.01 0.09 ± 0.01 0.58 
III 0.09 ± 0.05 0.21 ± 0.02 0.43 
IV  HD3XT3 0.14 ± 0.03 0.13 ± 0.02 1.06 
V       Messer 0.07 ± 0.006 0.09 ± 0.008 0.81 
VI 0.10 ± 0.003 0.20 ± 0.009 0.51 
        
mean 0.09 ± 0.03 0.15 ± 0.05 0.63 
        ± 0.26 
        
Student t-
test 
                  (paired): p = 0.03                       (unpaired): p = 0.02 
 
3.5.10 Identity and mechanism of modification 
Results from this chapter suggest that troponin from the HOCM heart has a modification 
(possible of the TnT subunit) which plays some role in uncoupling the relationship between 
TnI phosphorylation and thin filament Ca2+-sensitivity. The identity of this modification is 
the topic of parallel investigation started by Dr. Clare Gallon and currently being undertaken 
by Dr. Judy Leung. The possibility of this post-translational modification is a glycosylation 
was investigated. More recently Dr. Leung has investigated if the modification could be O-
linked β-N- acetylglucosamine (O-GlcNAc) (Slawson et al., 2006), it has been suggested 
that this specific glycosylation modification may affect cardiac myofillament proteins 
(Ramirez-Correa et al., 2008). However, Dr Leung has found no evidence of this. Dr. Leung 
has also investigated lysine acetylation (Choudhary et al., 2009), but no evidence of this was 
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found either. Since the role of TnT was only recently discovered, the modification has not 
been identified, although several possibilities have been eliminated. Current studies are 
attempting to resolve differences between donor and HOCM troponin using mass 
spectroscopy. The mechanism of how the post-translational modification disrupts the 
relationship between TnI phosphorylation and thin filament Ca2+-sensitivity can only be 
speculated upon. As discussed in the introduction a study by Howarth et al suggested that the 
phosphorylation of the N-terminal extension of TnI results in a change of conformation from 
one position where it can influence the affinity of TnC for Ca2+ to a position where this 
influence is lost (Howarth et al., 2007). One possible inference from this is that this 
relationship is relatively easily to disrupt. Thus a modification to TnT (the structural 
backbone of troponin) may also result in a small conformational change that would also 
result in the movement of the N-terminal of TnI away from TnC, hence removing the 
influence on Ca2+ binding, therefore permamently uncoupling thin filament Ca2+-sensitivity 
and TnI phoshorylation.  
3.5.11 The phenotype of HOCM troponin  
 
Troponin purified from HOCM heart samples removed from patients with a severe LVOTO 
have a low level of TnI phosphorylation. This is either due to increase in the activation level 
of endogenous phosphatases or due to the down regulation of kinase activity. In the failing 
heart β-adrenergic receptors have been shown to be internalised as a result of chronic 
exposure to adrenaline, thus reducing the activation level of PKA. As the extent of the 
hypertrophy increases the HOCM heart is likely to suffer a similar fate, it will become a less 
efficient pump and thus require longer periods of signalling to elicit a response. By 
uncoupling the Ca2+-sensitivity from the TnI phosphorylation the HOCM troponin can 
remain relatively insensitive to Ca2+. Thus allowing the HOCM heart to relax faster if 
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required in the absence of an increase in TnI phosphorylation which may be beneficial. This 
account obviously does not take into account the fact that the thin filament Ca2+-sensitivity is 
not only regulated by TnI phosphorylation but also by a number of other factors in a highly 
integrated system. However any imbalance or change to this system brought about by one 
element, e.g. TnI phosphorylation, must result in some form of overall change.  
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4 Chapter 4 – Investigation of actin, tropomyosin and myosin in 
HCM 
4.1 Introduction 
The focus of this thesis is to characterise regulatory function in myofillament proteins from 
HCM tissues samples, using the IVMA. This chapter investigates functional differences in 
actin, tropomyosin and myosin. The first part investigated the functional effect of the 
different isoform composition of sarcomeric actin found in donor and HOCM heart. The 
second investigated the potential functional effect of different isoform composition of 
cardiac tropomyosin in donor and failing heart. The final section describes work completed 
to develop a new protocol for purifying human cardiac myosin from relatively small tissue 
samples for analysis by IVMA.  
4.2 Investigation of the composition of sarcomeric α-actin in donor and 
HOCM hearts. 
It has been found previously that the α-actin present in human heart muscle is comprised of 
the products of two genes; ACTC which encodes cardiac α-actin and ACTA1 which encodes 
skeletal α-actin (Vandekerckhove et al., 1986). The products of these genes are very similar, 
the only differences are an N-terminal sequence transposition of DEDETT in (ACTA1) to 
DDEETT in (ACTC) and the substitution of methionine at 299 (ACTA1) with a leucine 
(ACTC) and threonine at 358 (ACTA1) with a serine (ACTC). Normal human hearts have 
been shown to contain around 20% skeletal α-actin (Vandekerckhove et al., 1986, Copeland 
et al., 2010a). A quantitative antibody protocol was developed by O’Neal Copeland to 
measure the ratio of skeletal α-actin to cardiac α-actin in myofibrilar samples from donor, 
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failing and HOCM heart using a skeletal α-actin specific antibody. The results of this work 
were that skeletal α-actin comprised ~20% of the total actin present in donor hearts, ~50% in 
failing hearts and ~70% in HOCM hearts (Figure 4.1)(Copeland et al., 2010a). This led to 
the question; does a change in the isoform composition of actin cause a functional change 
that can be detected with the IVMA? 
 
Figure 4.1: Dot plot showing proportion of skeletal α-actin found in a range of human heart samples 
taken from (Copeland et al., 2010a) 
 
Dot plot from (Copeland et al., 2010a) summarising the proportion of sarcomeric α-actin which is skeletal α-
actin in donor (green), failing (red) and HOCM (black) hearts. The remaining proportion consists of cardiac α-
actin (data not shown). 
 
4.2.1 IVMA investigation of actin purified from donor and HOCM heart. 
To answer these questions F-actin was purified from donor heart NC and HOCM heart 
sample MD by methods previous described as ‘purification of human cardiac F-actin’ (see 
2.2.2.3). The donor heart sample (NC) was from a male aged 27 and the HOCM sample 
(MD) was from a male aged 48.  
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Figure 4.2: SDS-PAGE loaded with actin purified from samples NC and MD 
 
SDS-PAGE of actin purified from donor heart NC and HOCM heart MD. The numbers represent the volume of 
sample loaded in µl. Molecular weight marker were loaded in the first (left) lane, the 45kDa marker is labelled.  
 
Both of the purified F-actin samples were fluorescently labelled with TRITC-phalloidin and  
investigated using the IVMA. There were no visible difference between the two preparations 
of F-actin (Figure 4.3). There was no difference between either the sliding speed or the 
fraction motile of plain donor or HOCM actin as summarised in Table 4.1. 
 
Figure 4.3: Images of plain actin 
 
Screen shots of flow cells loaded with plain actin from samples NC and MD taken from the tracker program.  
NC MD 
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Table 4.1: Summary of IVMA measurements of plain F-actin from donor and HOCM heart 
Actin Sample Fraction Motile Sliding Speed 
(µm/s) 
Donor HOCM Donor HOCM Donor HOCM 
0.85 ±0.10 0.79 ±0.09 2.50 ±0.09 2.23 ±0.10 
0.78 ±0.04 0.81 ±0.04 2.19 ±0.20 2.13 ±0.17 
0.82 ±0.07 0.83 ±0.05 2.26 ±0.05 2.31 ±0.15 
NC  MD 
0.87 ±0.02 0.83 ±0.03 2.44 ±0.17 2.45 ±0.03 
Mean ± SD 
n = 4 
0.83 ±0.04 0.81 ±0.02 2.35 ±0.15 2.28 ±0.14 
Student t-test (Paired)      p=0.5 
(unpaired)  p=0.61 
(Paired)      p=0.41 
(unpaired)   p=0.37 
 
4.2.2 No difference between F-actin purified from donor and HOCM hearts 
The two F-actin samples were reconstituted into thin filaments with human cardiac 
tropomyosin and human cardiac troponin. The human cardiac troponin was purified from 
donor sample by previously described methods (2.2.4.1). A short troponin titration was 
completed to confirm that the two actin samples formed thin filaments that were regulated by 
Ca2+. An example of a troponin titration is shown in Figure 4.4 where 20nM and 30nM of 
cardiac troponin was used. This shows that at high [Ca2+] (3.7µM) the fraction motile was 
>0.7 and at low [Ca2+] (1nM) the fraction motile was reduced to <0.2 for both sets of 
filaments. For the zero troponin point, measurements of plain F-actin are used instead of F-
actin and tropomyosin (A.Tm). This was to conserve the limited volume of F-actin 
preparations.  
 
At high [Ca2+] (3.7µM) the sliding speed of both set of filaments was faster than that 
measured for the respective sets of plain F-actin. The mean sliding speed for plain donor F-
actin was 2.35±0.15 µm/s compared to 2.71±0.53 µm/s measured from donor F-actin 
reconstituted into thin filaments at maximal [Ca2+]. The difference is similar with HOCM 
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actin, the mean sliding speed of plain HOCM F-actin was 2.28±0.14 µm/s which increased to 
2.75±0.55µm/s in fully activated thin filaments. This is an example of the activating effect of 
tropomyosin and troponin.  
 
Figure 4.4: IVMA experiment titrating actin-tropomyosin with human donor troponin 
  
  
IVMA experiments titrating human cardiac donor (NE) troponin over the range 20-40nM. Thin filaments were 
composed of 10nM donor (blue) or HOCM (red) and 60nM human cardiac tropomyosin and troponin. The 
sliding speed of the reconstituted thin filaments were measured at A) high [Ca2+] (3.7µM) and B) low [Ca2+] 
(1nM) and the fraction motile was measured at C) high [Ca2+] (3.7µM) and D) low [Ca2+] (1nM). The open 
symbols represent measurements with plain actin filaments.  
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Five Ca2+-concentration titrations were completed comparing donor and HOCM F-actin in 
the presence of donor heart troponin. Three preparations of donor heart troponin (from 
sample NE) were used, the first for curves I-III, the second for curves IV and the third for 
curve V. The bar graph below (Figure 4.5) shows fraction motile for the maximum activation 
at high [Ca2+] (3.7µM) and inhibition at low [Ca2+] (1nM) for both sets of filaments for each 
of the five Ca2+-concentration titrations completed. Overall, at high [Ca2+] (3.7µM) the 
fraction motile was >0.7 and <0.2 at low [Ca2+] (1nM).  
 
Figure 4.5: Summary of fraction motile measurements at high and low [Ca2+] from IVMA Ca2+-
sensitivity curve experiments comparing donor and HOCM actin 
 
Regulation of fraction motile data with thin filaments reconstituted with donor troponin (NE) comparing donor 
(blue) and HOCM (red) actin at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The troponin 
concentrations used were I & II) 40nM, III) 20nM IV) 60nM & V) 20nM. 
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4.2.3 No difference in maximum sliding speed of thin filaments reconstituted with 
donor troponin and F-actin from either donor or HOCM heart 
 
There was no difference in the maximum sliding speed of thin filaments composed of donor 
troponin and either donor or HOCM F-actin. The maximum sliding speed for thin filaments 
with donor actin was 2.71±0.53µm/s compared to 2.75±0.55µm/s for thin filaments with 
HOCM actin (paired student t-test, p=0.44, n=5). The full data is shown in Table 4.2.  
 
Table 4.2: Maximum sliding speed of thin filaments with either donor or HOCM actin 
 
Experiment 
No. 
 
NC actin 
max. sliding 
speed 
(µm/s) 
SD 
 
 
MD actin max. 
sliding speed 
(µm/s) 
SD 
 
 
HOCM/ 
Donor 
 
I        2.43 ± 0.17 2.34 ± 0.09 0.96 
II 2.46 ± 0.06 2.67 ± 0.07 1.09 
III 2.28 ± 0.08 2.28 ± 0.07 1.00 
IV 3.61 ± 0.22 3.65 ± 0.15 1.01 
V 2.76 ± 0.12 2.81 ± 0.11 1.02 
        
mean 2.71 ± 0.53 2.75 ± 0.55 1.02 
       ± 0.05 
        
Student t-test 
(paired):p =0.44                              (unpaired) p = 0.49 
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4.2.4 No difference in Ca2+-sensitivity of thin filaments composed of donor troponin 
and either HOCM or donor F-actin 
 
When thin filaments composed of donor heart troponin and either donor or HOCM F-actin 
were compared by IVMA no difference in Ca2+-sensitivity was obvious. The overall range of 
sliding speed was relatively short as with previous experiments. Figure 4.6 is representative 
of the sliding speed data.  
 
Figure 4.6: Ca2+-concentration titration curves comparing thin filaments containing either donor or 
HOCM F-actin and donor troponin.  
 
IVMA Ca2+-concentration titration comparing the sliding speed of actin purified from donor and HOCM heart. 
The thin filaments were composed of 10nM donor actin (blue) or HOCM actin (red), 60nM human cardiac 
tropomyosin and 20nM troponin. 
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Ca2+-concentration titrations of the fraction motile of the respective sets of thin filaments are 
shown in Figure 4.7, and calculated fits shown in Table 4.3. Although EC50 for thin filament 
with HOCM actin tended to be slightly lower than filaments with donor actin the difference 
was not statistically significant. The EC50 ratio (HOCM/donor) was 0.88±0.1. A paired 
student t-test that compared the EC50 values for the respective sets of filaments gave a p 
value of 0.13 (n=5). The EC50 ratio for each curve was compared to the value 1 (for no 
difference) by unpaired student t-test, p=0.07 (n=5). Therefore, it seems that a difference in 
isoform composition of F-actin does not lead to any significant functional changes in thin 
filament Ca2+-sensitivity as measured by IVMA.  
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Figure 4.7: Ca2+-concentration titration comparing fraction motile of thin filaments containing donor or 
HOCM F-actin in the presence of donor troponin.  
 
 
 
IVMA Ca2+ concentration titration comparing the fraction motile of actin purified from donor and HOCM 
heart. The thin filaments were composed of 10nM donor actin (blue) or HOCM actin (red) and 60nM human 
cardiac tropomyosin and I & II) 40nM, III) 20nM, IV) 60nM troponin (NE). 
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Figure 4.8: Ca2+-sensitivity curves comparing the fraction motile of thin filaments containing donor or 
HOCM F-actin in the presence of donor troponin 
 
IVMA Ca2+-concentration titration comparing the fraction motile of actin purified from donor and HOCM 
heart. The thin filaments were composed of 10nM donor actin (blue) or HOCM actin (red) and 60nM human 
cardiac tropomyosin and V) 20nM troponin (NE). 
 
Table 4.3: Fraction motile EC50 values of thin filaments with either donor or HOCM F-actin 
Experiment 
No. 
Donor actin 
EC50 (mM)  
SD 
 
 
HOCM actin 
EC50 (mM) 
SD 
 
 
HOCM/ 
Donor 
I 0.27 ± 0.03 0.25 ± 0.03 0.93 
II 0.26 ± 0.10 0.20 ± 0.04 0.76 
III 0.20 ± 0.04 0.17 ± 0.04 0.83 
IV 0.07 ± 0.01 0.06 ± 0.01 0.89 
V 0.22 ± 0.06 0.23 ± 0.06 1.03 
      
mean 0.20 ± 0.08 0.18 ± 0.07 0.88 
       ± 0.10 
      
p = 0.07 Student  
t-test 
(paired): p = 0.13 
 (vs 1) 
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4.3 Tropomyosin 
Tropomyosin is generally considered to be invariable within the sarcomere, fulfilling 
structural and regulatory functions. In the heart the majority of sarcomeric tropomyosin is α-
tropomyosin encoded by the TPM1 gene (Perry, 2001). However recent evidence from mass 
spectroscopy completed by Dr. Robin Maytum compared tropomyosin isolated from a donor, 
a failing and a HOCM heart. Dr Maytum found two tropomyosin species, identified by their 
mass as α-tropomyosin and γ-tropomyosin (encoded by the TPM3 gene) (Maytum et al., 
2011). Both genes encode a protein 284 residues in length but the mass of α-tropomyosin is 
32,709 da whereas γ-tropomyosin is 32,819 da. The sequence alignment is shown below 
(Figure 4.9). 
Figure 4.9: Sequence alignment of TPM1 and TPM3 gene products 
 
The products of human TPM1 and TPM3 genes (skeletal muscle isoforms) were aligned using Uniprot 
(www.uniprot.org/uniprot/).The positions where the amino acid residue differs are circled in orange. 
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Analysis by Dr. Robin Maytim of purified tropomyosin from donor, failing and HOCM 
samples using mass spectroscopy suggested that a second species other than α-tropomyosin 
was present in all three samples. This was putatively identified as γ-tropomyosin. The α:γ-
tropomyosin ratio also appeared to be different between the three samples. The aim of the 
next section was to investigate if a difference in ratio of α:γ-tropomyosin resulted in a 
functional change that could be identified with the IVMA. 
 
Figure 4.10: Mass spectroscopy trace of tropomyosin purified from donor heart supplied by Dr. Maytum 
 
This is a deconvoluted matrix-assisted laser desorption/ionization (MALDI) mass spectroscopy trace supplied 
by Dr. Maytum, the bands are assigned to products of the TPM1 gene (circled in blue) and TPM3 (circled in 
red) (Maytum et al., 2011). 
 
4.3.1 Tropomyosin was purified from small tissue samples 
To analyse tropomyosin from donor and failing heart using the IVMA a purification protocol 
was adapted for small tissue samples. The final protocol is summarised in Figure 4.11 the 
full protocol is described in the methods (see 2.2.3.2). Tropomyosin from donor heart NE, 
was compared to tropomyosin from failing heart FC. NE was taken from a 29 year old male 
patient and FC was from a 30 year old male patient. 
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Figure 4.11: Summary of tropomyosin purification protocol 
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Figure 4.12: SDS-PAGE of tropomyosin purification process
 
SDS-PAGE of samples taken throughout the purification of tropomyosin from donor heart sample NE and 
failing heart sample FC. The stages are noted on the flow diagram of the protocol shown in Figure 4.11. 
Molecular weight markers (M) were included. 
 
Three pairs of tropomyosin from donor heart sample NE and failing heart sample FC were 
purified. As demonstrated in the gel above (Figure 4.12) the final product was almost pure 
tropomyosin. 
 
4.3.2 IVMA investigation of human cardiac tropomyosin 
4.3.2.1 No difference between donor heart tropomyosin and failing heart tropomyosin 
found during tropomyosin titration experiments. 
 
The tropomyosin samples purified from NE and FC were compared using the IVMA (Figure 
4.13). Two tropomyosin titrations were completed. There was no distinguishable difference 
between the two sets of filaments in both of these experiments. Filaments composed of 
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tropomyosin and actin had a higher sliding speed than plain actin filaments. At 60nM the 
mean increase in sliding speed was ~20% for both samples of tropomyosin.  
 
Figure 4.13: IVMA experiments titrating donor and failing heart tropomyosin 
 
 
IVMA investigation of filaments formed of 10nM of rabbit skeletal actin and either 10nM, 20nM, 30nM, 
40nM, 60nM and 100nM of human cardiac tropomyosin from donor heart (blue) or failing heart (crimson). 
Two IVMA parameters measured were the A & B) sliding speed and C & D) fraction motile. 
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4.3.2.2 Measurement of Ca2+ regulation using rabbit skeletal muscle troponin 
 
For preliminary experiments tropomyosin samples purified from NE and FC were 
reconstituted into thin filaments with rabbit skeletal troponin. Skeletal troponin is more 
functionally stable then cardiac troponin and retains this function after freeze-thawing. Three 
Ca2+-concentration titration curves were completed. The donor and failing heart tropomyosin 
both formed filaments that were fully regulated by Ca2+. This is illustrated in Figure 4.14, at 
high [Ca2+] the fraction motile for both sets of filaments was >0.8 and was <0.1 at low [Ca2+] 
throughout.  
 
Figure 4.14: Summary bar graph of thin filaments with human cardiac tropomyosin purified from NE 
and FC and skeletal troponin. 
 
Regulation of fraction motile data was plotted from the IVMA Ca2+-sensitivity curve experiments completed 
with thin filaments reconstituted with skeletal troponin comparing donor (blue) and failing (crimson) 
tropomyosin at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The troponin concentrations used 
60nM for all three curves. 
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4.3.2.3 No difference in maximum sliding speed was measured between thin filament with 
either donor or failing heart tropomyosin 
 
Thin filaments were reconstituted with rabbit skeletal troponin and either NE or FC 
tropomyosin. IVMA analysis showed there was no difference in the sliding speed at maximal 
[Ca2+] between the two respective sets of filaments. These data are summarised in Table 4.4. 
 
Table 4.4: Maximum sliding speed of thin filaments with either donor or failing heart tropomyosin and 
rabbit skeletal troponin 
 
4.3.2.4 There was no definite pattern between the Ca2+-sensitivities of thin filaments 
composed of either donor or failing tropomyosin and skeletal troponin 
 
There was also no clear difference in Ca2+ regulation between thin filaments composed of 
either NE or FC tropomyosin and skeletal muscle troponin. These data are summarised in 
Table 4.5 and the full curves are shown in Figure 4.15.  
ew 
 
NE Tm  
max. sliding 
speed 
(µm/s) 
SD 
 
 
FC Tm 
max. sliding 
speed 
(µm/s) 
SD 
 
 
Failing/ 
Donor 
 
I        3.50 ± 0.14 3.53 ± 0.13 1.01 
II 3.13 ± 0.25 2.82 ± 0.13 0.90 
III 4.09 ± 0.03 3.91 ± 0.10 0.96 
        
mean 3.57 ± 0.48 3.42 ± 0.55 0.96 
       ±  0.05 
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Figure 4.15: Ca2+-concentration titrations comparing thin filaments containing donor and failing 
tropomyosin with skeletal troponin.  
  
 
 
IVMA Ca2+-concentration titrations comparing tropomyosin purified from donor and failing heart. The thin 
filaments were composed of 10nM skeletal actin and 60nM (NE) donor (blue) or (FC) failing (crimson) 
tropomyosin and SK Tn I & II) 60nM, SK Tn III) 80nM, skeletal muscle troponin. 
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Table 4.5: Fraction motile EC50 values of thin filaments with either donor or failing tropomyosin and 
skeletal troponin 
Experiment 
No. 
Donor Tm 
EC50 (mM)  
SD 
 
 
Failing Tm 
EC50 (mM) 
SD 
 
 
Failing/ 
Donor 
Sk Tn I 0.10 ± 0.01 0.10 ± 0.01 0.96 
Sk Tn II 0.05 ± 0.00 0.05 ± 0.01 0.96 
Sk Tn III 0.08 ± 0.01 0.06 ± 0.01 0.74 
      
mean 0.08 ± 0.03 0.07 ± 0.03 0.89 
       ± 0.13 
 
 
4.3.2.5 Preliminary results suggest that thin filaments that contained failing heart 
tropomyosin may be more Ca2+-sensitive than filaments with donor tropomyosin in 
the presence of cardiac troponin  
 
The aim of the skeletal troponin work was to confirm that tropomyosin purified from a small 
tissue samples would form functional Ca2+-sensitive thin filaments and this was achieved. 
Although no functional difference was resolved between the respective sets of filaments the 
true test would involve using human cardiac troponin instead of muscle troponin. Two full 
Ca2+-sensitivity curves and one part curve were completed using donor heart troponin (NE). 
There was no difference in maximal sliding speed between the two sets of filaments, data 
shown in Table 4.6. 
 
 
221 
Table 4.6: Maximum sliding speed of thin filaments with either donor or failing heart tropomyosin and 
human cardiac troponin 
 
Experiment 
No. 
 
NE Tm  
max. sliding 
speed 
(µm/s) 
SD 
 
 
FC Tm 
max. sliding 
speed 
(µm/s) 
SD 
 
 
Failing/ 
Donor 
 
I        3.62 ± 0.14 3.65 ± 0.09 1.01 
II 3.79 ± 0.26 3.59 ± 0.50 0.95 
III 3.33 ± 0.07 3.33 ± 0.16 1.00 
        
mean 3.58 ± 0.23 3.52 ± 0.17 0.98 
       ± 0.03 
 
Both the sliding speed and fraction motile curves are shown in Figure 4.16 and summary 
data in Table 4.7 & Table 4.8. Comparison of the EC50 values suggest that the thin filaments 
reconstituted with the FC tropomyosin are slightly more Ca2+-sensitive. This pattern is 
stronger in fraction motile curves. As only two Ca2+-concentration titrations were completed 
using only one preparation of donor heart troponin further experimentation is required to 
confirm this pattern. However this work does show that tropomyosin can be purified from 
relatively small tissue samples and investigated by IVMA. This would allow investigation of 
tissue from HOCM heart or from a patients biopsy with tropomyosin mutations if one 
became available in the future.  
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Figure 4.16: Ca2+-sensitivity curves comparing thin filaments containing donor and failing tropomyosin 
with cardiac troponin 
  
 
 
IVMA Ca2+-concentration titrations comparing tropomyosin purified from donor and failing heart. The thin 
filaments were composed of 10nM skeletal actin and 60nM (NE) donor (blue) or (FC) failing (crimson) 
tropomyosin and cTn I & II) 80nM, cardiac troponin (NE). The measured parameters are A) sliding speed and 
B) fraction motile. 
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Table 4.7: Sliding speed EC50 values of thin filaments with either donor or failing tropomyosin and 
cardiac troponin. 
Experiment 
No. 
Donor actin 
EC50 (mM) 
SD 
 
 
Failing Tm 
EC50 (mM) 
SD 
 
 
Failing/ 
Donor 
cTn I 0.53 ± 0.02 0.46 ± 0.04 0.86 
cTn II 0.22 ± 0.01 0.20 ± 0.04 0.94 
      
mean 0.37 ± 0.22 0.33 ± 0.18 0.90 
       ± 0.05 
 
Table 4.8: Fraction motile EC50 values of thin filaments with either donor or failing tropomyosin and 
cardiac troponin. 
Experiment 
No. 
Donor Tm 
EC50 (mM)  
SD 
 
 
Failing Tm 
EC50 (mM) 
SD 
 
 
Failing/ 
Donor 
cTn I 0.31 ± 0.11 0.21 ± 0.04 0.68 
cTn II 0.23 ± 0.03 0.13 ± 0.02 0.55 
      
mean 0.27 ± 0.06 0.17 ± 0.06 0.61 
       ± 0.09 
 
4.3.3 Recombinant titrations 
NE and FC were not the samples analysed by Dr. Maytum and subsequent investigation with 
γ-tropomyosin specific antibodies have not determined a consistent pattern of isoform ratios. 
Therefore there is currently no direct evidence that these samples have different ratios of α:γ-
tropomyosin. The final part of this study compared recombinant α-tropomyosin and γ-
tropomyosin expressed in Baculovirus/SF9 system kindly supplied by Dr. El-Mezgueldi 
(University of Leciester). The aim of this study was to clarify the results found in the 
previous section, e.g. that the presence of different isoforms of tropomyosin lead to 
functional changes that can be measured by IVMA. Thus recombinant α-tropomyosin and γ-
tropomyosin were compared by IVMA. The first step was to complete a tropomyosin 
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titration comparing α-Tm and γ-Tm. No difference was detected between the α-Tm and γ-
Tm filaments over the range of the titration.  
 
Figure 4.17: IVMA experiments titrating α-Tm and γ-Tm 
   
   
IVMA investigation of filaments formed of 10nM rabbit skeletal actin incubated with 10nM, 20nM, 40nM, 
60nM, 80nM and 100nM of α- tropomyosin (green) or γ-tropomyosin (yellow). Two IVMA parameters were 
measured the A & B) sliding speed and C & D) fraction motile. 
 
After the tropomyosin titration the next step was to complete Ca2+-concentration titrations. 
However even with skeletal troponin, Ca2+-sensitive thin filaments could not be formed 
0
0.5
1
1.5
2
2.5
3
0 20 40 60 80 100 120
!-Tm "-Tm
S
lid
in
g
 s
p
e
e
d
 (
µ
m
/s
)
[Tm] nM
0
0.5
1
1.5
2
2.5
3
0 20 40 60 80 100 120
!-Tm "-Tm
S
lid
in
g
 s
p
e
e
d
 (
µ
m
/s
)
[Tm] nM
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80 100 120
!-Tm "-Tm
F
ra
c
ti
o
n
 m
o
ti
le
[Tm] nM
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80 100 120
!"Tm #-Tm
F
ra
c
ti
o
n
 m
o
ti
le
[Tm] nM
D C 
B A 
225 
using either of these recombinant tropomyosin samples. Therefore no further experiments 
were completed. This work with tropomyosin forms a good pilot study from which further 
work could easily be completed. Further experimentation would have been completed for 
this thesis had time permitted but other experiments were given a higher priority.  
 
4.4 Investigation of cardiac myosin from small tissue samples 
4.4.1 Development of a novel protocol for purification of cardiac myosin from a small 
biopsy sample 
 
The MYH7 gene is one of the genes most frequently mutated leading to HCM (Richard et 
al., 2003). Genotype screening of the samples in the local tissue bank identified three 
samples with MYH7 mutations, MF (K847E), ML (R719Q) and MU (L427M). The R719Q 
MHC mutation has been studied previously (Kohler et al., 2002, Yamashita et al., 2000). The 
aim of the next section was to investigate the effects of this mutation with the IVMA. 
Normally for the IVMA myosin is purified from a relatively large amount of skeletal rabbit 
tissue (see 2.2.2.1). This protocol, or even a scaled down version, could not be used to purify 
myosin from small amounts of myocardium (<1g) since cardiac myosin is very unstable. 
Therefore a method was developed to purify myosin from a small biopsy sample so that the 
effects of the mutation could be studied by IVMA. Myosin has been purified from small 
tissue samples in other studies (Palmiter et al., 2000, Jacques et al., 2008b).  
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Figure 4.18: Flow diagram of protocol to purify human cardiac myosin from the study by Palmiter et al 
 
 
The main property of myosin manipulated to order to purify it is that it forms filaments in 
solutions with a salt concentration <100mM. Therefore washing the tissue in a low salt 
buffer will remove other soluble proteins and myosin will remain undissolved. The main 
hindrance to purifying myosin is its strong affinity for actin. F-actin will form a pellet under 
ultracentrifugation, but if the myosin is still associated with the actin, then the myosin will 
also pellet. In the presence of ATP myosin undergoes cross-bridge cycling, where actin and 
myosin dissociate and re-associate to one another. The protocols above (Figure 4.18) 
dissolve myosin in a high salt buffer that contains ATP. Upon ultracentrifugation the F-actin 
is pelleted, the proportion of myosin that is dissociated from that F-actin remains in the 
supernatant. The final stages of both protocols also precipitate the myosin by lowering the 
salt solution of the buffer, this is then centrifuged and the pellet which (should contain pure 
myosin) is then resuspended.  
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The Palmiter method was used by previous members of this laboratory to investigate the 
properties of human β-cardiac myosin (encoded by the MYH7 gene) purified from HOCM 
samples (Jacques et al., 2008b). Cardiac myosin purified by this method was only functional 
for a short time (~2 hours) and full Ca2+-concentration titrations could not be completed. 
Therefore a new protocol for purifying myosin was developed (summarised Figure 4.19) and 
this is described in full in the methods section (see 2.2.1.3). 
 
Figure 4.19: Flow diagram summarising novel protocol to purify human cardiac myosin 
 
 
The motive behind this new protocol was to shorten the time required to complete the  
protocol, with the aim of maintaining myosin function. The initial wash steps used are the 
same for those of troponin extraction. Myosin will remain in the pellet due to the low salt 
concentration of the buffer. The myosin was then dissolved in a high salt buffer in the 
presence of ATP and blebbistatin. Blebbistatin is a small molecule (C18H16N2O2, m.w. 292.3) 
that inhibits the acto-myosin interaction (Kovacs et al., 2004, Allingham et al., 2005, Dou et 
al., 2007). In the presence of ATP myosin will dissociate from actin, the addition of the 
blebbistatin was designed to further inhibit re-association of actin and myosin. Therefore the 
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ultra centrifugation step, which is designed to remove the F-actin, should have resulted in 
less myosin also being removed. This protocol does not involve a final stage of myosin 
precipitation and resuspension in order to reduce the length of the protocol.  
 
Figure 4.20: SDS-PAGE of purified myosin 
 
SDS-PAGE of myofibril (N10), skeletal muscle HMM (HMM), purified myosin (M) and further purified 
myosin (FP-M). Volumes stated are the total volume loaded when mixed 1:1 with SDS sample buffer. The gel 
was stained with Coomassie Blue protein stain. 
 
The gel shown in Figure 4.20 is representative of the purity of cardiac myosin obtained using 
the new protocol. The other myofilament proteins have not been completely removed, 
however most importantly the majority of actin has been removed successfully. This is clear 
when comparing the SDS-myofilament N10 sample which has a thick actin band (~45 kDa) 
to the purified myosin sample (M) which only has a light actin band. To confirm that cardiac 
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myosin was indeed present, the sample was further purified. To do this 250µl of the cardiac 
myosin sample (M) was diluted 20 fold in dH2O (1mM DTT) and centrifuged for 15 minutes 
31,000 xg (16,000 rpm, Sorvall Evolution RC, SS-34 rotor) at 4°C. The pellet was then 
resuspended in SDS sample buffer. The further purification resulted in almost pure cardiac 
myosin. This clearly lines up with the original cardiac myosin on the gel, demonstrating that 
myosin is obtained using this new protocol.  
 
4.4.2 IVMA experimentation with myosin purified by novel protocol 
4.4.2.1 IVMA analysis of cardiac myosin 
Due to the slow sliding speed (~1µm/s) of cardiac myosin the acquisition parameters had to 
be changed on the tracker software. 12 images was collected at 1.7s intervals. The total 
number of images recorded per acquisition had to be reduced, if it had remained the same the 
total acquisition time would have been lengthened to a point where photo bleaching of 
filaments would have occurred. To collect enough vector measurements the field of view 
was widened, thus a larger number of filaments were recorded over a shorter time period. 
 
4.4.2.2 Cardiac myosin was purified from mouse myocardium 
Initial experiments purified cardiac myosin from wild type mouse hearts that were snap 
frozen and stored in liquid N2 immediately after excision to prevent degradation. In total 11 
cardiac myosin preparations were produced from mouse myocardium. The average 
concentration, as measured by Bradford assay, was 5.18 ±1.32 mg/ml. Myosin purified in 
this manner was not affinity precipitated, to reduce the time from purification to 
investigation by IVMA. However this meant that the rigor or dead heads were not removed. 
If >1% of the total number of myosin heads present on the flow cell surface are locked in 
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rigor (dead heads) this will almost completely inhibit any movement of actin in the IVMA 
(Marston et al., 1996)  
 
Thus, not removing the dead heads has a deleterious effect on the movement of plain actin in 
the IVMA. Three myosin preparations were prepared and were investigated using the same 
IVMA protocol as before (see 2.4). The cell loading protocol was slightly modified as the 
purified myosin was diluted to 0.1mg/ml in buffer A and used in place of HMM. The 
fraction motile was consistently low (<0.2) for all three myosin preparations. The sliding 
speed was also relatively slow ~0.6 µm/s but this was expected as cardiac myosin has a 
slower turnover rate compared to fast skeletal myosin.   
Table 4.9: Results of IVMA experiments with plain actin and mouse cardiac myosin 
Myosin prep. 
Fraction 
motile 
SD 
 
 
Sliding speed 
(µm/s) 
SD 
 
 
M1 0.19 ± 0.07 0.65 ± 0.05 
M2 0.14 ± 0.04 0.69 ± 0.02 
M3 0.11 ± 0.03 0.64 ± 0.01 
     
mean 0.15 ± 0.04 0.66 ± 0.03 
       
 
4.4.2.3 Actin-doping: an in situ protocol for improving motile parameters in non-affinity 
precipitated myosin 
 
Instead of using an affinity precipitation an in situ protocol described as ‘actin doping’ was 
used to improve the fraction motile. Normally the flow cell is coated with myosin followed 
by buffer B (BSA blocking buffer) and then the plain actin/thin filaments are infused. The 
actin doping protocol requires the infusion of two further solutions before the addition of the 
plain actin/thin filaments. These two solutions have been named buffer α and buffer β. 
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Buffer α consists of 1ml of buffer B and 1mM ATP and buffer β consists of 0.5ml of buffer 
α and 5µM F-actin. The sequence of actin doping, after the myosin and buffer B have been 
infused to the flow cell, was 120µl of buffer β was added, followed by 80µl of buffer α and 
then the actin/thin filaments were added as before.  
 
The actin doping process is designed to bind unlabelled actin to myosin in locked in rigor 
(dead heads), myosin heads not stuck in rigor will dissociate from actin due to the presence 
of ATP. Subsequently, when the labelled filaments are added the dead heads remain bound 
to the unlabelled actin, thus leaving the live heads available to bind and move the 
fluorescently labelled actin. Ideally the majority of F-actin (in buffer α) that do not bind to a 
dead head is washed out before the addition of the labelled filaments. When the movement of 
plain actin by cardiac myosin was measured by IVMA with actin doping the fraction motile 
was greatly increased, as shown in Table 4.10. The mean fraction motile of plain actin with 
cardiac myosin (M1) was 0.76 and mean sliding speed was 0.9 µm/s.  
 
Table 4.10: Results of IVMA experiments with plain actin and cardiac myosin sample M1 with actin 
doping. 
Experiment 
No. 
Fraction 
motile 
SD 
 
 
Sliding speed 
(µm/s) 
SD 
 
 
I 0.76 ± 0.09 1.01 ± 0.08 
II 0.88 ± 0.06 1.18 ± 0.16 
III 0.65 ± 0.04 0.57 ± 0.06 
IV 0.63 ± 0.09 0.94 ± 0.09 
V 0.80 ± 0.12 0.87 ± 0.21 
VI 0.77 ± 0.07 0.87 ± 0.11 
VII 0.81 ± 0.012 0.86 ± 0.11 
     
mean 0.76 ± 0.09 0.9 ± 0.18 
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However actin doping is not as ‘clean’ a process as the affinity precipitation. This is because 
a residual amount of F-actin is not washed out, this F-actin can become partially labelled 
with TRITC-Phalloidin and this can affect the acquisition of images. Actin-doping also 
appears to affect how the fluorescently labelled F-actin move. In flow cells that were actin-
doped the fluorescently labelled F-actin appeared to move in ordered (vertical) tracks up and 
down the flow cell with no changes in direction rather than the movement in random paths 
with many changes in direction as normally seen. The three screen shots (Figure 4.21) 
illustrate the alignment of fluorescent actin in these actin-doped flow cells. 
 
Figure 4.21: Screen shots of flow cells that have been actin doped. 
 
Flow cells were coated with 100µl of myosin cardiac myosin (0.1mg/ml). 100µl of fluorescently labelled 
skeletal actin was infused and the movement of the filaments were recorded from four randomly selected areas 
(as normal for the IVMA protocol). After these images had been saved they were reviewed and a sample were 
selected to demonstrate the ‘tracks’ seen if the actin-doping protocol had been applied to the cell.  
 
These ‘tracks’ must be caused by the presence of the unlabelled F-actin from the actin-
doping process. A previous studies by Jacques et al found that an excess of unlabelled F-
actin prevented measurement of the Ca2+-sensitivity of thin filaments with myosin that had 
been actin-doped (Jacques et al., 2008b). Three approaches were considered to reduce the 
effect of unlabelled F-actin in the actin-doping process. The first was to reduce the 
concentration of unlabelled F-actin used in the actin-doping procedure. However any 
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reduction in this concentration from 5µM was shown to reduce both the motile parameters of 
the labelled F-actin. The next approach considered was to use an F-actin severing and 
capping protein; Gelsolin (Sun et al., 1999) with the aim of producing very short lengths of 
unlabelled F-actin that would block dead heads but not affect the movement of the 
fluorescently labelled F-actin. However a workable protocol could not be produced. The 
final possibility that was briefly considered was to use monomeric actin (G-actin), but this 
was not investigated fully.  
 
The first conclusion from this work is that it was difficult to purify a functionally stable 
version of cardiac myosin from a small biopsy sample for IVMA analysis. The initial work 
completed with this protocol produced myosin that remained functional for three days. This 
was an improvement on the previous protocol used by Jacques et al. However, the problems 
of completing Ca2+-concentration titrations with this myosin were not resolved. Myosin 
produced by this novel method still required actin-doping for a good quality of motility and 
the actin-doping protocol could not be modified to allow completion of Ca2+-sensitivity 
experiments. Therefore no experiments were completed with human cardiac myosin.  
If this study were to be continued using an alternative in situ purification protocol should be 
considered. This could be based on a protocols used by Höök & Larrsen and Cuda et al who 
used a myosin heavy chain antibody to directly trap cardiac myosin on the flow cell (Cuda et 
al., 1997, Hook and Larsson, 2000). However the damaged myosin heads fixed in rigor (dead 
heads) will still have to be dealt with, but the reduction of the extraction period that this 
protocol would allow may sufficiently reduce the number of these.  
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4.5 Discussion 
In the previous chapter troponin purified from HOCM heart was shown to be abnormal, this 
chapter aimed to investigate if actin, tropomyosin and myosin from the HOCM heart were 
also abnormal. The investigation of F-actin purified from HOCM tissue was triggered by the 
results of a study by Copeland et al who found that the proportion of skeletal actin was 
increased in HOCM heart (72%) compared to donor heart (21%). Two previous studies have 
found adult (human & bovine) ventricles contained ~20% of α-skeletal actin 
(Vandekerckhove et al., 1986, Bergen et al., 2003). To determine if this difference in isoform 
distribution had a functional effect F-actin was purified from a donor and HOCM heart 
sample and investigated by IVMA. The appearance of purified ‘plain’ F-actin was similar to 
that of rabbit skeletal actin. F-actin has previously been purified from tissue samples and 
investigated by IVMA by Dr. Emma Dyer (Song et al., 2011). Dr. Dyer purified F-actin from 
a wild type (to compare with a transgenic mouse). The mean sliding speed for mouse F-actin 
was 2.84±0.11 µm/s and the fraction motile was 0.78±0.03 which compares well with mean 
sliding speeds obtained for donor (2.35±0.15) and HOCM (2.28±0.14) and fraction motile 
for donor (0.83±0.04) and HOCM 0.81±0.02 F-actin. Thus the purification protocol 
produced F-actin of a comparable quality to previous studies. 
 
The results suggest that although the F-actin from HOCM heart consisted of a much larger 
proportion of skeletal actin, this was not functionally different from F-actin from a donor 
heart. In a previous study that compared pure ‘plain’ skeletal F-actin to pure ‘plain’ cardiac 
F-actin only a very small difference (4%) in sliding speed was measured (Balaz and 
Mansson, 2005). It is perhaps unsurprising that no functional difference is apparent as the 
only structural differences between α-cardiac and α-skeletal actin are the transposition of an 
N-terminal asparatate and glutamate residue and the substitutions Met299Leu and Thr358Ser 
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(Bergen et al., 2003). The increase in proportion of α-skeletal actin has been linked to degree 
of cardiac hypertrophy in a rat model (Stilli et al., 2006). Changes occur in the isoform 
distribution of a number of myofilament proteins during the progression of a cardiac disease 
such as HCM. These changes have been proposed to be linked to the up-regulation of the 
fetal gene programme (Barry et al., 2008).  
 
The next section focused on an investigation of tropomyosin. Tropomyosin is obviously an 
integral part of the thin filament. A number of mutations have been identified in tropomyosin 
that cause both HCM (e.g. Asp175Asn & Glu180Gly) and dilated cardiomyopathy (e.g. 
Glu40Lys & Glu54Lys) (Thierfelder et al., 1994, Chang and Potter, 2005). However the 
different compositions of the tropomyosin dimer may also result in functional differences. A 
previous study by Boussouf et al used the IVMA to compare recombinant tropomyosin 
dimers composed of either αα or ββ subunits reconstituted with cardiac troponin. The study 
showed that the thin filament that contained the ββ-tropomyosin were 0.23pCa units 
(1.10µM) more Ca2+-sensitive then the αα-tropomyosin (Boussouf et al., 2007). Thus a 
change in tropomyosin composition has been shown to result in a functional change. Thus 
when preliminary experiments suggested that there was a difference in the composition of 
tropomyosin from failing and HOCM heart (lower proportion of γ-tropomyosin) compared to 
donor heart this warranted further investigation. As tropomyosin had not been purified from 
small tissue samples before, a method was developed to do this. This protocol produced an 
almost pure sample of tropomyosin which were investigated by IVMA.  
 
Tropomyosin was purified from a donor heart sample and a failing heart sample. These were 
compared by IVMA over a range of tropomyosin concentrations. No difference between the 
two tropomyosin samples was apparent. Both the tropomyosin samples showed a ~20% 
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increase in sliding speed at 60nM, this compares well to experiments using 60nM human 
cardiac tropomyosin (produced from ethanol-ether powder) completed by Dr. Andrew 
Messer who found a ~30% increase in sliding speed and Dr. Emma Dyer who found a ~12% 
increase in sliding speed. These tropomyosin samples were also reconstituted into thin 
filaments with both skeletal and cardiac troponin, both of these sets of filaments were Ca2+-
sensitive. Although no conclusions can be drawn from the Ca2+-concentration titrations. 
Subsequent investigation completed by O’Neal Copeland with specific anti-α-Tm and anti-γ-
Tm monoclonal antibodies suggest the level of γ-tropomyosin present in HOCM and failing 
heart is actually minimal (unpublished). The IVMA results suggest that even if the level of γ-
Tm were increased it would probably not lead to a functional difference in the heart.  
 
The myosin study was designed to build on a previous study completed by Jacques et al who 
investigated myosin purified from HOCM heart samples (Jacques et al., 2008b). In the 
Jacques study, myosin from donor and HOCM hearts was purified (in pairs) and compared 
by IVMA. When the movement of plain F-actin was measured there was no difference in 
sliding speed between the two myosin preparations but the fraction motile for the HOCM 
myosin was 21% less than the donor myosin and this was a statistically significant (p<0.001 
n=20) (Jacques et al., 2008b). However myosin produced by this method could not be used 
in Ca2+-concentration titrations due to the short lived nature of myosin preparations and the 
need to use actin-doping to produce a good standard of basic motility. 
 
Studies investigating specific HCM myosin mutations have found diverging results. A study 
by Cuda et al found that cardiac myosin with Arg403Gln and Leu908Val moves F-actin 
more slowly than control myosin (Cuda et al., 1997). Whereas studies by Palmiter et al and 
Yamashita et al found that these mutations lead to enhanced speed when analysed by IVMA 
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(Palmiter et al., 2000, Yamashita et al., 2000). All of these studies only analysed the 
movement of ‘plain’ F-actin filaments and not reconstituted thin filaments. Thus the next 
step would be to investigate if HOCM myosin (especially myosin with a mutation) would 
have any affects on the motile parameters or Ca2+-sensitivity of thin filaments. A new 
protocol was designed for this purpose and myosin purified by this method remained 
functional for up to three days. Mouse cardiac myosin produced by this method had a sliding 
speed of ~ 0.9µm/s which compares well with the speed measure by Palmiter of 1.4µm/s and 
other studies including Nguyen et al who measured 1.3µm/s (Nguyen et al., 1996, Palmiter 
et al., 2000). However myosin produced by this method still required actin-doping which 
increases the difficulty in completing Ca2+-concentration titration curves. Attempts were 
made to develop an actin-doping procedure that would negate this difficulty, unfortunately 
these were not successful.   
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5 Chapter 5 – A study of a human biopsy samples from two 
patients with the HCM causing cardiac actin mutation 
E99K  
5.1 Introduction 
Hypertrophic cardiomyopathy has been described as ‘a disease of the sarcomere’ 
because the majority of causative mutations identified to-date exist in genes that 
encode sarcomeric proteins. The genes with the highest frequency of HCM causing 
mutations are those that encode MyBP-C and MHC, but genes that encode thin 
filament proteins are also commonly affected (Richard et al., 2003). One such 
mutation, in the cardiac actin (ACTC) gene leads to a substitution of the glutamate (E) 
residue at position 99 to a lysine (K) residue. This mutation has been linked with 
HCM, predominantly the apical hypertrophy form, and left ventricular non 
compaction (LVNC) in a number of studies (Monserrat et al., 2007, Arad et al., 2005, 
Olson et al., 2000). A further ongoing study has identified 76 individuals from 10 
families with this mutation, of which 62 patients were reported to have developed 
some form of hypertrophy (Song et al., 2011). Taken together these studies have 
established that the ACTC E99K mutation causes the development of HCM, that the 
mutation is inherited in a dominant fashion (as illustrated in Figure 5.1) and that the 
mutation is highly penetrant, since most carriers suffer from the disease.  
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Figure 5.1: Pedigree of a family found to possess the E99K mutation. 
The (+) plus symbols represent the presence of the mutation and the solid symbols represents the 
presence of the disease. (taken from (Monserrat et al., 2007) 
 
The mutation results in a charge change from -1 to +1 of the cardiac actin at the 
position of the 99th residue. This residue is in a surface loop in the subdomain 1 of the 
actin molecule (Figure 5.2). Three negatively charged residues in the subdomain 1 
region of F-actin, E-93, E-99 and E-100, constitute a putative interaction site with a 
positively charged loop in the lower 50-kDa domain of the myosin head (Bookwalter 
and Trybus, 2006) and the E93K mutation profoundly effects Ca2+-regulation (Bing et 
al., 1998). Therefore the introduction of a positive charge at residue 99 is likely to 
adversely effect contractility. 
 
5.1.1.1 Cardiac E99K actin mouse model 
As the E99K cardiac actin mutation had been clearly linked to HCM, a mouse model 
was produced through a collaboration between Prof. Steve Marston & Prof. D. Wells, 
Royal Veterinary College, London. The molecular phenotype of transgenic mouse 
E99K actin was investigated by Dr. Emma Dyer and physiological studies were 
completed by Dr. Weihua Song (Song et al., 2011).   
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Figure 5.2: Position of E99K mutation within actin filament.  
 
 
A ribbon representation of an F-actin filament produced using Chimera. The residue at the 99th position 
is represented in black. 
 
5.2 Study of E99K mutant cardiac actin from human patients 
This chapter will summarise work investigating biopsy samples from two patients 
identified as carriers of the ACTC E99K mutation. This is the first study to investigate 
actin purified from human patients. Both these samples were supplied by Prof. 
Monsserat, La Coruna, Spain. Upon excision the biopsies were snap frozen and stored 
in liquid nitrogen. Patient 1 underwent a heart transplant as she had advanced heart 
failure and patient 2 underwent an operation to repair an atrial septal defect but 
exhibited no other signs of cardiac problems. The patient details are summarised in 
Table 5.1. 
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Table 5.1: Clinical details of biopsy patients 
Biopsy sample E99K Patient 1 E99K Patient 2 
Diagnosis Hypertrophic cardiomyopathy-
Non Compaction 
Atrial septal defect 
Gender F M 
Age when diagnosed 31 19 
Age at operation 55 32 
Operation Heart transplant Atrial septal defect closure 
Family History Multiple relatives with LVNC-
Apical HCM 
Multiple relatives with LVNC-
Apical HCM, some with ASD. 
Current Treatment Betablockers: Bisoprolol 
Dose (mg/24h): 
Angiotensin coverting enzyme 
inhibitors (ACEI): Enalapril 
Dose (mg/24h): 5 
Loop diuretics: · Furosemide 
Dose (mg/24h): 80 
Potasium sparing diuretic: · 
Espironolactone Dose (mg/24h) 
Anticoagulation: Warfarine 
Digoxin: Dose (mg/24h): 0.2 
aspirin 
 
5.3 F-actin was purified from biopsy samples containing the ACTC 
E99K mutation 
 
Cardiac actin was purified in pairs consisting of donor and E99K F-actin. Each actin 
preparation was labelled with TRITC-phalloidin. Three pairs were produced for this 
study. Two samples of actin were purified from the first E99K patient biopsy (named 
E99K 1a and 1b), these were paired with actin preparations from donor heart ND and 
N9 respectively. Sample ND was from a female aged 49 and sample N9 was from a 
male aged 54. One sample of actin was produced from the second E99K patient 
biopsy (named E99K 2) and this was paired with actin from donor sample NE. NE 
was taken from a male aged 29. Cardiac actin was purified by previously described 
methods (see 2.2.2.3). The protocol involved a number of ultra centrifugation steps, in 
the presence of ATP (and one step with blebbistatin) to dissociate the actin from 
myosin. No polymerisation – reploymerisation steps were used since previous studies 
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showed that mutations could render monomeric actin unstable (Dyer unpublished). 
Images of flow cells loaded with plain actin are shown in Figure 5.3, there is no 
visible difference between the donor and E99K preparations. 
Figure 5.3: Images of plain actin 
 
 
Screen shots of flow cells loaded with plain actin A) N9, B) E99K 1b, C) NE, D) E99K 2 taken from 
the tracker program. 
 
To determine its purity, the final product was analysed by SDS-PAGE and then fixed 
and stained with SYPRO (Figure 5.4). A clear band was present in the region 
corresponding to actin. There were no other defined bands present, illustrating that the 
protocol produced pure actin and removed the other myofilament proteins. This gel 
was also used to determine the concentration of the purified cardiac actin samples 
using the skeletal actin, whose concentration had previously been determined by 
Lowry assay. The concentration of both the actin preparations from human biopsy 1 
and donor heart tissue was estimated to be ~1µM. 
A B 
C D 
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Figure 5.4: SDS-PAGE of purified F-actin from E99K biopsy sample 1, donor heart ND and 
skeletal muscle stained with SYPRO 
 
Purified cardiac actin from the human E99K biopsy 1a and donor heart ND and skeletal F-actin (stock 
0.1mg/ml) were diluted by a factor shown under the gel in dH2O. These were then further diluted 1:1 
with 2xSDS sample buffer and 20µl was loaded into the corresponding lane of the gel. Upon 
completion of electrophoresis the gel was stained with SYPRO. 
 
Dr. Judy Leung produced and examined myofibril samples purified from the first 
human E99K biopsy using SDS-PAGE (Figure 5.5) and found that a noticeable 
degree of degradation was present. Multiple bands were present in the actin-TnT 
region. This degradation of the actin may have affected the IVMA results found with 
this sample. 
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Figure 5.5: SDS-PAGE gel of myofibril preparation from the first human E99K biopsy 
demonstrating degradation of sample completed by Dr. Judy Leung. 
  
Myofibrils were produced from the first human E99K biopsy sample. Two repeat lanes were loaded 
with 2µl. After electrophoresis the gel was fixed and stained with SYPRO. The major myofilament 
phosphoproteins, MyBP-C, TnT, TnI and MLC-2 are labelled on the picture of the gel. The production 
of myofibril samples and electrophoresis work was completed by Dr. Judy Leung. 
 
5.3.1 E99K mutant cardiac actin purified from human biopsies had an slower 
sliding speed than actin purified from a donor heart sample 
 
The first set of IVMA experiments completed compared movement of ‘plain’ E99K 
actin filaments to ‘plain’ donor actin. The tables below (Table 5.2, Table 5.3 & Table 
5.4) summarise the data comparing E99K actin preparations 1a and 1b and E99K 2 to 
donor actin. A common finding was that actin preparations purified from E99K 
patient biopsies had a slower sliding speed then donor actin. For the first pair (E99K 
1a and ND) the average sliding speed of E99K actin filaments was 21% slower than 
control donor actin (paired student t-test p < 0.001). But there was no significant 
difference in the fraction motile. The comparison of the second pair (E99K 1b and 
N9) showed a statistically significant decrease in the sliding speed of 12% (paired 
student t-test p = 0.02) and fraction motile of 12% (paired student t-test p=0.03). The 
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final comparison between E99K 2 and NE showed a statistically significant decrease 
in the sliding speed of 6% (paired student t-test p=0.002) and no significant decrease 
in fraction motile. This reduction in sliding speed suggests that the presence of the 
mutation is affecting the interaction between the actin and myosin. The next question 
to answer was: were there any functional differences between actin-tropomyosin 
filaments that contained either E99K actin or donor actin?  
Table 5.2: Percentage motile and mean sliding speed of plain ND and E99K 1a actin 
Actin Sample Actin Fraction Motile Actin Sliding Speed 
(µm/s) 
Donor E99K Donor E99K Donor E99K 
0.82 ±0.14 0.88 ±0.02 1.96 ±0.24 1.74 ±0.07 
0.88 ±0.05 0.85 ±0.05 1.86 ±0.18 1.61 ±0.17 
0.81 ±0.03 0.67 ±0.08 1.96 ±0.14 1.42 ±0.04 
0.86 ±0.04 0.80 ±0.04 2.06 ±0.11 1.55 ±0.04 
0.87 ±0.02 0.84 ±0.01 2.04 ±0.11 1.49 ±0.08 
ND  E99K 
1a 
0.82 ±0.09 0.85 ±0.04 2.31 ±0.41 1.81 ±0.33 
Mean ± SD 
n = 6 
0.84 ±0.03 0.81 ±0.07 2.03 ±0.15 1.60 ±0.15 
Student t-test (Paired) p = 0.32  
(Unpaired) p = 0.36 
(Paired) p < 0.001 
(Unpaired) p <0.001 
 
Table 5.3: Percentage motile and mean sliding speed of plain N9 and E99K 1b actin  
Actin Sample Actin Fraction Motile Actin Sliding Speed 
(µm/s) 
Donor E99K Donor E99K Donor E99K 
0.77 ±0.08 0.55 ±0.21 1.72 ±0.10 1.54 ±0.10 
0.82 ±0.08 0.72 ±0.04 1.99 ±0.13 1.68 ±0.16 
0.86 ±0.01 0.75 ±0.03 1.77 ±0.05 1.79 ±0.14 
0.86 ±0.05 0.75 ±0.02 1.85 ±0.17 1.77 ±0.12 
0.83 ±0.04 0.63 ±0.11 2.16 ±0.25 1.54 ±0.14 
0.80 ±0.06 0.67 ±0.15 1.81 ±0.08 1.54 ±0.07 
0.58 ±0.13 0.60 ±0.09 1.44 ±0.21 1.62 ±0.21 
0.83 ±0.05 0.67 ±0.10 2.05 ±0.16 1.49 ±0.03 
0.63 ±0.15 0.69 ±0.07 1.97 ±0.21 1.61 ±0.09 
0.68 ±0.10 0.59 ±0.11 2.26 ±0.36 1.70 ±0.15 
N9 E99K 
1b 
0.57 ±0.11 0.65 ±0.14 1.63 ±0.13 1.88 ±0.1 
Mean ± SD 
n = 11 
0.75 ±0.11 0.66 ±0.06 1.88 ±0.24 1.65 ±0.12 
Student t-test (Paired) p= 0.02 
(Unpaired) p= 0.03 
(Paired) p= 0.03 
(Unpaired) p= 0.05 
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Table 5.4: Percentage motile and mean sliding speed of plain NE and E99K 2 actin 
Actin Sample Actin Fraction Motile Actin Sliding Speed 
(µm/s) 
Donor E99K Donor E99K Donor E99K 
0.88 ±0.06 0.89 ±0.04 1.85 ±0.03 1.62 ±0.04 
0.90 ±0.06 0.87 ±0.01 2.02 ±0.08 1.76 ±0.18 
0.79 ±0.04 0.70 ±0.06 2.23 ±0.02 1.97 ±0.04 
0.80 ±0.08 0.82 ±0.04 1.97 ±0.24 1.86 ±0.03 
0.85 ±0.06 0.80 ±0.02 2.67 ±0.08 2.46 ±0.11 
0.84 ±0.05 0.66 ±0.08 2.16 ±0.13 2.08 ±0.12 
0.84 ±0.04 0.75 ±0.09 2.04 ±0.06 1.93 ±0.08 
0.84 ±0.02 0.80 ±0.05 2.46 ±0.03 2.42 ±0.18 
0.78 ±0.04 0.71 ±0.04 2.00 ±0.10 2.03 ±0.07 
NE  E99K 
2 
0.70 ±0.03 0.82 ±0.03 2.44 ±0.04 2.33 ±0.05 
Mean ± SD 
n = 10 
0.82 ±0.06 0.78 ±0.08 2.18 ±0.26 2.05 ±0.28 
Student t-test (Paired) p = 0.15 
(Unpaired) p= 0.35 
(Paired) p = 0.002 
(Unpaired) p= 0.06 
 
To test for normality the data from the second set of pair of comparisons were plotted 
as histograms as these contained the most number of repeats (11) (see Figure 5.6). 
Both of these look normally distributed thus it was appropriate to use the Student t-
test. 
 
Figure 5.6: Histograms of sliding speed data from E99K 1b and N9 
 
Histogram plots of the sliding speed data from E99K 1b (A) and N9 (B). 
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5.3.2 Cardiac actin from human E99K biopsy 2 had a consistently slower 
sliding speed when titrated with tropomyosin 
To determine if any function differences could be detected in the presence of 
tropomyosin E99K 2 actin and donor NE actin were titrated over a range of 0-100nM 
with human cardiac tropomyosin. At the zero point, where no tropomyosin was 
present (plain actin), the E99K 2 actin showed a slower sliding speed than the NE 
donor actin as demonstrated previously (Figure 5.7). A difference in sliding speed 
was maintained throughout the titration. This adds further evidence to notion that the 
presence of the E99K mutation is affecting the acto-myosin interaction. No difference 
in the fraction motile was detected between the two sets of filaments over the same 
titration range. The next set of experiments investigated the functional effects of 
E99K actin in fully reconstituted thin filaments.  
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Figure 5.7: Tropomyosin titration with donor (blue) and E99K (red) actin. 
 
100nM of human cardiac actin from donor heart sample NE (blue) or Human E99K biopsy 2 was 
incubated with 100nM, 200nM, 400nM, 600nM and 1µM tropomyosin. This was then diluted 10-fold 
in motility buffer A and analysed by IVMA, two parameters were measured the A) sliding speed and 
B) fraction motile. 
 
5.3.3 Cardiac actin preparations from human E99K biopsies were regulated by 
troponin in a Ca2+-sensitive manner when constituted into thin filaments 
 
Troponin was purified from donor tissue sample NL by methods previously described 
(see 2.2.4.1). Cardiac actin from E99K 1b and N9 was reconstituted into thin 
filaments with 60nM human cardiac tropomyosin and human donor (NL) cardiac 
troponin. A troponin titration was completed over the range 0-30nM (see Figure 5.8). 
There was no difference at the points with 10nM and 30nM troponin at high [Ca2+] 
(3.7µM). There is much more variability in the measurements of sliding speed at low 
[Ca2+] (1nM), where no clear difference is visible. For the zero troponin point, 
measurements of plain actin are used instead of actin and tropomyosin (A.Tm). This 
was to conserve the limited amount of actin. This was justifiable as there was no 
difference between the 60nM point on the tropomyosin titration and plain actin 
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(Figure 5.7). The fraction motile was maintained ≥0.7 for both actin preparations at 
high [Ca2+] (3.7µM) and was reduced to ≤ 0.25 at low [Ca2+] (1nM) with troponin 
concentrations of 20nM and 30nM. This titration demonstrated that cardiac actin 
purified from donor heart tissue (N9) and E99K biopsy 1 was regulated in a Ca2+-
sensitive manner by troponin. Therefore Ca2+-concentration titrations comparing 
E99K 1b actin and donor actin could be completed.  
 
Actin purified from the second E99K human patient biopsy (E99K 2) was analysed 
with the IVMA, as shown (Figure 5.9) when it was reconstituted into thin filaments 
with human cardiac tropomyosin and 10nM and 20nM human cardiac donor (NE) 
troponin. The sliding speeds did not differ at either high (3.7µM) or low (1nM) 
[Ca2+]. The fraction motile was ≥0.7 at high [Ca2+] (3.7nM) for both sets of filaments. 
At low [Ca2+] (1nM) the filaments that contained donor actin had a fraction motile of 
≤0.2 at both points, whereas the E99K actin filaments were less inhibited with a 
fraction motile of ≤0.35. However, reduced inhibition of E99K containing thin 
filament was not a common finding (as shown in Figure 5.10). 
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Figure 5.8: IVMA troponin titration comparing thin filaments composed of human cardiac 
donor troponin and tropomyosin and either E99K 1b actin or donor N9 actin  
 
 
 
IVMA experiments titrating human cardiac donor (NL) troponin over a range of 0-30nM. Thin 
filaments were composed of 10nM donor actin N9 (blue) or E99K 1b actin (red) and 60nM human 
cardiac tropomyosin and troponin. The sliding speed of the reconstituted thin filaments were measured 
at A) high [Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile was measured at C) high 
[Ca2+] (3.7µM) D) low [Ca2+] (1nM). The troponin concentrations used were 10nM and 30nM at high 
[Ca2+] with an addition measurement at 20nM at low [Ca2+]. The open symbols represent 
measurements of plain actin.  
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Figure 5.9: IVMA troponin titration comparing thin filaments composed of human cardiac 
donor troponin and tropomyosin and either E99K 2 actin or donor NE actin  
 
 
 
IVMA experiments titrating human cardiac donor (NL) troponin over a range of 0-30nM. Thin 
filaments were composed of 10nM donor actin N9 (blue) or E99K 1b actin (red) and 60nM human 
cardiac tropomyosin and troponin. The sliding speed of the reconstituted thin filaments were measured 
at A) high [Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile was measured at C) high 
[Ca2+] (3.7µM) D) low [Ca2+] (1nM). The troponin concentrations used were 10nM and 20nM. The 
open symbols represent measurements of plain actin.  
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After the troponin titrations experiments Ca2+-concentration titrations were 
completed. Bar graphs shown in Figure 5.10 demonstrate the consistent level of thin 
filament regulation by the respective troponin for both the E99K 1b / N9 and the 
E99K 2/ NE pair of actin preparations. The bar graphs show the fraction motile 
measured at high [Ca2+] (3.7µM) and low [Ca2+] (1nM) for the each of sets of thin 
filaments used to produce a Ca2+-concentration titration. The majority of the sets of 
thin filaments have a mean fraction motile of ≥0.7 for both actin preparations at high 
[Ca2+] (3.7µM) and ≤ 0.2 at low [Ca2+] (1nM). Thus the thin filaments were saturated 
with functional troponin and consistently well regulated 
 
Figure 5.10: Summary of fraction motile measurement at high and low [Ca2+] from IVMA Ca2+-
concentration titrations comparing E99K to donor actin 
  
Fraction motile data was plotted from all of the IVMA Ca2+-sensivity curve experiments completed 
with thin filament reconstituted with donor troponin A) NL B) NE, comparing E99K actin (red) A) 
E99K 1b B) E99K 2 to donor actin (blue) A) N9 B) NE at high [Ca2+] (3.7µM) (solid) and low [Ca2+] 
(1nM) (striped). The final troponin concentration was 10nM in all repeat experiments apart from 
experiment V using E99K2 and NE actin (panel B) where 20nM was used. 
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These tables highlight that there is no difference between the sliding speed or fraction 
motile of thin filaments that contain donor troponin and either E99K or donor actin at 
both high and low [Ca2+]. Apart from a small difference between fraction motile of 
thin filaments that contained E99K 2 actin and NE actin of 2% was statistically 
significant (paired student t-test p=0.05).  
 
Taken together, the data in Table 5.5 & Table 5.6 and the bar graphs (Figure 5.10) 
show that the activity at high [Ca2+] and inhibition at low [Ca2+] of thin filament with 
E99K actin is equal to that of thin filaments with donor actin. The bar graphs also 
demonstrate that although there is some variation between repeat experiments these 
differences are due to variability of the regulating troponin and are independent of the 
actin. 
254 
 
Table 5.5: Summary table of mean sliding speed for thin filaments with either donor or E99K 
actin at high [Ca2+] (3.7µM) and low [Ca2+] (1nM). 
Samples  Mean sliding speed [Ca2+] 
(3.7µM) 
Mean sliding speed  
[Ca2+] (1nM) 
Donor E99K Donor E99K Donor E99K 
N9 E99K 
1b 
1.97±0.51 1.93±0.47 1.38±0.37 1.45±0.31 
Student t-test Paired       p= 0.71 
Unpaired   p= 0.81 
Paired        p= 0.52 
Unpaired    p= 0.41 
   
NE E99K 2 2.20±0.18 2.16±0.13 2.18±0.26 2.25±0.17 
Student t-test Paired      p= 0.24 
Unpaired  p= 0.36 
Paired        p= 0.39 
Unpaired    p= 0.34 
 
Table 5.6: Summary table of mean percentage motile 
Samples  Mean Fraction Motile [Ca2+] 
(3.7µM) 
Mean Fraction Motile  [Ca2+] 
(1nM) 
Donor E99K Donor E99K Donor E99K 
N9 E99K 1b 0.77±0.08 0.72±0.03 0.17±0.07 0.16±0.04 
Student t-test Paired         p= 0.14 
Unpaired     p= 0.19 
Paired        p= 0.62 
Unpaired    p= 0.85 
   
NE E99K 2 0.74±0.04 0.72±0.03 0.14±0.06 0.19±0.13 
Student t-test Paired         p= 0.05 
Unpaired     p= 0.05 
Paired        p= 0.41 
Unpaired    p= 0.34 
 
Incomplete relaxation is a phenotype associated with some HCM causing mutations 
(Marston, 2011). The data demonstrates that there is no difference in the inhibition of 
filament movement at low [Ca2+] between the thin filament with E99K actin or donor 
actin. Therefore the actin purified from these human samples with the E99K mutation 
does not seem to cause incomplete relaxation when investigated with the IVMA.  
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5.3.4 There was no difference in the Ca2+-sensitivity of thin filaments that 
contained donor troponin and either actin purified from the first E99K 
patient biopsy or donor heart N9.  
 
Four Ca2+-concentration titrations were completed comparing thin filaments 
reconstituted with either E99K 1b or N9 donor actin and donor heart troponin (NL). 
Examples of sliding speed Ca2+-concentration curves are shown below (Figure 5.11). 
These have been selected as the best representation of the data. All of the unfitted 
sliding speed data is present in the appendix. These data show no measureable 
difference in sliding speed regulation between thin filaments with the E99K or donor 
actin. The data was not fitted with the Hill equation.  
Figure 5.11: Ca2+-concentration titrations comparing thin filaments containing donor and E99K 
actin. The measured parameter is the sliding speed 
  
IVMA Ca2+-concentration titrations comparing the sliding speed of actin purified from E99K biopsy 
and donor heart. A) Thin filaments composed of 10nM actin N9 (blue) or E99K 1b actin (red) and 
60nM human cardiac tropomyosin and troponin 10nM. B) Thin filaments composed of 10nM actin NE 
(blue) or E99K 2 actin (red) and 60nM human cardiac tropomyosin and troponin 10nM.  
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The fraction motile Ca2+-concentration curves for E99K 1b are shown in Figure 5.12. 
Two preparations of donor heart troponin NL were used and gave different results. 
The first troponin preparation (experiments I) suggests that the presence of the mutant 
E99K actin causes a decrease in thin filament Ca2+-sensitivity. Whereas the results 
from the experiments that used the second troponin preparation (II – IV) show no 
difference in the Ca2+-sensitivity between the two sets of thin filaments. All the data is 
summarised in Table 5.7. When all the data is taken together there is no significant 
statistical difference in EC50 between thin filaments with the E99K actin and the 
donor actin (student t-test, unpaired p=0.46, paired p=0.47, n=4). 
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Figure 5.12: Ca2+-concentration titrations comparing thin filaments containing donor N9 and 
E99K 1b actin.  
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of actin purified from E99K biopsy 
and donor heart (I-IV). Thin filaments composed of 10nM actin N9 (blue) or E99K 1b actin (red) and 
60nM human cardiac tropomyosin and troponin 10nM.  
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Table 5.7: Fraction motile EC50 values of thin filaments with either E99K 1b or N9 actin 
Experiment 
No. 
Donor actin 
EC50 (mM)  
SD 
 
 
E99K actin 
EC50 (mM) 
SD 
 
 
E99K/ 
Donor 
I 0.08 ± 0.01 0.16 ± 0.03 1.91 
II 0.12 ± 0.07 0.11 ± 0.11 0.88 
III 0.16 ± 0.04 0.17 ± 0.05 1.05 
IV 0.07 ± 0.01 0.06 ± 0.03 0.96 
      
mean 0.11 ± 0.04 0.12 ± 0.05 1.20 
       ±0.48 
      
Student  
t-test 
                (paired): p = 0.47                                (unpaired) p = 0.46  
 
5.3.5 Thin filaments that contained F-actin purified from the second biopsy 
sample and donor troponin were 1.3-fold more Ca2+-sensitive than thin 
filaments with donor F-actin and troponin. 
 
Only a small amount of tissue was obtained from each biopsy and this was distributed 
between more than one research group. Therefore only a small amount of tissue was 
received for this study. This was the limiting factor as to how much data could be 
acquired. It was only possible to produce two actin preparations from the first biopsy 
sample and only one was possible from the second. The first E99K sample 
purification (E99K 1a) was used up examining the behaviour of plain actin and acto-
tropomyosin. A considerable proportion was also used to optimise the method for 
producing Ca2+-concentration titration. The second purification was then completed 
(E99K 1b) and this was used for the Ca2+-concentration titration shown above and 
experiments comparing E99K actin to donor actin in the presence of failing heart 
troponin (see 5.3.6). Tissue from the second biopsy was used for the final actin 
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preparation (E99K 2). This was used for a further five Ca2+-concentration titrations 
comparing thin filaments E99K actin to donor actin, the results of which are shown in 
Figure 5.13 & Figure 5.14. Again two troponin preparations were required to 
complete the five curves. For this second set of Ca2+-concentration titrations troponin 
was purified from donor heart NE. A consistent pattern was present in all five Ca2+-
concentration titrations. The thin filaments with the E99K actin were more Ca2+-
sensitive than the thin filaments that contained the donor actin. On average the thin 
filaments with E99K 2 actin were 1.3-fold more Ca2+-sensitive. This difference was 
statistically significant (student t-test unpaired p=0.03, paired p =0.02 n=5). An 
increase in thin filament Ca2+-sensitivity is a common molecular phenotype measured 
in proteins with HCM causing mutations (see Table 1.1 & Table 1.2) and may play a 
role in the onset and development of the disease. 
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Figure 5.13: Ca2+-concentration titrations comparing thin filaments containing donor NE and 
E99K 2 actin. The measured parameter is the fraction motile. 
  
  
IVMA Ca2+-concentration titrations comparing the sliding speed of actin purified from E99K biopsy 
and donor heart. I-IV) Thin filaments composed of 10nM actin NE (blue) or E99K 2 actin (red) and 
60nM human cardiac tropomyosin and troponin (NE) 10nM.  
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Figure 5.14: Ca2+-concentration titrations comparing thin filaments containing donor NE and 
E99K 2 actin. The measured parameter is the fraction motile. 
 
IVMA Ca2+-concentration titrations comparing the sliding speed of actin purified from E99K biopsy 
and donor heart. V) Thin filaments composed of 10nM actin NE (blue) or E99K 2 actin (red) and 
60nM human cardiac tropomyosin and troponin (NE) 20nM.  
 
Table 5.8: Fraction motile EC50 values of thin filaments with either E99K 2 or NE actin 
Experiment 
No. 
Donor actin 
EC50 (mM)  
SD 
 
 
E99K actin 
EC50 (mM) 
SD 
 
 
E99K/ 
Donor 
I 0.50 ± 0.02 0.48 ± 0.06 0.96 
II 0.36 ± 0.09 0.28 ± 0.15 0.77 
III 0.42 ± 0.02 0.35 ± 0.06 0.84 
IV 0.29 ± 0.13 0.17 ± 0.09 0.57 
V 0.54 ± 0.14 0.40 ± 0.29 0.73 
      
mean 0.42 ± 0.10 0.34 ± 0.12 0.78 
           0.14 
      
Student  
t-test 
           (paired): p = 0.02                                   (unpaired) p = 0.03 
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5.3.5.1 Further work with human cardiac E99K actin sample 
 
The next stage of this study was to investigate if actin that contained the E99K 
mutation had any effect on the regulation of thin filament Ca2+-sensitivity by TnI 
phosphorylation. This was completed in two ways: the first step was to compare 
donor actin and E99K actin in the presence of failing human heart troponin. Failing 
heart troponin has a low level of TnI phosphorylation and any differences caused by 
the E99K actin in thin filament Ca2+-sensitivity at the low level of TnI 
phosphorylation would be detected. The final set of experiments compared E99K 
actin in the presence of donor or failing human heart troponin. This was to determine 
if the thin filament Ca2+-sensitivity remained regulated by the level of TnI 
phosphorylation in filaments that contained E99K actin. 
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5.3.6 E99K mutant cardiac actin was regulated by failing heart troponin in a 
Ca2+-sensitive manner when constituted into thin filaments 
 
Troponin was purified from failing heart sample FH and reconstituted into thin 
filaments with either E99K actin or donor actin and analysed by IVMA. The aim of 
these experiments was to determine if there was a difference in thin filament Ca2+-
sensitivity between filaments, that contained either E99K actin or non-mutant actin, 
reconstituted with a troponin sample with a low level of TnI phosphorylation. The 
native level of TnI phosphorylation of failing heart sample FH was 0.15 ± 0.05 
molsPi/molsTnI (n=5) as measured by Dr. Andrew Messer. Failing heart troponin has 
previously been used in an IVMA study to demonstrate the relationship between TnI 
phosphorylation and thin filament Ca2+-sensitivity (Messer et al., 2007). Three Ca2+-
concentration titrations (I-III) were completed comparing thin filaments with failing 
troponin and either E99K 1b actin or N9 donor actin. Only one failing heart troponin 
sample was used for these experiments. The failing heart troponin regulated the 
movement of both sets of thin filaments in a Ca2+-sensitive manner (see Figure 5.15). 
The fraction motile was > 0.7 at high [Ca2+] (3.7µM) for all sets of filaments (except 
the E99K thin filaments in the first curve (I)) and was <0.2 at low [Ca2+] (1nM) for all 
three experiments.  
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Figure 5.15: Summary of fraction motile measurement at high and low [Ca2+] from IVMA Ca2+-
concentration titrations comparing E99K to donor actin reconstituted with failing heart troponin 
 
Fraction motile data plotted from all of the IVMA Ca2+-sensivity curve experiments completed with 
thin filament reconstituted with failing troponin FH comparing E99K 1b actin (red) to donor actin N9 
(blue) at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The concentration of troponin 
used was 10nM for all experiments. 
 
5.3.7 Thin filaments that contained E99K mutant cardiac actin and failing 
heart troponin appeared to be more Ca2+-sensitive then thin filaments 
that contained donor heart actin and failing heart troponin  
 
Thin filaments were reconstituted with failing troponin (FH) and either E99K actin 
(1b) or donor actin (N9). Three Ca2+-concentration titrations were completed. The 
Ca2+-concentration titrations from the third (III) experiment is shown (Figure 5.16). 
This data has not been fitted with the Hill equation due to the short range of the 
(sliding speed) data. There is no consistent pattern within the figure suggesting no 
0
0.2
0.4
0.6
0.8
1
I II III
Donor actin (3.7µM)
Donor actin (1nM)
E99K actin (3.7µM)
E99K actin (1nM) 
F
ra
c
ti
o
n
 m
o
ti
le
265 
difference in Ca2+-sensitivity of sliding speed between the two sets of filaments. The 
remaining data is shown in the appendix. 
Figure 5.16: Ca2+-concentration titrations comparing thin filaments containing donor and E99K 
actin in the presence of failing heart troponin.  
 
IVMA Ca2+-concentration titrations comparing the sliding speed of actin purified from E99K biopsy 
and donor heart. Thin filaments composed of 10nM actin N9 (blue) or E99K 1b actin (red) and 60nM 
human cardiac tropomyosin and failing heart (FH) troponin 10nM.  
 
A consistently higher Ca2+-sensitivity was measured for the thin filament containing 
E99K actin compared those with donor actin, in the presence of failing troponin (see 
Table 5.9). An increase in thin filament Ca2+-sensitivity was measured between the 
second pair of actin preparations (E99K 2 & NE) in the presence of donor troponin 
but no such difference was measured between this pair (E99K 1b and N9). For a 
difference to emerge in the presence of failing troponin is difficult to explain. The 
data from the Ca2+-concentration titrations with donor troponin comparing E99K 1b 
to N9 is the most variable but in none of the curves are the E99K thin filament more 
Ca2+-sensitive. As previously discussed (5.3.5) there was a substantial degree of 
degradation present in the biopsy from the first patient. This may have caused 
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discrepancies in the experimentation and this pattern of results may not be a truly 
representative of E99K mutant actin. 
Figure 5.17: Ca2+-concentration titrations comparing thin filaments containing donor N9 and 
E99K 1b actin in the presence of failing heart troponin.  
  
 
IVMA Ca2+-concentration titrations comparing the fraction motile of actin purified from E99K biopsy 
and donor heart (I-III). Thin filaments composed of 10nM actin N9 (blue) or E99K 1b actin (red) and 
60nM human cardiac tropomyosin and failing heart troponin (FH) 10nM.  
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Table 5.9: Fraction motile EC50 values of thin filaments with either E99K 2 or NE actin in the 
presence of failing troponin 
 
Experiment 
No. 
 
Donor actin 
EC50 (µM) 
 
SD 
 
E99K actin 
EC50 (µM) 
 
SD 
 
E99K/ 
Donor 
 
I        0.33 ± 0.05 0.20 ± 0.01 0.60 
II 0.21 ± 0.05 0.21 ± 0.03 0.99 
III 0.30 ± 0.04 0.26 ± 0.04 0.87 
        
mean 0.28 ± 0.06 0.22 ± 0.04 0.82 
      ± 0.2 
 
5.4 IVMA experiments comparing thin filament with actin purified 
from human E99K biopsy 2 and either donor heart or failing 
heart troponin 
 
Chapter 3 of this thesis investigated uncoupling of thin filament Ca2+-sensitivity from 
the level of constituent TnI phosphorylation in HOCM troponin as a secondary effect. 
Work by Dr. Emma Dyer suggested that the presence of the E99K mutation directly 
disrupts the TnI phosphorylation – thin filament Ca2+-sensitivity relationship in thin 
filaments with transgenic mouse E99K actin (Song et al., 2011). The key experiment 
to demonstrate a direct disruption to this relationship is to measure Ca2+-sensitivity of 
thin filaments reconstituted with a single actin type and a troponin that has either a 
high level of TnI phosphorylation or low level of TnI phosphorylation. Therefore 
experiments that compared thin filaments with E99K actin and troponin from either 
donor heart sample NE (1.51±0.34 molsPi/molsTnI) or failing heart sample FH 
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(0.15±0.05 molsPi/molsTnI) were completed (TnI phosphorylation measurements 
completed by Dr Andrew Messer on myofibril preparations).  
 
5.4.1 E99K mutant cardiac actin was regulated by both donor and failing heart 
troponin in a Ca2+-sensitive manner when reconstituted into thin 
filaments 
 
Troponin titrations were completed as the first point of IVMA experimentation with 
thin filaments that consisted of E99K actin, human cardiac tropomyosin and either 
donor or failing heart troponin. As demonstrated in the summary bar graph (see 
Figure 5.18) all but one of the donor (NE) and failing (FH) heart troponin samples 
regulated their respective sets of thin filaments with a fraction motile of >0.7 
measured at high [Ca2+] (3.7µM) and <0.25 at low [Ca2+] (1nM). 
Figure 5.18: Summary of fraction motile measurement at high and low [Ca2+] from IVMA Ca2+-
concentration titrations comparing thin filaments with E99K and donor or failing heart troponin 
  
Fraction motile data was correlated from all of the IVMA Ca2+-sensivity curve experiments completed 
(I-III) with thin filament reconstituted with E99K 2 actin and either donor heart (NE) troponin (red) or 
failing heart (FH) troponin (crimson) at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). 
The concentration of troponin used was 30nM in all experiments. 
0
0.2
0.4
0.6
0.8
1
I II III
E99K actin with donor troponin (3.7µM)
E99K actin with donor troponin (1nM)  
E99K actin with failing troponin (3.7µM)   
E99K actin with failing troponin (1nM) 
F
ra
c
ti
o
n
 m
o
ti
le
269 
5.4.2 There was no difference in maximum sliding speed of thin filaments that 
contained E99K actin and either donor or failing heart troponin.  
 
No difference in sliding speed at high [Ca2+] (3.7µM) was measured between thin 
filaments composed of E99K (2) actin and either donor heart (NE) or failing heart 
(FH) troponin. This data is shown in Table 5.10. As E99K actin is present in both sets 
of thin filaments this result is unsurprising.  
 
Table 5.10: Maximum sliding speed of E99K thin filaments with either donor or failing troponin  
 
Experiment 
No. 
 
E99K actin 
(donor Tn) 
max. sliding 
speed 
(µm/s) 
SD 
 
 
 
E99K actin 
(failing Tn) 
max. sliding 
speed 
(µm/s) 
SD 
 
 
 
Donor/ 
Failing 
troponin 
 
I        2.14 ± 0.09 2.26 ± 0.08 0.95 
II 1.99 ± 0.09 2.01 ± 0.19 0.99 
III 2.38 ± 0.04 2.23 ± 0.05 1.07 
        
mean 2.17 ± 0.20 2.17 ± 0.14 1.00 
       ± 0.06 
 
 
5.4.3 There was no difference in the Ca2+-sensitivity of thin filaments that 
contained E99K mutant cardiac actin and either donor or failing heart 
troponin 
 
No difference was detectable between the sliding speed Ca2+-sensitivity of the two 
respective sets of thin filaments. The Ca2+-concentration titrations from experiment I 
is shown in Figure 5.19. The remaining unfitted data is shown in the appendix. 
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Figure 5.19: Ca2+-concentration titrations comparing thin filaments containing E99K actin in the 
presence of either donor or failing heart troponin.  
 
IVMA Ca2+-concentration titrations comparing the sliding speed of actin purified from E99K biopsy 
and donor heart. Thin filaments composed of 10nM actin E99K 2 actin and 60nM human cardiac 
tropomyosin and either donor heart (NE) troponin (red) or failing heart (FH) troponin (crimson) 30nM.  
 
The results from the three Ca2+-concentration titrations completed using E99K actin 
and either donor or failing heart troponin suggest an uncoupling effect similar to that 
found in the work by Dyer (Song et al., 2011, Dyer et al., 2008). The first curve (I) 
(see Figure 5.20) shows the thin filaments with donor heart were more ~1.2 fold more 
Ca2+-sensitive than failing troponin filaments (EC50 ratio donor/failing = 0.77). The 
second curve (II) shows follows a similar pattern but with the difference in Ca2+-
sensitivities being much smaller (EC50 ratio donor/failing = 0.89). The final curve (III) 
shows no difference between the two sets of filaments. This data is summarised in 
Figure 5.10. 
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Figure 5.20: Ca2+-concentration titrations comparing thin filaments containing E99K actin in the 
presence of either donor or failing heart troponin.  
  
 
IVMA Ca2+-concentration titrations comparing the fraction motile of actin purified from E99K biopsy 
and donor heart. (I-III) Thin filaments composed of 10nM actin E99K 2 actin, 60nM human cardiac 
tropomyosin and either donor heart (NE) troponin (red) or failing heart (FH) troponin (crimson) 30nM.  
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Table 5.11: Fraction motile EC50 values of thin filaments with E99K 2 and either donor heart or 
failing heart troponin 
Experiment 
No. 
E99K actin  
(donor Tn) 
EC50 (mM)  
SD 
 
 
E99K actin 
(failing Tn) 
EC50 (mM) 
SD 
 
Donor/ 
Failing 
troponin 
I 0.08 ± 0.01 0.10 ± 0.01 0.77 
II 0.13 ± 0.01 0.15 ± 0.01 0.89 
III 0.08 ± 0.00 0.08 ± 0.01 1.02 
      
mean 0.10 ± 0.03 0.11 ± 0.03 0.89 
       ±  0.12 
 
This is only a small set of data but it does suggest that the presence of the E99K 
mutation disrupts the relationship between TnI phosphorylation and thin filament 
Ca2+-sensitivity since a 2.5-fold increase in thin filament Ca2+-sensitivity was not 
found. Further repeat experiments are required to strengthen the observations found in 
this chapter. The actin from the first sample was degraded and thus reduced the 
amount of experimentation that was possible and the reliability of the data that was 
obtained. Coupled to the difficult nature of completing the actin experiments, perhaps 
it would have been more sensible to concentrate on a smaller number of questions. 
Looking at both the difference between donor and E99K actin in the presence of 
failing troponin and the possibility of uncoupling in E99K thin filaments was unwise.  
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5.5 Discussion 
This was the first study to investigate a cardiac actin HCM causing mutation (E99K) 
in thin filaments purified from human biopsy samples. Both of these biopsy samples 
consisted of only a small amount of tissue and this was a limiting factor to the depth 
of investigation possible. Also the quality of the first biopsy sample was not optimal. 
The F-actin purification protocol used was the same method used by Dr Emma Dyer 
(Song et al., 2010), with the addition of blebbistatin to the thin filament extraction 
buffer, but this was the first time this protocol was used to purify cardiac actin from 
human myocardium. The concentration of F-actin purified from the first human 
biopsy was ~1µM this was around 10-fold less than that obtained by Dr. Dyer from a 
mouse heart, however she did start with double the amount of tissue. For the IVMA 
the F-actin concentration is adjusted to 1µM when it fluorescently labelled and 
therefore this was still an acceptable yield. 
5.5.1 The level of mutant protein expression in human HCM patient biopsy 
samples 
Results from the transgenic (E99K) mouse study by Dr. Dyer showed that ~50% of 
the total actin purified from the mouse heart sample was mutant actin (Song et al., 
2011). Dr. Dyer also showed that this level of expression was maintained in the 
purified samples of F-actin. The percentage of mutant actin present in the human 
samples, as measured by Dr Judy Leung, were; 39%, 38,%, 34% for biopsy 1 and 
17% & 7% for biopsy 2 (Song et al., 2011). The difference in the two human samples 
perhaps illustrates that the ratio of mutant protein to total protein is highly variable 
among the heterozygotic carrier population or perhaps in different areas of the heart. 
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This would be an interesting topic to study. This would require taking a number of 
tissue samples from identified carriers of the mutation which would be difficult, but 
could be conducted in the E99K transgenic mouse.  
 
The age and disease severity of the patients should also be taken into account. The 
first patient was a 55 year old female who underwent a heart transplant, as she was 
suffering from heart failure. She had been diagnosed with HCM at 31 years old and 
the disease had progressed to heart failure despite multiple drug therapies prior to 
transplantation. This is compared to a non-symptomatic second patient who was a 32 
year old male identified as a carrier of this mutation. The biopsy was obtained from 
the second patient as he underwent an operation to repair an atrial septal defect. The 
difference in the severity of the disease between these two patients could be related to 
the proportion of mutant to total cardiac actin. This raises an interesting question: 
what level of mutant protein is required to cause a symptomatic disease? 
 
5.5.2 Phosphorylation of myofilament proteins in human HCM patient biopsy 
samples as measured by Dr. Leung 
Dr. Judy Leung completed a limited survey of the myofibrillar phosphoproteins from 
the second human patient biopsy sample which showed that there was no difference in 
the level of phosphorylation of the major myofilament phosphoproteins in the second 
biopsy sample compared to donor sample NA (Song et al., 2011). However HOCM 
samples, taken during septal myectomy operations, have been shown to have much 
reduced levels of phosphorylation of MyBP-C and TnI when compared to donor 
samples (Jacques et al., 2008c, Messer et al., 2009, Copeland et al., 2010b)(also see 
3.1.3).  
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Different regions of the heart may have varying degrees of myofilament protein 
phosphorylation. All of the HOCM heart samples are taken from a hypertrophied 
septum of a heart with a LVOTO, during a septal myectomy, whereas the first human 
biopsy sample was taken from the left ventricle and the second was taken from the 
region of the atrial septum. Measurements completed by Dr. Messer shown in chapter 
6 illustrate that a sample removed from the left ventricular free wall of a HCM patient 
was found to have a high level of TnI phosphorylation similar to that measured for the 
E99K patient biopsies. 
 
5.5.3  IVMA work with purified F-actin from human HCM patient biopsy 
samples 
Table 5.12: Summary table comparing motility of E99K F-actin to donor F-actin 
Source of 
sample 
 
Ratio of sliding 
speed of plain 
actin 
(E99K/control) 
Ratio of fraction 
motile of plain 
actin 
(E99K/control) 
Ratio of sliding 
speed of thin 
filaments at high 
Ca2+ (E99K/control) 
Ratio of fraction 
moile of thin 
filaments at high 
Ca2+ (E99K/control) 
Human 1(a) 0.79 ** 0.96   
Human 1(b) 0.9 * 0.9 * 0.99 0.94 
Human 2 0.94 * 0.96 * 0.98 0.97 * 
Mouse ♯  0.92 *  0.96  0.99 1 
Bookwalter 
&Trybus 0.79-0.87 *    
Debold et al 0.7 *  0.85 *  
♯ data from mouse work by Dr. Dyer published in (Song et al., 2011) 
* p<0.05, ** p<0.001 (paired Student t-test) 
 
The comparison of F-actin purified from E99K samples and donor heart samples are 
summarised in Table 5.12. The only consistent difference between the samples is that 
the sliding speed of plain E99K F-actin is lower than that of donor F-actin. This is in 
accordance with the results of Bookwalter & Trybus and Debold et al who showed 
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that bacculovirus expressed E99K had a slower sliding speed than both recombinant 
wild type and tissue purified actin (Bookwalter and Trybus, 2006, Debold et al., 
2010). This difference was lost when these F-actin samples were reconstituted into 
thin filament with donor troponin. This may be due to the fact that when actin is 
incorporated into thin filaments it becomes part of a cooperative system where its 
interaction with myosin is regulated by troponin. Therefore in fully activating 
conditions the troponin will ‘switch on’ the movement of the thin filaments, thus 
masking the weakening effect of the mutation on the acto-myosin interaction. 
Nevertheless the actual measured values are similar to IVMA measurements made by 
Dr Dyer on F-actin from mouse myocardium. Taken together these results suggest 
that the presence of E99K actin had a deleterious effect on the interaction between 
actin and myosin and that this effect was larger in the sample that had a higher 
proportion of mutant actin. 
 
5.5.4 IVMA result for thin filament with E99K F-actin and donor troponin  
 
Table 5.13: Comparison of data from human biopsy samples and transgenic mouse work 
♯ data from mouse work by Dr. Dyer published in (Song et al., 2011) 
 § data from work by Dr. Leung published in (Song et al., 2011) 
 
Source of 
sample 
 
Proportion of 
mutation 
(2DE) 
TnI 
phosphorylation 
 
2P-1P-0P ratio & 
molsPi/molsTnI 
EC50 ratio 
Native Tn 
 
E99K actin   
Control actin 
EC50 ratio 
E99K actin 
 
TnI +P 
TnI -P 
Mouse ♯  49.5±4.5 % 
37-42-21 
1.17± 0.02 
0.39±0.09 
p=0.03, n=5 
1.14±0.06 
p=0.16, n=4 
Human 1(b) 37±3 % 
 1.2±0.48 
p=0.47 n=4 
 
Human 2 12±7 % 
§    56-40-4 
§   1.52 ± 0.05 
0.78±0.14 
p=0.02 n=5 
0.92±0.21 
n=3 
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The results from the first sample were not consistent with results from the transgenic 
mouse and the second human biopsy sample. The latter both show that the presence of 
the E99K mutation resulted in an increase in thin filament Ca2+-sensitivity. This is in 
concordance with other studies that have shown HCM mutations result in an increase 
in thin filament Ca2+-sensitivity (see Table 1.1 & Table 1.2). The smaller effect seen 
in the experiments with actin from the second biopsy sample compared with the E99K 
transgenic mouse (completed by Dr. Dyer) is probably due to the lower proportion of 
mutant actin to total actin. Thus if the ‘dose’ of mutant protein was as high in the 
human sample as it was in the transgenic mouse then the magnitude of the difference 
in thin filament Ca2+-sensitivity could be similar. However, in this assumption the 
results from the first sample are effectively disregarded. This can be justified for two 
reasons. The first takes into account the degraded state of the sample (see 5.3). There 
are clearly multiple bands that correspond to actin (and the other myofilament 
proteins) and a loss of MyBP-C. This suggests that proteolysis has occurred at some 
point. As the methods of harvest, storage and transportation of the sample were 
outside of the control Marston laboratory this may have been completed in a 
substandard fashion. Thus the starting material for the preparation of F-actin was not 
ideal. However when F-actin was purified from this sample and electrophoresed, only 
a single band was present (see Figure 5.5), but that protein may have been damaged. 
Other reasons why no increase in thin filament Ca2+-sensitivity was seen in the first 
biopsy sample are that the mutant actin either did not reconstitute well into thin 
filaments or that thin filaments containing mutant actin did not bind to the HMM as 
found by Dyer using transgenic mouse actin isolated by the acetone powder method 
(Song et al., 2010). A study by Vang et al showed that the recombinant E99K actin 
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failed to become incorporated into filaments as well as demonstrating an increased 
tendency to form aggregates (Vang et al., 2005).  
 
The nature of the F-actin filaments should also be taken into consideration.  It is 
highly unlikely that F-actin filaments purified from human myocardium would 
comprise either totally of mutant actin or totally of non-mutant actin as F-actin 
filaments break-up and anneal frequently in solution. Thus the F-actin filaments were 
composed of both mutant and non-mutant monomers. It is possible that filaments 
composed of a large proportion of E99K monomers were outcompeted when binding 
to HMM by filaments with a lower E99K content. This may have resulted in the thin 
filaments that contained F-actin filaments with a high proportion of E99K monomers 
being washed out during the loading protocol of the flow cell. Thus these filaments 
would not have been present when the movement of filaments were recorded. 
However, the reasons why this would occur in thin filaments and not in plain actin is 
a further unanswered question. The final factor to take into consideration is that the 
work completed with the first biopsy sample, this was the first time F-actin was 
purified from human myocardium by this investigator and although no gross 
differences in protocol occurred, subtle optimisations in subsequent preparations may 
have increased the quality of the final product. 
 
5.5.5 IVMA result for E99K F-actin with donor or failing heart troponin 
The final set of experiments (also included in Table 5.13) compared thin filaments 
with E99K F-actin from the second biopsy and either donor or failing troponin. The 
difference in TnI phosphorylation did not result in the ~2.5-fold difference in thin 
filament Ca2+-sensitivity that was measured with non-mutant F-actin (Song et al., 
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2010). The combination of results from the transgenic mouse study by Dr. Dyer (Song 
et al., 2011, Dyer et al., 2008) and work in this chapter suggest that the presence of 
the E99K F-actin results in the disruption of the relationship between thin filament 
Ca2+-sensitivity and TnI phosphorylation. This disruption must be directly related to 
the presence of the mutation in the F-actin and can therefore be described as a primary 
effect of the disease. This disruption or uncoupling of the thin filament Ca2+-
sensitivity from TnI phosphorylation is a different effect from that discussed in 
chapter 3. The uncoupling discussed in chapter 3 was a result of a modification to the 
TnT subunit, which is a secondary effect to due to the disease. Therefore the 
relationship between TnI phosphorylation and thin filament Ca2+-sensitivity can be 
disrupted as a result of at least two divergent causes, and thus seems to be a relatively 
labile relationship. Furthermore the ability to uncouple this relationship may be a 
compensationary response built into the heart. A similar uncoupling effect was found 
in a study by Dr. Dyer who investigated the DCM causing cardiac actin mutation 
E361G, and found that no difference in Ca2+-sensitivity of thin filament reconstituted 
with E361G F-actin and either donor or phosphatase treated donor troponin (Song et 
al., 2010).  
 
The limiting factor in this study was the amount of experimentation that was possible. 
Working with human tissue is the gold standard but there is obviously only very 
limited availability to such material. Thus, complete studies must couple mouse 
model work with human diseased tissue. The work completed in this chapter is the 
second part to a more in-depth study completed with transgenic mouse tissue by Dr. 
Emma Dyer (Dyer, 2008, Song et al., 2011). If considered independently the work 
completed in this chapter may only be considered as preliminary data. There is a 
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degree of variability within the data from which only further experimentation would 
be able resolve any patterns. However, coupling these results to those from the study 
by Dr. Dyer allows clear conclusions to be drawn. The two major conclusions are that 
the presence of E99K mutation in cardiac actin increases the inherent Ca2+-sensitivity 
of the thin filament, and secondly the presence of the mutation disrupts the 
relationship between thin filament Ca2+-sensitivity and TnI phosphorylation.  
 
281 
6 Chapter 6 –A study of a human biopsy sample with an 
HCM-causing thin filament mutation in Troponin T. 
6.1 Introduction 
Chapter 3 focused on the uncoupling of Ca2+-sensitivity from constituent TnI 
phosphorylation in thin filaments with HOCM troponin. It was postulated that this 
uncoupling comes about as secondary effect of the disease. However, HCM-causing 
mutations present in thin filament proteins have been shown to increase thin filament 
Ca2+-sensitivity as was found for the E99K actin HCM mutation in chapter 5. 
Therefore the question arises, if troponin has a HCM causing mutation what effect 
would this have on thin filament Ca2+-senstivity? 
 
A Biopsy sample from the left ventricle of an explanted failing heart identified as 
carrying a homozygous TnT mutation lysine (K) to asparagine (N) at position 273 by 
Dr Jolanda van der Velden, VU University Medical Center, Amsterdam was made 
available to study by Prof. Cris dos Remeidos, University of Sydney. The patient was 
a 26 year old male, who had previously undergone a myectomy operation and a triple 
heart bypass. This mutation has previously been linked with HCM leading to DCM 
(Fujino et al., 2002). At the molecular level the replacement of a lysine residue with 
an asparagine residue results in a charge chance from +1 to 0. Thus a positive charge 
is removed from the C-terminal region of TnT. This is probably significant as this 
region interacts with tropomyosin, TnI and TnC. Therefore any changes or disruption 
in this region of the TnT is likely to affect thin filament regulation. This sample will 
be referred to as HCM TnT sample or HT. 
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6.1.1 Protein content and phosphoprotein profiling measurements of the HCM 
TnT sample 
6.1.1.1 The sarcomeric TnT content of the HCM TnT sample was not reduced 
 
The HCM TnT sample was investigated to determine if the presence of the mutation 
had any effect on the total amount of sarcomeric TnT. To do this myofilaments 
samples were prepared from the HCM TnT sample and an age and sexed matched 
HOCM (MR) and a donor sample (NE). These samples were loaded in triplicate (at 5, 
10 and 15µl) onto a mini gel. After electrophoresis was complete the gels were fixed 
and then stained with SYPRO Ruby. The level of actin was used as a loading control 
as this is not thought to change. Any change in the amount of cardiac TnT 
incorporated into myofilaments would be signalled by a change in the TnT to actin 
ratio. However, as the TnT to actin ratios are similar across the three different 
samples it suggests that the mutation does not affect the amount of cardiac TnT 
incorporated into myofilaments (see Figure 6.1). 
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Figure 6.1: Measurement of total sarcomeric TnT content 
 
 
A) Myofilament SDS-PAGE samples from HCM TnT mutant (HT), HOCM sample (MR) and donor 
heart (NE) were electrophoresis and stained with SYPRO. Three volumes (5µl, 10µl & 15µl) of each 
sample were loaded. Actin and TnT are marked in both A and B. B) The area that contained the actin 
and TnT bands has been enlarged. 
 
-  
C) Two duplicate gels were analysed by densitometry. Gel 1 is shown in solid red and gel 2 in striped 
red. The mean ratio of TnT/Actin was calculated for each sample from the triplicate lanes on each gel. 
The error bars represent the S.D. 
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6.1.1.2 The levels of phosphoproteins phosphorylation in the HCM TnT sample are 
not reduced as in HOCM samples obtained by a myectomy operation. 
 
The phosphorylation of myofilament phosphoproteins were compared using 
preparation of HCM TnT, HOCM, and donor samples separated by SDS-PAGE 
followed by staining with Pro-Q Diamond and SYPRO. The four main 
phosphoproteins, MyBP-C, TnT, TnI and MLC-2 were analysed (Figure 6.3). The 
ratio of the band volumes from Pro-Q Diamond to SYPRO stain (Q/S) were compared 
for each of these phosphoproteins. It is clear that the phosphoprotein profile of the 
HCM TnT sample is more similar to the donor sample than the other HOCM sample, 
the only exception is MLC-2, which is more similar to HOCM myectomy sample.  
Figure 6.2: Phosphorylation measurement of myofilament proteins in HCM TnT sample  
 
10µl of Chads myofibril SDS-PAGE sample of TnT HCM, HOCM (MR) and donor (NE) were loaded 
on to a gel in triplicate. After electrophoresis the gel was stained with A) Pro-Q Diamond and then B) 
SYPRO. 
A 
B 
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Figure 6.3: Bar graph of relative phosphorylation of myofilament phosphoproteins 
  
Two gels were analysed: Gel 1 and Gel 2. The mean ratio of band volume for Pro-Q Diamond and 
SYPRO was calculated for each myofilament phosphoprotein from the three triplicate lanes, error bars 
represent standard deviation. 
 
The level of TnI phosphorylation of the HCM TnT sample was measured by Dr. 
Andrew Messer using phosphate affinity PAGE and Western blotting of myofibril 
preparations (unpublished). The measurement was 1.44 molsPi/molsTnI (n=8). This 
confirmed that the level of TnI phosphorylation was similar to that found in troponin 
from donor heart (1.62molsPi/molsTnI) rather than HOCM tissue (0.29 
molsPi/molsTnI) (Messer et al., 2009).  
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6.2 The comparison of donor and HCM TnT troponin by IVMA  
6.2.1 Troponin purified from HCM TnT sample regulated thin filaments in a 
Ca2+-sensitivity manner 
 
Three troponin samples were purified from donor heart tissue (DA1-3) and the HCM 
TnT sample (HT1-3) in tandem. The donor sample (NE) was from a 29 year old male. 
The HCM TnT sample was from a 26 year old male. A troponin titration was 
completed for each pair of troponin samples over the concentration range 0-60nM. 
The reconstituted thin filaments were analysed with the IVMA at high [Ca2+] (3.7µM) 
and low [Ca2+] (1nM) to determine the optimal troponin concentration to use for the 
Ca2+-concentration titrations.  
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Figure 6.4: IVMA troponin titration comparing thin filaments containing either donor or HCM 
TnT troponin 
 
 
 
IVMA experiments titrating human cardiac donor (DA3) or HCM TnT (HT3) troponin over the range 
0-60nM. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The sliding speed of the reconstituted filaments were measured at A) high 
[Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile measured at C) high [Ca2+] (3.7µM) 
and D) low [Ca2+] (1nM). 
 
The troponin titration for the DA3 HT3 pair is shown (Figure 6.4) and confirmed that 
when troponin purified from the HCM TnT sample was reconstituted into thin 
filaments and investigated using the IVMA that both the fraction motile and sliding 
speed remained uninhibited at high [Ca2+]. At low [Ca2+] the fraction motile of both 
samples was inhibited to < 0.2. Demonstrating that troponin purified from the HCM 
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TnT sample regulated thin filaments in a Ca2+-sensiitive manner. The bar graph 
(Figure 6.5) demonstrates that each pair of donor and HCM TnT troponin samples 
regulated thin filaments in the IVMA. 
 
Figure 6.5:  Summary of fraction motile measurements at high and low [Ca2+] from IVMA 
troponin titration experiments comparing donor and HCM TnT troponin samples 
   
Fraction motile data was plotted from three troponin titration experiments completed with thin 
filaments reconstituted with donor troponin (blue) and HCM TnT troponin (red) at high [Ca2+] (3.7µM) 
(solid) and low [Ca2+] (1nM) (striped). The troponin concentration used in all experiments was 30nM. 
 
0
0.2
0.4
0.6
0.8
1
DA1    HT1 DA2   HT2 DA3    HT3
Donor troponin (3.7µM)
Donor troponin (1nM)
HOCM troponin with TnT mutation (3.7µM)   
HOCM troponin with TnT mutation (1nM)  
F
ra
c
ti
o
n
 m
o
ti
le
289 
 
6.2.2 No difference was found between thin filaments reconstituted with donor 
troponin or HCM TnT troponin when investigated by IVMA 
 
Eight Ca2+-concentration titrations were completed in total using the samples DA1-3 
and HT1-3. No difference was apparent in the sliding speed at maximal [Ca2+] 
activation (Table 6.1). The overall range of sliding speed was again not large enough 
to warrant fitting with the Hill equation. Unfitted data is shown in the appendix.  
 
Figure 6.6: Ca2+-concentration titration comparing thin filaments containing either donor or 
HCM TnT troponin  
 
IVMA Ca2+-concentration titration comparing the sliding speed of thin filaments that contained either 
donor or HCM TnT troponin. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM 
human cardiac tropomyosin and 30nM troponin. 
0
0.5
1
1.5
2
2.5
3
3.5
0.001 0.01 0.1 1 10
Donor troponin
HOCM troponin with TnT mutation
Sl
idi
ng
 s
pe
ed
 (µ
m
/s
)
[Ca2+] µM
ErrorValue
589.2112.803Hill Coefficient
3.47440.29645EC50
ErrorValue
46.09510.261Hill Coefficient
0.474990.31831EC50
290 
 
Table 6.1: Summary table of the sliding speed for thin filaments that contained either donor or 
HOCM troponin at high [Ca2+] (3.7µM) 
No. 
Donor max. 
sliding 
speed 
(µm/s) 
SD 
 
 
HOCM 
max. sliding 
speed 
(µm/s) 
SD 
 
 
HOCM/ 
Donor 
 
I    HT1DA1 2.74 ± 0.31 2.53 ± 0.1 0.92 
II 2.56 ± 0.11 2.45 ± 0.13 0.96 
III  HT2DA2 2.43 ± 0.13 2.32 ± 0.13 0.95 
IV 2.76 ± 0.06 2.91 ± 0.11 1.05 
V 3.15 ± 0.14 3.43 ± 0.39 1.09 
VI  HT3DA3 2.32 ± 0.15 2.89 ± 0.04 1.25 
VII 2.42 ± 0.13 2.63 ± 0.13 1.09 
VIII 2.48 ± 0.05 2.39 ± 0.06 0.96 
        
mean 2.61 ± 0.27 2.69 ± 0.37 1.03 
       ±0.11 
        
 
  
Student t-test:     (paired): p=0.39                        (unpaired): p=0.41 
 
 
Comparison by IVMA of thin filaments reconstituted with donor and HCM TnT 
troponin showed no difference in the fraction motile Ca2+-sensitivity. The summary 
table (Table 6.2) shows the overall mean of the EC50 values for the donor thin 
filaments and HCM TnT thin filaments only differ by 5%. Also, the mean of the 
HCM TnT to donor EC50 ratio is nearly one. Statistical analysis shows the Ca2+-
sensitivity of both sets of thin filaments were not significantly different (Student t-
test, unpaired p=0.81, paired p=0.95). 
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Figure 6.7: Ca2+-concentration titrations comparing thin filaments with either donor or HCM 
TnT troponin 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of thin filament that contained either 
donor (blue) or HCM TnT (red) troponin. The reconstituted filaments were composed of 10nM rabbit 
skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentration of troponin used for 
I-IV was 30nM for both samples. 
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Figure 6.8: Ca2+-concentration titrations comparing thin filaments with either donor or HCM 
TnT troponin 
 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of thin filament that contained either 
donor (blue) or HCM TnT (red) troponin. The reconstituted filaments were composed of 10nM rabbit 
skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentration of troponin used was 
V) 60nM, VI) 30nM and VII-VIII) was 60nM for both samples. 
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Table 6.2: Summary table of the fraction motile EC50 for thin filaments that contained either 
donor troponin or HOCM troponin with a TnT mutation 
No. 
 
Donor 
EC50 (µM) 
 SD 
 
HCM TnT 
EC50 (µM) 
SD 
 
HCM TnT/ 
Donor 
I     HT1DA1 0.22 ± 0.09 0.17 ± 0.02 0.75 
II 0.23 ± 0.04 0.22 ± 0.06 0.98 
III   HT2DA2 0.12 ± 0.01 0.13 ± 0.01 1.07 
IV 0.23 ± 0.02 0.20 ± 0.01 0.84 
V 0.14 ± 0.01 0.14 ± 0.02 1.02 
VI   HT3DA3 0.20 ± 0.02 0.19 ± 0.01 0.97 
VII 0.16 ± 0.02 0.22 ± 0.07 1.37 
VIII 0.18 ± 0.01 0.21 ± 0.01 1.14 
        
mean 0.19 ±0.04 0.18 ±0.04 1.02 
      ±0.19 
        
 
  
Student t-test:       (paired): p=0.95                       (unpaired): p=0.81 
 
From these results it is impossible to determine whether the lack of a difference in 
thin filament Ca2+-sensitivity was due to the secondary effect seen in HOCM samples 
as (discussed in chapter 3), or unlike other HCM mutations, if this particular HCM 
mutation does not alter thin filament Ca2+-sensitivity. To answer this question 
recombinant TnT containing the K273N mutation was exchanged into donor heart 
troponin. 
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6.3 Exchange of recombinant TnT3 with the mutation K273N into 
donor troponin 
 
Recombinant TnT3 with the K273N mutation used in this study was generous 
supplied by Dr. Charles Redwood, University of Oxford, UK. This was expressed in 
e.coli. This recombinant K273N TnT3 was exchanged into donor troponin by the 
same method as the non-mutant TnT was exchanged into the HOCM troponin (see 
2.2.5.2). In summary, the myofilament proteins were washed and extracted, denatured 
(in urea), and then renatured either with or without (control) the addition of the 
recombinant K273N TnT. The troponin was then purified using an anti-TnI affinity 
chromatography column. The donor troponin used was from sample NH.  
 
6.3.1 Recombinant K273N TnT replaces 90% of native TnT in exchanged 
troponin 
The distinguishing feature of the recombinant K273N TnT is that it is 
unphosphorylated unlike native TnT. Thus, the level of TnT exchange was calculated 
from the reduction in the ratio of Pro-Q Diamond/SYPRO signal of the TnT band. 
Exchange of TnT was 91% for DT1 and 90% for DT2. Only two measurements were 
made as the all of the troponin was used up during IVMA experimentation (see Figure 
6.10). Taken together with the more extensive evidence of successful exchange of 
native TnT with recombinant TnT in Chapter 3 (see 3.3.1 & 3.4.1), this would suggest 
that these subunits had been adequately exchanged.  
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Figure 6.9: Two SDS-PAGE gels illustrating exchange of recombinant K273N TnT in donor 
troponin 
 
 
Gels were loaded with 10µl of SDS sample solutions from each elution fraction (SE, FT, W1, W2, E1, 
E2, E3, E4, E5) from troponin purification of A)C) exchanged donor troponin and B)D) unexchanged 
donor troponin. The gels were stained with A)B) Pro-Q diamond followed by C)D) SYPRO. 
 
Figure 6.10: Bar graph showing the ratio of Pro-Q Diamond to SYPRO signal for the two pairs 
used (D1 & DT1, D2 & DT2) 
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6.3.2 IVMA experiments with donor troponin exchanged with recombinant 
TnT (K273N) and unexchanged donor troponin  
6.3.2.1 Donor troponin exchanged with recombinant TnT K273N conferred Ca2+-
sensitive regulation to thin filament movement in the IVMA 
 
The troponin titration was important to demonstrate that the thin filaments were 
saturated with functional troponin. As before, the concentration of the exchanged 
troponin was estimated from the Coomassie blue staining of the SDS-PAGE gel of the 
affinity column elution fraction to save both time and volume of sample. This 
troponin titration clearly shows a larger increase in sliding speed at high [Ca2+] for 
both samples compared with any other IVMA troponin titration experiments. More 
importantly the troponin titration shown (Figure 6.11) and the bar graph (Figure 6.12) 
demonstrate that there was a consistent movement of filament at high [Ca2+] and a 
good inhibition of filament movement (<0.1) at low [Ca2+] for both the pairs of 
samples (DB1-2) and (DXT1-2). 
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Figure 6.11: IVMA troponin titration comparing thin filaments containing either unchanged 
donor troponin or donor troponin exchanged with recombinant TnT K273N 
 
 
IVMA experiments titrating unexchanged human cardiac donor or donor troponin exchanged with 
recombinant TnT K273N over the range 0-60nM. Thin filaments were composed of 10nM rabbit 
skeletal actin, 60nM human cardiac tropomyosin and troponin. The sliding speed of the reconstituted 
filaments were measured at A) high [Ca2+] (3.7µM) and B) low [Ca2+] (1nM) and the fraction motile 
measured at C) high [Ca2+] (3.7µM) and D) low [Ca2+] (1nM). 
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Figure 6.12: Summary bar graph of fraction motile measurements at high and low [Ca2+] from 
IVMA troponin titration experiments comparing unexchanged donor and donor troponin 
exchanged with TnT K273N  
   
Fraction motile data was plotted from three troponin titration experiments completed with thin 
filaments reconstituted with donor troponin (blue) and donor troponin exchanged with recombinant 
TnT K273N (grey) at high [Ca2+] (3.7µM) (solid) and low [Ca2+] (1nM) (striped). The concentration of 
troponin used was 30nM for DB1 & DXT1 and 20nM for DB2 & DXT2. 
 
6.3.3 Thin filaments reconstituted with donor troponin exchanged with 
recombinant TnT K273N are more Ca2+-sensitive than thin filaments that 
contained unexchanged donor troponin 
 
Five Ca2+-concentration titrations were completed using the samples D1-2 and DXT1-
2. The thin filaments with recombinant TnT K273N exchanged donor troponin had a 
6% higher sliding speed at high [Ca2+]. This was verging on statistically significance 
even with a low number of repeat experiments. An example of a Ca2+-concentration 
titration curve of the sliding speed as the measured parameter has been selected 
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(Figure 6.13) and fitted with the hill equation. The remaining curves are shown in the 
appendix and are not fitted with hill equation.  
Figure 6.13:  Ca2+-concentration titration comparing thin filaments containing either 
unexchanged donor troponin or donor troponin exchanged with TnT K273N 
 
IVMA Ca2+-concentration titration comparing the sliding speed of thin filaments that contained either 
donor (blue) or donor troponin exchanged with recombinant TnT K273N (grey). Thin filaments were 
composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and 20nM troponin. 
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Table 6.3: Summary table of the sliding speed for thin filaments that contained either donor 
troponin or donor troponin exchanged with recombinant TnT with the mutation K273N at high 
[Ca2+] (3.7µM) 
No. 
 
 
Donor XT 
max sliding 
speed 
(µm/s) 
SD 
 
 
  
Donor max. 
sliding 
speed 
(µm/s) 
SD 
 
 
  
Donor XT/ 
Donor 
 
 
I     DB1DXT1 3.99 ± 0.24 3.59 ± 0.26 1.11 
II 3.88 ± 0.14 3.56 ± 0.14 1.09 
III   DB2DTX2 3.64 ± 0.22 3.77 ± 0.21 0.97 
IV 3.20 ± 0.12 3.05 ± 0.09 1.05 
V 3.18 ± 0.06 2.90 ± 0.09 1.10 
      
mean 3.58 ± 0.38 3.37 ± 0.38 1.06 
      ±0.06 
      
 
 
Student t-test: (paired): p=0.09                              (unpaired): p=0.07 
 
 
Thin filaments reconstituted with donor troponin exchanged with recombinant TnT 
K273N were 2-fold more Ca2+-sensitive then thin filaments that contained 
unexchanged donor troponin. This difference is illustrated in Table 6.4. This result 
was highly statistically significant (Student t-test unpaired p=0.004, paired p=0.006).  
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Figure 6.14: The Ca2+-concentration titrations comparing thin filaments with either unexchanged 
donor troponin or donor troponin exchanged with TnT K273N 
  
 
IVMA Ca2+-concentration titrations comparing the fraction motile of thin filament that contained either 
donor (blue) or donor troponin exchanged with recombinant TnT K273N (grey). The reconstituted 
filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and 
troponin. The concentration of troponin used for I-III) 30nM and IV) 20nM for both samples. 
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Figure 6.15: The Ca2+-concentration titrations comparing thin filaments with either unexchanged 
donor troponin or donor troponin exchanged with TnT K273N 
 
IVMA Ca2+-concentration titrations comparing the fraction motile of thin filament that contained either 
donor (blue) or donor troponin exchanged with recombinant TnT K273N (grey). The reconstituted 
filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and 
troponin. The concentration of troponin used was V) 20nM for both samples. 
 
Table 6.4: Summary of the fraction motile EC50 for thin filaments that contained either donor 
troponin exchanged with recombinant (K273N) TnT or unexchanged donor troponin  
No. 
 
Donor XT 
EC50 (µM)   
SD 
 
 
Donor  
EC50 (µM) 
SD 
 
 
Donor XT/ 
Donor 
I    D1DT1 0.22 ± 0.15 0.41 ± 0.02 0.53 
II 0.18 ± 0.04 0.47 ± 0.06 0.38 
III  D2DT2 0.61 ± 0.03 0.74 ± 0.06 0.83 
IV 0.16 ± 0.07 0.35 ± 0.02 0.47 
V 0.08 ± 0.03 0.17 ± 0.04 0.48 
      
mean 0.25 ± 0.21 0.43 ± 0.21 0.54 
        ±0.17 
      
 
 
Student t-test: (paired): p=0.006                          (unpaired): p=0.004 
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The aim of this part of the study was to identify any primary effects that this TnT 
mutation had on thin filament Ca2+-sensitivity in the IVMA. The successful exchange 
of recombinant TnT K273N into donor troponin meant this was possible. The overall 
result from the IVMA experiments showed that thin filaments that contained donor 
troponin exchanged with recombinant TnT K273N were 2-fold more sensitive than 
thin filaments with unexchanged donor troponin whilst exchange of wild type TnT 
into donor troponin had no effect (see 6.4). Thus two primary effects were shown, the 
first was a small increase in maximal sliding speed and the second was a 2-fold 
increase in thin filament Ca2+-sensitivity. Taken together with work on the human 
sample this suggests that a primary effect of the mutation is to increase thin filament 
Ca2+-sensitivity but this effect is either lost or masked by secondary effects. To 
confirm this result further control experimentation will have to be completed.  
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6.4 Discussion 
This chapter focused on the investigation of a biopsy sample taken from the left 
ventricular free wall of an explanted heart from a HOCM patient who was 
subsequently determined to possess a homozygous mutation in TnT. This therefore 
offered the possibility of a unique chance to study the effects of a HCM-causing 
mutation in human heart since homozygous patients are rarely observed. The 
discovery of the mutation in this sample was fortuitous and hence clinical details are 
limited. However, it is known that the patient had a previous myectomy. The first 
question to ask was whether this homozygous mutation acts as a poison peptide, like 
most heterozygous troponin mutations, or via haploinsufficiency, as observed with 
most MyBP-C mutations (Marston, 2011). Therefore it was important to determine if 
the presence of the TnT mutation had any effect on the amount of TnT present in the 
sarcomere. The comparison of the TnT HCM sample with another HOCM sample and 
a donor sample showed that there was no decrease in the total amount of TnT present, 
therefore the mutation must act as a poison peptide. 
 
Another interesting finding was that the phosphorylation profile of sarcomeric 
phosphoproteins of the HCM TnT sample was more similar to that measured in a 
donor tissue samples then that of a myectomy HOCM sample. This is perhaps best 
highlighted by the measurements made by Dr. Messer of TnI phosphorylation (HCM 
TnT 1.44±0.02 molsPi/molsTnI, mean donor 1.62±0.06 molsPi/molsTnI, mean 
HOCM 0.29±0.04molsPi/molsTnI). This difference could be explained by a 
difference in the method of harvesting or storing the sample, but both the donor and 
TnT mutation samples were collected by the same research team whilst the low level 
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of sarcomeric phosphoprotein phosphorylation of HOCM samples is well documented 
by the Marston laboratory. A more interesting permutation is this may represent 
further evidence for differences in the phosphorylation levels of sarcomeric 
phosphoprotein from different regions of the heart. The HCM TnT sample was taken 
from the left ventricle, whereas the HOCM (myectomy) samples were taken from the 
septum. Thus reduction in sarcomeric phosphoprotein phosphorylation may be 
isolated to only certain regions of the heart, most notably the septum. It has been 
postulated that this reduction in sarcomeric phosphoprotein phosphorylation in the 
septum may related to the pressure overload due to the LVOTO. 
 
The EC50 values obtained in this chapter were similar to those measured in chapter 3. 
In chapter 3 the mean fraction motile EC50 values (µM) for thin filaments 
reconstituted with donor troponin was 0.19±0.082 and 0.16±0.054 for HOCM 
troponin. Whereas the result in this chapter measured the mean EC50 values (µM) for 
thin filaments reconstituted with donor troponin to be 0.19±0.043 and 0.18±0.036 for 
HCM TnT. Examples of HCM-causing TnT mutations that have been investigated in 
other studies are I79N, R92Q, F110I, E163K, E244D and R278C, all of which were 
found to caused an increase in Ca2+-sensitivity of isometric force measurements on 
skinned myocytes, acto-myosin ATPase assay or with the IVMA (Knollmann and 
Potter, 2001, Robinson et al., 2002, Marston, 2011). An increase in thin filament 
Ca2+-sensitivity was found in the work completed in this chapter with donor troponin 
exchanged with recombinant K273N.  However no difference in thin filament Ca2+-
sensitivity was measured with native troponin purified from the HCM TnT sample 
compared to donor. The reasons for this could be two-fold, the first is that this 
specific mutation does not cause an increase in thin filament Ca2+-sensitivity. 
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However the finding that when recombinant TnT K273N was exchanged into donor 
troponin gave an increase in thin filament Ca2+-sensitivity can be used as evidence 
that this mutation ought to result in a higher Ca2+-sensitivity. Therefore, a second 
explanation is that the troponin can no longer modulate thin filament Ca2+-sensitivity 
as a result of secondary modification(s), such as those that cause uncoupling (as found 
in chapter 3). Two other biopsy samples from this heart were sent to the laboratory of 
Dr. Jolanda van der Velden for investigation. These samples were from two different 
regions of the same heart, one was from the interventricular septum and the other 
from the free wall of the left ventricle. Phosphorylation measurements of these 
samples showed no difference in MyBP-C phosphorylation, and only a small decrease 
in TnI phosphorylation as found in the sample investigated in this chapter. However, 
the van der Velden et al study found a decrease in TnT phosphorylation and an 
increase in MLC-2 phosphorylation, these are different from the results of this study 
(van Dijk et al., 2011). The results from the van der Velden et al experiments were 
completed using 2-DE and therefore may be more accurate then the Pro-Q/SYPRO 
gel staining protocol used in this study. Skinned myocyte experiments were also 
completed which showed a slightly higher Ca2+-sensitivity than donor heart cells with 
a decrease in maximal force (van Dijk et al., 2011). To confirm that differences in 
TnT phosphorylation did not lead to any functional changes, Dr. Messer completed a 
pilot experiment which compared thin filaments with donor troponin and donor 
troponin exchanged with recombinant (wild type) TnT (unpublished). No difference 
in thin filament Ca2+-sensitivity was apparent (see Figure 6.16). 
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Figure 6.16: Ca2+-concentration titration comparing fraction motile of thin filament reconstituted 
with donor troponin and donor troponin exchanged with recombinant TnT completed by Dr. 
Messer 
 
IVMA Ca2+-concentation titration comparing the fraction motile of thin filaments containing either 
donor (blue) or donor troponin exchanged with recombinant wild type TnT (yellow). Thin filaments 
were composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and troponin (90nM). 
The experiment was completed by Dr. Messer. 
 
After the completion of the experimental work for this chapter new evidence emerged 
from the laboratory of Dr. van der Velden that the TnT HCM sample did not contain 
the K to N substitution at position 273, it was in fact at position 280. This was very 
disappointing as it very much affects the conclusions of this chapter. To make 
absolutely sure of the nature of the mutation, mRNA from the tissue samples was 
analysed in the laboratory of Dr. Lucy Carrier by Dr. Saskia Schlossarek who showed 
that the only TnT present coded for the K280N varient (see Figure 6.17). Thus 
confirming both the site of mutation, and the homozygous expression, as indicated by 
the initial genotyping. 
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Figure 6.17: Genotyping of HCM biopsy sample with TnT mutation completed by Dr. 
Schlossarek 
 
The consequence sequence of the mutation at the mRNA level is shown. The substitution of 
guanine residue at position 840 results results in a change of amino acid from a lysine (K) to an 
asparagine (N) at position 280. The mutation found at the homozygous state in cDNA from both 
samples. The affected residue is circled in orange. This work was completed by Dr. Saskia 
Schlossarek in the laboratory of Dr. Lucie Carrier (University Medical Center Hamburg-Eppendorf). 
 
Nevertheless, no increase in Ca2+-sensitivity was measured in thin filaments 
reconstituted with troponin purified from the HCM TnT sample. This is despite the 
presence of a TnT mutation. Thus the relationship between the state of troponin and 
thin filament Ca2+-sensitivity had been disrupted. This effect parallels the effect seen 
in Chapter 3, where thin filament Ca2+-sensitivity is uncoupled from TnI 
phosphorylation. Therefore the TnT modification that results in the uncoupling in 
Chapter 3, may also be responsible for the effect seen in this chapter. It would seem 
that this modification, the so-called secondary effect of the disease, overrides the 
primary effects of the mutation. Since it was observed that HCM TnT is abnormal and 
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that this mutation is in TnT, unravelling the situation is particularly difficult compared 
to the ACTC E99K mutations where the mutated protein could be studied separately 
from the effect of HCM on troponin function. Future work should include exchange 
of recombinant TnT K280N into donor samples to confirm that this mutations results 
in a higher Ca2+-sensitivity and the exchange of K273N into another HOCM troponin 
to add further evidence of secondary modifications in HCM. 
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7 General discussion 
This thesis was aimed at analysing how HCM-causing mutations affect myofibrilar 
function in human heart. The opportunities to study human myocardium tissue are 
limited. However tissue was obtained from two explanted failing hearts identified 
with HCM-causing mutations (ACTC E99K and TNNT2 K280N) and one from the 
repair of an atrial-septal defect from a patient also identified with the ACTC E99K 
mutation. The majority of tissue came from septal myectomy operations which 
present a rare opportunity to study human myocardium from live patients afflicted 
with HOCM. An important factor of myectomy samples is; that not only was tissue 
obtained from human patients, it was obtained from the abnormal area of the heart. 
Over 40 samples have been obtained and stored under liquid nitrogen in a tissue bank 
onsite. A number of samples from explanted donor hearts and failing hearts were 
kindly supplied by Prof. C. dos Remedios, and were also stored in the tissue bank and 
were thus available for study. This resource was vital to this study. HOCM samples 
from the tissue bank were sent to HealthinCode™ for genotyping to screen for the 
presence of known HCM-causing mutations. 
 
7.1 Increased myofibrillar Ca2+-sensitivity is the molecular 
phenotype of a HCM causing mutation 
 
A large number of studies have examined HCM-causing mutations in a range of 
systems, predominantly using recombinant mutant proteins or animal models (see 
Table 7.1). The general findings of these studies were that HCM-causing mutations, 
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independent of mutated protein, result in an increase in myofibrillar Ca2+-sensitivity. 
Other common consequences of HCM-causing mutations were incomplete relaxation 
at low [Ca2+] and faster crossbridge turnover rates but these were not universal. This 
was confirmed by the results from the experiments that exchanged recombinant TnT3 
K273N into human donor heart troponin described in chapter 6 and the human actin 
sample with ACTC E99K mutation that was tested with human tropomyosin and 
troponin in chapter 5.  The exchange experiments showed that the introduction of the 
TnT K273N mutation, known to cause HCM (Fujino et al., 2002), led to an increase 
in the Ca2+-sensitivity of thin filament. The E99K work showed that thin filaments 
reconstituted with E99K F-actin were also more Ca2+-sensitive than thin filaments 
with donor heart F-actin, however there was no evidence of an increase in cross-
bridge turnover rate or incomplete relaxation in either case. The work with the E99K 
actin samples was further strengthened by a parallel study of transgenic E99K mouse 
model (Song et al., 2011). IVMA experiments with F-actin purified from the E99K 
transgenic mouse, tested with human tropomyosin and troponin, also found an 
increase in thin filament Ca2+-sensitivity with an absence of increased cross-bridge 
turnover rate or incomplete relaxation.  
 
An interesting point arising from the E99K actin experiments is that; not only 
troponin or tropomyosin mutations lead to an increase in thin filament Ca2+-
sensitivity. It appears that HCM-causing mutations in any sarcomeric protein can 
increase myofibrilar Ca2+-sensitivity: mutations in actin (Song et al., 2011) and 
especially MLC-2 are well documented (Szczesna-Cordary et al., 2004). MyBP-C  
mutations have also been found to increase Ca2+-sensitivity  although the correlation 
here may be less clear because of confounding effects of protein phosphorylation 
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differences in the skinned myocytes used for these studies (van Dijk et al., 2009). This 
may explain how different mutations in the different sarcomeric protein genes can 
lead to the same disease phenotype. If all of these mutations lead to an increase in thin 
filament Ca2+-sensitivity, as found so far, this is most likely to be the trigger for the 
onset of the disease. Thus future work should concentrate on gaining further evidence 
that this is a universal effect of HCM-causing mutations within other sarcomeric 
proteins, especially non-thin filament proteins such as MHC and MyBP-C and where 
possible using different experimental systems.  
 
An additional finding from the work from both the human E99K actin samples and 
the transgenic mouse ACTC E99K model work was that the relationship of thin 
filament Ca2+-sensitivity to the level of TnI phosphorylation was disrupted or 
uncoupled. This adds further complication to interpreting the results of this 
investigation as a similar uncoupling effect was also found when troponin was 
extracted from HOCM heart samples and reconstituted into thin filaments. The 
uncoupling in the troponin from HOCM heart was hypothesised to be a result of a 
modification or secondary effect, whereas the uncoupling effect seen within E99K 
actin is clearly an additional primary effect of the mutation. The causes and 
consequences of this uncoupling effect are discussed later.  
 
The study of E99K actin from the human biopsy samples and transgenic mouse is the 
first to investigate native cardiac F-actin with a HCM-causing mutation in fully 
reconstituted Ca2+-sensitive thin filaments. A study by Debold et al has already been 
published, but this utilised recombinant E99K F-actin expressed in Baculovirus 
reconstituted into thin filaments with tropomyosin and troponin (TnI phosphorylation 
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level not stated) purified from bovine heart (Debold et al., 2010). This study found 
only a very small increase in thin filament Ca2+-sensitivity of filaments that contained 
the recombinant E99K actin compared to wild type. It is likely that the discrepancy is 
due to the non-native system used by Debold et al. 
 
There are two outcomes for the majority of symptomatic HCM patients, these are 
sudden cardiac death (SCD) and/or onset of myocardial hypertrophy. Sudden cardiac 
death is not very common (it affects about 1% of the HCM population, rising to 2-4% 
in children and adolescents) (Elliott and McKenna, 2004). Both of these outcomes are 
the result of a mutation within the cardiac sarcomere. HCM-causing mutations are 
generally considered to act in a dominant negative manner, whereby a sarcomere of a 
heterozygous patient would contain up to 50% mutant protein as was demonstrated 
with the ACTC E99K samples (Chapter 5). The K280N sample is unusual since it is 
homozygous and expresses only mutant mRNA (and presumably protein). The mutant 
protein is thought to exert pathological effects by acting as a poison peptide (Marston, 
2011). This assumes that life is still viable in the presence of this poison peptide and 
that there is no post-transcriptional regulation that removes the transcript of the 
mutant protein. However, MyBP-C mutations appear to be an exception as 
investigation of samples with MYBPC3 HCM-causing mutations found that rather 
then possessing the mutated version of the protein, there was a reduction in the total 
amount of the MyBP-C present in the sarcomere, a haploinsufficiency effect. A study 
from the Marston laboratory found a mean reduction of 24% in the total amount of 
MyBP-C in 9 samples taken during a myectomy operation from patients identified 
with mutations in MYBPC3 gene (Marston et al., 2009). In 7 of the 9 samples an 
intronic mutation generated a premature stop codon, thus encoding a truncated 
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version of the protein. However a truncated version was not found within the human 
samples, hence the haploinsufficiency. This adds further complication to the 
delineation of how sarcomeric mutations can cause HCM, acting not only as missense 
mutations encoding poison peptides but also haploinsufficiency of MyBP-C leading 
to the same disease phenotype. As discussed previously, the common effect of HCM-
causing mutations in every other gene is to increase thin filament Ca2+-sensitivitity. 
MyBP-C has been shown to be involved in the regulation of thin filament Ca2+-
sensitivity, and a reduction in the total amount of sarcomeric MyBP-C may effect the 
Ca2+-sensitivity of the thin filament (Hofmann et al., 1991, Kulikovskaya et al., 
2003). Thus, although the expression of the mutated genes leads to a different 
molecular phenotype, the overall effect of the mutation is still the same, an increase in 
thin filament Ca2+-sensitivity.  
 
7.2 Higher myofibrillar Ca2+-sensitivity leads to inefficient 
contraction 
It is important to consider the working sarcomere as a tightly balanced system set up 
to respond to a number of signals and influences. An increase in thin filament Ca2+-
sensitivity may well unbalance this system, perhaps in the worst-case scenario 
causing complete derangement of Ca2+ handling. The thin filament is at its most Ca2+-
sensitive state in a heart which is undergoing a minimum of β-adrenergic stimulation 
and the rate of relaxation is at its slowest. Thus an increase in Ca2+-sensitivity (due to 
mutation) would require Ca2+ to be reduced to a lower level by SERCA and the other 
Ca2+ extrusion pumps. The gross consequence of this is that the HCM heart will 
contract with greater force during systole and relaxation will be impaired during 
diastole (diastolic dysfunction is a key characteristic of HCM). Another key 
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consideration is the extra requirement for energy a hypercontractile heart will require. 
A hypothesis published by Ashrafian et al suggested in the HCM heart the increased 
demand for energy will eventually result in deprivation of energy in some subcellular 
compartments rendering the cardiomyocyte unable to maintain Ca2+-homeostasis 
(Ashrafian et al., 2003). This hypothesis is supported by a study by Crilley et al who 
found a reduction in the ratio of phosphocreatine to ATP in 31 HCM human patients, 
(assuming that phosphocreatine remains relatively constant), this suggested that a 
larger amount of ATP was used in the hearts of these patients compared to unaffected 
control patients (Crilley et al., 2003). The reduced efficiency of contraction in the 
HCM heart may be related directly to mechanical factors such as incomplete 
relaxation and deranged length-dependent activation (Vemuri et al., 1999) or 
indirectly to an increased requirement for ATP by the various Ca2+- extrusion pumps. 
These studies suggest that the cardiomyocte can sense the inefficient use of ATP and 
disturbance to Ca2+-homeostasis of the cell. Thus aberrant Ca2+ handling by the 
cardiomyocyte triggered by the higher myofibrillar Ca2+-sensitivity may provide the 
signal to activate hypertrophy and this could possibly link the molecular phenotype, 
of increased Ca2+-sensitivity, to cellular hypertrophy. An alternative route is through 
abnormal mechanosensation driving the development of hypertrophy by switching on 
the hypertrophic gene programme (Buyandelger et al., 2011).  
 
The primary cause of SCD in HCM patients is ventricular tachyarrhythmia (Cha et al., 
2007). A study by Baudenbacher et al suggested that by increasing thin filament Ca2+-
sensitivity due to an HCM-causing TnT mutation or a Ca2+-sensitising agent, was 
enough to induce ventricular tachyarrhythmia in the absence of any anatomical 
substrates (Baudenbacher et al., 2008). This was reviewed by Huke & Knollmann 
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who stated that an increase in the Ca2+-sensitivity of the myofilament contributes to 
the risk of ventricular arrhythmias (Huke and Knollmann, 2010). The ACTC E99K 
mouse study showed that 22% of males and 48% of female mice died in peri-post-
adolescence period (Song et al., 2011). This was a high enough proportion to assume 
this was due to the mutation and that the mechanism mirrored that of the SCD found 
in HCM patients. 
 
This has implications as to how HCM is studied in the future. Mouse models are 
clearly a vital part of scientific research but the legitimacy of using transgenic mouse 
models to understand the development of HCM has to be questioned (Kehat and 
Molkentin, 2010). Taking the E99K transgenic mouse model as an example, the high 
SCD mortality in a short period is not observed in the human patient population with 
this mutation (8/72 overall) (Song et al., 2011). It is also known that the relative 
importance of Ca2+-induced Ca2+ -release and the Na+/Ca2+ exchanger are different in 
mouse and man. Although 50% of the sarcomeric F-actin contained the mutation, the 
degree of arrhythmias, fibrosis and hypertrophy measured in surviving mice was 
similar but not identical to human cases (Song et al., 2011). This emphasises that the 
consequences of a mutated sarcomeric protein may be different in humans. Therefore 
a larger amount of work needs to be completed on myocardial biopsy samples from 
patients with HCM. Samples from septal myectomy are one example of a source of 
this tissue, however these samples only provide a snapshot from hearts in the 
advanced stages of HOCM and only account for 25% of HCM patients. If other 
samples could be ethically obtained from patients identified as carriers of HCM-
causing mutations, but who have not begun to exhibit signs or symptoms of the 
disease (for example the second E99K biopsy sample), these would provide valuable 
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additional information that will be required to delineate the developed of HCM in 
humans.  
7.3 Functional abnormalities in contractile proteins from HOCM 
samples are independent of causative mutation 
 
The HCM-causing mutation has been identified in only 10 of the collection of 40 
myectomy samples. None of these mutations were found in genes that code for thin 
filament proteins yet these samples have uniform properties. Mutations had 
previously been identified in the HOCM myectomy sample M1, M5 and M15, 
subsequently samples MA, MF, MI, ML, MT, MU & MV also had mutations 
identified. Some of these samples have also been sent to other laboratories for 
investigation using other techniques such as chemically skinned myocytes (Hoskins et 
al., 2010) and myofibrillar mechanics (Vikhorev, 2011). A summary of this work is 
shown in the table below (Table 7.1).  
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Table 7.1: Ca2+-regulatiion of troponin and phosphorylation in HOCM muscle 
Sample Age Sex Source of 
tissue 
Mutation P of TnI 
(molsPi/m
olsTnI) 
relative to 
donor 
IVMA 
Ca2+-
sensitivity 
relative to 
donor 
Skinned 
myocytes 
Ca2+-
sensitivity 
relative to 
donor 
Other 
observations 
from skinned 
myocyte and 
Myofibril 
studies 
M1 24 F Myectomy MYH7 
mutation 
(Arg719Gln) 
0 
 
 1   
M2  M Myectomy Not found 0.2 1   
M3 42 M Myectomy Not found 0.2 
 
1   
M4 49 M Myectomy Not found 0 1   
M15 30 M Myectomy MYPBC3 
T2604A  
Deletion of 
2605C 
0.2 (a) 1 2 (b) Decreased 
maximum 
isometric force 
(a) 
M18 59 M Myectomy Not found   2.5 (b) Decreased 
maximum 
isometric force 
(b) 
M20 61 F Myectomy Not found   2 (b) Decreased 
maximum 
isometric force 
(b) 
MA 23 M Myectomy MYPBC3 
R502W 
0.4  2.8 (b) Decreased 
maximum 
isometric force 
(b) 
MM 58 M Myectomy Not found 0.1  2 (b) Decreased 
maximum 
isometric force 
(b) 
ML 27 F Myectomy MYH7 
R719Q 
0.2  1.3 (b) No difference 
(b) 
MT 46 F Myectomy MYBPC3 
IVS17+4A>T 
0.2 1  Decreased 
maximum 
isometric force  
and Kact, 
increased 
Krel(c) 
K280N 26 M Failing heart TNNT2 
K280N 
0.9 1 1.2 (d) Decreased 
maximal 
isometric force 
(d) 
 
 
Data taken from references a) (Jacques et al., 2008a)  b) (Hoskins et al., 2010) c) (Vikhorev, 2011) d) 
(van Dijk et al., 2011) Other data is unpublished work from Marston laboratory. 
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7.4 Abnormal troponin function 
To summarise, a number of different samples have been investigated using two main 
techniques the IVMA and single skinned myocytes, with some evidence from a third 
technique measuring myofibrils mechanics. Two samples have been studied using 
both of the main techniques, M15 and K280N. The two different techniques seem to 
give discordant results. Work completed using the IVMA compared reconstituted thin 
filaments containing troponin purified from HOCM and donor heart tissue. This work 
found no difference in thin filament Ca2+-sensitivity between the respective sets of 
filaments despite a difference in TnI phosphorylation. This phenomenon was first 
observed by Dr Jacques and Dr. Messer (Jacques et al., 2006) and has been confirmed 
in subsequent experimentation completed in this thesis.  
 
In skinned myocytes the Ca2+-sensitivity was always higher in HOCM myocytes 
when compared to myocytes from donor hearts. This was observed for samples with 
MYBPC3 and MYH7 mutations and samples where the mutations were not identified 
(Hoskins et al., 2010). The abnormalities in Ca2+-sensitivity in the thin filaments 
tension measured in skinned myocytes may be due to the low level of TnI and MyBP-
C phosphorylation. The Ca2+-sensitivity of skinned HOCM myocytes could be 
lowered (restored to the level of donor) by treatment with PKA (Hoskins et al., 2010, 
van Dijk et al., 2009). However when purified HOCM troponin was treated with PKA 
and then reconstituted into thin filaments there was no resultant change in the thin 
filament Ca2+-sensitivity, thus confirming there is an abnormality in troponin purified 
from HOCM samples (as described in Chapter 3). This abnormality does not appear 
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to have the same effect on the myofibrilar Ca2+-sensitivity of force of the skinned 
myocyte.  
7.5 Development of HCM 
Figure 7.1 summarises how a primary mutation in a sarcomeric gene may lead to the 
disease phenotype in HCM. The signalling pathways involved are still to be 
determined. 
Figure 7.1: Flow chart of development of HCM 
 
 
7.6 Uncoupling of Ca2+-sensitivity from changes in TnI 
phosphorylation 
The abnormality in troponin responsible for the similarity in thin filament Ca2+-
sensitivity despite a difference in TnI phosphorylation was explained by work in 
Chapter 3 of this thesis. This directly demonstrated that thin filaments reconstituted 
with HOCM troponin were insensitive to the level of TnI phosphorylation, when 
untreated and PKA-treated samples were compared. Work in this chapter went further 
to suggest that this insensitivity to TnI phosphorylation was linked to the native TnT 
subunit. It was hypothesised that the TnT subunit was modified in some fashion, 
possibly a post-translational modification, as a result of the disease. This was termed a 
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secondary effect (of the disease) as the (primary) HCM-causing mutation was not 
present in the troponin.  
 
A number of other secondary changes have also been observed in the other 
sarcomeric proteins in HOCM tissue. The change in the ratio of cardiac to skeletal 
isoforms present in sarcomeric α-actin was investigated in Chapter 4. Although this 
did not result in a functional change, it is still an example of secondary changes that 
occur due to the disease. A study by Jacques et al investigated myosin purified from 
myectomy samples from HOCM patients. This study found that the fraction of actin 
filaments moved by HOCM myosin was 21% lower than myosin from donor heart 
(Jacques et al., 2008b). These results were found in samples that did not contain a 
myosin mutation and thus were the consequence of secondary changes. Thus it is 
likely that the secondary modification of TnT found in HOCM troponin is one of a 
number of modifications that occur in HOCM myocardium due to the pathological 
course of the disease. 
7.7 Phosphorylation levels of MyBP-C and TnI are relatively low in 
HOCM samples 
The major sarcomeric phosphoproteins are TnI, MyBP-C and MLC-2. The level of 
phosphorylation of each of these proteins is reduced in myectomy samples taken from 
HOCM patients (Jacques et al., 2007). This is probably due to a change in balance 
between kinase and phosphatase activity (Pearce et al., 2010, Gallego and Virshup, 
2005). A similar reduction in the phosphorylation of these proteins was also found in 
failing heart biopsy samples but in this case Ca2+-sensitivity was correspondingly 
increased (Messer et al., 2007). The reduction in phosphorylation of sarcomeric 
phosphoproteins in failing heart tissue has been explained by chronic β-adrenergic 
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signalling, leading to internalisation of GPCRs, leading to reduced downstream 
signalling with the consequence of reduced PKA activity (Hajjar and MacRae, 2002). 
It should be considered that HOCM patients who qualify for a myectomy operation 
have a severe obstruction. This would also probably result in chronic β-adrenergic 
signalling and may also explain the reduction in phosphorylation found in HOCM 
samples.  
 
However measurements from the TnT K280N sample and the second actin E99K 
biopsy sample completed by Dr Leung (Song et al., 2011) should be taken into 
consideration as these samples were not obtained from a myectomy operation. The 
second E99K biopsy was obtained from an operation to repair an atrial-septal defect 
and the K280N sample was obtained from an explanted failing heart. Both of these 
samples did not show a reduction in phosphorylation of the sarcomeric 
phosphoproteins. This may be explained when considering what region of the heart 
the samples were taken from. The second actin E99K sample was taken from the 
region of the atria whereas the K280N was taken from the left ventricle. Thus neither 
of these samples were removed from the region of the ventricular septum. A possible 
explanation for this is that in different regions of the heart sarcomeric 
phosphoproteins have differing level of phosphorylation.  
 
In a study Dyer et al investigated a sample from an explanted heart from a human 
patient with the DCM mutation TNNC1 G159D, this also did not show a reduction in 
the phosphorylation level of sarcomeric phosphoproteins when compared to donor 
heart tissue even though the patient had end-stage heart failure (Dyer et al., 2009). A 
current idea in the Marston laboratory is that the reduction in phosphorylation in the 
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intra-ventricular septum measured in HOCM samples is related to high pressure 
gradient caused by the left ventricular outflow tract obstruction (LVOTO), although a 
possible mechanism for this is yet to be composed. One possible way of testing this 
theory would be to measure sarcomeric phosphoproteins phosphorylation from 
samples from patients with pressure overload (PO), where a pressure gradient is 
present without a causative mutation. To date samples have yet to be obtained for 
such an investigation. Alternatively, it would be interesting to complete further 
comparison of phosphorylation levels in the septum and free wall of a heart with 
HOCM. 
 
7.8 Mechanism of Uncoupling  
The Ca2+ sensing component of the thin filament is troponin, specifically the TnC 
subunit. The concentration of Ca2+ required to activate the thin filament is affected by 
a number of factors including sarcomere length, pH and temperature (Bers, 2001). 
However, the Ca2+ -sensitivity of the thin filament can also be modified as a 
downstream effect of β-adrenergic signalling. The result of phosphorylation of TnI, at 
cardiac isoform specific residues serine 22 &23, reduces the Ca2+-sensitivity of the 
thin filament. This is part of the lusitropic effect to increase the rate of relaxation 
(Bers, 2001). Work completed in this thesis presents strong evidence that the 
relationship between thin filament Ca2+-sensitivity and TnI phosphorylation is 
disrupted in the HOCM heart. Work by Dr. Dyer found a similar uncoupling effect in 
thin filament composed of F-actin from wild type and the HCM (ACTC E99K) 
transgenic mouse model (Song et al., 2011), this was mirrored by the work with the 
second human biopsy sample in chapter 5. Uncoupling was also found in a study by 
Deng et al who investigated the HCM-causing mutation in TNNI3 (R145G) (Deng et 
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al., 2001). However uncoupling is not only a phenomenon identified in HCM. Thin 
filament mutations known to cause dilated cardiomyopathy (DCM) have been 
investigated in the Marston laboratory, these include ACTC E361G, TNNT2 R141W 
& ΔK210, TNNI3 R36Q, TPM1 E54K and TNNC1 G159D (Dyer et al., 2009, Song et 
al., 2010)(Memo unpublished), when reconstituted into thin filaments and analysed by 
IVMA. All these mutated sarcomeric proteins caused uncoupling. Thus the 
uncoupling of thin filament Ca2+-sensitivity from the constituent level of TnI 
phosphorylation seems to be a common effect and may be a default state for abnormal 
troponin.  
 
A model has been proposed by Howarth et al (illustrated in Figure 7.2) that suggests 
that the N-terminal extension of cardiac TnI interacts weakly with the N-lobe of the 
TnC subunit when unphosphorylated at serine 22/23. When associated the affinity of 
TnC for Ca2+ is increased. Phosphorylation of the serine 22/23 residues causes a 
conformational change within the troponin subunit. Upon phosphorylation the N-
terminal extension of TnI can no longer interact with the N-terminal lobe of TnC, thus 
removing its influence on affinity for Ca2+ (Howarth et al., 2007). This model 
suggests that the phosphorylation of the cardiac specific N-terminus of TnI is enough 
to disrupt the interaction with the TnC subunit. An inference from the experimental 
results and the model is that the interaction between TnI and TnC, which modifies the 
thin filament Ca2+-sensitivity, is a relatively labile interaction. If this is the case, then 
it may be disrupted by other allosteric interactions. These could include a mutation 
within the thin filament system, such as the E99K mutation of cardiac actin, or a post-
translational modification of the integral structural subunit of troponin, TnT. As 
previously discussed (Chapter 3), the post-translational modification responsible has 
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not been clearly defined yet. Perhaps uncoupling pre-sets the heart in a less Ca2+-
sensitive “safe mode” to partially counteract the higher Ca2+-sensitivity due to the 
HCM-causing mutation.  
  
Figure 7.2: Ribbon structures of the troponin when N-terminal of TnI is phosphorylated and 
unphosphorylated 
 
Supplied by Prof. Steve Marston, based on structure from (Howarth et al., 2007) 
 
7.9 Final Conclusions 
This work confirms that a higher thin filament Ca2+-sensitivity is the most likely 
molecular phenotype that initiates HCM in man. It also demonstrates that secondary 
modifications occur in HOCM myectomy samples as a result of the disease 
pathology. In particular, modification of the TnT subunit uncouples the relationship 
between thin filament Ca2+-sensitivity and TnI phosphorylation in HOCM samples 
taken from hypertrophied interventricular septum. Secondary effects may contribute 
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to the disease phenotype, and in some experimental systems such secondary effects 
could mask the fundamental process by which the mutation cause HCM, introducing 
the possibility of misleading interpretations.  
327 
 
Bibliography 
AGARKOVA, I. & PERRIARD, J. C. 2005. The M-band: an elastic web that 
crosslinks thick filaments in the center of the sarcomere. Trends Cell Biol, 15, 
477-85. 
ALLINGHAM, J. S., SMITH, R. & RAYMENT, I. 2005. The structural basis of 
blebbistatin inhibition and specificity for myosin II. Nat Struct Mol Biol, 12, 
378-9. 
ARAD, M., PENAS-LADO, M., MONSERRAT, L., MARON, B. J., SHERRID, M., 
HO, C. Y., BARR, S., KARIM, A., OLSON, T. M., KAMISAGO, M., 
SEIDMAN, J. G. & SEIDMAN, C. E. 2005. Gene mutations in apical 
hypertrophic cardiomyopathy. Circulation, 112, 2805-11. 
ASHLEY, E. A. & NIEBAUER, J. 2004. Cardiology explained, London, Remedica. 
ASHRAFIAN, H., REDWOOD, C., BLAIR, E. & WATKINS, H. 2003. Hypertrophic 
cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet, 
19, 263-8. 
AYAZ-GUNER, S., ZHANG, J., LI, L., WALKER, J. W. & GE, Y. 2009. In vivo 
phosphorylation site mapping in mouse cardiac troponin I by high resolution 
top-down electron capture dissociation mass spectrometry: Ser22/23 are the 
only sites basally phosphorylated. Biochemistry, 48, 8161-70. 
BALAZ, M. & MANSSON, A. 2005. Detection of small differences in actomyosin 
function using actin labeled with different phalloidin conjugates. Anal 
Biochem, 338, 224-36. 
BALINT, M., SRETER, F. A., WOLF, I., NAGY, B. & GERGELY, J. 1975. The 
substructure of heavy meromyosin. The effect of Ca2+ and Mg2+ on the 
tryptic fragmentation of heavy meromyosin. J Biol Chem, 250, 6168-77. 
BAREFIELD, D. & SADAYAPPAN, S. 2010. Phosphorylation and function of 
cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol, 
48, 866-75. 
BARRY, S. P., DAVIDSON, S. M. & TOWNSEND, P. A. 2008. Molecular 
regulation of cardiac hypertrophy. Int J Biochem Cell Biol, 40, 2023-39. 
BARTON, P. J., TOWNSEND, P. J., BRAND, N. J. & YACOUB, M. H. 1997. 
Localization of the fast skeletal muscle troponin I gene (TNNI2) to 11p15.5: 
genes for troponin I and T are organized in pairs. Ann Hum Genet, 61, 519-23. 
BAUDENBACHER, F., SCHOBER, T., PINTO, J. R., SIDOROV, V. Y., 
HILLIARD, F., SOLARO, R. J., POTTER, J. D. & KNOLLMANN, B. C. 
2008. Myofilament Ca2+ sensitization causes susceptibility to cardiac 
arrhythmia in mice. J Clin Invest, 118, 3893-903. 
BELUS, A., PIRODDI, N., SCELLINI, B., TESI, C., AMATI, G. D., GIROLAMI, F., 
YACOUB, M., CECCHI, F., OLIVOTTO, I. & POGGESI, C. 2008. The 
familial hypertrophic cardiomyopathy-associated myosin mutation R403Q 
accelerates tension generation and relaxation of human cardiac myofibrils. J 
Physiol, 586, 3639-44. 
328 
BERGEN, H. R., 3RD, AJTAI, K., BURGHARDT, T. P., NEPOMUCENO, A. I. & 
MUDDIMAN, D. C. 2003. Mass spectral determination of skeletal/cardiac 
actin isoform ratios in cardiac muscle. Rapid Commun Mass Spectrom, 17, 
1467-71. 
BERS, D. M. 2001. Excitation-contraction coupling and cardiac contractile force, 
Dordrecht ; London, Kluwer Academic. 
BING, W., RAZZAQ, A., SPARROW, J. & MARSTON, S. 1998. Tropomyosin and 
troponin regulation of wild type and E93K mutant actin filaments from 
Drosophila flight muscle. Charge reversal on actin changes actin-tropomyosin 
from on to off state. J Biol Chem, 273, 15016-21. 
BOOKWALTER, C. S. & TRYBUS, K. M. 2006. Functional consequences of a 
mutation in an expressed human alpha-cardiac actin at a site implicated in 
familial hypertrophic cardiomyopathy. J Biol Chem, 281, 16777-84. 
BOUSSOUF, S. E., MAYTUM, R., JAQUET, K. & GEEVES, M. A. 2007. Role of 
tropomyosin isoforms in the calcium sensitivity of striated muscle thin 
filaments. J Muscle Res Cell Motil, 28, 49-58. 
BRADFORD, M. M. 1976. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem, 72, 248-54. 
BRENNER, B. 1988. Effect of Ca2+ on cross-bridge turnover kinetics in skinned 
single rabbit psoas fibers: implications for regulation of muscle contraction. 
Proc Natl Acad Sci U S A, 85, 3265-9. 
BROCK, R. 1957. Functional obstruction of the left ventricle; acquired aortic 
subvalvar stenosis. Guys Hosp Rep, 106, 221-38. 
BRUM, P. C., ROLIM, N. P., BACURAU, A. V. & MEDEIROS, A. 2006. 
Neurohumoral activation in heart failure: the role of adrenergic receptors. An 
Acad Bras Cienc, 78, 485-503. 
BUYANDELGER, B., NG, K. E., MIOCIC, S., GUNKEL, S., PIOTROWSKA, I., 
KU, C. H. & KNOLL, R. 2011. Genetics of mechanosensation in the heart. J 
Cardiovasc Transl Res, 4, 238-44. 
CHA, Y. M., GERSH, B. J., MARON, B. J., BORIANI, G., SPIRITO, P., HODGE, 
D. O., WEIVODA, P. L., TRUSTY, J. M., FRIEDMAN, P. A., HAMMILL, 
S. C., REA, R. F. & SHEN, W. K. 2007. Electrophysiologic manifestations of 
ventricular tachyarrhythmias provoking appropriate defibrillator interventions 
in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc 
Electrophysiol, 18, 483-7. 
CHANG, A. N. & POTTER, J. D. 2005. Sarcomeric protein mutations in dilated 
cardiomyopathy. Heart Fail Rev, 10, 225-35. 
CHIU, C., BAGNALL, R. D., INGLES, J., YEATES, L., KENNERSON, M., 
DONALD, J. A., JORMAKKA, M., LIND, J. M. & SEMSARIAN, C. 2010. 
Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-
wide analysis. J Am Coll Cardiol, 55, 1127-35. 
CHOUDHARY, C., KUMAR, C., GNAD, F., NIELSEN, M. L., REHMAN, M., 
WALTHER, T. C., OLSEN, J. V. & MANN, M. 2009. Lysine acetylation 
targets protein complexes and co-regulates major cellular functions. Science, 
325, 834-40. 
COPELAND, O., NOWAK, K. J., LAING, N. G., RAVENSCROFT, G., MESSER, 
A. E., BAYLISS, C. R. & MARSTON, S. B. 2010a. Investigation of changes 
in skeletal muscle alpha-actin expression in normal and pathological human 
and mouse hearts. J Muscle Res Cell Motil, 31, 207-14. 
329 
COPELAND, O., SADAYAPPAN, S., MESSER, A. E., STEINEN, G. J., VAN DER 
VELDEN, J. & MARSTON, S. B. 2010b. Analysis of cardiac myosin binding 
protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol, 49, 
1003-11. 
COX, L., UMANS, L., CORNELIS, F., HUYLEBROECK, D. & ZWIJSEN, A. 2008. 
A broken heart: a stretch too far: an overview of mouse models with mutations 
in stretch-sensor components. Int J Cardiol, 131, 33-44. 
CRILLEY, J. G., BOEHM, E. A., BLAIR, E., RAJAGOPALAN, B., BLAMIRE, A. 
M., STYLES, P., MCKENNA, W. J., OSTMAN-SMITH, I., CLARKE, K. & 
WATKINS, H. 2003. Hypertrophic cardiomyopathy due to sarcomeric gene 
mutations is characterized by impaired energy metabolism irrespective of the 
degree of hypertrophy. J Am Coll Cardiol, 41, 1776-82. 
CUDA, G., FANANAPAZIR, L., EPSTEIN, N. D. & SELLERS, J. R. 1997. The in 
vitro motility activity of beta-cardiac myosin depends on the nature of the 
beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J 
Muscle Res Cell Motil, 18, 275-83. 
CUNNINGHAM, J. G. 2002. Textbook of veterinary physiology, Philadelphia, Pa. ; 
London, W.B. Saunders Co. 
DE TOMBE, P. P., MATEJA, R. D., TACHAMPA, K., AIT MOU, Y., FARMAN, 
G. P. & IRVING, T. C. 2010. Myofilament length dependent activation. J Mol 
Cell Cardiol, 48, 851-8. 
DEBOLD, E. P., SABER, W., CHEEMA, Y., BOOKWALTER, C. S., TRYBUS, K. 
M., WARSHAW, D. M. & VANBUREN, P. 2010. Human actin mutations 
associated with hypertrophic and dilated cardiomyopathies demonstrate 
distinct thin filament regulatory properties in vitro. J Mol Cell Cardiol, 48, 
286-92. 
DENG, Y., SCHMIDTMANN, A., REDLICH, A., WESTERDORF, B., JAQUET, K. 
& THIELECZEK, R. 2001. Effects of phosphorylation and mutation R145G 
on human cardiac troponin I function. Biochemistry, 40, 14593-602. 
DOS REMEDIOS, C. G. & MOENS, P. D. 1995. Actin and the actomyosin interface: 
a review. Biochim Biophys Acta, 1228, 99-124. 
DOU, Y., ARLOCK, P. & ARNER, A. 2007. Blebbistatin specifically inhibits actin-
myosin interaction in mouse cardiac muscle. Am J Physiol Cell Physiol, 293, 
C1148-53. 
DYER, E., SONG, W., WELLS, D. & MARSTON, S. 2008. *Functional 
investigation of transgenic mouse model of apical HCM with ACTC E99K 
mutation. J Mol Cell Cardiol, 44, 730. 
DYER, E. C. 2008. A functional investigation of mutations associated with 
hypertrophic and dilated cardiomyopathy. Imperial College. 
DYER, E. C., JACQUES, A. M., HOSKINS, A. C., WARD, D. G., GALLON, C. E., 
MESSER, A. E., KASKI, J. P., BURCH, M., KENTISH, J. C. & MARSTON, 
S. B. 2009. Functional analysis of a unique troponin c mutation, GLY159ASP, 
that causes familial dilated cardiomyopathy, studied in explanted heart muscle. 
Circ Heart Fail, 2, 456-64. 
EISENBERG, E. & KIELLEY, W. W. 1974. Troponin-tropomyosin complex. 
Column chromatographic separation and activity of the three, active troponin 
components with and without tropomyosin present. J Biol Chem, 249, 4742-8. 
ELLIOTT, K., WATKINS, H. & REDWOOD, C. S. 2000. Altered regulatory 
properties of human cardiac troponin I mutants that cause hypertrophic 
cardiomyopathy. J Biol Chem, 275, 22069-74. 
330 
ELLIOTT, P. & MCKENNA, W. J. 2004. Hypertrophic cardiomyopathy. Lancet, 
363, 1881-91. 
ELLIOTT, P. M., GIMENO, J. R., TOME, M. T., SHAH, J., WARD, D., THAMAN, 
R., MOGENSEN, J. & MCKENNA, W. J. 2006. Left ventricular outflow tract 
obstruction and sudden death risk in patients with hypertrophic 
cardiomyopathy. Eur Heart J, 27, 1933-41. 
FLASHMAN, E., REDWOOD, C., MOOLMAN-SMOOK, J. & WATKINS, H. 
2004. Cardiac myosin binding protein C: its role in physiology and disease. 
Circ Res, 94, 1279-89. 
FRASER, I. D. & MARSTON, S. B. 1995. In vitro motility analysis of actin-
tropomyosin regulation by troponin and calcium. The thin filament is switched 
as a single cooperative unit. J Biol Chem, 270, 7836-41. 
FUJINO, N., SHIMIZU, M., INO, H., YAMAGUCHI, M., YASUDA, T., NAGATA, 
M., KONNO, T. & MABUCHI, H. 2002. A novel mutation Lys273Glu in the 
cardiac troponin T gene shows high degree of penetrance and transition from 
hypertrophic to dilated cardiomyopathy. Am J Cardiol, 89, 29-33. 
GALLEGO, M. & VIRSHUP, D. M. 2005. Protein serine/threonine phosphatases: 
life, death, and sleeping. Curr Opin Cell Biol, 17, 197-202. 
GEEVES, M. A., FEDOROV, R. & MANSTEIN, D. J. 2005. Molecular mechanism 
of actomyosin-based motility. Cell Mol Life Sci, 62, 1462-77. 
GEEVES, M. A. & HOLMES, K. C. 1999. Structural mechanism of muscle 
contraction. Annu Rev Biochem, 68, 687-728. 
GEEVES, M. A. & HOLMES, K. C. 2005. The molecular mechanism of muscle 
contraction. Adv Protein Chem, 71, 161-93. 
GEEVES, M. A. & LEHRER, S. S. 1994. Dynamics of the muscle thin filament 
regulatory switch: the size of the cooperative unit. Biophys J, 67, 273-82. 
GEISTERFER-LOWRANCE, A. A., KASS, S., TANIGAWA, G., VOSBERG, H. P., 
MCKENNA, W., SEIDMAN, C. E. & SEIDMAN, J. G. 1990. A molecular 
basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy 
chain gene missense mutation. Cell, 62, 999-1006. 
GORDON, A. M., HOMSHER, E. & REGNIER, M. 2000. Regulation of contraction 
in striated muscle. Physiol Rev, 80, 853-924. 
GORDON, A. M., HUXLEY, A. F. & JULIAN, F. J. 1966. The variation in isometric 
tension with sarcomere length in vertebrate muscle fibres. J Physiol, 184, 170-
92. 
GREENFIELD, N. J., HUANG, Y. J., SWAPNA, G. V., BHATTACHARYA, A., 
RAPP, B., SINGH, A., MONTELIONE, G. T. & HITCHCOCK-
DEGREGORI, S. E. 2006. Solution NMR structure of the junction between 
tropomyosin molecules: implications for actin binding and regulation. J Mol 
Biol, 364, 80-96. 
GUNNING, P. W., SCHEVZOV, G., KEE, A. J. & HARDEMAN, E. C. 2005. 
Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends 
Cell Biol, 15, 333-41. 
HABER, E. 1995. Scientific American molecular cardiovascular medicine, New 
York, NY, Scientific American. 
HAJJAR, R. J. & MACRAE, C. A. 2002. Adrenergic-receptor polymorphisms and 
heart failure. N Engl J Med, 347, 1196-9. 
HAMDANI, N., KOOIJ, V., VAN DIJK, S., MERKUS, D., PAULUS, W. J., 
REMEDIOS, C. D., DUNCKER, D. J., STIENEN, G. J. & VAN DER 
331 
VELDEN, J. 2008. Sarcomeric dysfunction in heart failure. Cardiovasc Res, 
77, 649-58. 
HARRIS, S. P., BARTLEY, C. R., HACKER, T. A., MCDONALD, K. S., 
DOUGLAS, P. S., GREASER, M. L., POWERS, P. A. & MOSS, R. L. 2002. 
Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout 
mice. Circ Res, 90, 594-601. 
HITCHCOCK-DEGREGORI, S. E. & SINGH, A. 2010. What makes tropomyosin an 
actin binding protein? A perspective. J Struct Biol, 170, 319-24. 
HODGKINSON, J. L. 2000. Actin and the smooth muscle regulatory proteins: a 
structural perspective. J Muscle Res Cell Motil, 21, 115-30. 
HOFMANN, P. A., HARTZELL, H. C. & MOSS, R. L. 1991. Alterations in Ca2+ 
sensitive tension due to partial extraction of C-protein from rat skinned cardiac 
myocytes and rabbit skeletal muscle fibers. J Gen Physiol, 97, 1141-63. 
HOFMANN, P. A. & MOSS, R. L. 1992. Effects of calcium on shortening velocity in 
frog chemically skinned atrial myocytes and in mechanically disrupted 
ventricular myocardium from rat. Circ Res, 70, 885-92. 
HOLMES, K. C. 1997. The swinging lever-arm hypothesis of muscle contraction. 
Curr Biol, 7, R112-8. 
HOLMES, K. C., POPP, D., GEBHARD, W. & KABSCH, W. 1990. Atomic model 
of the actin filament. Nature, 347, 44-9. 
HOOK, P. & LARSSON, L. 2000. Actomyosin interactions in a novel single muscle 
fiber in vitro motility assay. J Muscle Res Cell Motil, 21, 357-65. 
HOSHIJIMA, M. 2006. Mechanical stress-strain sensors embedded in cardiac 
cytoskeleton: Z disk, titin, and associated structures. Am J Physiol Heart Circ 
Physiol, 290, H1313-25. 
HOSKINS, A. C., JACQUES, A., BARDSWELL, S. C., MCKENNA, W. J., 
TSANG, V., DOS REMEDIOS, C. G., EHLER, E., ADAMS, K., 
JALILZADEH, S., AVKIRAN, M., WATKINS, H., REDWOOD, C., 
MARSTON, S. B. & KENTISH, J. C. 2010. Normal passive viscoelasticity 
but abnormal myofibrillar force generation in human hypertrophic 
cardiomyopathy. J Mol Cell Cardiol, 49, 737-45. 
HOUDUSSE, A., LOVE, M. L., DOMINGUEZ, R., GRABAREK, Z. & COHEN, C. 
1997. Structures of four Ca2+-bound troponin C at 2.0 A resolution: further 
insights into the Ca2+-switch in the calmodulin superfamily. Structure, 5, 
1695-711. 
HOWARTH, J. W., MELLER, J., SOLARO, R. J., TREWHELLA, J. & 
ROSEVEAR, P. R. 2007. Phosphorylation-dependent conformational 
transition of the cardiac specific N-extension of troponin I in cardiac troponin. 
J Mol Biol, 373, 706-22. 
HUKE, S. & KNOLLMANN, B. C. 2010. Increased myofilament Ca2+-sensitivity 
and arrhythmia susceptibility. J Mol Cell Cardiol, 48, 824-33. 
HUXLEY, A. F. 1957. Muscle structure and theories of contraction. Prog Biophys 
Biophys Chem, 7, 255-318. 
HUXLEY, H. E. 1969. The mechanism of muscular contraction. Science, 164, 1356-
65. 
JACQUES, A., HOSKINS, A. C., KENTISH, J. C. & MARSTON, S. B. 2008a. From 
genotype to phenotype: a longitudinal study of a patient with hypertrophic 
cardiomyopathy due to a mutation in the MYBPC3 gene. J Muscle Res Cell 
Motil, 29, 239-46. 
332 
JACQUES, A. M., BRICENO, N., MESSER, A. E., GALLON, C. E., JALILZADEH, 
S., GARCIA, E., KIKONDA-KANDA, G., GODDARD, J., HARDING, S. E., 
WATKINS, H., ESTEBAN, M. T., TSANG, V. T., MCKENNA, W. J. & 
MARSTON, S. B. 2008b. The molecular phenotype of human cardiac myosin 
associated with hypertrophic obstructive cardiomyopathy. Cardiovasc Res, 79, 
481-91. 
JACQUES, A. M., COPELAND, O., MESSER, A. E., GALLON, C. E., KING, K., 
MCKENNA, W. J., TSANG, V. T. & MARSTON, S. B. 2008c. Myosin 
binding protein C phosphorylation in normal, hypertrophic and failing human 
heart muscle. J Mol Cell Cardiol, 45, 209-16. 
JACQUES, A. M., MESSER, A. E., GALLON, C. E., TSANG, V. T., MCKENNA, 
W. J. & MARSTON, S. 2007. *A comparison between TnT, TnI, MyBP-C 
and MLC-2 phosphorylation in tissue from septal myectomies of hypertrophic 
obstructive cardiomyopathy patients and donor hearts. Biophys J, 2007 
Conference proceedings, 541A. 
JACQUES, A. M., MESSER, A. E., TSANG, V. T., MCKENNA, W. J. & 
MARSTON, S. 2006. *Evidence for reduced troponin I phosphorylation and 
altered troponin function in patients with Hypertrophic Obstructive 
Cardiomyopathy. J Mol Cell Cardiol, 40, 939. 
JAENICKE, T., DIEDERICH, K. W., HAAS, W., SCHLEICH, J., LICHTER, P., 
PFORDT, M., BACH, A. & VOSBERG, H. P. 1990. The complete sequence 
of the human beta-myosin heavy chain gene and a comparative analysis of its 
product. Genomics, 8, 194-206. 
KATRUKHA, A. G., BEREZNIKOVA, A. V., ESAKOVA, T. V., FILATOV, V. L., 
BULARGINA, T. V. & GUSEV, N. B. 1995. A new method of human cardiac 
troponin I and troponin T purification. Biochem Mol Biol Int, 36, 195-202. 
KATZ, A. M. 2006. Physiology of the heart, Philadelphia, Pa. ; London, Lippincott 
Williams & Wilkins. 
KEHAT, I. & MOLKENTIN, J. D. 2010. Molecular pathways underlying cardiac 
remodeling during pathophysiological stimulation. Circulation, 122, 2727-35. 
KENTISH, J. C., MCCLOSKEY, D. T., LAYLAND, J., PALMER, S., LEIDEN, J. 
M., MARTIN, A. F. & SOLARO, R. J. 2001. Phosphorylation of troponin I by 
protein kinase A accelerates relaxation and crossbridge cycle kinetics in 
mouse ventricular muscle. Circ Res, 88, 1059-65. 
KERRICK, W. G., KAZMIERCZAK, K., XU, Y., WANG, Y. & SZCZESNA-
CORDARY, D. 2009. Malignant familial hypertrophic cardiomyopathy 
D166V mutation in the ventricular myosin regulatory light chain causes 
profound effects in skinned and intact papillary muscle fibers from transgenic 
mice. FASEB J, 23, 855-65. 
KINOSHITA, E., KINOSHITA-KIKUTA, E., TAKIYAMA, K. & KOIKE, T. 2006. 
Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol 
Cell Proteomics, 5, 749-57. 
KINOSHITA-KIKUTA, E., AOKI, Y., KINOSHITA, E. & KOIKE, T. 2007. Label-
free kinase profiling using phosphate affinity polyacrylamide gel 
electrophoresis. Mol Cell Proteomics, 6, 356-66. 
KNOLLMANN, B. C. & POTTER, J. D. 2001. Altered regulation of cardiac muscle 
contraction by troponin T mutations that cause familial hypertrophic 
cardiomyopathy. Trends Cardiovasc Med, 11, 206-12. 
333 
KNOTT, A. J. 2002. Regulation of cardiac contractility in the normal, failing and 
hypertrophic human heart : an in vitro motility study. Ph.D., University of 
London. 
KOBAYASHI, T. & SOLARO, R. J. 2005. Calcium, thin filaments, and the 
integrative biology of cardiac contractility. Annu Rev Physiol, 67, 39-67. 
KOCICA, M. J., CORNO, A. F., CARRERAS-COSTA, F., BALLESTER-RODES, 
M., MOGHBEL, M. C., CUEVA, C. N., LACKOVIC, V., KANJUH, V. I. & 
TORRENT-GUASP, F. 2006. The helical ventricular myocardial band: global, 
three-dimensional, functional architecture of the ventricular myocardium. Eur 
J Cardiothorac Surg, 29 Suppl 1, S21-40. 
KOHLER, J., WINKLER, G., SCHULTE, I., SCHOLZ, T., MCKENNA, W., 
BRENNER, B. & KRAFT, T. 2002. Mutation of the myosin converter domain 
alters cross-bridge elasticity. Proc Natl Acad Sci U S A, 99, 3557-62. 
KOVACS, M., TOTH, J., HETENYI, C., MALNASI-CSIZMADIA, A. & SELLERS, 
J. R. 2004. Mechanism of blebbistatin inhibition of myosin II. J Biol Chem, 
279, 35557-63. 
KRON, S. J. & SPUDICH, J. A. 1986. Fluorescent actin filaments move on myosin 
fixed to a glass surface. Proc Natl Acad Sci U S A, 83, 6272-6. 
KRUGER, M. & LINKE, W. A. 2009. Titin-based mechanical signalling in normal 
and failing myocardium. J Mol Cell Cardiol, 46, 490-8. 
KULIKOVSKAYA, I., MCCLELLAN, G., LEVINE, R. & WINEGRAD, S. 2003. 
Effect of extraction of myosin binding protein C on contractility of rat heart. 
Am J Physiol Heart Circ Physiol, 285, H857-65. 
LAEMMLI, U. K. 1970. Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature, 227, 680-5. 
LAYLAND, J., CAVE, A. C., WARREN, C., GRIEVE, D. J., SPARKS, E., 
KENTISH, J. C., SOLARO, R. J. & SHAH, A. M. 2005a. Protection against 
endotoxemia-induced contractile dysfunction in mice with cardiac-specific 
expression of slow skeletal troponin I. FASEB J, 19, 1137-9. 
LAYLAND, J., SOLARO, R. J. & SHAH, A. M. 2005b. Regulation of cardiac 
contractile function by troponin I phosphorylation. Cardiovasc Res, 66, 12-21. 
LEGRICE, I. J., SMAILL, B. H., CHAI, L. Z., EDGAR, S. G., GAVIN, J. B. & 
HUNTER, P. J. 1995. Laminar structure of the heart: ventricular myocyte 
arrangement and connective tissue architecture in the dog. Am J Physiol, 269, 
H571-82. 
LEHMAN, W. & CRAIG, R. 2008. Tropomyosin and the steric mechanism of muscle 
regulation. Adv Exp Med Biol, 644, 95-109. 
LEHMAN, W., VIBERT, P., UMAN, P. & CRAIG, R. 1995. Steric-blocking by 
tropomyosin visualized in relaxed vertebrate muscle thin filaments. J Mol 
Biol, 251, 191-6. 
LEHRER, S. S. & GEEVES, M. A. 1998. The muscle thin filament as a classical 
cooperative/allosteric regulatory system. J Mol Biol, 277, 1081-9. 
LEVICK, J. R. 2009. An introduction to cardiovascular physiology, London, Hodder 
Arnold. 
LEWINTER, M. M. & GRANZIER, H. 2010. Cardiac titin: a multifunctional giant. 
Circulation, 121, 2137-45. 
LEWINTER, M. M., WU, Y., LABEIT, S. & GRANZIER, H. 2007. Cardiac titin: 
structure, functions and role in disease. Clin Chim Acta, 375, 1-9. 
334 
LI, X. E., TOBACMAN, L. S., MUN, J. Y., CRAIG, R., FISCHER, S. & LEHMAN, 
W. 2011. Tropomyosin position on F-actin revealed by EM reconstruction and 
computational chemistry. Biophys J, 100, 1005-13. 
LINKE, W. A. 2008. Sense and stretchability: the role of titin and titin-associated 
proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc 
Res, 77, 637-48. 
LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. & RANDALL, R. J. 1951. 
Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 265-75. 
LUTHER, P. K. & VYDYANATH, A. 2011. Myosin binding protein-C: an essential 
protein in skeletal and cardiac muscle. J Muscle Res Cell Motil, 31, 303-5. 
LYMN, R. W. & TAYLOR, E. W. 1971. Mechanism of adenosine triphosphate 
hydrolysis by actomyosin. Biochemistry, 10, 4617-24. 
MALNIC, B., FARAH, C. S. & REINACH, F. C. 1998. Regulatory properties of the 
NH2- and COOH-terminal domains of troponin T. ATPase activation and 
binding to troponin I and troponin C. J Biol Chem, 273, 10594-601. 
MARGOSSIAN, S. S. & LOWEY, S. 1982. Preparation of myosin and its 
subfragments from rabbit skeletal muscle. Methods Enzymol, 85 Pt B, 55-71. 
MARON, B. J. 1997. Hypertrophic cardiomyopathy. Lancet, 350, 127-33. 
MARON, B. J. 2002. Hypertrophic cardiomyopathy: a systematic review. JAMA, 287, 
1308-20. 
MARON, B. J. 2007. Controversies in cardiovascular medicine. Surgical myectomy 
remains the primary treatment option for severely symptomatic patients with 
obstructive hypertrophic cardiomyopathy. Circulation, 116, 196-206; 
discussion 206. 
MARON, B. J., GARDIN, J. M., FLACK, J. M., GIDDING, S. S., KUROSAKI, T. T. 
& BILD, D. E. 1995. Prevalence of hypertrophic cardiomyopathy in a general 
population of young adults. Echocardiographic analysis of 4111 subjects in the 
CARDIA Study. Coronary Artery Risk Development in (Young) Adults. 
Circulation, 92, 785-9. 
MARON, B. J., GOTTDIENER, J. S. & EPSTEIN, S. E. 1981. Patterns and 
significance of distribution of left ventricular hypertrophy in hypertrophic 
cardiomyopathy. A wide angle, two dimensional echocardiographic study of 
125 patients. Am J Cardiol, 48, 418-28. 
MARON, B. J., MCKENNA, W. J., DANIELSON, G. K., KAPPENBERGER, L. J., 
KUHN, H. J., SEIDMAN, C. E., SHAH, P. M., SPENCER, W. H., 3RD, 
SPIRITO, P., TEN CATE, F. J. & WIGLE, E. D. 2003a. American College of 
Cardiology/European Society of Cardiology clinical expert consensus 
document on hypertrophic cardiomyopathy. A report of the American College 
of Cardiology Foundation Task Force on Clinical Expert Consensus 
Documents and the European Society of Cardiology Committee for Practice 
Guidelines. J Am Coll Cardiol, 42, 1687-713. 
MARON, B. J., OLIVOTTO, I., SPIRITO, P., CASEY, S. A., BELLONE, P., 
GOHMAN, T. E., GRAHAM, K. J., BURTON, D. A. & CECCHI, F. 2000. 
Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a 
large non-referral-based patient population. Circulation, 102, 858-64. 
MARON, B. J. & SPIRITO, P. 1998. Implications of left ventricular remodeling in 
hypertrophic cardiomyopathy. Am J Cardiol, 81, 1339-44. 
MARON, M. S., OLIVOTTO, I., BETOCCHI, S., CASEY, S. A., LESSER, J. R., 
LOSI, M. A., CECCHI, F. & MARON, B. J. 2003b. Effect of left ventricular 
335 
outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. 
N Engl J Med, 348, 295-303. 
MARON, M. S., OLIVOTTO, I., ZENOVICH, A. G., LINK, M. S., PANDIAN, N. 
G., KUVIN, J. T., NISTRI, S., CECCHI, F., UDELSON, J. E. & MARON, B. 
J. 2006. Hypertrophic cardiomyopathy is predominantly a disease of left 
ventricular outflow tract obstruction. Circulation, 114, 2232-9. 
MARSTON, S. 2003. Random walks with thin filaments: application of in vitro 
motility assay to the study of actomyosin regulation. J Muscle Res Cell Motil, 
24, 149-56. 
MARSTON, S., COPELAND, O., JACQUES, A., LIVESEY, K., TSANG, V., 
MCKENNA, W. J., JALILZADEH, S., CARBALLO, S., REDWOOD, C. & 
WATKINS, H. 2009. Evidence from human myectomy samples that 
MYBPC3 mutations cause hypertrophic cardiomyopathy through 
haploinsufficiency. Circ Res, 105, 219-22. 
MARSTON, S. B. 2011. How do mutations in contractile proteins cause the primary 
familial cardiomyopathies? J Cardiovasc Transl Res, 4, 245-55. 
MARSTON, S. B., FRASER, I. D., BING, W. & ROPER, G. 1996. A simple method 
for automatic tracking of actin filaments in the motility assay. J Muscle Res 
Cell Motil, 17, 497-506. 
MARSTON, S. B., TREVETT, R. M. & WALTERS, M. 1980. Calcium ion-regulated 
thin filaments from vascular smooth muscle. Biochem J, 185, 355-65. 
MARSTON, S. B. & WALKER, J. W. 2009. Back to the future: new techniques show 
that forgotten phosphorylation sites are present in contractile proteins of the 
heart whilst intensively studied sites appear to be absent. J Muscle Res Cell 
Motil, 30, 93-5. 
MASON, J. M. & ARNDT, K. M. 2004. Coiled coil domains: stability, specificity, 
and biological implications. Chembiochem, 5, 170-6. 
MAYTUM, R., GUNNING, P., LIN, J., COPELAND, O. N., BAYLISS, C. & 
MARSTON, S. 2011. Analysis of Tropomyosin (Tm) Isoforms in Heart 
Muscle by LC/MS and Western Blotting Demonstrates Previously 
Uncharacterised High-Level Expression of [gamma] Tm. Biophysical Journal, 
100, 371a-371a. 
MAYTUM, R., LEHRER, S. S. & GEEVES, M. A. 1999. Cooperativity and 
switching within the three-state model of muscle regulation. Biochemistry, 38, 
1102-10. 
MCGUIGAN, J. A., LUTHI, D. & BURI, A. 1991. Calcium buffer solutions and how 
to make them: a do it yourself guide. Can J Physiol Pharmacol, 69, 1733-49. 
MCKILLOP, D. F. & GEEVES, M. A. 1993. Regulation of the interaction between 
actin and myosin subfragment 1: evidence for three states of the thin filament. 
Biophys J, 65, 693-701. 
MESSER, A. E., GALLON, C. E., MCKENNA, W. J., DOS REMEDIOS, C. G. & 
MARSTON, S. B. 2009. The use of phosphate-affinity SDS-PAGE to measure 
the cardiac troponin I phosphorylation site distribution in human heart muscle. 
PROTEOMICS – Clinical Applications, 3, 1371-1382. 
MESSER, A. E., JACQUES, A. M. & MARSTON, S. B. 2007. Troponin 
phosphorylation and regulatory function in human heart muscle: 
dephosphorylation of Ser23/24 on troponin I could account for the contractile 
defect in end-stage heart failure. J Mol Cell Cardiol, 42, 247-59. 
MIRZA, M., MARSTON, S., WILLOTT, R., ASHLEY, C., MOGENSEN, J., 
MCKENNA, W., ROBINSON, P., REDWOOD, C. & WATKINS, H. 2005. 
336 
Dilated cardiomyopathy mutations in three thin filament regulatory proteins 
result in a common functional phenotype. J Biol Chem, 280, 28498-506. 
MONSERRAT, L., HERMIDA-PRIETO, M., FERNANDEZ, X., RODRIGUEZ, I., 
DUMONT, C., CAZON, L., CUESTA, M. G., GONZALEZ-JUANATEY, C., 
PETEIRO, J., ALVAREZ, N., PENAS-LADO, M. & CASTRO-BEIRAS, A. 
2007. Mutation in the alpha-cardiac actin gene associated with apical 
hypertrophic cardiomyopathy, left ventricular non-compaction, and septal 
defects. Eur Heart J, 28, 1953-61. 
MOOLMAN-SMOOK, J., FLASHMAN, E., DE LANGE, W., LI, Z., CORFIELD, 
V., REDWOOD, C. & WATKINS, H. 2002. Identification of novel 
interactions between domains of Myosin binding protein-C that are modulated 
by hypertrophic cardiomyopathy missense mutations. Circ Res, 91, 704-11. 
MORIMOTO, S. 2008. Sarcomeric proteins and inherited cardiomyopathies. 
Cardiovasc Res, 77, 659-66. 
MORROW, A. G., REITZ, B. A., EPSTEIN, S. E., HENRY, W. L., CONKLE, D. 
M., ITSCOITZ, S. B. & REDWOOD, D. R. 1975. Operative treatment in 
hypertrophic subaortic stenosis. Techniques, and the results of pre and 
postoperative assessments in 83 patients. Circulation, 52, 88-102. 
NGUYEN, T. T., HAYES, E., MULIERI, L. A., LEAVITT, B. J., TER KEURS, H. 
E., ALPERT, N. R. & WARSHAW, D. M. 1996. Maximal actomyosin 
ATPase activity and in vitro myosin motility are unaltered in human mitral 
regurgitation heart failure. Circ Res, 79, 222-6. 
OAKLEY, C. E., CHAMOUN, J., BROWN, L. J. & HAMBLY, B. D. 2007. Myosin 
binding protein-C: enigmatic regulator of cardiac contraction. Int J Biochem 
Cell Biol, 39, 2161-6. 
ODA, T., IWASA, M., AIHARA, T., MAEDA, Y. & NARITA, A. 2009. The nature 
of the globular- to fibrous-actin transition. Nature, 457, 441-5. 
OKAMOTO, Y. & SEKINE, T. 1985. A streamlined method of subfragment one 
preparation from myosin. J Biochem, 98, 1143-5. 
OLSON, T. M., DOAN, T. P., KISHIMOTO, N. Y., WHITBY, F. G., ACKERMAN, 
M. J. & FANANAPAZIR, L. 2000. Inherited and de novo mutations in the 
cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol, 
32, 1687-94. 
PAGE, E. 1978. Quantitative ultrastructural analysis in cardiac membrane physiology. 
Am J Physiol, 235, C147-58. 
PALM, T., GRABOSKI, S., HITCHCOCK-DEGREGORI, S. E. & GREENFIELD, 
N. J. 2001. Disease-causing mutations in cardiac troponin T: identification of 
a critical tropomyosin-binding region. Biophys J, 81, 2827-37. 
PALMER, S. & KENTISH, J. C. 1997. Differential effects of the Ca2+ sensitizers 
caffeine and CGP 48506 on the relaxation rate of rat skinned cardiac 
trabeculae. Circ Res, 80, 682-7. 
PALMER, S. & KENTISH, J. C. 1998. Roles of Ca2+ and crossbridge kinetics in 
determining the maximum rates of Ca2+ activation and relaxation in rat and 
guinea pig skinned trabeculae. Circ Res, 83, 179-86. 
PALMITER, K. A., TYSKA, M. J., HAEBERLE, J. R., ALPERT, N. R., 
FANANAPAZIR, L. & WARSHAW, D. M. 2000. R403Q and L908V mutant 
beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy 
exhibit enhanced mechanical performance at the single molecule level. J 
Muscle Res Cell Motil, 21, 609-20. 
337 
PEARCE, L. R., KOMANDER, D. & ALESSI, D. R. 2010. The nuts and bolts of 
AGC protein kinases. Nat Rev Mol Cell Biol, 11, 9-22. 
PERRY, S. V. 1998. Troponin T: genetics, properties and function. J Muscle Res Cell 
Motil, 19, 575-602. 
PERRY, S. V. 1999. Troponin I: inhibitor or facilitator. Mol Cell Biochem, 190, 9-32. 
PERRY, S. V. 2001. Vertebrate tropomyosin: distribution, properties and function. J 
Muscle Res Cell Motil, 22, 5-49. 
PIRANI, A., VINOGRADOVA, M. V., CURMI, P. M., KING, W. A., 
FLETTERICK, R. J., CRAIG, R., TOBACMAN, L. S., XU, C., HATCH, V. 
& LEHMAN, W. 2006. An atomic model of the thin filament in the relaxed 
and Ca2+-activated states. J Mol Biol, 357, 707-17. 
POGGESI, C., TESI, C. & STEHLE, R. 2005. Sarcomeric determinants of striated 
muscle relaxation kinetics. Pflugers Arch, 449, 505-17. 
POHLMANN, L., KROGER, I., VIGNIER, N., SCHLOSSAREK, S., KRAMER, E., 
COIRAULT, C., SULTAN, K. R., EL-ARMOUCHE, A., WINEGRAD, S., 
ESCHENHAGEN, T. & CARRIER, L. 2007. Cardiac myosin-binding protein 
C is required for complete relaxation in intact myocytes. Circ Res, 101, 928-
38. 
POTTER, J. D. 1982. Preparation of troponin and its subunits. Methods Enzymol, 85 
Pt B, 241-63. 
RAMIREZ-CORREA, G. A., JIN, W., WANG, Z., ZHONG, X., GAO, W. D., DIAS, 
W. B., VECOLI, C., HART, G. W. & MURPHY, A. M. 2008. O-linked 
GlcNAc modification of cardiac myofilament proteins: a novel regulator of 
myocardial contractile function. Circ Res, 103, 1354-8. 
RAYMENT, I., RYPNIEWSKI, W. R., SCHMIDT-BASE, K., SMITH, R., 
TOMCHICK, D. R., BENNING, M. M., WINKELMANN, D. A., 
WESENBERG, G. & HOLDEN, H. M. 1993. Three-dimensional structure of 
myosin subfragment-1: a molecular motor. Science, 261, 50-8. 
REDWOOD, C. S., MOOLMAN-SMOOK, J. C. & WATKINS, H. 1999. Properties 
of mutant contractile proteins that cause hypertrophic cardiomyopathy. 
Cardiovasc Res, 44, 20-36. 
RICHARD, P., CHARRON, P., CARRIER, L., LEDEUIL, C., CHEAV, T., 
PICHEREAU, C., BENAICHE, A., ISNARD, R., DUBOURG, O., BURBAN, 
M., GUEFFET, J. P., MILLAIRE, A., DESNOS, M., SCHWARTZ, K., 
HAINQUE, B. & KOMAJDA, M. 2003. Hypertrophic cardiomyopathy: 
distribution of disease genes, spectrum of mutations, and implications for a 
molecular diagnosis strategy. Circulation, 107, 2227-32. 
RICHARDSON, P., MCKENNA, W., BRISTOW, M., MAISCH, B., MAUTNER, 
B., O'CONNELL, J., OLSEN, E., THIENE, G., GOODWIN, J., GYARFAS, 
I., MARTIN, I. & NORDET, P. 1996. Report of the 1995 World Health 
Organization/International Society and Federation of Cardiology Task Force 
on the Definition and Classification of cardiomyopathies. Circulation, 93, 
841-2. 
ROBERTSON, S. P., JOHNSON, J. D., HOLROYDE, M. J., KRANIAS, E. G., 
POTTER, J. D. & SOLARO, R. J. 1982. The effect of troponin I 
phosphorylation on the Ca2+-binding properties of the Ca2+-regulatory site of 
bovine cardiac troponin. J Biol Chem, 257, 260-3. 
ROBINSON, P., MIRZA, M., KNOTT, A., ABDULRAZZAK, H., WILLOTT, R., 
MARSTON, S., WATKINS, H. & REDWOOD, C. 2002. Alterations in thin 
filament regulation induced by a human cardiac troponin T mutant that causes 
338 
dilated cardiomyopathy are distinct from those induced by troponin T mutants 
that cause hypertrophic cardiomyopathy. J Biol Chem, 277, 40710-6. 
SADAYAPPAN, S., FINLEY, N., HOWARTH, J. W., OSINSKA, H., KLEVITSKY, 
R., LORENZ, J. N., ROSEVEAR, P. R. & ROBBINS, J. 2008. Role of the 
acidic N' region of cardiac troponin I in regulating myocardial function. 
FASEB J, 22, 1246-57. 
SCHAUB, M. C., HEFTI, M. A., ZUELLIG, R. A. & MORANO, I. 1998. 
Modulation of contractility in human cardiac hypertrophy by myosin essential 
light chain isoforms. Cardiovasc Res, 37, 381-404. 
SCHULENBERG, B., AGGELER, R., BEECHEM, J. M., CAPALDI, R. A. & 
PATTON, W. F. 2003. Analysis of steady-state protein phosphorylation in 
mitochondria using a novel fluorescent phosphosensor dye. J Biol Chem, 278, 
27251-5. 
SEVERS, N. J. 2000. The cardiac muscle cell. Bioessays, 22, 188-99. 
SLAWSON, C., HOUSLEY, M. P. & HART, G. W. 2006. O-GlcNAc cycling: how a 
single sugar post-translational modification is changing the way we think 
about signaling networks. J Cell Biochem, 97, 71-83. 
SMITH, C. A. & RAYMENT, I. 1996. Active site comparisons highlight structural 
similarities between myosin and other P-loop proteins. Biophys J, 70, 1590-
602. 
SOLARO, R. J., ROSEVEAR, P. & KOBAYASHI, T. 2008. The unique functions of 
cardiac troponin I in the control of cardiac muscle contraction and relaxation. 
Biochem Biophys Res Commun, 369, 82-7. 
SOLARO, R. J. & VAN DER VELDEN, J. 2010. Why does troponin I have so many 
phosphorylation sites? Fact and fancy. J Mol Cell Cardiol, 48, 810-6. 
SOLOMON, S. D., JARCHO, J. A., MCKENNA, W., GEISTERFER-LOWRANCE, 
A., GERMAIN, R., SALERNI, R., SEIDMAN, J. G. & SEIDMAN, C. E. 
1990. Familial hypertrophic cardiomyopathy is a genetically heterogeneous 
disease. J Clin Invest, 86, 993-9. 
SONG, W., DYER, E., STUCKEY, D., LEUNG, M. C., MEMO, M., MANSFIELD, 
C., FERENCZI, M., LIU, K., REDWOOD, C., NOWAK, K., HARDING, S., 
CLARKE, K., WELLS, D. & MARSTON, S. 2010. Investigation of a 
transgenic mouse model of familial dilated cardiomyopathy. J Mol Cell 
Cardiol, 49, 380-9. 
SONG, W., DYER, E., STUCKEY, D. J., COPELAND, O., LEUNG, M. C., 
BAYLISS, C., MESSER, A., WILKINSON, R., TREMOLEDA, J. L., 
SCHNEIDER, M. D., HARDING, S. E., REDWOOD, C. S., CLARKE, K., 
NOWAK, K., MONSERRAT, L., WELLS, D. & MARSTON, S. B. 2011. 
Molecular mechanism of the Glu99lys mutation in cardiac actin (ACTC gene) 
that causes apical hypertrophy in man and mouse. J Biol Chem. 
SPIRITO, P., SEIDMAN, C. E., MCKENNA, W. J. & MARON, B. J. 1997. The 
management of hypertrophic cardiomyopathy. N Engl J Med, 336, 775-85. 
SPRANG, S. R. 1997. G protein mechanisms: insights from structural analysis. Annu 
Rev Biochem, 66, 639-78. 
SPUDICH, J. A. 2001. The myosin swinging cross-bridge model. Nat Rev Mol Cell 
Biol, 2, 387-92. 
SPUDICH, J. A. & WATT, S. 1971. The regulation of rabbit skeletal muscle 
contraction. I. Biochemical studies of the interaction of the tropomyosin-
troponin complex with actin and the proteolytic fragments of myosin. J Biol 
Chem, 246, 4866-71. 
339 
SQUIRE, J. M., LUTHER, P. K. & KNUPP, C. 2003. Structural evidence for the 
interaction of C-protein (MyBP-C) with actin and sequence identification of a 
possible actin-binding domain. J Mol Biol, 331, 713-24. 
SQUIRE, J. M. & MORRIS, E. P. 1998. A new look at thin filament regulation in 
vertebrate skeletal muscle. FASEB J, 12, 761-71. 
SQUIRE, J. M. & PARRY, D. A. 2005. Comparative motile mechanisms in cells. Adv 
Protein Chem, 71, 1-15. 
STEHLE, R., KRUGER, M. & PFITZER, G. 2002. Force kinetics and individual 
sarcomere dynamics in cardiac myofibrils after rapid ca(2+) changes. Biophys 
J, 83, 2152-61. 
STEINBERG, T. H., AGNEW, B. J., GEE, K. R., LEUNG, W. Y., GOODMAN, T., 
SCHULENBERG, B., HENDRICKSON, J., BEECHEM, J. M., 
HAUGLAND, R. P. & PATTON, W. F. 2003. Global quantitative 
phosphoprotein analysis using Multiplexed Proteomics technology. 
Proteomics, 3, 1128-44. 
STELZER, J. E., PATEL, J. R., WALKER, J. W. & MOSS, R. L. 2007. Differential 
roles of cardiac myosin-binding protein C and cardiac troponin I in the 
myofibrillar force responses to protein kinase A phosphorylation. Circ Res, 
101, 503-11. 
STILLI, D., BOCCHI, L., BERNI, R., ZANIBONI, M., CACCIANI, F., 
CHAPONNIER, C., MUSSO, E., GABBIANI, G. & CLEMENT, S. 2006. 
Correlation of alpha-skeletal actin expression, ventricular fibrosis and heart 
function with the degree of pressure overload cardiac hypertrophy in rats. Exp 
Physiol, 91, 571-80. 
STRAUB, F. B. 1942. Actin. Studies from the Institute of Medical Chemsitry, 
University of Szeged, 2, 3-15. 
SUN, H. Q., YAMAMOTO, M., MEJILLANO, M. & YIN, H. L. 1999. Gelsolin, a 
multifunctional actin regulatory protein. J Biol Chem, 274, 33179-82. 
SZCZESNA-CORDARY, D., GUZMAN, G., NG, S. S. & ZHAO, J. 2004. Familial 
hypertrophic cardiomyopathy-linked alterations in Ca2+ binding of human 
cardiac myosin regulatory light chain affect cardiac muscle contraction. J Biol 
Chem, 279, 3535-42. 
TAKEDA, S., YAMASHITA, A., MAEDA, K. & MAEDA, Y. 2003. Structure of the 
core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature, 
424, 35-41. 
TEARE, D. 1958. Asymmetrical hypertrophy of the heart in young adults. Br Heart J, 
20, 1-8. 
THIERFELDER, L., WATKINS, H., MACRAE, C., LAMAS, R., MCKENNA, W., 
VOSBERG, H. P., SEIDMAN, J. G. & SEIDMAN, C. E. 1994. Alpha-
tropomyosin and cardiac troponin T mutations cause familial hypertrophic 
cardiomyopathy: a disease of the sarcomere. Cell, 77, 701-12. 
TOBACMAN, L. S. 1996. Thin filament-mediated regulation of cardiac contraction. 
Annu Rev Physiol, 58, 447-81. 
TORRENT-GUASP, F., BUCKBERG, G. D., CLEMENTE, C., COX, J. L., 
COGHLAN, H. C. & GHARIB, M. 2001. The structure and function of the 
helical heart and its buttress wrapping. I. The normal macroscopic structure of 
the heart. Semin Thorac Cardiovasc Surg, 13, 301-19. 
VAN DER VELDEN, J., BOONTJE, N. M., PAPP, Z., KLEIN, L. J., VISSER, F. C., 
DE JONG, J. W., OWEN, V. J., BURTON, P. B. & STIENEN, G. J. 2002. 
340 
Calcium sensitivity of force in human ventricular cardiomyocytes from donor 
and failing hearts. Basic Res Cardiol, 97 Suppl 1, I118-26. 
VAN DER VELDEN, J., PAPP, Z., ZAREMBA, R., BOONTJE, N. M., DE JONG, J. 
W., OWEN, V. J., BURTON, P. B., GOLDMANN, P., JAQUET, K. & 
STIENEN, G. J. 2003. Increased Ca2+-sensitivity of the contractile apparatus 
in end-stage human heart failure results from altered phosphorylation of 
contractile proteins. Cardiovasc Res, 57, 37-47. 
VAN DIJK, S. J., DOOIJES, D., DOS REMEDIOS, C., MICHELS, M., LAMERS, J. 
M., WINEGRAD, S., SCHLOSSAREK, S., CARRIER, L., TEN CATE, F. J., 
STIENEN, G. J. & VAN DER VELDEN, J. 2009. Cardiac myosin-binding 
protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, 
deranged phosphorylation, and cardiomyocyte dysfunction. Circulation, 119, 
1473-83. 
VAN DIJK, S. J., DOOIJES, D., DOS REMEDIOS, C., STIENEN, G. J. M. & VAN 
DER VELDEN, J. 2011. Reduced Maximal Force and Increased Ca2+-
Sensitivity of Human Myofilaments Harbouring the HCM-Associated Cardiac 
Troponin T Mutation K273N. Biophysical Journal, 100, 361a-361a. 
VAN EERD, J. P. & TAKAHASHI, K. 1975. The amino acid sequence of bovine 
cardiac tamponin-C. Comparison with rabbit skeletal troponin-C. Biochem 
Biophys Res Commun, 64, 122-7. 
VANDEKERCKHOVE, J., BUGAISKY, G. & BUCKINGHAM, M. 1986. 
Simultaneous expression of skeletal muscle and heart actin proteins in various 
striated muscle tissues and cells. A quantitative determination of the two actin 
isoforms. J Biol Chem, 261, 1838-43. 
VANG, S., CORYDON, T. J., BORGLUM, A. D., SCOTT, M. D., FRYDMAN, J., 
MOGENSEN, J., GREGERSEN, N. & BROSS, P. 2005. Actin mutations in 
hypertrophic and dilated cardiomyopathy cause inefficient protein folding and 
perturbed filament formation. FEBS J, 272, 2037-49. 
VEMURI, R., LANKFORD, E. B., POETTER, K., HASSANZADEH, S., TAKEDA, 
K., YU, Z. X., FERRANS, V. J. & EPSTEIN, N. D. 1999. The stretch-
activation response may be critical to the proper functioning of the 
mammalian heart. Proc Natl Acad Sci U S A, 96, 1048-53. 
VIKHOREV, P., G,. SONG, W,. MARSTON, S,M,. FERENCZI, M,. 2011. Effect of 
mutations causing Hypertrophic Cardiomyopathy on cardiac myofibril 
contractility in man and mouse. Biophysical Society 55th Annual Meeting, 
March 5-9, 2011, Baltimore, Maryland, Addendum & Late Abstract Listings. 
VINOGRADOVA, M. V., STONE, D. B., MALANINA, G. G., KARATZAFERI, C., 
COOKE, R., MENDELSON, R. A. & FLETTERICK, R. J. 2005. Ca(2+)-
regulated structural changes in troponin. Proc Natl Acad Sci U S A, 102, 5038-
43. 
VOET, D. & VOET, J. G. 1995. Biochemistry, New York ; Chichester, J. Wiley & 
Sons. 
WALKER, J. S., LI, X. & BUTTRICK, P. M. 2010. Analysing force-pCa curves. J 
Muscle Res Cell Motil, 31, 59-69. 
WEEDS, A. G. & TAYLOR, R. S. 1975. Separation of subfragment-1 isoenzymes 
from rabbit skeletal muscle myosin. Nature, 257, 54-6. 
WIGLE, E. D., SASSON, Z., HENDERSON, M. A., RUDDY, T. D., FULOP, J., 
RAKOWSKI, H. & WILLIAMS, W. G. 1985. Hypertrophic cardiomyopathy. 
The importance of the site and the extent of hypertrophy. A review. Prog 
Cardiovasc Dis, 28, 1-83. 
341 
XIE, X., HARRISON, D. H., SCHLICHTING, I., SWEET, R. M., KALABOKIS, V. 
N., SZENT-GYORGYI, A. G. & COHEN, C. 1994. Structure of the 
regulatory domain of scallop myosin at 2.8 A resolution. Nature, 368, 306-12. 
XU, C., CRAIG, R., TOBACMAN, L., HOROWITZ, R. & LEHMAN, W. 1999. 
Tropomyosin positions in regulated thin filaments revealed by cryoelectron 
microscopy. Biophys J, 77, 985-92. 
YAMASHITA, H., TYSKA, M. J., WARSHAW, D. M., LOWEY, S. & TRYBUS, 
K. M. 2000. Functional consequences of mutations in the smooth muscle 
myosin heavy chain at sites implicated in familial hypertrophic 
cardiomyopathy. J Biol Chem, 275, 28045-52. 
 
 
Appendix I 
From Chapter 3.2: 
Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with donor and 
HOCM troponin. 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of troponin purified from donor (blue) and 
HOCM (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentrations of troponin used were 1) 30nM, II) 30nM, III) 20nM, IV) 
20nM 
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Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with donor and 
HOCM troponin. 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of troponin purified from donor (blue) and 
HOCM (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human cardiac 
tropomyosin and troponin. The concentrations of troponin used were V) 10nM, VI) 60nM, VII) 60nM, 
VIII) 60nM 
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From Chapter 3.3 
Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with HOCM and 
PKA-treated HOCM troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing troponin purified 
from HOCM (red) and PKA-treated HOCM troponin (green). Thin filaments were composed of 10nM 
rabbit skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentrations of troponin used 
were 1) 20nM, II) 20nM, III) 20nM, IV) 10nM 
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I II 
Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with HOCM and 
PKA-treated HOCM troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing troponin purified 
from HOCM (red) and PKA-treated HOCM troponin (green). Thin filaments were composed of 10nM 
rabbit skeletal actin, 60nM human cardiac tropomyosin and troponin. The concentrations of troponin used 
were V) 60nM, VI) 10nM, VII) 30nM, VIII) 30nM 
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From chapter 3.4 
Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with HOCM 
troponin or HOCM troponin exchanged with recombinant TnI 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing troponin purified 
from HOCM (red) and HOCM troponin exchanged with recombinant TnI (purple). Thin filaments were 
composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and troponin. The 
concentrations of troponin used were 1) 20nM, II) 60nM, III) XI 80nM, H100nM, IV) XI 80nM, H100nM 
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From chapter 3.5 
Ca2+-concentration titration comparing sliding speed of thin filaments reconstituted with HOCM 
troponin or HOCM troponin exchanged with recombinant TnT 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing troponin purified 
from HOCM (red) and HOCM troponin exchanged with recombinant TnT (black). Thin filaments were 
composed of 10nM rabbit skeletal actin, 60nM human cardiac tropomyosin and troponin. The 
concentrations of troponin used were 1) 20nM, II) 30nM, III) XT 60nM, H 50nM, IV) 100nM 
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From chapter 4.2 
Ca2+-concentration titration comparing sliding speed of thin filaments containing donor and HOCM 
F-actin in the presence of donor troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from HOCM and donor heart in the presence of donor troponin (NE). Thin filaments were composed of 
10nM actin NC (blue) or HOCM MD (red), 60nM human cardiac tropomyosin and troponin 1) 40nM, II) 
40nM, III) 20nM, IV)60nM 
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IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing tropomyosin 
purified from donor and failing heart. Thin filaments were composed of 10nM actin rabbit skeletal actin, 
60nM human cardiac (NE) donor (blue) or (FC) failing (crimson) tropomyosin and skeletal troponin I) 
60nM, II) 60nM, III) 80nM. 
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From chapter 4.2 
Ca2+-concentration titration comparing sliding speed 
of thin filaments containing donor or HOCM F-actin 
in the presence of donor troponin 
 
From chapter 4.3 
Ca2+-concentration titration comparing 
sliding speed of thin filaments containing 
donor and HOCM F-actin in the presence 
of donor troponin 
IVMA Ca2+-concentration titrations comparing sliding speed of thin 
filaments containing actin purified from HOCM and donor heart in 
the presence of donor troponin (NE). Thin filaments were composed 
of 10nM actin NC (blue) or HOCM MD (red), 60nM human cardiac 
tropomyosin and troponin V) 20nM 
 
From chapter 5.2 
Ca2+-concentration titration comparing sliding speed of thin filaments containing donor and E99K 
(1b) F-actin in the presence of donor troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from E99K and donor heart. Thin filaments were composed of 10nM actin N9 (blue) or E99K 1b (red), 
60nM human cardiac tropomyosin and troponin I-IV) 10nM. 
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Ca2+-concentration titration comparing sliding speed of thin filaments containing donor and E99K 
(2) F-actin in the presence of donor troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from E99K and donor heart in the presence of donor heart troponin (NE). Thin filaments were composed of 
10nM actin NE (blue) or E99K 2 (red), 60nM human cardiac tropomyosin and troponin I-IV) 10nM. 
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 IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from E99K and donor heart in the presence of donor heart troponin (NE). Thin filaments were composed of 
10nM actin NE (blue) or E99K 2 (red), 60nM human cardiac tropomyosin and troponin V) 20nM. 
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From chapter 5.3 
Ca2+-concentration titration comparing sliding speed of thin filaments containing donor and E99K 
(1b) F-actin in the presence of donor troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from E99K and donor heart in the presence of failing heart troponin (FH). Thin filaments were composed 
of 10nM actin N9 (blue) or E99K 1b (red), 60nM human cardiac tropomyosin and troponin I-III) 10nM. 
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From chapter 5.4 
Ca2+-concentration titration comparing sliding speed of thin filaments containing E99K (2) F-actin 
and with donor or failing heart troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing actin purified 
from E99K and troponin from either donor or failing heart. Thin filaments were composed of 10nM E99K 
2 F-actin, 60nM human cardiac tropomyosin and either donor heart (NE) troponin (red) or failing heart 
(FH) troponin (crimson) 30nM. 
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From chapter 6.2 
Ca2+-concentration titration comparing sliding speed of thin filaments with either donor or HCM 
TnT troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of troponin purified from donor (blue) and 
HOCM TnT K280N (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human 
cardiac tropomyosin and troponin. The concentrations of troponin used were I-IV) 30nM 
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III IV 
Ca2+-concentration titration comparing sliding speed of thin filaments with either donor or HCM 
TnT troponin 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of troponin purified from donor (blue) and 
HOCM TnT K280N (red) heart. Thin filaments were composed of 10nM rabbit skeletal actin, 60nM human 
cardiac tropomyosin and troponin. The concentrations of troponin used were V) 60nM, VI) 30nM, VII-
VIII) 60nM. 
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From chapter 6.3 
Ca2+-concentration titration comparing sliding speed of thin filaments with either unexchanged 
donor troponin or donor troponin exchanged with recombinant TnT K273N 
 
 
 
IVMA Ca2+-concentration titrations comparing sliding speed of thin filaments containing troponin purified 
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Appendix II 
Molecular Mechanism of the E99KMutation in Cardiac Actin
(ACTC Gene) That Causes Apical Hypertrophy in Man and
Mouse*□S
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Wegenerated a transgenicmousemodel expressing the apical
hypertrophic cardiomyopathy-causingmutationACTC E99K at
50%of total heart actin and compared itwith actin frompatients
carrying the samemutation. The actinmutation caused a higher
Ca2 sensitivity in reconstituted thin filaments measured by in
vitromotility assay (2.3-fold for mice and 1.3-fold for humans)
and in skinned papillary muscle. The mutation also abolished
the change in Ca2 sensitivity normally linked to troponin I
phosphorylation. MyBP-C and troponin I phosphorylation lev-
els were the same as controls in transgenic mice and human
carrier heart samples. ACTC E99K mice exhibited a high death
rate between 28 and 45 days (48% females and 22%males). At 21
weeks, the hearts of the male survivors had enlarged atria,
increased interstitial fibrosis, and sarcomere disarray. MRI
showed hypertrophy, predominantly at the apex of the heart.
End-diastolic volume and end-diastolic pressure were in-
creased, and relaxation rates were reduced compared with non-
transgenic littermates. End-systolic pressures and volumeswere
unaltered. ECG abnormalities were present, and the contractile
response to -adrenergic stimulation was much reduced. Older
mice (29-week-old females and 38-week-old males) developed
dilated cardiomyopathywith increased end-systolic volume and
continuing increased end-diastolic pressure and slower con-
traction and relaxation rates. ECG showed atrial flutter and fre-
quent atrial ectopic beats at rest in some ACTC E99K mice. We
propose that theACTC E99Kmutation causes highermyofibril-
lar Ca2 sensitivity that is responsible for the sudden cardiac
death, apical hypertrophy, and subsequent development of
heart failure in humans and mice.
Hypertrophic cardiomyopathy (HCM)2 is the most com-
monly inherited cardiomyopathy with an estimated incidence
of 1 in 500 of the population (1, 2). More than 600 mutations
have been discovered to be associated with HCMwith all but a
few in the genes coding for the contractile apparatus of the
myofibril, predominantlymyosin-binding protein C and-my-
osin heavy chain (3–6). Eleven mutations have been identified
in the cardiac actin gene, ACTC (7–11), including the E99K
mutation that has been intensively investigated as it has been
shown to co-segregate with an unusual apical hypertrophic
phenotype (12, 13). HCM is defined clinically as the presence of
unexplained ventricular hypertrophy; usually the thickening is
most prominent in the interventricular septum, but other
pathologies can also occur, such as apical and concentric hyper-
trophy or left ventricular noncompaction. Electrocardiogram
abnormalities are also common, including abnormal repolar-
ization or Q-waves (for normal HCM). Histologically, HCM is
characterized by myocyte disarray and interstitial fibrosis. The
hypertrophy leads to decreased left ventricular volume andmay
cause outflow tract obstruction, which along with impaired
relaxation can lead to heart failure.
HCM is also associated with sudden cardiac death due to
arrhythmias especially in young active adults. The overall risk of
fatal complications of HCM is 1–2% per year (2, 14). Although
hypertrophy and sudden cardiac death are both caused by
HCMmutations, the connection between them is unclear. The
mutant protein in HCM is expressed from birth but is compen-
sated for in almost all cases until adolescence, and sometimes
symptoms never develop. This variable penetrance indicates
that genetic background is significant to the outcome of HCM
mutations.
We and others have expendedmuch effort to determine how
HCMmutations alter myofibrillar function to induce the phe-* This work was funded by grants from the British Heart Foundation, a gen-
erous donation fromTheDr. E. G. J. OlsenCharitable Fund, the BritishHeart
Foundation Centre of Research Excellence, and the 7th Framework Pro-
gram of the European Union Grant 241577 (“BIG-HEART”).
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Supplemental Material can be found at:
notype. It has been widely supposed that mutant protein would
be expressed in the heart at up to 50% of total protein and that
it exerts its pathological effects by acting as a poison peptide
that alters normal function. Direct measurements in human
heart tissue have confirmed the poison peptide hypothesis in a
few cases (15–17). The challenge is to explain how over 600
different mutations can cause the same phenotype. In vitro
studies, either using recombinant proteins or proteins from
transgenic mouse models, have shown that HCM mutations
can cause a higher Ca2 sensitivity of the contractile apparatus,
a faster cross-bridge turnover rate, and incomplete relaxation at
109 M Ca2 (18–21). Thus HCMmutations seem to involve a
“gain of function” that would lead to a hypercontractile cardiac
phenotype, as is indeed seen in many younger HCM patients.
A problemwithmost of these in vitro studies is that when the
mutant protein is obtained from bacterial or baculovirus
expression systems it will not have native post-translational
modifications, especially phosphorylation. Moreover, mea-
surements are usually made in heterologous systems with the
mutation introduced into mouse or human isoforms of a pro-
tein and then tested in a system containing partner proteins
from a different species. Recent studies have shown that spe-
cies, isoform, and post-translational modification context can
have a significant influence on the functional effect of a muta-
tion (16, 22, 23).
This study reports our observations on a transgenic mouse
model of HCM due to the E99K mutation in cardiac actin that
avoids most of the problems with interpretation of data as
described above (the mutation is in codon 101 of the ACTC
gene, but two N-terminal amino acids are removed by post-
translational processing to form the mature protein (24)).
Uniquely among the contractile proteins, both skeletal and car-
diac actin have identical amino acid sequences in humans and
mice and an identical isoform distribution in heart (25%
ACTA1 and 75% ACTC) (25, 26). In vivo there are no post-
translational modifications of actin that regulate activity. We
have expressed the ACTC mutant without any adducts that
could alter function at a level similar to the level expressed in
patients with this mutation. A further advantage of the ACTC
mutation is that transgenic expression of actin in the heart has
been extensively studied, and it has been demonstrated that
overexpression of actin in the heart does not lead to any alter-
ation in the stoichiometry or structure of the myofibrils or any
accumulation of actin in the cytoplasm (27). In functional stud-
ies, we have reconstituted thin filaments with mutant actin and
tropomyosin and troponin fromhumanheartmuscle so thatwe
can reproduce exactly the human mutant thin filament.
The ACTC E99K mutation is the subject of an extensive
ongoing clinical study with 76 mutation carriers in 10 families
currently identified (13). This mutation is associated with a
unique form of hypertrophy where the apex of the heart is
thickened, with a phenotype overlapping both HCM and
left ventricular hypertrabeculation/noncompaction. We have
therefore been able to compare the phenotype of our transgenic
mice with the patient population. In addition, we have obtained
patient biopsies, enabling us to perform the first direct compar-
ison of the functional properties of an HCM-causing mutation
in hearts from humans and mice at the molecular level.
Here, we show that the ACTC E99K mutant mice have a
distinctive phenotype with increased myofilament Ca2 sensi-
tivity and a blunting of the response to PKA phosphorylation of
troponin I at the single filament level. The mice develop apical
hypertrophy progressing to dilated cardiomyopathy, and a high
proportion die suddenly at 4–6 weeks old. Many of these char-
acteristics reproduce the phenotype of patients with this
mutation.
MATERIALS ANDMETHODS
The generation of transgenic mice, using the -MyHC pro-
moter, and their phenotypic characterization by echocardiog-
raphy, electrocardiography, magnetic resonance imaging, and
conductance catheter is described in the supplemental mate-
rial. Force was measured in mouse papillary muscle strips as
described by Song et al. (28) (see supplemental material). All
procedures were performed in accordance with the United
Kingdom Animals (Scientific Procedures) Act of 1986.
Polymeric actin was isolated from nontransgenic and ACTC
E99K mice and from donor human hearts and E99K patient
biopsies as described by Song et al. (28). Thin filaments were
reconstitutedwith actin, native human troponin, and tropomy-
osin. Human cardiac troponin was prepared from donor heart
myofibrils using an anti-TnI antibody affinity column as
described by Messer et al. (29). Phosphorylation of troponin I
and troponin T was measured by staining SDS-polyacrylamide
gels of troponin or myofibrils with the Pro-Q Diamond phos-
phoprotein-specific stain followed by Coomassie Blue total
protein stain as described previously (29) or by phosphate affin-
ity SDS-PAGE as described byMesser et al. (30). Troponin was
dephosphorylated by treatment with acid phosphatase (Sigma)
as described previously (29). Human cardiac tropomyosin was
isolated as described by Knott et al. (31).
The in vitro motility assay technique was used to study
TRITC-phalloidin-labeled actin (actin-) filaments moving
over immobilized rabbit fast muscle heavy meromyosin (100
g/ml) on a dichlorodimethylsilane-coated surface (32, 33).
Thin filament movement was observed at 28 °C in 50 mM KCl,
25 mM imidazole HCl, pH 7.4, 4 mMMgCl2, 1 mM EDTA, 5 mM
DTT, 0.5 mg/ml BSA, 0.1 mg/ml glucose oxidase, 0.02 mg/ml
catalase, 3 mg/ml glucose, 0.5% methylcellulose, 5 mM
Ca/EGTA buffer (range 1 nM to 3.7 M Ca2), 1 mM MgATP,
and troponin at the appropriate concentrations. Filament
movement was recorded and analyzed as described previously
(34). For complete details see the supplemental material.
Heart muscle biopsies were obtained from the hearts of two
heterozygous carriers of the ACTC E99Kmutation undergoing
surgery related to the disease-causing mutation. Sample 1 was
fromaheart transplant for end-stage heart failure, and sample 2
was from a patient undergoing surgery for atrial septal defect
(supplemental data A). Donor heart tissue was obtained from
hearts where no suitable transplant recipient was found. These
patients had no history of cardiac disease and normal electro-
cardiography (ECG) and ventricular function. Ethical approval
was obtained from Comite´ E´tico de Investigatio´n Clínica de
Galicia and St. Vincent’s Hospital, Sydney, Australia. This
investigation conforms to the principles of the Declaration of
Helsinki.
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RESULTS
Generation and Characterization of the E99K Mice—Two
mouse lines tested positive for the ACTC E99K mutation. The
level of expression, assessed by two-dimensional electrophore-
sis, was 11–50%. One line that consistently expressed 50 5%
E99K actin was investigated further (Fig. 1). Themice appeared
healthy when born; litter size (8  2) and male to female ratio
(53:47) were normal. Transgenic/nontransgenic mouse ratios
were 106:182 at birth. The E99K transgenic mice exhibited a
high death rate over a short period between 28 and 45 days; 48%
of all the females died in this period and 22% of the males (Fig.
1). After this period, the survivors showed a low level of spo-
radic mortality that is more prominent in females than males
and is higher than the nontransgenic (NTG) littermates.
The 21-week-old male ACTC E99K hearts had enlarged left
and right atria, especially the left atrium (Fig. 2). Myocyte dis-
array and interstitial fibrosiswas apparent in ventricularmuscle
(Fig. 2). At 29 and 38 weeks, ACTC E99Kmice started showing
body weight loss, and the hearts were enlarged compared with
their littermates with a significantly increased heart/body
weight ratio (supplemental data G). Three of 5 female ACTC
E99Kmice and 2 of 5maleACTC E99Kmice had severe hydro-
thorax with enlarged and dark-colored left atria with scar tis-
sue. Under magnetic resonance imaging (MRI), some of the
mice showed that the hearts were in themiddle or the right side
of their chests (supplemental data B).
Molecular Phenotype of E99K Actin from Transgenic Mice—
Protein and phosphoproteins inmyofibrils from nontransgenic
and ACTC E99K mouse hearts were analyzed by SDS-PAGE at
5, 21, 29, and 38 weeks. The protein content of the myofibrils
was identical with no evidence for the loss of actin or actin-
binding proteins in theACTC E99Kmousemyofibrils (Fig. 3A).
Staining the gels with Pro-Q Diamond showed that myosin-
binding protein C (MyBP-C), troponin T (TnT), troponin I
(TnI), andmyosin light chain 2 (MLC-2) were the predominant
phosphoproteins and that the phosphorylation levels in ACTC
E99Kheartswere not significantly different fromNTGbetween
5 and 29 weeks (Fig. 3B).
The phosphorylation of troponin I in myofibrils was investi-
gated in more detail using the phosphate affinity SDS-PAGE
technique (Fig. 3C). In 21-week-oldmice, troponin I phosphor-
ylation was identical in NTG and ACTC E99K; troponin I was
predominantly mono (1P)- and bisphosphorylated (2P) (NTG,
36 2% 2P, 47 2% 1P;ACTC E99K, 37 1% 2P; 42 2% 1P),
and calculated total phosphorylation was 1.18  0.03 mol of
phosphate/mol of TnI in NTG and 1.17 0.02 in ACTC E99K
myofibrils (p 0.772, unpaired t test). At 38 weeks, wheremice
showed symptoms of heart failure, troponin I phosphorylation
was significantly reduced compared with NTG (total TnI phos-
phorylation of ACTC E99K/NTG 0.64, p 0.001).
We made functional measurements on thin filaments incor-
porating actin from NTG or ACTC E99K mice using the quan-
titative in vitromotility assay. We isolated polymeric actin fila-
ments directly from NTG and ACTC E99K mouse hearts by
isolating thin filaments and then stripping off regulatory pro-
teins; in our previous studies, monomeric mouse cardiac actin,
isolated by the conventional acetone powder method, did not
yield mutant-containing thin filaments (28).
E99K actin filament sliding speed on immobilized rabbit fast
skeletal muscle heavy meromyosin was 8% slower than wild-
type actin (WT 2.84 0.11 m/s and ACTC E99K 2.61
0.10m/s, n 14, p 0.004 paired t test). In the presence of 40
mM tropomyosin, sliding speed increased by 10% for E99K actin
(to 2.84  0.18 m/s) and 6.5% for wild-type actin (to 2.95 
FIGURE 1. A, location of the E99K mutation in the actin filament. Model of a 5-actin monomer segment of the actin filament (Actin_Model.pdb (60)). Surface
renderingusingPyMol. Glutamic acid 99 (arrows) is shown in red at the surfaceon the edgeof subdomain 1.B, two-dimensional electrophoresis demonstrating
the expression ofmutant actin inmyofibrils from transgenicmouse heart and patient heart samples 1 (S1) and 2 (S2). C, Kaplan-Meir plot showingmortality in
male and female ACTC E99K mice.
ACTC E99KMouseModel of Apical Hypertrophic Cardiomyopathy
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0.14 m/s, so that the difference between the two actins
became insignificant (n  10, p  0.34, paired t test; see sup-
plemental data H).
Thin filaments were reconstituted with mouse actin, human
cardiac tropomyosin, and human donor heart troponin. The
fraction of motile filaments, measured with both NTG and
E99Kactin,was fullyCa2-regulated, but sliding speed changed
by less than 40% between relaxing and activating Ca2 concen-
trations. This pattern of results is typical of thin filaments in our
IVMA system that uses a trimethysilane-coated surface (28, 32,
35). The motility of NTG and E99K actin-containing thin fila-
ments was indistinguishable at both activating and relaxing
Ca2 concentrations (supplemental data H). When the Ca2
concentration dependence of thin filament motility was
assayed, the E99K actin thin filaments had a consistently higher
Ca2 sensitivity (EC50 wild-type/EC50 E99K actin 2.3 0.6,
p 0.02, see Fig. 4 and supplemental data I).
We also measured Ca2 regulation of isometric force in
skinnedmouse heart papillarymuscles. In this system, theCa2
sensitivity ofACTC E99Kmouse heart muscle was again signif-
icantly higher thanNTGheartmuscle (EC50NTGmuscle/EC50
ACTC E99K muscle  1.30  0.03, p  0.003, see Fig. 4). The
difference was less than in the isolated thin filaments, as has
been frequently observed with HCM-causing mutations (36).
The maximum force in skinned papillary muscles tended to be
lower in the ACTC E99K samples (NTG 27  6 kilonewtons/
m2, ACTC E99K 20 9 kilonewtons/m2, p 0.124).
We used IVMA to determine the effect of a change of tro-
ponin I phosphorylation on Ca2 sensitivity by treating donor
heart troponin (1.6 mol of phosphate/mol) with phosphatases
to reduce TnI phosphorylation levels to less than 0.2 mol of
phosphate/mol (Fig. 4D and supplemental data I). Thin fila-
ments reconstituted with wild-type actin and dephosphory-
lated troponin showed a 2.9 0.3-fold higher Ca2 sensitivity
compared with native phosphorylated troponin (actin from
five hearts assayed, p  0.03, paired t test), but this charac-
teristic response to dephosphorylation of troponin I of Ser-
23/24 (PKA sites) was not observed with E99K actin. The
Ca2 sensitivity of E99K actin-containing thin filaments
with dephosphorylated troponin was not significantly higher
thanwith natively phosphorylated troponin (EC50 phosphor-
ylated E99K Tn/EC50 dephosphorylated E99K Tn  1.14 
0.06, actin from four hearts assayed, p  0.16, paired t test,
see Fig. 4). Thus, the E99K actin mutation increases Ca2
sensitivity of thin filaments and blunts the response to
changes in troponin I phosphorylation.
Cardiac Contractility in 21-Week-old Male ACTC E99K
Survivors—We investigated the effect of the E99K mutation in
cardiac actin on the contraction of mouse hearts in situ. MRI,
echocardiography, ECG, and conductance catheter studies
were performed onmale 21-week-oldmice (Fig. 5, Table 1, and
supplemental data C–E). Compared with NTG littermates,
21-week-old ACTC E99K mouse hearts had significant hyper-
trophy in the apical region of the left ventricular posterior wall
and interventricular septum, with no differences at the base.
Wall thickening during contraction was significantly reduced
in the apical region in both the septum and left ventricular
posterior wall of ACTC E99K heart compared with NTG but
was unaltered at the base. End-diastolic volume (EDV), stroke
volume (SV), ejection fraction (EF), and cardiac output (CO)
were lower in ACTC E99K mice (EDV, 52.71  3.40 versus
66.04 3.89,p 0.01; SV, 26.69 2.65 versus 40.67 2.83,p
0.01; EF, 50.27 2.27 versus 62.19 3.54, p 0.01; CO, 9.06
0.76 versus 17.22  1.06, p  0.001). ACTC E99K mice had
higher end-diastolic pressure (5.693  1.412 versus 1.364 
0.610, p  0.05) than NTG littermates, although end-systolic
pressure (73.89  4.35 versus 75.42  3.43, p  0.05) was the
same. End-systolic elastance (6.284  1.231 versus 12.08 
FIGURE 2. Morphology of 21-week-old male mouse hearts. A, isolated
hearts: the ACTC E99K mouse heart shows enlarged atria but normal ventri-
cles. B, fibrosis in mouse heart visualized in Sirius red-stained sections. The
E99K mice show more interstitial fibrosis and less well ordered myocytes.
C, confocal microscopy of mouse papillary muscle. Both samples were
stretched to a sarcomere length of 2.1 m; actin was labeled with TRITC-
phalloidin.D,electronmicroscopyof apical regionof amouseheart. TheACTC
E99K mouse showed significant myocyte disarray.
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1.307, p  0.05) was reduced, and end-diastolic pressure vol-
ume relationship (0.714 0.116 versus 0.217 0.047, p 0.01)
and Tau_g (17.72 1.21 versus 9.518 1.023, p 0.001) were
increased. Taken together, these data suggest apical hypertro-
phy with left ventricular diastolic dysfunction in 21-week-old
male ACTC E99K mouse heart.
Echocardiography of 21-week-old male ACTC E99K mice
revealed a blunted response to-adrenergic stimulation, with a
less pronounced increase in heart rate, wall thickening, and
fractional shortening compared with NTG mice (Fig. 5). No
significant arrhythmia was recorded in 21-week-old male
ACTC E99K mice (n 6) using lead II ECG; however, T-wave
flattening occurred in the majority of ACTC E99K mice, mak-
ing measurements of QT intervals impossible (Fig. 6). Deep
S-wave (1 mouse) and double S-waves (1 mouse) were
recorded, indicating intraventricular conduction abnormalities
in some ACTC E99K mice.
Changes in Cardiac Contractility with Age—ACTC E99K
micewere further comparedwithNTGmice at 29 and 38weeks
old using MRI, echocardiography, and conductance catheter.
Table 2 summarizes the changes in cardiac parameters in
ACTC E99K mice expressed relative to the NTG littermates.
Where a single parameter was measured by several techniques
(for example EDV) the percentage change in the parameters
were essentially the same, although the absolute magnitude
could be different for technical reasons (for instance MRI
FIGURE 3. SDS-PAGE analysis of myofibrillar proteins and phosphoproteins. A, myofibril fraction of heart muscle separated by SDS-PAGE and stained
successively with Pro-QDiamond phosphoprotein stain and SYPRO Ruby total protein stain. Left,NTG and ACTC E99Kmouse heartmyofibrils (38weeksmale).
Right,donor andACTC E99K heart sample 2myofibrils. B, relative phosphorylation levels forMyBP-C, troponin T, troponin I, andMLC-2 for human sample 2 and
ACTC E99Kmice at 5 and 29weeks as determined fromPro-QDiamond-stained SDS-PAGE as inA. Means S.E. of 4–6measurements are shown.C,phosphate
affinity SDS-PAGE analysis of troponin I phospho-species. Left, comparison of troponin I phosphorylation in 21-week-old female ACTC E99K and NTG mouse
myofibrils. Right, comparison of troponin I phosphorylation inmyofibrils from ACTC E99K sample 2, donor heart, and a typical interventricular septum sample
from a patient with hypertrophic obstructive cardiomyopathy (HOCM).
ACTC E99KMouseModel of Apical Hypertrophic Cardiomyopathy
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always records a much higher volume than Millar catheter
(37)).
We found a different time course of development of cardiac
contractile dysfunction in male and female ACTC E99K mice
(Table 2 and supplemental data B and E–G). 29-Week-oldmale
ACTC E99K had a similar phenotype to 21-week-old mice with
increased wall thickness and reduced EDV, SV, EF, and CO
compared with controls. At 38 weeks, the male ACTC E99K
mice also had increased end-systolic volume and Tau_g, and
reduced dV/dtmin and dV/dtmax compared with NTG mice
indicating both impaired myocardial contraction and relax-
ation. At this stage, the male mouse heart was progressing
toward dilated cardiomyopathy.
At 29 weeks old, the female ACTC E99K mice retained the
reducedEDV,SV,EF, andCObutadditionally showedevidenceof
progression toward dilated cardiomyopathy, with increased end-
systolic volume and Tau_g and reduced dV/dtmin relative to
NTG. 38-Week-old female ACTC E99K mice had further
increased EDV and end-systolic volume and lower EF, sug-
gesting left ventricular remodeling and progression to
dilated cardiomyopathy with diastolic dysfunction, impaired
contraction, and relaxation.
At 29 weeks old, ECG recordings showed frequent episodes
of atrial ectopic fibrillation in 7/8 male and 2/5 female ACTC
E99K mice. Atrial flutter at steady status was present in 2/8
male and 1/5 female ACTC E99Kmice. The T-wave was iden-
FIGURE 4. Ca2 activation curves comparing ACTC E99K (red squares) with wild-type actin (blue triangles). Standard error of 4–6 measurements is
plotted. Solid line is best fit to the Hill equation; calculated parameters are shown in the table below. A, thin filaments reconstituted with ACTC E99K or NTG
mouse actin, donor heart tropomyosin (Tm) and troponin (Tn), measured by in vitro motility assay. B, isometric force from ACTC E99K or NTG mouse heart
papillary muscle strips. C, thin filaments reconstituted from actin from human ACTC E99K sample 2 or donor with donor heart tropomyosin and troponin,
measured by in vitromotility assay.D, thin filaments reconstitutedwithACTC E99Kmouse actin, donor heart tropomyosin, and natively phosphorylated donor
(filled squares, solid line) or dephosphorylated donor troponin (open squares, dotted line), measured by in vitro motility assay. Inset, Pro-Q Diamond-stained
SDS-PAGE showingphosphorylated TnI and TnT in donor heart and absence of phosphorylation in the dephosphorylated donor troponin. The table shows the
mean values of EC50; data from individual experiments are given in supplemental data I and J.
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tifiable in most ACTC E99K mice, but QTc was not different
from controls (Fig. 6 and supplemental data H).
Echocardiography of -agonist-stimulated 29-week-old
female and 38-week-oldmalemice revealed a blunted response
to -adrenergic stimulation, with less pronounced increases in
heart rate, wall thickening, and fractional shortening compared
with NTG mice. Upon -agonist infusion, QTc increased in
NTG mice but was unaltered in ACTC E99K mice.
Effects of the ACTCE99KMutation in the Patient Population—
In addition to our measurements on transgenic mice, we also
studied heartmuscle samples from two patients with theACTC
E99K mutation. Patient 1 had a heart transplant, and patient 2
had repairs for an atrial septal defect (supplemental data A).
The level of expression, based on two-dimensional electropho-
resis (Fig. 1) was 39% in sample 1 and 18% in sample 2. Sample
1 was similar but showed signs of protein degradation and was
FIGURE 5. A, MRI imaging. The pictures show short axis sections at the base of the heart and 4-chamber views in diastole. Arrow shows thickened wall, and
arrowhead showsenlarged left atrium.Graphs showwall thickness at thebase andapexof thehearts (see supplemental dataBandC).B,pressure-volume loops
from 21-week-old male mice at base line and with inferior vena cava transient occlusion. Graphs compare calculated end-systolic (ESV) and diastolic (EDV)
volumes, end-systolic (ESP) and diastolic (EDP) pressures, end-systolic elastance (Ees), and Tau_g for ACTC E99Kmice and NTG littermates. Details are given in
supplemental data D. C, M-mode echocardiography traces from 21-week-old male ACTC E99K mice and NTG littermates at base line and after dobutamine
infusion. The graph shows the calculated percentage change in contractile parameters because of dobutamine for ACTC E99Kmice (red) and NTG littermates
(light blue) (see supplemental data E). LV, left ventricular; IVS, interventricular septum.
TABLE 1
The effect of age and gender on cardiac morphology and contraction parameters
Ratio of mean valueACTC E99K/NTG is shown, and the statistical significance of the difference is indicated (*, p0.05; **, p0.01; and ***, p0.001). Parameters
weremeasured byMRI (boldface type), echocardiography (italic type), and conductance catheter. Not all parameters weremeasured for every age and gender. The following
abbreviations are used: ED, end-diastolic; ESV, end-systolic volume; EDP, end-diastolic pressure; ESP, end-systolic pressure; P, phosphorylated; dP, dephosphorylated.
Cardiac parameter
Male Female
21 weeks 29 weeks 38 weeks 29 weeks 38 weeks
% % % % %
Apical septum thickness ED 41*** 35** 43* 81*
Apical wall thickness ED (LVPW) 46* 48*** 30* 40*
EDV 20** 30*** 8 11 49**
21*
ESV 3 13 62* 53*** 159***
1
SV 34** 38*** 20 44* 22
33*
EF 19** 13** 26* 36** 48**
CO 47*** 42*** 40** 50* 12
EDP 317** 82** 9 48*
ESP 2 6 5 1.55
dV/dtmin 34 35* 34 24
dV/dtmax 26 37* 26 21
dP/dtmin 35* 35 106*** 32*
dP/dtmax 5 5 24 7
Tau_g 86*** 132* 191* 99*
FIGURE 6.Waterfall plots of ECG recordings. At least 250 heart cycles are stacked in the z axis. 1st row, from left to right: ECG from normal 21-week-old male
mice; deep S-wave recordedon21-week-oldmale TGmice (double the averagenormal S amplitude); double S-waves recordedon21-week-oldmalemice; 2nd
row, from left to right: negative T-wave recorded on 21-week-old male TG mice; negative T-wave recorded on 29-week-old female TG mice; atrial flutter
recorded on 38-week-old male TG mice; 3rd row, atrial ectopic beats recorded on 29-week-old female TG mice.
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not studied further. Measurements of myofibrillar protein
phosphorylation in sample 2 were not significantly different
from donor heart tissue (Fig. 5) and were also similar to trans-
genic mice (Table 2).
Functional analysis of pure actin by in vitro motility assay
showed a 6% reduced sliding speed (p  0.002) in the ACTC
E99K human heart sample 2 compared with donor heart actin,
similar to that observed with the ACTC E99K transgenic mice
(Table 2 and supplemental data J). TomeasureCa2 regulation,
actin isolated from sample 2 or donor control muscle was
reconstituted with donor heart tropomyosin and troponin. The
maximum sliding speed of thin filaments with E99K actin was
the same as thin filaments with donor heart actin at both 3.5
and 0.001 M Ca2. Ca2 sensitivity of thin filaments contain-
ing E99K actin was 32% greater than thin filaments with donor
actin, which is a smaller increase than observed with themouse
actin samples (50% mutant) using the same troponin and tro-
pomyosin. We also observed that Ca2 sensitivity of ACTC
E99K-containing thin filaments was the samewith native phos-
phorylated and dephosphorylated troponin, as was also found
with the mouse ACTC E99K actin (Fig. 6 and Table 2). The
Ca2 sensitivity of E99K-containing thin filaments was 19%
greater than donor heart when the troponin was fully dephos-
phorylated, compared with 18% greater for the mouse E99K
thin filaments compared with NTG. Thus, the E99K mutation
in human sample 2 increased Ca2 sensitivity and uncoupled
Ca2 sensitivity from troponin I phosphorylation in the same
way as E99K actin from transgenic mice.
DISCUSSION
ACTC E99K Mouse Model of HCM—We developed the
ACTCE99Kmouse as amodel of hypertrophic cardiomyopathy
designed to recapitulate the disease found in patients. Cardiac
actin is the only contractile protein that has an identical amino
acid sequence in humans and mice as well as an identical iso-
form distribution (80% cardiac actin, ACTC and 20% skeletal
actin). This is an important property because we have found
that the effect ofHCMandDCMmutations on function in vitro
can vary significantly depending on species, isoform, and post-
translational modifications (16, 22, 28). Actin transgenes with
the MHC promoter lead to substitution of actin rather than
overexpression (27), and we observed that myofibrillar protein
content is normal (Fig. 3), and there is no unincorporated actin
in the cytoplasm. Glutamic acid 99 is located on the surface of
the actin monomer on the outside edge of subdomain 1 and is
believed to be involved in the initial nonstereo-specific binding
of myosinADPPi to actin during the cross-bridge cycle, conse-
quently the charge-reversal glutamic acid to lysine mutation at
this location is expected to produce a phenotype.
Although mutations in ACTC are not a common cause of
HCM, the clinical consequences of the ACTC E99K mutation
have been studied in a large population (13). Hypertrophy was
reported from 62 of 76 mutation carriers. The distribution of
the hypertrophy was predominantly apical. ECG investigation
showed abnormalities in 53 of 61 carriers. Atrial fibrillation or
flutter was found in 7/53. The 22 adverse events reported
included eight sudden deaths (five of which were in a single
family). We have been able to study two patient biopsies and
make a direct comparison of the molecular phenotype in the
patients and the mouse model.
At the single filament level and in skinned papillary muscle,
50% E99K/wild-type actin caused an increase in Ca2 sensitiv-
ity of contractile activation. The ACTC E99K mice exhibited a
remarkable tendency to sudden death at 4–6 weeks old. At 21
weeks, the mice showed hypertrophy, diastolic dysfunction,
and fibrosis; at 29–38 weeks, the mice additionally showed evi-
dence of arrhythmia, dilation, and progression to heart failure.
Thus, this model reproduces many of the features of hyper-
trophic cardiomyopathy as found in patients.
Molecular Phenotype of HCM Caused by ACTC E99K
Mutation—A higher Ca2 sensitivity of regulation of the con-
tractile apparatus is usually associated with the HCM pheno-
type (21, 36, 38). This is due to an increased affinity of thin
filaments for Ca2 (23, 39), associated with a faster rate of
Ca2-binding to troponin C (40). Higher Ca2 sensitivity was
observed in the ACTC E99K mouse and in the patient biopsy
samples. The 2.3-fold higher Ca2 sensitivity in mouse E99K
actin-containing thin filaments may be compared with values
of 2.0–2.1-fold with troponin Tmutations, measured by IVMA
and around 1.5-fold for troponin I mutations measured by
ATPase assay (21, 22, 38, 41). The 1.3-fold higher Ca2 sensi-
tivity of isometric force in ACTC E99K papillary muscle com-
pares with a mean 1.23-fold higher Ca2 sensitivity observed
with a series of seven different HCMmutations in TnI and TnT
(21, 36, 42, 43). The increase in Ca2 sensitivity was less with
the human heart E99K actin (1.3-fold), which may reflect the
lower mutant actin content compared with the mouse E99K
actin (Fig. 1).
The higher Ca2 sensitivity in IVMA was a direct result of
the mutation because it was observed by comparing thin
filaments reconstituted with mutant actin or wild type with
the same human heart troponin and tropomyosin. Because
the level of MyBP-C and troponin I phosphorylation, which
TABLE 2
Comparison of molecular phenotype of the ACTC E99Kmutation in mouse andman
Statistical significance of the difference in ratio relative to 1 is indicated (*, p0.05; ***, p0.001). P, phosphorylated; dP, dephosphorylated.
Expression of mutation
(two-dimensional
electrophoresis)
Troponin I phosphorylation,
2P-1P-0 ratios and mol of
phosphate/mol
Sliding speed,
E99K actin/control
actin
Ca2 sensitivity,
native troponin,
EC50 E99K actin/EC50 control actin
Ca2 sensitivity, E99K
actin, EC50 P troponin/EC50
dP troponin
Mouse 49.5 4.5% 38:42:21 0.92 0.02*** 0.39 0.09* 1.14 0.06
1.17 mol of phosphate/mol p 0.004, n 14 p 0.03, n 5 p 0.16, n 4
Human 39% sample 1 57:30:13 0.94 0.03*** 0.76 0.05* 0.92 0.21
18% sample 2 1.44 mol of phosphate/mol p 0.002, n 10 p 0.05 n 4 n 3
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could also change Ca2 sensitivity, was the same in ACTC
E99K andNTGmousemuscle, the increased Ca2 sensitivity
in skinned papillary muscle must also be a primary effect of
the mutation.
A recent IVMA study using baculovirus-expressed E99K
actin in combination with bovine cardiac tropomyosin and tro-
ponin did not find any shift in Ca2 sensitivity but did observe
a reduced sliding speed; however, these discrepancies may be
due to using non-human proteins for all three components of
the thin filaments (44). This study also revealed reduced thin
filament cooperativity; this may influence Ca2 sensitivity
under some conditions, although our previous analysis of tro-
pomyosin DCM mutations found no connection between
cooperativity and phenotype (23). Studies on the kinetics of
baculovirus-expressed E99K actin-activated myosin S-1-
ATPase show that the Km is 4-fold greater than wild type, indi-
cating a weakening of the weak binding interaction between
actin and myosinADPPi (45). This was interpreted as leading
to lower force production, but we found the maximum devel-
oped pressure in ACTC E99K hearts was not different from
nontransgenic mice.
In addition, we have demonstrated that the Ca2 sensitivity
of E99K actin-containing thin filaments was uncoupled from
the PKA-dependent phosphorylation of troponin I. Uncou-
pling has been reported with other HCM- or DCM-causing
mutations in thin filament proteins (16, 28, 46), and in DCM it
seems to be the only consistent effect of disease-causing muta-
tions (21). In contrast, HCM mutations are always associated
with higher myofibrillar Ca2 sensitivity.
We therefore believe that a constitutively high myofibrillar
Ca2 sensitivity is the trigger for the major symptoms of HCM,
potentially fatal arrhythmias and hypertrophy of heart muscle.
HigherCa2 sensitivity will impact upon contractility at several
points. Most directly, in the absence of compensatory changes
in the Ca2 transient, HCM muscle will be hypercontractile
with greater force in systole but also impaired relaxation, which
could account for diastolic dysfunction. Increased Ca2 sensi-
tivity will also affect the modulation of Ca2 sensitivity by PKA
phosphorylation of troponin I (29, 47, 48) (important in the
lusitropic response to -adrenergic stimulation), the length-
dependent modulation of Ca2 sensitivity (responsible for the
Frank-Starling effect) (49) and intracellular Ca2 homeostasis
(50).
Causes of Sudden Death—The ACTC E99K transgenic mice
show a distinctive progression of the disease phenotype. Partic-
ularly striking is the highmortality over short period between 4
and 6 weeks old, which is more pronounced in females (Fig. 1).
Because only a proportion of mice die over this short time
period and the survivors have almost normal mortality, it is
probable that mortality is in part determined by the hybrid
genetic background of the C57BL/6xCBA/Ca mice used in this
study. There is an interesting parallel in theACTCE99Kpatient
population where 5 of the 8 sudden cardiac deaths recorded
were in a single family, again suggesting a strong contribution of
genetic background to the propensity for sudden cardiac death.
It is notable that the surviving ACTC E99K mice showed ECG
abnormalities, including spontaneous arrhythmias, suggesting
that the mutation per semay induce arrhythmias although the
sudden death may depend upon additional factors (Fig. 6).
It is likely that the increased probability of arrhythmia,
observed in ECG records, is linked to higher myofibrillar Ca2
sensitivity with its associated increased Ca2 buffering in the
sarcoplasm. These differences can disturb intracellular Ca2
homeostasis and dynamics leading to alteration of the Ca2
transient, which could influence the shape and duration of the
action potential. In troponin T mutant transgenic mice with
increased myofibrillar Ca2 sensitivity, the shape of the ven-
tricular action potentials was changed compared with non-
transgenic controls, resulting in shorter effective refractory
periods, greater beat-to-beat variability of APD, and increased
dispersion of ventricular conduction velocities at high heart
rates. It was proposed that these changes created an arrhyth-
mogenic substrate (50, 51). This is compatible with our finding
that early mortality in ACTC E99K mice is twice as frequent in
females than males because it is known that female mice have
an inherently longer APD that could make the mutation-re-
lated alterations inAPDworse;moreover, the age of early death
corresponds to puberty where the APD lengths of males and
females diverge in humans (52, 53).
Hypertrophy in the ACTC E99K Heart—The mechanisms of
development of hypertrophy are poorly understood. It is
assumed that the same compensatory pathways are involved in
physiological exercise hypertrophy and HCM, but in HCM the
initiating signal, high myofibrillar Ca2 sensitivity, persists,
leading to inappropriate and irreversible hypertrophy.
One hypothesis of the causative pathway was proposed by
Watkins and co-workers (54). The hypercontractile phenotype
in HCMwith impaired relaxation and deranged length-depen-
dent activation leads to inefficient contraction at rest, requiring
the consumption of more ATP than usual and compromising
the capacity of the cardiomyocyte to maintain energy levels. It
was proposed that this could trigger signaling pathways to
induce hypertrophy (54).
TheACTC E99Kmutation is unique amongHCMmutations
because most patients (57/61) show apical hypertrophy and
noncompaction rather than the “classical” septal hypertrophy.
This does not seem to be due to genetic background because
apical hypertrophy co-segregates with the ACTC E99K muta-
tion in families that have unrelated haplotypes (12). In our
transgenic mice, hypertrophy was also confined to the apex of
the heart, thus confirming that apical hypertrophy is a direct
consequence of the ACTC E99K mutation. The origin of this
specific hypertrophic morphology is currently not known.
The ACTC E99K mutation is associated with left ventricular
noncompaction as well as hypertrophy, and a minority of cases
(10%, including patient 2) also have atrial septal defects, sug-
gesting this mutation may also cause developmental defects
(13).Wedid not see evidence of left ventricular noncompaction
in MRI images of our ACTC E99K mice, but this abnormal
anatomymaynot develop, or be undetectable, in the small heart
of amouse. Nearly twice asmany nontransgenic asACTC E99K
mice were born, which may be indicative of a developmental
defect caused by the E99K mutation.
It is interesting to note that HCM in human heart has mostly
been studied in tissue obtained from patients with septal thick-
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ening who undergo surgery to relieve left ventricular outflow
tract obstruction. These septal samples are characterized by a
low level of phosphorylation ofMyBP-C and troponin I (29, 30,
55–57). In contrast, the two samples examined here, from free
wall and from the atrial-septal junction region, showed high
levels of phosphorylation similar to those in donor hearts (Fig.
3), and the ACTC E99K mouse hearts also had the same high
level of phosphorylation as NTGmice. Therefore, the derange-
ment of phosphorylation observed in HCM is a secondary
change, perhaps a consequence of the pressure overload that
occurs in left ventricular outflow tract obstruction.
There is controversy as to whether donor hearts, with a high
level of phosphorylation, are suitable controls because theymay
not be normal (58). Sample 2 is relevant to this question because
this patient had nomedication and showed no cardiac dysfunc-
tion and could be regarded as having close to a normal heart
(supplemental dataA). Levels of phosphorylation in this sample
were indistinguishable from donor hearts.
Uncoupling of Myofibrillar Ca2 Sensitivity from Troponin I
Phosphorylation Level—Ourmeasurements of Ca2 sensitivity,
together with measurement and manipulation of troponin I
phosphorylation, have revealed that inACTC E99Kmice, Ca2
sensitivity is independent of the level of troponin I phosphory-
lation. Uncoupling was previously reported in the TNNTI3
R145Gmutation (46) and the TNNC1 L29Qmutation (40) that
causeHCMbut also inDCMmutations (ACTCE361G,TNNC1
G149D, and TPM1 E40K (16, 21, 28)) and in troponin from
human myectomy samples (56). Thus, it appears that uncou-
plingmay be a default consequence of structural perturbations.
A structural model of the interaction between the N terminus
of troponin I and troponin C indicates a weak ionic interaction
with the Ca2-binding loop of troponin C, responsible for the
high Ca2 sensitivity associated with unphosphorylated tro-
ponin I, which is destabilized by phosphorylation (59). We
speculate that the ACTC E99Kmutation causes structural per-
turbations in the I-C interface that destabilizes this interaction
independently of phosphorylation.
Heart Failure in Older Mice—Older ACTC E99K mice
develop increased end-diastolic and end-systolic volumes,
whereas the increased end-diastolic pressure, present in
younger mice, is maintained. Interestingly, the dilation devel-
ops earlier in females than males (Table 1) and is probably
responsible for the higher mortality of older ACTC E99K mice
compared with nontransgenic littermates. This pattern paral-
lels the development of severe heart failure in a minority of
HCM patients (ACTC E99K patient 1 is an example), which is
related to a combination of severe diastolic dysfunction and
moderate systolic dysfunction.
It is noteworthy that uncoupling of Ca2 sensitivity from the
troponin I phosphorylation level in the ACTC E99K mouse
resembles our recent findings with familial DCM mutations.
We have proposed that heart failure due to DCMmutations is
due to uncoupling causing a blunted response to -adrenergic
stimulation leading to a reduced cardiac reserve (16, 28). The
ACTC E99K mice clearly show a blunted response to -adre-
nergic stimulation (Fig. 5C). Thus, uncoupling due to theACTC
E99K HCM mutation may contribute to the development of
heart failure in older mice.
In conclusion, the ACTC E99K transgenic mice reproduce
many of the characteristics of hypertrophic cardiomyopathy
seen in patients at the single filament and whole animal levels.
The variability of the phenotype depending on genetic back-
ground, age, and sex and the high rate of sudden death make
this a valuable tool for further investigations of the disease
process in hypertrophic cardiomyopathy.
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Abstract We have developed a quantitative antibody-
based assay to measure the content of skeletal muscle
a-actin relative to cardiac a-actin. We found 21 ± 2%
skeletal muscle a-actin content in normal heart muscle of
adult man and mouse. In end stage failing heart 53 ± 5%
of striated actin was skeletal muscle a-actin and in samples
of inter-ventricular septum from patients with hypertrophic
obstructive cardiomyopathy (HOCM) skeletal muscle
a-actin was 72 ± 2% of sarcomeric actin. Thin filaments
containing actin isolated from normal and HOCM heart
muscle were functionally indistinguishable when studied
by quantitative in vitro motility assay. We also found
elevated skeletal muscle a-actin (60 ± 7%) in a mouse
model of dilated cardiomyopathy.
Keywords ACTA1  ACTC  Skeletal muscle alpha-actin
 Cardiac muscle alpha-actin  Heart muscle  Heart failure 
Hypertrophic cardiomyopathy  Isoform switching
Introduction
It has been known for some time that heart muscle contains
two isoforms of striated actin, cardiac a-actin (ACTC) and
skeletal muscle a-actin (ACTA1) (Vandekerckhove et al.
1986). Actin is one of the most highly conserved families
of proteins and these two isoforms differ at only 4 amino
acids. The N terminal sequences are transposed, ACTA1 is
DEDETT, ACTC is DDEETT; methionine (in ACTA1) is
substituted by leucine at 299 and threonine (ACTA1) by
serine at 358. Quantification of the expression of the two
isoforms is therefore rather difficult. Most studies have
used complex and sophisticated techniques based on
N-terminal sequencing or mass spectroscopy (Alonso et al.
1990; Bergen et al. 2003; Vandekerckhove et al. 1986),
although simpler antibody-based studies have been used for
qualitative analysis (Clement et al. 1999; Suurmeijer et al.
2003). Normal human and animal heart contains around
20% of its striated actin as skeletal muscle a-actin
(Vandekerckhove et al. 1986). It was also found that the
skeletal muscle a-actin content varies between strains of
mouse, being particularly high in the BALB/c strain
(Alonso et al. 1990).
mRNA assays and the use of skeletal muscle a-actin-
specific antibodies have shown that in pathological condi-
tions, such as heart failure or hypertrophy there is a higher
skeletal muscle a-actin content (Berni et al. 2009; Boheler
et al. 1991; Stilli et al. 2006; Suurmeijer et al. 2003). In
mouse strains with differing levels of skeletal muscle
a-actin, a positive correlation was found between skeletal
muscle a-actin content and higher rates of heart muscle
contraction and relaxation (Hewett et al. 1994). This result
suggested that skeletal muscle a-actin may increase in heart
disease to compensate for decreased contractility.
To study these questions in human heart muscle we have
developed a quantitative antibody-based assay for skeletal
muscle a-actin in heart muscle. We have confirmed the
20% skeletal muscle a-actin content in normal cardiac
muscle of man and mouse and the elevated skeletal muscle
a-actin content in the hearts of BALB/c mice. In end stage
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failing heart and in samples of inter-ventricular septum
from patients with hypertrophic obstructive cardiomyopathy
(HOCM), skeletal muscle a-actin is increased to 70–80%
and we also found elevated skeletal muscle a-actin in a
mouse model of dilated cardiomyopathy (DCM). Although
a high skeletal muscle a-actin content is a characteristic of
pathological heart muscle, we could not detect any func-
tional differences between actin with low and high skeletal
a-actin contents.
Methods
Polyclonal skeletal muscle actin-specific antibody
Two rabbits were immunised with the N0 terminally acet-
ylated decamer peptide DEDETTALVC (corresponding to
the first 10 amino acids of the mature skeletal muscle actin
protein), that had been conjugated to keyhole limpet
haemocyanin (KLH) via cysteine as described by Clement
et al. (1999). IgG was purified and concentrated from
immune sera by protein A affinity chromatography. The
two anti-skeletal muscle a-actin polyclonal antibodies were
affinity purified on a column containing the N0 acetyl-
DEDETTALVC skeletal muscle a-actin peptide coupled to
SulfoLink Coupling Resin (Pierce). Remaining anti-cardiac
a-actin activity was removed by pre-adsorption of the
skeletal muscle a-actin polyclonal antibody (1 mg/ml in
PBS) with the N-terminal cardiac a-actin peptide N0 acetyl-
DDEETTALVC (20 lg/ml) overnight at 4C.
We used the two different anti-skeletal muscle a-actin
antibody preparations. Antibody 1 (Ab1) showed no cross-
reaction with cardiac a-actin, whilst Ab2 showed 5% cross-
reaction (Fig. 1E). Measurements were adjusted to account
for this.
Human heart samples
Donor heart tissue and end-stage failing heart tissue from
explanted hearts were supplied by Prof. Cris Dos Reme-
dios, University of Sydney, Australia. Ethical approval was
obtained from the Brompton, Harefield and NHLI Research
Ethics Committee, London, and St Vincent’s Hospital,
Sydney. The donor heart tissue was obtained from hearts
where no suitable transplant recipient was found. These
patients had no history of cardiac disease, a normal cardiac
examination, normal ECG, and normal ventricular function
on echocardiography within 24 h of heart explantation.
Tissue from the interventricular septum was obtained from
patients with hypertrophic obstructive cardiomyopathy
(HOCM) undergoing the septal myectomy operation for
relief of left ventricular outflow tract obstruction (LVOTO)
at the Heart Hospital, Westmoreland Street, London, in
collaboration with Prof. William J. McKenna. Local ethical
approval was obtained from University College London
Hospitals and the Brompton, Harefield and NHLI ethics
committees for collection and use of tissue samples. The
investigation conformed to the principles outlined in the
Declaration of Helsinki. We studied tissue from 4 non-
failing donor hearts, 3 explanted hearts with end-stage
heart failure (ejection fraction: \20%) and 6 myectomy
samples from HOCM patients.
Preparation of heart muscle myofibril fraction
Human and mouse heart, frozen in liquid nitrogen
(20–50 mg w/w) was crushed into a fine powder using a
liquid N2-cooled percussion mortar. Pulverised human
heart muscle was manually homogenised in 1.5 ml of a
wash buffer containing 5 mM NaH2PO4, 5 mM Na2HPO4
pH 7.0, 0.1 M NaCl, 5 mM MgCl2, 0.5 mM EGTA, 0.1%
Triton X-100 and 5 mM DTT with 2 lg/ml each of the
protease inhibitors E-64, chymostatin, leupeptin and pep-
statin A. The homogenate was then centrifuged at
25,0009g for 3 min and the supernatant discarded. This
step was repeated twice. The pellet was then mixed with
60–150 ll of sample solution (8 M urea, 2 M thiourea,
0.05 M Tris–HCl pH 6.8, 75 mM DTT, 3% SDS and
0.05% bromophenol blue). The solution was homogenized
and heated for 3 min at 100C. The samples were briefly
placed in a vortex mixer before centrifugation for 10 min at
25,0009g. The resulting supernatant was used for SDS-
PAGE.
SDS-PAGE and western blotting
Preliminary experiments established the range of protein
loadings and antibody dilutions that yielded a linear
response in the ECL measurements (see Figs. 1E, 2C).
Sample dilution was adjusted so that all samples contained
an equal actin concentration. Myofibrillar protein equiva-
lent to 0.25, 0.5 and 1 lg actin per lane (based on 30%
actin content in heart myofibrils) was loaded into 8–18%
SDS-polyacrylamide gels (Excelgel, GE Healthcare). The
proteins of the myofibril were separated by electrophoresis
and then trans-blotted onto nitrocellulose membranes.
The nitrocellulose membrane was stained with Mem-
Code Blue total protein stain (Perbio) according to the
manufacturer’s instructions. The stained membrane was
imaged using a SYNGENE G-BOX. Protein stain was
removed from the membrane by adding 20–25 ml of Stain
Eraser (Perbio) and then the membrane was processed for
immunodetection with the anti-skeletal muscle a-actin
antibody, anti sarcomeric a-actin antibody 5C5 and anti
smooth muscle a-actin antibody 1F4 (Sigma) (all at 1/1,000
dilution) overnight followed by secondary antibody (1/500
208 J Muscle Res Cell Motil (2010) 31:207–214
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anti-rabbit IgG-horseradish peroxidase, GE Healthcare) for
1 h. Detection was by chemiluminiscence using ECL wes-
tern blotting reagents (GE Healthcare). The chemilumi-
nescence was imaged in a SYNGENE G-BOX. Quantitative
densitometry of total actin (from the MemCode-stained
membrane) and skeletal muscle a-actin (from the anti-
skeletal muscle a-actin antibody chemiluminescence) were
performed using GeneTools software (Syngene).
A
B
C
D
E
Fig. 1 Specificity of anti-skeletal muscle a-actin antibody. Western
blots of muscle myofibrils containing 0.5 lg actin, separated by SDS-
PAGE. A Stained with MemCode Blue total protein stain, the actin
band is indicated. B The same membrane probed with anti-skeletal a-
actin antibody (1/1,000). C Western blot of duplicate gel probed with
5C5 anti-sarcomeric a-actin antibody. D Western blot of duplicate gel
probed with 1A4 anti smooth muscle a-actin antibody. E Specificity
of anti-skeletal a-actin antibody. Quantification of ECL measure-
ments of western blots. The band volume (arbitrary units) is plotted
against the quantity of muscle myofibril gel solution loaded on the
SDS-PAGE gel. Squares, skeletal muscle a-actin, circles, 100%
cardiac a-actin. 100% cardiac a-actin sample gave an undetectable
signal with the anti-skeletal muscle a-actin antibody Ab1 and a 5%
background signal with Ab2. Samples: skeletal a-actin control is
mouse leg muscle. Cardiac a-actin control is leg muscle from
ACTCCO/ACTA1 KO mice; these are skeletal a-actin null mice
rescued by overexpression of cardiac a-actin in skeletal muscle
(Nowak et al. 2009). Heart myofibrils are from donor (D), failing (F)
and HOCM (M) human heart muscle. Smooth muscle myofibrils are
from mouse aorta
J Muscle Res Cell Motil (2010) 31:207–214 209
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Study of reconstituted thin filaments by in vitro motility
assay
Human cardiac troponin was prepared from donor heart
myofibrils using an anti-TnI antibody affinity column as
described by Messer et al. (2009). Human cardiac tropo-
myosin was isolated as described by Knott et al. (2002).
Polymeric actin was isolated from heart muscle as descri-
bed (Song et al. 2010). Thin filaments were reconstituted
with human heart troponin and tropomyosin.
The in vitro motility assay technique was used to study
TRITC-Phalloidin labelled actin (actin-/) filaments mov-
ing over immobilised rabbit fast muscle heavy meromyosin
(Bing et al. 1997; Fraser and Marston 1995; Messer et al.
2009). The actomyosin system was reconstituted in a flow
cell, constructed from a microscope slide and a siliconised
coverslip. Actin-/ was pre-mixed with tropomyosin and
troponin at 109 working concentration prior to dilution
and infusion into the assay flow cell. Thin filament
movement over a bed of immobilised rabbit fast skeletal
muscle heavy meromyosin (100 lg/ml) was observed in
motility buffer D (50 mM KCl, 25 mM imidazole–HCl pH
7.4, 4 mM MgCl2, 1 mM EDTA, 5 mM DTT, 0.5 mg/ml
BSA, 0.1 mg/ml glucose oxidase, 0.02 mg/ml catalase,
3 mg/ml glucose, 0.5% methylcellulose, 5 mM Ca/EGTA
buffer (range 3.7 lM to 1 nM Ca2?), 1 mM MgATP and
troponin at the appropriate concentration. Filament move-
ment was recorded and analysed as previously described
(Marston et al. 1996).
In vitro motility measurements were made in paired
cells within 2 days of preparation of troponin. In the Ca2?-
concentration dependency measurements the data were
fitted to the 4-parameter Hill equation: y = a ? Xmax
[Ca2?]n / (EC50 ? [Ca
2?]n).
Results
Assay of skeletal muscle actin expression in heart
muscle
The anti-skeletal muscle a-actin antibody cross-reacted
with skeletal muscle myofibrils (Fig. 1) but did not cross-
react with myofibrils from a mouse expressing only cardiac
actin in its skeletal muscles (ACTCco/ACTA1 KO (Nowak
et al. 2009)). The anti-skeletal muscle a-actin antibody also
did not cross react with vascular smooth muscle myofibrils
(mouse aorta). In contrast the anti-a-actin antibody, 5C5,
cross-reacted with every sample whilst the anti-smooth
muscle a-actin antibody, 1A4, cross-reacted only with the
smooth muscle sample. Samples of human heart muscle
myofibrils did cross-react with anti-skeletal muscle a-actin
antibody, confirming the presence of skeletal a-actin in
heart muscle but smooth muscle a-actin was not detected.
For quantitative measurements we separated heart
muscle myofibrillar protein by SDS-PAGE and probed
western blots with anti-skeletal muscle a-actin antibody.
Myofibril loadings were adjusted to be the same for all
samples; however, to eliminate errors due to small differ-
ences in loading, the western blot was stained with Mem-
Code Blue total protein stain prior to immunodetection and
the skeletal muscle a-actin antibody response was nor-
malized to total protein measured in the same sample. The
skeletal muscle a-actin control gave a linear response in
most cases (Fig. 2) Heart muscle samples gave slopes in
the range 90 to 10% of the control actin slope.
Skeletal muscle a-actin expression in normal
and pathological human heart
Samples of non-failing donor heart muscle showed a slope
21 ± 2% of the skeletal muscle control determined in 3–8
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Fig. 2 Measurement of skeletal muscle a-actin content in heart
muscle. Samples of normal, failing and HOCM heart myofibrils, plus
a skeletal muscle a-actin control, equivalent to 0.25, 0.5 and 1 lg
actin per lane were separated by SDS-PAGE and trans-blotted onto
nitrocellulose membranes. A Membrane stained with MemCode Blue
total protein stain. B The same membrane probed with anti-skeletal
muscle a-actin antibody (Ab1). C Skeletal a-actin signal (from B) is
normalised to the loading (from A) (arbitrary units) and plotted
against sample volume. The slopes are determined by least squares
analysis (dotted lines). The percentage expression of skeletal muscle
a-actin is determined from the slope relative to the 100% skeletal
muscle a-actin control as indicated
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assays each of 4 donor samples (Figs. 2, 3A). There was a
substantially greater skeletal muscle a-actin content in
pathological heart muscle. The mean skeletal muscle a-
actin proportion determined in 11 assays using 3 end-stage
failing heart samples (failing) was 53 ± 5% and in 30
assays of myectomy samples from 6 HCM patients with
pressure overload due to left ventricular outflow constric-
tion (HOCM), the skeletal muscle a-actin content was even
higher: 72 ± 2% (Figs. 2, 3A).
Skeletal muscle a-actin expression in mouse hearts
It has been reported that the skeletal muscle a-actin content
of mouse heart varies between strains. We found that the
common hybrid mouse strain C57BL6 9 CBA/Ca
expressed 21 ± 3% skeletal muscle a-actin in its heart,
similar to that in human heart. The BALB/c mouse strain
expressed a higher level of skeletal muscle a-actin
(45 ± 2%) in agreement with previous determinations
(Alonso et al. 1990) (Fig. 3B).
We examined several mouse models of inherited heart
disease. The homozgous TnT DK210 (DCM mutation)
knock-in mouse model shows a very high skeletal muscle
a-actin content, similar to failing human heart (60 ± 7%)
(Du et al. 2007). We also examined two transgenic mouse
models that incorporate mutant cardiac a-actin at 50% of
total sarcomeric actin (Dyer et al. 2008; Song et al. 2010).
The ACTC E361G transgenic mouse shows few signs of
heart failure and expressed skeletal muscle a-actin at
10 ± 2% (Song et al. 2010); the ACTC E99K mutation
causes HCM and heart failure develops in older mice (as
tested here (Dyer et al. 2008)). They expressed more
skeletal muscle a-actin (24 ± 2%). It is likely that the
endogenous a-actin is replaced by the transgenic expres-
sion of mutant ACTC, since we have shown it represents
50% of myofibrillar actin in these transgenic models, and
thus it dilutes out endogenous a-actin (Song et al. 2010).
Allowing for 50% dilution by the transgenic actin, the
skeletal muscle a-actin content of endogenous actin would
be 20% in E361G mouse heart and 48% in E99K mouse
heart.
In vitro motility assay study of reconstituted
thin filaments
We isolated actin from donor (DC, 20 ± 7% skeletal
a-actin) and HOCM muscle samples (MD, 60 ± 8%
skeletal a-actin) and compared their functional properties
by in vitro motility assay. Figure 4 shows that the fraction
of filaments moving and the sliding speed of motile fila-
ments of the two samples, was indistinguishable for pure
actin, actin-tropomyosin and fully reconstituted thin fila-
ments at activating and relaxing Ca2?-concentrations;
moreover the Ca2?-activation curves were not significantly
different (EC50 donor = 0.24 ± 0.02 lM, EC50 HOCM =
0.21 ± 0.02 lM, n = 4, P = 0.12, paired t test).
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Fig. 3 Skeletal muscle a-actin content of normal and pathological
human and mouse heart muscle Dot plot, each point represents the
normalized slope relative to the 100% skeletal control from an
experiment similar to that in Fig. 2. A Skeletal a-actin content of
human heart myofibrils. Donor samples, D; failing samples, F;
HOCM samples, M. Individual sample codes are given in numbers or
letters to allow correlation with prevously published data on these
samples (Fig. 4, Jacques et al. 2008a, b; Messer et al. 2009).
Horizontal lines indicate the mean skeletal a-actin content for each
sample. Mean and S.E.M. for each heart muscle type is shown.
Failing and HOCM samples are significantly different from donor
(P \ 0.0001) but failing and HOCM are not significantly different
(P = 0.59, unpaired t test). B Skeletal muscle a-actin content of
mouse heart myofibrils. Individual measurements are plotted. Hori-
zontal lines indicate the mean skeletal muscle a-actin content for each
muscle type; mean and S.E.M is shown above. Balb-C and TnT
DK201 are significantly higher than C57BL6/CBA (P = 0.0003 and
\0.0001, respectively)
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Discussion
We have developed an antibody specific to skeletal muscle
a-actin and used it to quantify the skeletal muscle a-actin
content of heart muscle. The method gives similar skeletal
muscle a-actin contents to previous determinations in
normal human and mouse hearts and also indicates a high
proportion of skeletal muscle a-actin in pathological mus-
cle (Table 1).
The skeletal muscle a-actin content of human donor
hearts was found to be 21 ± 2% of total actin. This sub-
stantial quantity was also found in previous studies using
the more complex techniques of quantitative N-terminal
Edman reaction (Vandekerckhove et al. 1986) or ESI-FTR
mass spectroscopy (Bergen et al. 2003). In mice the
proportion of skeletal muscle a-actin is reported to vary
between strains with the BALB/c strain having a particu-
larly high level (Alonso et al. 1990; Jackaman et al. 2007).
C57BL6 x CBA/Ca mice, commonly used in physiological
experimentation and to produce transgenic mice, have a
skeletal muscle a-actin content similar to man. BALB/c
mice contained 45% skeletal muscle a-actin (P = 0.0003),
which should be taken into consideration when this strain
of mice are used for various transgenic mouse experiments.
There is a substantial and significantly higher skeletal
muscle a-actin content in pathological human heart
(P \ 0.0001). In failing heart samples (ejection fraction
\25% described by Messer et al. (2009)) we observed
53 ± 5% skeletal muscle a-actin, whilst in samples from
patients with familial hypertrophic obstructive cardiomy-
opathy (HOCM) there was even more (72 ± 2%). An
enhanced skeletal muscle a-actin content (P \ 0.0001) was
also found in the transgenic mouse model of familial
dilated cardiomyopathy (due to the DK210 mutation in the
troponin T gene) which had a severe failing heart pheno-
type (Du et al. 2007). Thus it seems likely that increased
skeletal muscle a-actin content is associated with con-
tractile dysfunction in heart muscle, independent of the
cause (Berni et al. 2009; Stilli et al. 2006). It is interesting
to note that Suurmeijer et al. (2003) observed an increase in
the number of cardiomyocytes expressing skeletal muscle
a-actin in pathological heart; indeed the percentage of
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Fig. 4 Comparison of motility of thin filaments containing donor or
HOCM muscle actin. Thin filaments were reconstituted with actin
isolated from donor DC (20% skeletal a-actin) or HOCM MD (60%
skeletal muscle a-actin) and compared by in vitro motility assay. A,
B Comparison of sliding speed and fraction of filaments motile for
10 nM actin, 10 nM actin ? 60 nM tropomyosin and 10 nM
actin ? 60 nM tropomyosin ? 40 nM human heart troponin at
1 nM and 3.9 lM Ca2?. Mean and S.E.M. of 3–6 measurements.
Pale blue, donor; red, HOCM. C Representative Ca2?-activation curve
for fraction of filaments motile of thin filaments reconstitued with DC
(blue line and triangles) and MD (red line and squares). Points are
mean and S.E.M. of 4 measurements from a single motility cell. Lines
are best fit of the points to the Hill equation. DC EC50 = 0.22 ±
0.06 lM nH = 1.13 ± 0.29, MD EC50 = 0.22 ± 0.06 lM nH =
1.28 ± 0.37. Four curves were measured with two pairs of DC and
MD actin. DC mean EC50 = 0.24 ± 0.015 (S.E.M.) lM, MD mean
EC50 = 0.21 ± 0.019 lM. There was no significant difference:
P = 0.123, paired t test and 0.267 unpaired t test, n = 4. (Color
figure online)
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skeletal muscle a-actin positive cardiomyocytes they
measured is roughly equivalent to the percentage of skel-
etal muscle a-actin expressed in muscle homogenates
determined in this paper (see Table 1). This indicates the
likelihood that cardiomyocytes express either skeletal
muscle a-actin or cardiac a-actin (Suurmeijer et al. 2003).
The change in a-actin isoform expression in pathologi-
cal heart is remarkably large compared with other con-
tractile proteins. Myosin heavy chain in human heart has
been reported to change from predominantly b isoform
(85–100%) to almost completely b isoform (98–100%)
(Palmer 2005) and expression of the atrial isoform of
myosin light chain-1 increases from near zero to as much
as 27% of total myosin light chain-1 (Jacques et al. 2008a;
Morano et al. 1997). The troponin T isoform changes are
probably minimal and no changes in troponin C or troponin
I isoforms occur (Marston and Redwood 2003). In fact the
major changes in failing heart muscle are in post-transla-
tional modification with reduced phosphorylation of myo-
sin binding protein-C (MyBP-C) and troponin I (Jacques
et al. 2008b; Messer et al. 2009; Zaremba et al. 2007).
Is the increased skeletal muscle a-actin expression in
heart failure functionally relevant? Skeletal muscle and
cardiac a-actin amino acid sequences are virtually identi-
cal, the only differences being in the transposition of glu-
tamic and aspartic acids in the N-terminus (ACTA1 is
DEDETT, ACTC is DDEETT: the difference used to
generate the skeletal muscle a-actin-specific antibody), and
the substitutions of methionine (in ACTA1) for leucine at
299 and threonine for serine at 358. In yeast actin, changes
of the N-terminal sequence had measureable effects (Lu
et al. 2005) but there are no measurements showing a
difference in function between skeletal and cardiac actin-
containing thin filaments except for a very small change in
sliding speed for pure actin (Balaz and Mansson 2005). Our
own comparison of native human actin containing 20% or
60% skeletal a-actin isolated in parallel and studied by in
vitro motility assay shows no detectable differences in
basic motility or its regulation by troponin-tropomyosin
and Ca2? (Fig. 4).
A study of hearts from mouse strains with different
proportions of skeletal muscle a-actin found that a higher
skeletal muscle a-actin content was associated with faster
heart dynamics (contraction and relaxation rates) (Hewett
et al. 1994). These rates are generally slower in failing
heart and it was proposed that the increase in skeletal
muscle a-actin content is part of a compensation mecha-
nism to maintain crossbridge turnover rate. Since there are
no functional correlations with changes in skeletal muscle
a-actin content in our direct assay, an enhanced skeletal
muscle a-actin content cannot account for this compensa-
tory process. The striated a-actin isoform switch could be a
consequence of a changed programme of gene expression
in which other co-regulated gene products are responsible
for enhanced contractility (van Rooij et al. 2007). One
possibility currently under investigation is a switch in
tropomyosin isoform expression.
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Table 1
Heart sample % skeletal muscle a-actin
this paper
% skeletal muscle a-actin % skeletal muscle a-actin
positive fibres
Human donor 21 ± 2, n = 21 18–24 (Bergen et al. 2003;
Vandekerckhove et al. 1986)
27
Human end-stage failing 53 ± 5, n = 11 30, DCMa
55, ARVC
84, LVHHuman HCM (myectomy) 72 ± 2, n = 30
Mouse C57B10 9 CBCa 21 ± 3, n = 11 15–25 (Alonso et al. 1990)
Mouse BALB/c 45 ± 2, n = 4 43 (Alonso et al. 1990)
Mouse TnT DK210 60 ± 7, n = 4
Mouse ACTC E361G 10 ± 2, n = 8 (20% allowing
for transgene)
Mouse ACTC E99K 24 ± 2, n = 7 (48% allowing
for transgene)
DCM Idiopathic dilated cardiomyopathy
ARVC Arrhythmogenic right ventricular cardiomyopathy
LVH Left ventricular hypertrophy
a Data from Suurmeijer et al. (2003)
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